ï‚·ï‚·
ï‚·Title: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and 
Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) Candidate in Flavivirus 
NaÃ¯ve and Primed Healthy Adults Aged 18 to 49 Years 
Study ID: [REMOVED]
Protocol Approve Date: 12 September 2018 
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information ([COMPANY_003]) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
TITLE PAGE
A Phase 1, Randomized, Observer -Blind, Placebo -Controlled, Safety, Immunogenicity, and Dose 
Ranging Study of Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) Candidate in Flavivirus NaÃ¯ve 
and Primed Healthy Adults Aged 18 to 49 Years
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in 
Healthy Adults
Sponsor: [COMPANY_005] Vaccines, Inc.
[ADDRESS_208866]
Cambridge, MA 02139[LOCATION_003]
Study Identifie r: ZIK-101
IND Number: [ADDRESS_208867] Number: Not applicable
Vaccine Name: ï‚·Investigational vaccine: Purified Inactivated Zika Virus Vaccine
(PI[INVESTIGATOR_177760]) candidate (TAK-426)
ï‚·Placebo: saline solution
Date: 12September 2018
Version: Protocol Amendment 3-Version 7.0
0002Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseControlled, Safety, Immunogenicity, and Dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseControlled, Safety, Immunogenicity, and Dose 
Flavivirus NaÃ¯ve 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus NaÃ¯ve 
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in 
EudraCT Number:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEudraCT Number:
Investigational vaccine: Purified Inactivated Zika Virus Vaccine
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigational vaccine: Purified Inactivated Zika Virus Vaccine
(PI[INVESTIGATOR_177760]) candidate (TAK
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(PI[INVESTIGATOR_177760]) candidate (TAK
Placebo: saline solution
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePlacebo: saline solution
September 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSeptember 2018
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2018
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProtocol Amendment 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProtocol Amendment 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
3XULILHG,QDFWLYDWHG=LND9LUXV9DFFLQH3,=9
7ULDO1R=,. 3DJHRI
3URWRFRO$PHQGPHQW9HU VLRQ  6HSWHPEHU
$'0,1,675$7,9(,1)25 0$7,21
&RQWDFWV
$VHSDUDWHFRQWDFWLQIRUPDWLRQO LVWZLOOEHSURYLGHGWRHDFKVL WH&RQWDFWLQIRUPDWLRQLVDOVR
SURYLGHGLQ 7DEOHD
7KHVSRQVRUZLOOSURYLGHLQYHVWLJDWRUVZLWKVLWH VSHFLILFHPHUJHQF\PHGLFDOFRQWDFWLQIRUPDWLRQ
FDUGVWREHFDUULHGE\HDFKVXEMHFW
*HQHUDODGYLFHRQ SURWRFROSURFHGXUHVVKRXOGEHREWDLQHGWKURXJKWKHPRQLWRUDVVL JQHGWRWKHWULDO
VLWH,QIRUPDWLRQRQWULDOUHODWHGUHVSRQVLELOLWLHVLVJLYHQLQ 6HFWLRQDQGUHOHYDQWJXLGHOLQHVZLOO
EHSURYLGHGWRWKHVLWH
7DEOHD&RQWDFW,QIRUPDWLRQ
,VVXH &RQWDFW
6HULRXVDGYHUVHHYHQWDQG
SUHJQDQF\UHSRUWLQJ
)D[DQGWHOHSKRQHQXPEHUVI RUVHULRXVDGYHUVHHYHQWDQG
SUHJQDQF\UHSRUWLQJZLOO EHSURYLGHGWRWKHVLWH
0HGLFDO0RQLWRU
PHGLFDODGYLFHRQFRQGXFWRI
SURWRFRORUFRPSRXQG(PHUJHQF\PHGLFDOFRQWDFWLQIRUPDWLRQZLOOEHSURYLGHGWR
WKHVLWH
5HVSRQVLEOH0HGLFDO2IILFHU
FDUULHVRYHUDOOUHVSRQVLELOLW\IRUWKHFRQG XFWRIWKHWULDO(PHUJHQF\PHGLFDOFRQWDFWLQIRUPDWLRQZLOOEHSURYLGHGWR
WKHVLWH
0003[COMPANY_003]
Property of [COMPANY_005]: For Non-CommerRUercial Use OnJHQF\PHQF\Only andSKRQHQXKRQHQ
\UHSRUWLUHSRU
VLWHVLWHOn
((P
Wiabject to the Applicable Terms of UseLQIRUPDLQIRUP
DVVLJQHDVVLJQ
UHOHYDQWHOHYDQ
tt
bj
Coercnd Subj
3XULILHG,QDFWLYDWHG=LND9LUXV9DFFLQH3,=9
7ULDO1R=,. 3DJHRI
3URWRFRO$PHQGPHQW9HU VLRQ  6HSWHPEHU
$SSURYDO
5(35(6(17$7,9(62)7$.('$
7KLVWULDOZLOOEHFRQGXFWHG ZLWKWKHKLJKHVWUHVSHFWIRU WKHLQGLYLGXDOSDUWLFLSDQWVLQDFFRUGDQFH
ZLWKWKHUHTXLUHPHQWVRIWKLVF OLQLFDOWULDOSURWRFRODQGDOVR LQDFFRUGDQFHZLWKWKHIROORZLQJ
x7KHHWKLFDOSULQFLSOHVWKDWKDYH WKHLURULJLQLQWKH'HFODUDWLRQRI+HOVLQNL 
x,QWHUQDWLRQDO&RXQFLOIRU +DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU3KDUPDFHXWLFDOVIRU
+XPDQ8VH (*RRG&OLQLFDO3UDFWLFH&RQVROLGDWHG*XLGHOLQH 
x$OODSSOLFDEOHODZVDQGUHJXODWLRQVLQFOXGLQJEXWQRWOLPLWHGWRWKRVHUHODWHGWRGDWDSULYDF\
DQGFOLQLFDOWULDOGLVFORVXUH
6,*1$785(6
0004[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGDQFHGDQFH
RZLQJRZLQJ
UPDFHXUPDFH
VHUHODWHHUHODW
f [COMPANY_005]: For Non-Commercial Use Only and Subj
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208868] read and that I understand this protocol, the Investigatorâ€™s Brochure, and any 
other product information provided by [CONTACT_456]. I agree to conduct this trial in accordance with 
the requirements of this protocol, and also protect the rights, safety, privacy, and well -being of trial 
subjects in accordance with the following:
ï‚·The ethical principles that have their origin in the Declaration of Helsinki (1).
ï‚·International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use E6 Good Clini cal Practice: Consolidated Guideline (2).
ï‚·All applicable laws and regulations, including, but not limited to those related to data privacy 
and clinical trial disclosure.
ï‚·Regulatory requirements for reporting serious adverse events defined in Section 10.4 of this 
protocol.
ï‚·Terms outlined in the Clinical Study Site Agreement.
ï‚·Appendix Aâ€“Responsibilities of the Investigator.
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix Cof this protocol.
Signature [CONTACT_178088] (print or type)
Investigatorâ€™s Title
Location of Facility (City, State)
Location of Facility (Country)
0005Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseI confirm that I have read and that I understand this protocol, the Investigatorâ€™s Brochure, and any 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseI confirm that I have read and that I understand this protocol, the Investigatorâ€™s Brochure, and any 
other product information provided by [CONTACT_456]. I agree to conduct this trial in accordance with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useother product information provided by [CONTACT_456]. I agree to conduct this trial in accordance with 
being of trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebeing of trial 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
All applicable laws and regulations, including, but not limited to those related to data privacy 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll applicable laws and regulations, including, but not limited to those related to data privacy 
Regulatory requirements for reporting serious adverse events defined in Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRegulatory requirements for reporting serious adverse events defined in Section
I further authorize that my personal information may be processed and transferred in accordance 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseI further authorize that my personal information may be processed and transferred in accordance 
of this protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof this protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigator Name (print or type)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigator Name (print or type)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigatorâ€™s Title
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigatorâ€™s Title
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLocation of Facility (City, State)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLocation of Facility (City, State)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLocation of Facility (Country)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLocation of Facility (Country)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
3XULILHG,QDFWLYDWHG=LND9LUXV9DFFLQH3,=9
7ULDO1R=,. 3DJHRI
3URWRFRO$PHQGPHQW9HU VLRQ  6HSWHPEHU
3URWRFRO $PHQGPHQW 6X[COMPANY_003]U\RI&KDQJHV
3URWRFRO&KDQJH+LVWRU\
'DWH $PHQGPHQW1XPEHU $PHQGPHQW7\SH 5HJLRQ
0DUFK ,QLWLDO3URWRFRO9HUVLRQ  *OREDO
0D\ 3URWRFRO9HUVLRQ 1RWDSSOLFDEOH *OREDO
$XJXVW 3URWRFRO9HUVLRQ 1RWDSSOLFDEOH *OREDO
6HSWHPEHU 3URWRFRO9HUVLRQ 1RWDSSOLFDEOH *OREDO
2FWREHU 3URWRFRO$PHQGPHQW 9HUVLRQ 1RQVXEVWDQWLDO *OREDO
'HFHPEHU  3URWRFRO$PHQGPHQW9HUVLRQ 6XEVWDQWLDO *OREDO
 6HSWHPEHU  3URWRFRO$PHQGPHQW9HUVLRQ 6XEVWDQWLDO *OREDO
6X[COMPANY_003]U\RI&KDQJHV
$PHQGPHQWWR3URWRFRO9HUVLRQ'HFHPEHU
5DWLRQDOHIRUWKH$PHQGPHQW
7KHSXUSRVHRIWKLVVXEVWDQWLD ODPHQGPHQWLVWRFODULI\WKHUHF RUGLQJRILQIRUPDWLRQIURP
SK\VLFDOH[DPLQDWLRQVSHUIRUPHGGXULQJWKHVWXG\DQGWRH[WHQGWKHYLVLWZLQGRZRI9LVLW
0RQWK WRDOORZFRPPXQLFDWLRQZLWKVXEMHFWVZKRZLOOSDUWLFLSDWHLQWK H PRQWKV
IROORZXSSKDVH
7KHGHVFULSWLRQRIWKHLQWHULPDQDO\VH VKDVEHHQPRGLILHGWRLQGLFDWHWKDWWKHUHZLOOEHDQ
DGGLWLRQDO LQWHULPDQDO\VLVSHUIRUPHG IRUWKHIODYLYLUXVQDwYHFRKRUWRQO\ XSWR9LVLW,Q
DGGLWLRQWKHWLPLQJRIWKHWZRDQDO\VH VIRUGDWDDFFUXHGSDVW9LVLW 'D\KDVEHHQPRGLILHG
7KHQDPHVRI7DNHGDSHUVRQQHOKD YHEHHQXSGDWHGDQGW\SRJUDSKLF DOHUURUVKDYHEHHQFRUUHFWHG
6HFWLRQ 'HVFULSWLRQRIFKDQJH

0006[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and FODULI\WODULI
WXG\DQXG\D
VXEMHFWVXEMH
\VHHVKDVVKD
UPHGIRPHGIR
RDQDO\VHDQDO\d Subject to the Applicable Terms of Use5HJLRQ5HJLRms
*OR*OTeeee
EOHOHab
OLFDEOHFDEOHlic
XEVWDQWLEVWDQApp
6XEVWDQ6XEVWeA
66XEth
tt o
ub
VRQQHOKRQQHOd
HVFULSWLRVFULSWn-C
N
peFFor N[COMPANY_003]
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 6of 108
Protocol Amendment 3 Version 7.0 12September 2018
2.0 Interim Analys ies:
A first interim analysis will be performed to include immunogenicity and 
safety data from all flavivirus naÃ¯ve subjects up to Visit 6 (on Day 57, [ADDRESS_208869] dose 2); a second interim analysis will be performed for dose 
selection, and including safety data from all flavivirus primed subjects up to 
Visit 4 (on Day 29, [ADDRESS_208870] dose 1). This interim analysis is not intended 
for early termination of the trial. A second interim analysis will be performed 
to include the data describing the persistence of immunity at [ADDRESS_208871] dose 2.
Final Analysis:
The final safety and immunogenicity analysis will be performed when all 
(flavivirus naÃ¯ve and primed) subjects have completed Visit 6 (Day 57) to provide data to support the planning and execution of other trials in the development plan of PI[INVESTIGATOR_177760]. 
The subsequent analyses will include (1) the data 
up to Visit 9 ([ADDRESS_208872] dose 2) and (2) the data up to Visit 11 ([ADDRESS_208873] dose 2). The analyses will be performed by a separate set of 
unblinded statisticians and programmers at a Clinical Research Organization 
(CRO), who will have access to individual treatment assignments and will not be involved in subsequent trial conduct. The study team at [COMPANY_005] will have 
access to the group level unblinded results and will remain blinded to the 
individual treatment assignment. The remaining personnel (not mentioned 
before) involved in the conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, 
will remain blinded to the individual subject treatment 
assignment until unblinding after trial completion (database lock for data through Visit 11). More details regarding the analyses will be provided in the Statistical Analysis Plan (SAP).
The final study report will be written for the data up to Visit 6 (Day 57), and 
two additional addenda will be written: one to report the data from Visit 6 (Day 
57) to Visit 8 (Day 211, [ADDRESS_208874] dose 2) to Visit 9 (Day 393, [ADDRESS_208875] dose 2), and one to report the data from Visit 8 (Day 211) Visit 9 (Day 
393) until the end of the study, ie, Visit 11 (Day 757, [ADDRESS_208876] dose 2).
0007Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2); a second interim analysis will be performed for dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2); a second interim analysis will be performed for dose 
safety data from all flavivirus primed subjects up to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesafety data from all flavivirus primed subjects up to 
This interim analysis is not intended 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis interim analysis is not intended 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor early termination of the trial. A second interim analysis will be performed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor early termination of the trial. A second interim analysis will be performed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useence of immunity at 12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useence of immunity at [ADDRESS_208877] 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final safety and immunogenicity analysis will be performed when all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final safety and immunogenicity analysis will be performed when all 
(flavivirus naÃ¯ve and primed) subjects have completed Visit 6 (Day 57) to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(flavivirus naÃ¯ve and primed) subjects have completed Visit 6 (Day 57) to 
data to support the planning and execution of other trials in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedata to support the planning and execution of other trials in the 
The subsequent analyses will include (1) the data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subsequent analyses will include (1) the data 
up to Visit 9 ([ADDRESS_208878] dose 2) and (2) the data up to Visit 11 (24 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup to Visit 9 ([ADDRESS_208879] dose 2) and (2) the data up to Visit 11 (24 
The analyses will b
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe analyses will b e performed by a separate set of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee performed by a separate set of 
unblinded statisticians and programmers at a Clinical Research Organization 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunblinded statisticians and programmers at a Clinical Research Organization 
(CRO), who will have access to individual treatment assignments and will not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(CRO), who will have access to individual treatment assignments and will not 
be involved in subsequent trial conduct. The study team at [COMPANY_005] will
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe involved in subsequent trial conduct. The study team at [COMPANY_005] will
access to the group level unblinded results and will remain blinded to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccess to the group level unblinded results and will remain blinded to the 
individual treatment assignment. The remaining personnel (not mentioned 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useindividual treatment assignment. The remaining personnel (not mentioned 
before) involved in the conduct of the trial, including those at [COMPANY_005], the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebefore) involved in the conduct of the trial, including those at [COMPANY_005], the 
CRO, and the trial sites, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRO, and the trial sites, 
assignment until unblinding after trial completion (database lock for data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassignment until unblinding after trial completion (database lock for data 
through Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethrough Visit 11). More details regarding the analyses will be provided in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11). More details regarding the analyses will be provided in the 
Statistical Analysis Plan (SAP).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStatistical Analysis Plan (SAP).
The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefinal 
two additional addenda will be written: one to report the data from Visit 6 (Day 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetwo additional addenda will be written: one to report the data from Visit 6 (Day 
57) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use57) to Visit 8 (Day 211, [ADDRESS_208880] dose 2)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto Visit 8 (Day 211, [ADDRESS_208881] dose 2)
post dose 2)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepost dose 2)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 7of 108
Protocol Amendment 3 Version 7.0 12September 2018
2.1 Visit 7 (Day 133) anchored to v isit day Day 29 + 4Â½3Â½mo
Visit 9 (Day 393) acceptable visit window (days before/days after) -7/ +14+97
footnote (h): Complete physical examination will be performed at Screening 
Visit(s) (Visit 1A and/or Visit 1B). All subsequent symptom-directed physical examinations, performed if deemed necessary or indicated by [CONTACT_98272]â€™s medical history, sh
ould assess clinically significant changes from the 
baseline examination. The findings should be documented in the subjectâ€™s source document and
; findings consistent with the definition of AEs or SAEs 
(see Section 10.0) must be transcribed into the electronic Case Report Form 
(eCRF). For any procedures at the site, the investigator shall follow his/her standard practice. Refer to Section 9.1.4.
9.1.[ADDRESS_208882]â€™s source document and 
transcribed into the eCRF:
ï‚·The findings of complete physical examinations,
ï‚·the findings of symptom-directed physical examinations,
ï‚·if symptom-directed physical examinations were not required
Findings consistent with the definition of AEs or SAEs (see Section 10.0) must be transcribed into the eCRF.
[IP_ADDRESS]
(Table 9.a )PPT (partial thromboplastin time) PT (prothrombin time)
0008Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefootnote (h): Complete physical examination will be performed at Screening 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefootnote (h): Complete physical examination will be performed at Screening 
directed physical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedirected physical 
examinations, performed if deemed necessary or indicated by [CONTACT_177910]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexaminations, performed if deemed necessary or indicated by [CONTACT_177911]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useould assess clinically significant changes from the 
baseline examination. The findings should be documented in the subjectâ€™s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebaseline examination. The findings should be documented in the subjectâ€™s 
; findings consistent with the definition of AEs or SAEs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use; findings consistent with the definition of AEs or SAEs 
nic Case Report Form 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenic Case Report Form 
(eCRF). For any procedures at the site, the investigator shall follow his/her 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(eCRF). For any procedures at the site, the investigator shall follow his/her 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehould be documented in the subjectâ€™s source document 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehould be documented in the subjectâ€™s source document 
The findings of complete physical examinations,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe findings of complete physical examinations,
directed physical examinations,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedirected physical examinations,
directed physical examinations were not required
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedirected physical examinations were not required
consistent with the definition of AEs or SAEs (see Section 10.0) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsistent with the definition of AEs or SAEs (see Section 10.0) 
must be transcribed into the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be transcribed into the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePPT (partial thromboplastin time)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePPT (partial thromboplastin time)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208883] interim analysis will be performed to include immunogenicity and 
safety data from all flavivirus naÃ¯ve subjects up to Visit 6 (on Day 57, 
[ADDRESS_208884] dose 2); a second interim analysis will be performed for dose 
selection, and i ncluding safety data from all flavivirus primed subjects up to 
Visit 4 (on Day 29, [ADDRESS_208885] dose 1). This interim analysis is not intended 
for early termination of the trial. A second interim analysis will be performed 
to include the data describing the persistence of immunity at [ADDRESS_208886] dose 2.
The final safety and immunogenicity analysis will be performed when all 
(flavivirus naÃ¯ve and primed) subjects have completed Visit 6 (Day 57) to provide data to support the planning and execution of other trials in the development plan of PI[INVESTIGATOR_177760]. 
The subsequent analyses will include (1) the data 
up to Visit 9 ([ADDRESS_208887] dose 2) and (2) the data up to Visit 11 ([ADDRESS_208888] dose 2). The analyses will be performed by a separate set of 
unblinded statisticians and programmers at a Clinical Research Organization 
(CRO), who will have access to individual treatment assignments and will not be involved in subsequent trial conduct. The study team at [COMPANY_005] will have access to the group level unblinded results and will remain blinded to the individual treatment assignment. The remaining personnel (not mentioned before) involved in the conduct of the trial, including those at [COMPANY_005], the 
CRO, and the trial sites, will remain blinded to the individual subject treatment 
assignment until unblinding after trial completion (database lock for data through Visit 11).
More details regarding the analyses will be provided in the SAP.The final study report will be written for the data up to Visit 6 (Day 57), and 
two additional addenda will be written: one to report the data from Visit 6 (Day 
57) to Visit 8 (Day 211, [ADDRESS_208889] dose 2) to Visit 9 (Day 393, [ADDRESS_208890] dose 2), and one to report the data from Visit 8 (Day 211) Visit 9 (Day 
393) until the end of the study, ie, Visit 11 (Day 757, [ADDRESS_208891] dose 2).
0009Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesafety data from all flavivirus primed subjects up to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesafety data from all flavivirus primed subjects up to 
This interim analysis is not intended 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis interim analysis is not intended 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe performed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe performed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final safety and immunogenicity analysis will be performed when all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final safety and immunogenicity analysis will be performed when all 
completed Visit 6 (Day 57) to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecompleted Visit 6 (Day 57) to 
provide data to support the planning and execution of other trials in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprovide data to support the planning and execution of other trials in the 
The subsequent analyses will include (1) the data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subsequent analyses will include (1) the data 
up to Visit 9 ([ADDRESS_208892] dose 2) and (2) the data up to Visit 11 (24 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup to Visit 9 ([ADDRESS_208893] dose 2) and (2) the data up to Visit 11 (24 
The analyses will be performed by a separate set of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe analyses will be performed by a separate set of 
unblinded statisticians and programmers at a Clinical Research Organization 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunblinded statisticians and programmers at a Clinical Research Organization 
(CRO), who will have access to individual treatment assignments and will not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(CRO), who will have access to individual treatment assignments and will not 
conduct. The study team at [COMPANY_005] will have 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconduct. The study team at [COMPANY_005] will have 
access to the group level unblinded results and will remain blinded to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccess to the group level unblinded results and will remain blinded to the 
individual treatment assignment. The remaining personnel (not mentioned 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useindividual treatment assignment. The remaining personnel (not mentioned 
before) involved in the conduct of the trial, including those at
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebefore) involved in the conduct of the trial, including those at
CRO, and the trial sites, will remain blinded to the individual subject treatment 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCRO, and the trial sites, will remain blinded to the individual subject treatment 
assignment until unblinding after trial completion (database lock for data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassignment until unblinding after trial completion (database lock for data 
More details regarding the analyses will be provided in the SAP.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMore details regarding the analyses will be provided in the SAP.
study report will be written for the data up to Visit 6 (Day 57), and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy report will be written for the data up to Visit 6 (Day 57), and 
two additional addenda will be written: one to report the data from Visit 6 (Day 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetwo additional addenda will be written: one to report the data from Visit 6 (Day 
to Visit 8 (Day 211, [ADDRESS_208894] dose 2)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto Visit 8 (Day 211, [ADDRESS_208895] dose 2)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepost dose 2)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepost dose 2)
393) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use393) until the end of the study, ie, Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuntil the end of the study, ie, Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 9of 108
Protocol Amendment 3 Version 7.0 12September 2018
TABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ................................ ................................ .............. 2
1.1 Contacts ................................ ................................ ................................ .......................... 2
1.2 Approval ................................ ................................ ................................ ........................ 3
1.3 Protocol Ame ndment 3 Summary of Changes ................................ ............................... 5
1.3.1 Protocol Change History ................................ ................................ .......................... 5
1.3.2 Summary of Changes ................................ ................................ ............................... 5
2.0 TRIAL SUMMARY ................................ ................................ ................................ .......... 14
2.1 Schedule of Trial Procedures ................................ ................................ ....................... 25
3.0 TRIAL REFERENCE INFO RMATION ................................ ................................ ........... 29
3.1 Trial -Related Responsibilities ................................ ................................ ...................... 29
3.2 Principal Investigator/Coordinating Investigator ................................ ......................... [ADDRESS_208896] of Abbreviations ................................ ................................ ................................ ...30
3.4 Corporate Identification ................................ ................................ ............................... 32
4.0 INTRODUCTION ................................ ................................ ................................ ............. 33
4.1 Background ................................ ................................ ................................ .................. 33
4.1.1 Zika Virus ................................ ................................ ................................ .............. 33
4.1.2 Epi[INVESTIGATOR_82353] ................................ ................................ ................................ ......... 33
4.1.3 Transmission ................................ ................................ ................................ .......... 33
4.1.4 ZIKV Infection: Detection, Disease, Complications and Treatment ..................... [ADDRESS_208897] ................................ ................................ ....................... 37
4.2.3 Vaccines Under Development ................................ ................................ ............... 37
4.2.4 Summary of Available Non -clinical Data ................................ .............................. 37
4.2.5 Summary of Available Clinical Data ................................ ................................ .....37
4.2.6 [COMPANY_005] Vaccine Candidate ................................ ................................ .................... 37
4.2.7 Rationale for ZIK -101 Trial ................................ ................................ ................... 38
5.0 TRIAL OBJECTIVES AND ENDPOINTS ................................ ................................ ......40
5.1 Objectives ................................ ................................ ................................ .................... 40
5.1.1 Primary Objectives ................................ ................................ ................................ .40
5.1.2 Secondary Objectives ................................ ................................ ............................. 40
5.2 Endpoints ................................ ................................ ................................ ..................... 40
5.2.1 Primary Endpoints ................................ ................................ ................................ .40
5.2.2 Secondary Endpoints ................................ ................................ ............................. 41
0010Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..............
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............. 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2
..........................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.......................... 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2
........................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use........................
...............................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...............................
..........................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..........................
...............................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...............................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
ZIKV Infection: Detection, Disease, Complications and Treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV Infection: Detection, Disease, Complications and Treatment
Rationale for the Propos
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRationale for the Propos
Medical Need
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical Need ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
BARDA Funding Award
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBARDA Funding Award
Vaccines Under Development
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVaccines Under Development
Summary of Available Non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSummary of Available Non
4.2.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.2.5 Summary of Available Clinical Data
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSummary of Available Clinical Data
4.2.6
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.2.6
4.2.7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.2.7
5.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5.0
5.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5.1
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208898]â€™s Expected Participation in the Entire Trial ................................ 47
6.4 Premature Termination or Suspension of Trial or Investigational Site ....................... 47
6.4.1 Criteria for Premature Termination or Suspension of the Trial ............................. 47
6.4.2 Criteria for Premature Termination or Suspension of Investigational Sites .......... 47
6.4.3 Procedures for Premature Termination or Suspension of the Trial or the 
Participation of Investigational Site(s) ................................ ................................ ...48
7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL OF SUBJECTS ............... 49
7.1 Inclusion Criteria ................................ ................................ ................................ ......... 49
7.2 Exclusion Criteria ................................ ................................ ................................ ........ 49
7.3 Criteria for Delay of Vaccination and/or Blood Sampling ................................ .......... [ADDRESS_208899] ................................ ....................... 52
7.5 Criteria for Premature Discontinuati on of Trial Vaccine Application ......................... 53
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ................................ ......................... 55
8.1 Trial Vaccines and Materials ................................ ................................ ....................... 55
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling ................................ ......55
8.1.2 Storage ................................ ................................ ................................ ................... 55
8.1.3 Dose and Regimen ................................ ................................ ................................ .55
8.2 Investigational Vaccine/Placebo Assignment and Dispensing Procedures ................. [ADDRESS_208900] Blind Maintenance ................................ ................................ .57
8.5 Unblinding Procedure ................................ ................................ ................................ ..57
8.6 Accountability and Destruction of Sponsor -Supplied Vaccine/Placebo ..................... 58
9.0 TRIAL PLAN ................................ ................................ ................................ .................... 60
9.1 Trial Procedures ................................ ................................ ................................ ........... 60
9.1.1 Informed Consent ................................ ................................ ................................ ...60
9.1.2 Demographics, Medical History, Travel History, Prior/Concomitant 
Medications/Vaccinations, and Blood Donat ion................................ ................... 60
9.1.3 Documentation of Trial Entrance/Randomization ................................ ................. 61
9.1.4 Physical Examination ................................ ................................ ............................. 61
9.1.5 Vital Signs ................................ ................................ ................................ .............. 62
9.1.6 Bloo d Sample and Urine Sample Collection ................................ ......................... 62
9.1.7 Safety Assessments ................................ ................................ ................................ 65
9.1.8 Contraception and Avoidance of Sexually Transmitted Disease Guidance .......... 65
0011Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use47
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use47
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ 47
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use47
.......................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.......................
.............................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................
Criteria for Premature Termination or Suspension of Investigational Sites
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCriteria for Premature Termination or Suspension of Investigational Sites
Procedures for Premature Termination or Suspension of the Trial or the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProcedures for Premature Termination or Suspension of the Trial or the 
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
OF SUBJECTS
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOF SUBJECTS
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Criteria for Delay of Vaccination and/or Blood Sampling
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCriteria for Delay of Vaccination and/or Blood Sampling
Criteria for Early Study Termination of a Subject
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCriteria for Early Study Termination of a Subject ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
on of Trial Vaccine Application
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon of Trial Vaccine Application
IAL MANAGEMENT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIAL MANAGEMENT
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Dosage Form, Manufacturing, Packaging, and Labeling
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDosage Form, Manufacturing, Packaging, and Labeling
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Vaccine/Placebo Assignment and Dispensing Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVaccine/Placebo Assignment and Dispensing Procedures
Randomization Code Creation and Storage
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRandomization Code Creation and Storage
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigational Product Blind Maintenance
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigational Product Blind Maintenance
Unblinding Procedure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnblinding Procedure
Accountability and Destruction of Sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAccountability and Destruction of Sponsor
TRIAL PLAN
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTRIAL PLAN
Trial Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial Procedures
9.1.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.1
9.1.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.2
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208901] Treatment Compliance ................................ ................................ .67
9.3 Schedule of Observations and Procedures ................................ ................................ ...67
9.3.1 Screening Procedures (Screening Visit 1A/ Screening Visit 1B) .......................... 67
9.3.2 Pre-Vaccination Procedures (Day 1 and Day 29) ................................ .................. 67
9.3.3 Vaccination Procedures (Day 1 and Day 29) ................................ ......................... [ADDRESS_208902] Vaccination Procedures (Day 1 and Day 29) ................................ ................. 68
9.3.5 Clinic Visits after Vaccination (Day 8, Day 36, Day 57, Day 211, and Day 393)
................................ ................................ ................................ ................................ 70
9.3.6 Phone Contac ts (Day 133 and Day 575) ................................ ................................ 71
9.3.7 Final Visit (Day 211 or Day 757) ................................ ................................ .......... [ADDRESS_208903]-Trial Care ................................ ................................ ................................ .......72
9.4 Biological Sample Retention and Destruction ................................ ............................. 72
10.0 ADVERSE EVENTS ................................ ................................ ................................ ......... 73
10.1 Definitions ................................ ................................ ................................ .................... 73
10.1.1 Adverse Events (AEs) ................................ ................................ ............................ 73
10.1.2 Solicited Adverse Events ................................ ................................ ....................... 73
10.1.3 Serious Adverse Events (SAEs) ................................ ................................ ............. [ADDRESS_208904]-Trial Events ................................ ................................ ................................ ....80
11.0 TRIAL -SPECIFIC REQUI REMENTS ................................ ................................ ............. 81
11.1 Data Monitoring Committee Guidelines for Possible Study P ause ............................. 81
11.2 Trial -Specific Committees ................................ ................................ ........................... 81
11.2.1 External Data Monitoring Committee ................................ ................................ ...81
0012Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use67
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use67
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ...
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...67
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use67
..........................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..........................
..................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..................
.........................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.........................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Clinic Visits after Vaccination (Day 8, Day 36, Day 57, Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinic Visits after Vaccination (Day 8, Day 36, Day 57, Day 211, and Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use211, and Day
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Biological Sample Retention and Destruction
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBiological Sample Retention and Destruction ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSerious Adverse Events (SAEs)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSerious Adverse Events (SAEs)
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Relationship to Trial Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelationship to Trial Procedures
Outcome of AE
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOutcome of AE s
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Additional Points to Consider for AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdditional Points to Consider for AEs
Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProcedures ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Colle
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseColle ction and Reporting of AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usection and Reporting of AEs
Collection and Reporting of Solicited AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection and Reporting of Solicited AEs
10.4.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.4.3 Collection and Reporting of SAEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection and Reporting of SAEs
Follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFollow
10.5.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.5.1
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 12of 108
Protocol Amendment 3 Version 7.0 12September 2018
12.0 DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] ................................ .............................. 82
12.1 Electronic CRFs (eCRF) ................................ ................................ .............................. [ADDRESS_208905] Retention ................................ ................................ ................................ ......... 82
13.0 STATISTICAL METHODS ................................ ................................ .............................. 84
13.1 Statistical and Analytical Plans ................................ ................................ .................... 84
13.1.1 Analysis Sets ................................ ................................ ................................ .......... 84
13.1.2 Analysis of Demographics and Other Baseline Characteristics ............................ 84
13.1.3 Immunogenicity Analysis ................................ ................................ ...................... 84
13.1.4 Safet y Analysis ................................ ................................ ................................ ......85
13.2 Interim Analysis and Sequence of Analyses ................................ ................................ 86
13.3 Determination of Sample Size ................................ ................................ ..................... 86
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ................................ ................. 87
14.1 Trial -Site Monitoring Visits ................................ ................................ ......................... 87
14.2 Protocol Deviations ................................ ................................ ................................ ......87
14.3 Quality Assurance Audits and Regulatory Agency Inspections ................................ ..87
15.0 ETHICAL ASPECTS OF T HE TRIAL ................................ ................................ ............. 88
15.1 IRB and/or IEC Approval ................................ ................................ ............................ [ADDRESS_208906] Confidentiality ................................ ................................ ................................ 89
15.4 Publication, Disclosure, and Clinical Trial Registration Policy ................................ ..90
15.4.1 Publication and Dis closure ................................ ................................ .................... 90
15.4.2 Clinical Trial Registration ................................ ................................ ...................... 90
15.4.3 Clinical Trial Results Disclosure ................................ ................................ ........... 90
15.5 Insurance and Compensation for Inju ry................................ ................................ .......90
16.0 REFERENCES ................................ ................................ ................................ .................. 92
0013Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use82
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use82
..............................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.............................. 84
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use84
....................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use....................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ..........
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use..........
............................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use............................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ......................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use......................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
QUALITY ASSURANCE
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseQUALITY ASSURANCE ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Quality Assurance Audits and Regulatory Agency Inspections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseQuality Assurance Audits and Regulatory Agency Inspections
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Subject Information, Informed Consent and Subject Authorization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject Information, Informed Consent and Subject Authorization
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Publication, Disclosure, and Clinical Trial Registration Policy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePublication, Disclosure, and Clinical Trial Registration Policy
Publication and Dis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePublication and Dis
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclosure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclosure
Clinical Trial Registration
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Trial Registration
Clinical Trial Results Disclosure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Trial Results Disclosure
Insurance and Compensation for Inju
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInsurance and Compensation for Inju
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseREFERENCES
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseREFERENCES
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208907] Information ................................ ................................ ................................ .2
Table 8.a Sponsor -Supplied Vaccine and Placebo ................................ ................................ 56
Table 9.a Clinical Laboratory Assessments ................................ ................................ ........... 64
Table 10.a Local and Systemic AEs ................................ ................................ ........................ 74
Table 10.b Solicited Safety Parameters ................................ ................................ ................... 75
Table 16.a Table for Laboratory Abnormalities (Serum) ................................ ...................... 106
Table 16.b Table for Laboratory Abnormalities (Hematology) ................................ ............. 107
Table 16.c Table for Laboratory Abnormalities (Urine) ................................ ....................... 108
Table 16.d Table for Clinical Abnormalit ies (Vital Signs) ................................ .................... [ADDRESS_208908] Informed Consent Form ................................ ................ 101
Appendix CInvestigator Consent to Use of Personal Information ................................ .......... 104
Appendix DCDC Websites ................................ ................................ ................................ ......105
Appe ndix EFDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials ................................ ................... 106
0014Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ 56
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use56
...........
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use........... 64
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use64
........................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use........................
...................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use...................
......................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use......................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Schematic Representation of Trial Design
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSchematic Representation of Trial Design ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................ ................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
Schematic Representation of Trial Design
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSchematic Representation of Trial Design
................................
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use................................
nsibilities of the Investigator
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usensibilities of the Investigator
Elements of the Subject Informed Consent Form
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseElements of the Subject Informed Consent Form
Investigator Consent to Use of Personal Information
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigator Consent to Use of Personal Information
CDC Websites
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC Websites
FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnrolled in Preventive Vaccine Clinical Trials
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnrolled in Preventive Vaccine Clinical Trials
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208909] Name:
[CONTACT_178089] (PI[INVESTIGATOR_177760]) candidate (TAK -426)
Trial Title: A Phase 1, Randomized, Observer -Blind, Placebo -Controlled, Safety, Immunogenicity, and Dose 
Ranging Study of Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) Candidate in Flavivirus NaÃ¯ve and Primed HealthyAdults Aged 18 to 49 Years
IND No.: [ADDRESS_208910] No.: Not applicable
Study Identifier: ZIK-101 Phase: 1 Trial Blinding Schema: Observer -blind
Background and Rationale:
Zika virus (ZIKV) is a mosquito-borne single-stranded positive-sense ribonucleic acid (RNA) virus which belongs to 
the Flaviviridae family, genus Flavivirus, that presents structural similarities with other members of the Flaviviridae , 
including Spondweni virus, Yellow Fever (YF) virus, Dengue virus (DENV), West Nile virus (WNV), Japanese Encephalitis (JE) virus, and Tick-borne Encephalitis virus.
ZIKV was discovered in [ADDRESS_208911] Asia, and the Pacific Islands, and was considered a rare 
disease with mild symptoms; only [ADDRESS_208912] large outbreak of ZIKV disease was reported in Yap Island (Federal state of Micronesia) in 2007, and was 
followed by [CONTACT_177912] 2013-2014. The first cases of ZIKV disease in South America were 
reported in Easter Island in 2014, and the first reports of locally transmitted infection (ie, by [CONTACT_930]) came from Brazil in Ma y 2015, which triggered the third outbreak in [ADDRESS_208913] been estimates of more than 750,000 ZIKV -suspected cases reported from more than 
60countries/territories; most of these cases are from the South America continent.
The primary mode of transmission of ZIKV is through the bite of female mosquitoes, prominently Aedes aegypti and 
Ae. albopi[INVESTIGATOR_177761]. Vertical transmission from mother to fetus during pregnancy and the 
perinatal period, sexual contact, and blood transfusion are also confirmed modes of transmission of the disease. Potentially, the virus could be transmitted through laboratory exposure and by [CONTACT_177913], eg, tears, urine, 
breast milk, or through solid organ transplants, but there is limited evidence to support this.
More than 80% of ZIKV infections remain asymptomatic, and for the symptomatic cases, the disease is in general 
mild and of short duration. Some clinical manifestations include, but are not limited to, mild fever, maculopapular rash, conjunctivitis and arthralgia.
Despi[INVESTIGATOR_177762], ZIKV infection during pregnancy has been associated with 
serious outcomes for the fetus and newborn. The severity of the disease is related to the consequences in the fetus and 
newborn child from women with ZIKV infection during pregnancy. The spectrum of congenital anomalies associated 
with ZIKV infection, known as Congenital Zika Syndrome (CZS) , consists of severe microcephaly with partially 
collapsed skull, cerebral cortices with subcortical calcifications, macular scarring and focal pi[INVESTIGATOR_177763], congenital contractures, and marked early hypertonia with symptoms of extrapyramidal involvement. The exposure to ZIKV at any moment during pregnancy is a risk for fetal or postnatal developmental complications , 
primarily affecting brain development . Recent analysi s of the U.S. Zika Pregnancy Registry (USZPR) showed that the 
prevalence of newborns with congenital defects from pregnancies with laboratory-confirmed ZIKV infection is 10% 
(95% CI: 7%-14%). This is [ADDRESS_208914] been 3 689confirmed C ZS 
malformations potentially associated with ZIKV infection in 27 countries and territories of Latin America and the 
Caribbean.
ZIKV is a neurotropic flavivirus that can potentially cause disease within the central nervous system. Worldwide 
0015Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePurified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) candidate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePurified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) candidate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseControlled, Safety, Immunogenicity, and Dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseControlled, Safety, Immunogenicity, and Dose 
Ranging Study of Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) Candidate in Flavivirus NaÃ¯ve and Primed Healthy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRanging Study of Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760]) Candidate in Flavivirus NaÃ¯ve and Primed Healthy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial Blinding Schema: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial Blinding Schema: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesense ribonucleic acid (RNA) virus which belongs to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesense ribonucleic acid (RNA) virus which belongs to 
, that presents structural similarities with other members of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, that presents structural similarities with other members of the 
including Spondweni virus, Yellow Fever (YF) virus, Dengue virus (DENV), West Nile virus (WNV), Japanese 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincluding Spondweni virus, Yellow Fever (YF) virus, Dengue virus (DENV), West Nile virus (WNV), Japanese 
while testing samples taken from sentinel rhesus monkeys used as bait 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhile testing samples taken from sentinel rhesus monkeys used as bait 
during a surveillance of YF. The first human disease cases were reported in 1952 in Uganda and Tanzania. For 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring a surveillance of YF. The first human disease cases were reported in [ADDRESS_208915] Asia, and the P
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears, the virus circulated in areas of Africa, Southeast Asia, and the P acific Islands, and was considered a rare 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useacific Islands, and was considered a rare 
human cases were reported and no outbreaks were detected during that period.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehuman cases were reported and no outbreaks were detected during that period.
The first large outbreak of ZIKV disease was reported in Yap Island (Federal state of Micronesia) in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe first large outbreak of ZIKV disease was reported in Yap Island (Federal state of Micronesia) in 
2014. The first cases of ZIKV disease in South America were 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2014. The first cases of ZIKV disease in South America were 
reported in Easter Island in 2014, and the first reports of locally transmitted infection (ie, by [CONTACT_930]) came from 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereported in Easter Island in 2014, and the first reports of locally transmitted infection (ie, by [CONTACT_930]) came from 
y 2015, which triggered the third outbreak in 2015
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey 2015, which triggered the third outbreak in 2015
spreading through the South American continent and to other regions. In the current outbreak that started in 2015, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespreading through the South American continent and to other regions. In the current outbreak that started in 2015, 
there have been estimates of more than 750,00
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethere have been estimates of more than 750,00 0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use0ZIKV
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV
countries/territories; most of these cases are from the South America continent.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecountries/territories; most of these cases are from the South America continent.
The primary mode of transmission of ZIKV is through the bite of female mosquitoes, prominently 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe primary mode of transmission of ZIKV is through the bite of female mosquitoes, prominently 
species that have spread globally. Vertical transmission from mother to fetus during pregnancy and the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespecies that have spread globally. Vertical transmission from mother to fetus during pregnancy and the 
perinatal period, sexual contact, and blood transfusion are also confirmed modes of transmission of the disease. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useperinatal period, sexual contact, and blood transfusion are also confirmed modes of transmission of the disease. 
Potentially, the virus could be trans
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially, the virus could be trans mitted through laboratory exposure and by [CONTACT_177914]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemitted through laboratory exposure and by [CONTACT_177915], but there is limited evidence to support this.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor through solid organ transplants, but there is limited evidence to support this.
More than 80% of ZIKV infections remain asymptomatic, and for the symptomatic ca
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMore than 80% of ZIKV infections remain asymptomatic, and for the symptomatic ca
mild and of short duration. Some clinical manifestations include, but are not limited to, mild fever, maculopapular 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemild and of short duration. Some clinical manifestations include, but are not limited to, mild fever, maculopapular 
rash, conjunctivitis and arthralgia.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userash, conjunctivitis and arthralgia.
Despi[INVESTIGATOR_177762], ZIKV infection dur
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDespi[INVESTIGATOR_177762], ZIKV infection dur
serious outcomes for the fetus and newborn. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useserious outcomes for the fetus and newborn. 
newborn child from women with ZIKV infection during pregnancy. The spectrum of congenital anomali
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenewborn child from women with ZIKV infection during pregnancy. The spectrum of congenital anomali
with ZIKV infection, known as Congenital Zika Syndrome
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith ZIKV infection, known as Congenital Zika Syndrome
collapsed skull, cerebral cortices with subcortical calcifications, macular scarring and focal pi[INVESTIGATOR_177764]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecollapsed skull, cerebral cortices with subcortical calcifications, macular scarring and focal pi[INVESTIGATOR_177765], congenita
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemottling, congenita
exposure to ZIKV at any moment during pregnancy is a risk for fetal or postnatal developmental complications
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexposure to ZIKV at any moment during pregnancy is a risk for fetal or postnatal developmental complications
primarily affecting brain development
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprimarily affecting brain development
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 15of 108
Protocol Amendment 3 Version 7.0 12September 2018
concern over ZIKV causing Guillain -BarrÃ© syndrome ( GBS )emerged when an increased number of GBS cases was 
temporally associated with the 2013- [ADDRESS_208916] ZIKV, compared to 56% in the control group. Other 
neurological complications, such as encephalitis, meningoencephalitis, paresthesia, facial paralysis and myelitis, have 
also been associated with ZIKV infection. Based on these findings, the countries affected by [CONTACT_177916] 
2015-[ADDRESS_208917] increased 2 
to 9.8 times compared to baseline before the epi[INVESTIGATOR_903], and up to 20 times in French Polynesia. The 
association of GBS was only reported when the circulating strain was of Asian lineage. As of 01 February 2017, ZIKV 
of the Asian lineage was circulating in more than 80% of affected countries, including [ADDRESS_208918] ZIKV is currently available. As 
the disease is self-limiting, treatment for uncomplicated ZIKV infection is supportive and focuses on symptoms. The 
main recommendations to address outbreaks are through prevention (avoiding mosquito bites, reducing sexual 
transmission, improving the procedures for safe blood transfusion), and vector control measures. 
The risk of infection with ZIKV is increasing given that the spread of ZIKV is rapid and intense in tropi[INVESTIGATOR_177766]. Vector control is difficult to establish and maintain, and new areas continue to be colonized by [CONTACT_177917]. Climate changes may also create favorable environments to maintain the vector. There is an 
increased urban population and mobility, and the role of sexual transmission may be an important mechanism to spread rapi[INVESTIGATOR_177767], even in regions where the vector is uncommon.
ZIKV has posed a challenging situation for health, public and economic sectors of affected countries. The World 
Health Organization (WHO) declared on 01 February 2016 the Zika outbreak as a Public Health Emergency of International Concern (PHEIC) and recommended to focus the research on the causal association of ZIKV infection 
during pregnancy and microcephaly and other neurological abnormalities in newborns. By [CONTACT_58472] 2016, the U.S. 
Department of Health and Human Services declared Zika a public health emergency in Puerto Rico based on the 
significant threat to pregnant women and their childrenâ€™s health. In November 2016, and after evaluating the evidence 
about the causal association of ZIKV infection during pregnancy and microcephaly and other neurological abnormalities in newborns, WHO announced that Zika no longer represents a PHEIC but stressed the need to escalate the disease to a sustained work program with dedicated resources to address its long-term nature and its associated consequences.
Considering the conclusive associations between ZIKV infections and fetal and postnatal abnormalities, the 
development of a vaccine that can provide protection is crucial for countries where the epi[INVESTIGATOR_177768]/or persist, as well as in countries in which the virus has not yet been introduced . In order to address the urgent 
medical need and in anticipation of possible outbreaks with rapid onsets, [COMPANY_005] has initiated the development of a purified inactivated ZIKV vaccine candidate, PI[INVESTIGATOR_177760], for use in endemic areas and non-endemic areas for prevention of 
ZIKV associated illness of any severity and/or infection.
The Biomedical Advanced Research and Development Authority (BARDA) from the U.S. Department of Health and 
Human Servicesâ€™ Office of the Assistant Secretary for Preparedness and Response is providing funding to [COMPANY_005] for 
the US-based PI[INVESTIGATOR_177769]. Due to the need to vaccinate women and men of reproductive age, the target population of PI[INVESTIGATOR_177770] 9 years of age and older. In this phase 1 study, study population is limited to â‰¥ 18to 
â‰¤49years of age, and age expansion will be included in the next phase of development.
There are no clinical data currently available for PI[INVESTIGATOR_177760]. PI[INVESTIGATOR_177771] a 3- dose Good 
Laboratory Practice-compliant, repeat-dose toxicity and local tolerance study in New Zealand White Rabbits. 
Toxicology data will be available prior to study start and provided in the Investigatorâ€™s Brochure (IB). 
ZIK-[ADDRESS_208919]- in-human study. It will enroll both flavivirus naÃ¯ve and primed healthy adults aged â‰¥18 to â‰¤49 years . 
To ensure the enrollment of healthy adults, screening tests (hematology, biochemistry and urinalysis) will be 
performed prior to vaccine/placebo administration.
Flavivirus primed adults are included in this study to assess if there is any impact from pre-existing flavivirus 
antibodies. The testing of flaviviral serological status will be performed prior to randomization and will enable 
0016Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehave 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehave 
se findings, the countries affected by [CONTACT_177918]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usese findings, the countries affected by [CONTACT_177916] 
r the spread of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User the spread of 
, a total of 200 cases of GBS related to ZIKV 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, a total of [ADDRESS_208920] increased 2 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The incidences reported have increased 2 
and up to 20 times in French Polynesia. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand up to 20 times in French Polynesia. The 
February
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFebruary
countries in Latin America. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecountries in Latin America. 
per 100,000 cases of ZIKV infection.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useper 100,[ADDRESS_208921] ZIKV is currently available. As 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNo specific antiviral treatment is available for ZIKV infections and no vaccine against ZIKV is currently available. As 
limiting, treatment for uncomplicated ZIKV infection is supportive and focuses on symptoms. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselimiting, treatment for uncomplicated ZIKV infection is supportive and focuses on symptoms. The 
to address outbreaks are through prevention (avoiding mosquito bites, reducing sexual 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto address outbreaks are through prevention (avoiding mosquito bites, reducing sexual 
transmission, improving the procedures for safe blood transfusion), and vector control measures. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmission, improving the procedures for safe blood transfusion), and vector control measures. 
ZIKV is rapid and intense in tropi[INVESTIGATOR_177772]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV is rapid and intense in tropi[INVESTIGATOR_177766]. Vector control is difficult to establish and maintain, and new areas continue to be colonized by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubtropi[INVESTIGATOR_177773]. Vector control is difficult to establish and maintain, and new areas continue to be colonized by 
[CONTACT_164649]. Climate changes may also create favorable environments to maintain the vect
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespecies. Climate changes may also create favorable environments to maintain the vect
increased urban population and mobility, and the role of sexual transmission may be an important mechanism to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincreased urban population and mobility, and the role of sexual transmission may be an important mechanism to 
spread rapi[INVESTIGATOR_177767], even in regions where the vector is uncommon.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespread rapi[INVESTIGATOR_177767], even in regions where the vector is uncommon.
situation for health, public and economic sectors of affected countries. The World 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesituation for health, public and economic sectors of affected countries. The World 
Health Organization (WHO) declared on 01 February 2016 the Zika outbreak as a Public Health Emergency of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHealth Organization (WHO) declared on 01 February 2016 the Zika outbreak as a Public Health Emergency of 
International Concern (PHEIC) and recommended to focus the research 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational Concern (PHEIC) and recommended to focus the research 
during pregnancy and microcephaly and other neurological abnormalities in newborns. By [CONTACT_58472] 2016, the U.S. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring pregnancy and microcephaly and other neurological abnormalities in newborns. By [CONTACT_58472] 2016, the U.S. 
Department of Health and Human Services declared Zika a public health emergency in Puerto Rico based on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDepartment of Health and Human Services declared Zika a public health emergency in Puerto Rico based on
significant threat to pregnant women and their childrenâ€™s health. In November 2016, and after evaluating the evidence 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesignificant threat to pregnant women and their childrenâ€™s health. In November 2016, and after evaluating the evidence 
about the causal association of ZIKV infection during pregnancy and microcephaly and other neurological 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useabout the causal association of ZIKV infection during pregnancy and microcephaly and other neurological 
O announced that Zika no longer represents a PHEIC but stressed the need to escalate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseO announced that Zika no longer represents a PHEIC but stressed the need to escalate 
the disease to a sustained work program with dedicated resources to address its long
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe disease to a sustained work program with dedicated resources to address its long
Considering the conclusive associations b
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConsidering the conclusive associations b
development of a vaccine that can provide protection is crucial for countries where the epi[INVESTIGATOR_177774]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopment of a vaccine that can provide protection is crucial for countries where the epi[INVESTIGATOR_177775] 
, as well as in countries in which the virus has not yet 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, as well as in countries in which the virus has not yet 
medical need and in anticipation of possible outbreaks with rapid onsets, [COMPANY_005] has initiated the development of a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical need and in anticipation of possible outbreaks with rapid onsets, [COMPANY_005] has initiated the development of a 
purified inactivated ZIKV vaccine candidate, PI[INVESTIGATOR_177776]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepurified inactivated ZIKV vaccine candidate, PI[INVESTIGATOR_177777]/or infection
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV associated illness of any severity and/or infection
The Biomedical Advanced Research and Development Authority (BARDA) from the U.S. Department of Health and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Biomedical Advanced Research and Development Authority (BARDA) from the U.S. Department of Health and 
Human Servicesâ€™ Office of the Assistant Secretary for Preparedness a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHuman Servicesâ€™ Office of the Assistant Secretary for Preparedness a
-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-based PI[INVESTIGATOR_177769]. Due to the need to vaccinate women and men of reproductive age, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased PI[INVESTIGATOR_177769]. Due to the need to vaccinate women and men of reproductive age, the 
target population of PI[INVESTIGATOR_177770] 9 years of age and older. In this phase 1 study, study population is
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetarget population of PI[INVESTIGATOR_177770] 9 years of age and older. In this phase 1 study, study population is
â‰¤
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ‰¤49
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use49years of age, and age expansion will be included in the next phase of development.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears of age, and age expansion will be included in the next phase of development.
There are no clinical data currently available for PI[INVESTIGATOR_177760]. PI[INVESTIGATOR_177771] a 3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThere are no clinical data currently available for PI[INVESTIGATOR_177760]. PI[INVESTIGATOR_177771] a 3
Laboratory Practice
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLaboratory Practice
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208922] phase of the study. If positive recommendations from an 
external Data Monitoring Committee (DMC) are issued following the review of safety and tolerability data in this 
population, when the last flavivirus naÃ¯ve subject has completed study Visit 4 ([ADDRESS_208923] dose 1), vaccination of 
flavivirus primed subjects will start.
Due to the ongoing threat of ZIKV disease and the urgent need of a vaccine, this phase 1 study will be accelerated to 
assess dose finding for PI[INVESTIGATOR_177760], in addition to evaluation of safety and immunogenicity of the vaccine candidate. PI[INVESTIGATOR_177778]-naÃ¯ve and primed subjects, and geometric 
mean titers (GMT) of neutralizing anti-ZIKV antibody levels at [ADDRESS_208924] dose 2 in flavivirus naÃ¯ve subjects. 
Placebo serves as the control for the study vaccine and in the absence of effective treatment or prevention for ZIKV 
disease, the use of placebo in this trial is justified.
The rationale for the observer-blind approach is based on the different physical appearance of the investigational 
vaccine compared to the saline solution placebo that was selected and preferred to alum-containing placebo to avoid 
side effects associated with alum.
All enrolled subjects will receive two 0.5mL doses of either PI[INVESTIGATOR_177779] (IM) on Day [ADDRESS_208925] a single vaccine dose level from three 
different antigen concentrations (2, 5 or 10 Âµg) for further development. 
The primary rationale for selection of the three vaccine dose levels can be summarized as follows: 
ï‚·the low-dose level (2 Âµg) was selected for purposes of potentially identify an immunological threshold, and 
was based on the limit of the analytical methods for the drug product available at the time;
ï‚·the mid-dose level (5 Âµg) was selected to provide a mid-point on the dose response curve. In addition, this 
dose level is based on the Walter Reed Army Institute of Research (WRAIR) vaccine currently tested in Phase 1, which was originally based on initial studies in non-human primates (NHPs); and
ï‚·the high-dose level (10 Âµg) was selected to follow an approximate 2-fold range and to further define the 
potential dose-response curve in both naÃ¯ve and primed subjects.
The trial will be conducted in accordance with the protocol, the International Council for Harmonization of Technical Requirements for Pharmaceuticals (ICH) GCP Guidelines and applicable regulatory requirements.
Trial Design:
This is a phase 1, randomized, observer-blind, placebo-controlled, safety, immunogenicity, and dose ranging study of PI[INVESTIGATOR_177780]Ã¯ve and primed healthy adults aged â‰¥18 to â‰¤[ADDRESS_208926] for up to 2 weeks (14 days) prior to randomization, with the possibility that some subjects (Flavivirus primed subjects only) will need to repeat some screening procedures if they were not randomized right after the screening period (further clarification is provided in the schedule of trial procedures).
Flavivirus naÃ¯ve subjects: subjects without detectable serum antibodies against a panel of flaviviruses, as measured by 
a reactive antibody based assay (Luminex). 
Flavivirus primed subjects: subjects with serum antibodies against a panel of flavivirus es, as measured by a reactive 
antibody based assay (Luminex).
Approximately 240 subjects aged â‰¥18 to â‰¤49 years will be enrolled and equally randomized into four groups (1:1:1:1) 
of approximately 60 subjects, each comprised of approximately 30 flavivirus naÃ¯ve subjects and approximately 
30flavivirus primed subjects. Randomization within each cohort (flavivirus naÃ¯ve versus flavivirus primed subjects) 
will be stratified by [CONTACT_177919]: â‰¥18 to â‰¤ 29 years versus â‰¥30 to â‰¤49 years .
0017Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose 1), vaccination of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose 1), vaccination of 
Due to the ongoing threat of ZIKV disease and the urgent need of a vaccine, this phase 1 study will be accelerated to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDue to the ongoing threat of ZIKV disease and the urgent need of a vaccine, this phase 1 study will be accelerated to 
on of safety and immunogenicity of the vaccine candidate. PI[INVESTIGATOR_177781]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon of safety and immunogenicity of the vaccine candidate. PI[INVESTIGATOR_177782], and geometric 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects, and geometric 
se 2 in flavivirus naÃ¯ve subjects. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usese 2 in flavivirus naÃ¯ve subjects. 
Placebo serves as the control for the study vaccine and in the absence of effective treatment or prevention for ZIKV 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePlacebo serves as the control for the study vaccine and in the absence of effective treatment or prevention for ZIKV 
based on the different physical appearance of the investigational 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased on the different physical appearance of the investigational 
vaccine compared to the saline solution placebo that was selected and preferred to alum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine compared to the saline solution placebo that was selected and preferred to alum -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-containing placebo to avoid 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontaining placebo to avoid 
mL doses of either PI[INVESTIGATOR_177779] (IM) on Day 1 and on 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL doses of either PI[INVESTIGATOR_177779] (IM) on Day [ADDRESS_208927] a single vaccine dose level from three 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use101 is to assess the safety of PI[INVESTIGATOR_177783] a single vaccine dose level from three 
dose levels can be summarized as follows: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose levels can be summarized as follows: 
Âµg) was selected for purposes of potentially identify an immunological threshold, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseÂµg) was selected for purposes of potentially identify an immunological threshold, and 
cal methods for the drug product available at the time;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecal methods for the drug product available at the time;
Âµg) was selected to provide a mid
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseÂµg) was selected to provide a mid -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-point on the dose response curve. In addition, this 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepoint on the dose response curve. In addition, this 
dose level is based on the Walter Reed Army Institute of Research (WRAIR) vaccine currently 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose level is based on the Walter Reed Army Institute of Research (WRAIR) vaccine currently 
Phase 1, which was originally based on initial studies in non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePhase 1, which was originally based on initial studies in non
Âµg) was selected to follow an approximate 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseÂµg) was selected to follow an approximate 2
response curve in both naÃ¯ve and prim
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresponse curve in both naÃ¯ve and prim
The trial will be conducted in accordance with the protocol, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe trial will be conducted in accordance with the protocol, the 
(ICH) GCP Guidelines and applicable regulatory requirements.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(ICH) GCP Guidelines and applicable regulatory requirements.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis is a phase 1, randomized, observer
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis is a phase 1, randomized, observer -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-blind, placebo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useblind, placebo
PI[INVESTIGATOR_177780]Ã¯ve and primed healthy adults aged 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePI[INVESTIGATOR_177780]Ã¯ve and primed healthy adults aged 
last approximately 7 or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselast approximately [ADDRESS_208928] for up to 2 weeks (14 days) prior to randomization, with the possibility that some 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreening period will last for up to 2 weeks (14 days) prior to randomization, with the possibility that some 
(Flavivirus primed subjects only)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Flavivirus primed subjects only)
after the screening period (further clarification is provided in the schedule of trial procedures).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useafter the screening period (further clarification is provided in the schedule of trial procedures).
Flavivirus naÃ¯ve subjects: subjects without detectable serum antibodies aga
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus naÃ¯ve subjects: subjects without detectable serum antibodies aga
a reactive antibody based assay (Luminex). 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea reactive antibody based assay (Luminex). 
Flavivirus primed subjects: subjects with serum antibodies against a panel of flavivirus
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed subjects: subjects with serum antibodies against a panel of flavivirus
antibody based assay (Luminex).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useantibody based assay (Luminex).
Approximately 240
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseApproximately 240
of approximately 60
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof approximately 60
30
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use30
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 17of 108
Protocol Amendment 3 Version 7.0 12September 2018
Figure 2.a Schematic Representation of Trial Design
Staggered enrollment: There will be two study phases.
ï‚·The first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only.
All subjects who sign the informed consent form (ICF) and have confirmed eligibility at Screening Visit 1A will be tested for flavivirus serostatus.Eligible flavivirus naÃ¯ve subjects enrolled at Screening Visit 1A will be randomized at Visit 2, within 
twoweeks after Screening Visit 1A.
Flavivirus primed subjects will not be enrolled during the first phase of the study (ie, when identified at 
Screening Visit 1A) and will be invited to come back for the second phase of the study. They will be 
contact[CONTACT_177920]Ã¯ve subjects, when the last flavivirus naÃ¯ve subject has completed study Visit 4 ([ADDRESS_208929] dose 1). These flavivirus primed subjects will consequently undergo 2 screening visits: Visit 1A during the first phase of the study, and Visit 1B at the outset of the second phase of the study. 
Flavivirus primed subjects identified at Screening Visit 1A who do not participate in the second phase of the 
study will be declared screened failure (see Figure 2.b
Â§).
Enrollment will be put on hold after all naÃ¯ve subjects have been enrolled and will resume when positive 
recommendations from the external DMC are issued, as described above.
ï‚·The second phase of the study will be aimed at enrolling flavivirus primed subjects only.Newly identified eligible flavivirus primed subjects at Screening Visit 1B will be enrolled (randomized) at 
(second phase) Visit 2, within two weeks after Screening Visit 1B.
Previously identified flavivirus primed subjects (see Figure 2.b
Â§Â§) (who were tested at Screening Visit 1A 
during the first phase and accepted to enter the second phase of the study) will retain their initial subject identification (ID) number and undergo an additional screening visit (Visit 1B) to be tested for eligibility 
criteria again (except for the determination of flavivirus serostatus). 
Flavivirus naÃ¯ve subjects identified at Screening Visit 1B (during the second phase of the study) will be 
declared screened failure (see Figure 2.b
Â§Â§Â§).
0018Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStaggered enrollment: There will be two study phases.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStaggered enrollment: There will be two study phases.
The first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only.
All subjects who sign the informed consent form (ICF) and have confirmed eligibility at Scree
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll subjects who sign the informed consent form (ICF) and have confirmed eligibility at Scree
will be tested for flavivirus serostatus.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be tested for flavivirus serostatus.
Eligible flavivirus naÃ¯ve subjects enrolled at Screening Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEligible flavivirus naÃ¯ve subjects enrolled at Screening Visit
weeks after Screening Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks after Screening Visit
Flavivirus primed subjects will not be enrolled during the f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed subjects will not be enrolled during the f
Screening Visit 1A) and will be invited to come back for the second phase of the study. They will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening Visit 1A) and will be invited to come back for the second phase of the study. They will be 
contact[CONTACT_177921]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontact[CONTACT_177922]Ã¯ve subjects, when the last flavivirus naÃ¯ve subject has completed study 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand tolerability data in flavivirus naÃ¯ve subjects, when the last flavivirus naÃ¯ve subject has completed study 
Visit 4 ([ADDRESS_208930] dose 1). These flavivirus primed subjects will consequently undergo 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVisit 4 ([ADDRESS_208931] dose 1). These flavivirus primed subjects will consequently undergo [ADDRESS_208932] phase of the study, and Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A during the first phase of the study, and Visit
Flavivirus primed subjects identified at Screening Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed subjects identified at Screening Visit
study will be declared scree
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy will be declared scree
Enrollment will be put on hold after all naÃ¯ve subjects have been enrolled and will resume when positive 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnrollment will be put on hold after all naÃ¯ve subjects have been enrolled and will resume when positive 
recommendation
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecommendation
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 18of 108
Protocol Amendment 3 Version 7.0 12September 2018
Figure 2.b Staggered Enrollment
* All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177784] 9 at Day 393 ([ADDRESS_208933] dose 2) and Visit 11 at Day 757 ([ADDRESS_208934] dose 2), 
and will also be contact[CONTACT_177923] 575 (Visit 10) for safety follow- up.
0019Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use* All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177785]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use* All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177784] 9 at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopment will attend Visit 9 at 
and will also be contact[CONTACT_177924]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand will also be contact[CONTACT_177924]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208935] will receive two 0.5 mL doses of either PI[INVESTIGATOR_177760] (2, 5 or 10 Âµg) or pla cebo intramuscularly (IM) â€“onedose 
at Visit 2 (on Day 1) and one dose at Visit 4 (on Day 29) IM into the middle third of the deltoid muscle, preferably in 
the non-dominant arm.
Each subject will be required to attend 7, 8, 9 or 10 clinical visits and will receive 1 or 2 phone calls depending on their 
flavivirus serostatus at screening and the vaccine dose level they received:
ï‚·Flavivirus naÃ¯ve subjects identified during the Screening Visit 1A and flavivirus primed subjects identified during the Screening Visit 1B will attend 7 visits and will receive 1 phone call, and possibly 2 additional 
visits and 1 phone call (thus a maximum of 9 visits and 2 phone calls) if they were randomized to the placebo 
group or the PI[INVESTIGATOR_177786] 
ï‚·Flavivirus primed subjects identified during the Screening Visit 1A will attend 8 visits (including Visit 1A 
andVisit 1B) and will receive 1 phone call, and possibly 2 additional visits and 1 phone call (thus a maximum 
of 10 visits and 2 phone calls) if they were randomized to the placebo group or the PI[INVESTIGATOR_177787](s) (Visit 1A and/or Visit 1B), Visit 2 at Day 1, Visit 3 at 
Day 8 (7days post dose 1), Visit 4 at Day 29 ([ADDRESS_208936] dose 1), Visit 5 at Day 36 ([ADDRESS_208937] dose 2), Visit 6 at 
Day 57 (28 days pos t dose 2), and Visit 8 at Day 211 ([ADDRESS_208938] dose 2). All randomized subjects will also be 
contact[CONTACT_177923] 133 (Visit 7) for safety follow-up. In addition, subjects who were randomized to the 
placebo group or the PI[INVESTIGATOR_177788] 9 at Day 393 
(12months post dose 2)and Visit 11 at Day 757 ([ADDRESS_208939] dose 2), and will also be contact[CONTACT_177925] 575 (Visit 10) for safety follow- up.
Blood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 1B) for flavivirus serostatus determination and eligibility screening tests (including pregnancy testing), at Visits 3 and 5 for routine safety laboratory testing, and at Visits 2, 4, 6, 8, and (for subjects who will be randomized to the placebo group or the 
PI[INVESTIGATOR_177789] ) 9 and 11 for immunogenicity, as well as for further 
development and characterization of assays.
Urine samples will be collected for all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) for eligibility screening 
and at Visits 3 and 5 for routine safety laboratory testing; and for women of childbearing potential at Visits 2 and 4 
before each investigational vaccine/placebo administration for pregnancy testing. 
Each subject will receive diary cards to collect solicited adverse events (AEs) for 7 days after each dose (including the 
days of vaccine/placebo administration), and unsolicited AEs for 28 days after each dose (includ ing the days of 
vaccine/placebo administration). Additional safety assessments will include new medical conditions (neurological and 
neuroinflammatory disorders) with onset after the first vaccination, and serious adverse events (SAEs) collection for 
the duration of the entire trial. Immunogenicity will be assessed for all subjects 28 days after each vaccine/placebo administration and [ADDRESS_208940] dose 2.
Primary Objectives
ï‚·To describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart from three different antigen concentrations 
(2, 5 or 10 Âµg) in flavivirus naÃ¯ve and primed healthy adults t hrough [ADDRESS_208941] dose 2
ï‚·To select a single vaccine dose level of PI[INVESTIGATOR_177791]
ï‚·To describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart in flavivirus naÃ¯ve and primed healthy adults 
through the end of the study
ï‚·To describe the immune response to PI[INVESTIGATOR_177792]Ã¯ve and primed healthy adults at the following immunogenicity time points [ADDRESS_208942] dose 2
ï‚·To describe the persistence of immunity to PI[INVESTIGATOR_177793] [ADDRESS_208943] dose 2 in flavivirus naÃ¯ve and 
primed healthy adults from the placebo group and the PI[INVESTIGATOR_177794]
0020Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedepending on their 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedepending on their 
1A and flavivirus primed subjects identified 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A and flavivirus primed subjects identified 
additional 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadditional 
) if they were randomized to the placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) if they were randomized to the placebo 
visits (inclu
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevisits (inclu
additional visits and 1 phone call (thus a maximum 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadditional visits and 1 phone call (thus a maximum 
phone calls) if they were randomized to the placebo group or the PI[INVESTIGATOR_177795]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephone calls) if they were randomized to the placebo group or the PI[INVESTIGATOR_177796](s) (Visit 1A and/or Visit 1B), Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll randomized subjects will thus attend Screening Visit(s) (Visit 1A and/or Visit 1B), Visit
5 at Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5 at Day 36 (7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use36 (7
2). All randomized subjects will also be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2). All randomized subjects will also be 
up. In addition, subjects who were randomized to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup. In addition, subjects who were randomized to the 
lected for further development will attend Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselected for further development will attend Visit
and Visit 11 at Day 757 ([ADDRESS_208944] dose 2), and will also be contact[CONTACT_177926]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand Visit 11 at Day 757 ([ADDRESS_208945] dose 2), and will also be contact[CONTACT_177927]: ie, at Screening Visit(s) (Visit 1A and/or Visit 1B) for flavivirus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useite visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 1B) for flavivirus 
(including pregnancy testing)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(including pregnancy testing)
or subjects who will be randomized to the placebo group or the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor subjects who will be randomized to the placebo group or the 
PI[INVESTIGATOR_177797]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePI[INVESTIGATOR_177798](s) (Visit 1A and/or Visit 1B) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) 
for routine safety laboratory testing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor routine safety laboratory testing
vaccine/placebo a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo a dministration for pregnancy testing. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedministration for pregnancy testing. 
Each subject will receive diary cards to collect solicited adverse events (AEs) for 7 days after each dose (including the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach subject will receive diary cards to collect solicited adverse events (AEs) for 7 days after each dose (including the 
days of vaccine/placebo administration), and unsolicited AEs for 28 days after each dose (includ
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays of vaccine/placebo administration), and unsolicited AEs for 28 days after each dose (includ
vaccine/placebo administration). 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo administration). Additional safety assessments will include new medical conditions (neurological and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdditional safety assessments will include new medical conditions (neurological and 
neuroinflammatory disorders) with onset after the first vaccination, and serious adverse events (SAEs) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useneuroinflammatory disorders) with onset after the first vaccination, and serious adverse events (SAEs) 
uration of the entire trial. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuration of the entire trial. Immunogenicity will be assessed for all subjects 28 days after each vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseImmunogenicity will be assessed for all subjects 28 days after each vaccine/placebo 
administration and [ADDRESS_208946] dose 2, and for subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177781]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministration and [ADDRESS_208947] dose 2, and for subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177799]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedosing group that will be sel
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrimary Objectives
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrimary Objectives
To describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart from three different antigen concentrations 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart from three different antigen concentrations 
(2, 5 or 10
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(2, 5 or 10
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·To select a single vaccine dose level of PI[INVESTIGATOR_177800]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo select a single vaccine dose level of PI[INVESTIGATOR_177801]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecondary Objectives
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208948] Population:
Healthy subjects : Yes
Planned Age Range: â‰¥18 to â‰¤49 years 
Planned Number of Subjects : approximately 240
Planned Number of Arms: 4 arms ( n=60 per arm: approximately 30 flavivirus naÃ¯ve subjects and approximately 
30flavivirus primed subjects)
ï‚·Arm 1: Placebo saline solution
ï‚·Arm 2: PI[INVESTIGATOR_177760] 2 Âµg (Low) dose 
ï‚·Arm 3: PI[INVESTIGATOR_177760] 5 Âµg (Medium) dose 
ï‚·Arm 4: PI[INVESTIGATOR_177760] 10 Âµg (High) dose 
Criteria for Inclusion:
Subject eligibility is determined according to the following criteria:
ï‚·The subject is aged â‰¥18 to â‰¤49 years .
ï‚·Individuals who are in good health at the time of entry into the trial as determined by [CONTACT_9870], 
physical examination (including vital signs) and eligibility screening tests (hematology, biochemistry and 
urinalysis) and clinical judgment of the investigator. Vital signs must be within normal limits (ie, below 
Grade 1 as specified in the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers). Screening tests must be within normal limits or not be above Grade 1 as defined in the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers.
ï‚·The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local 
regulatory requirements.
ï‚·Individuals who can comply with trial procedures and are available for the duration of follow- up.
ï‚·All female participants of childbearing potential must have a negative serum beta human chorionic 
gonadotropin ( ï¢-hCG) pregnancy test at screening and a negative urine ï¢-hCG pregnancy test prior to 
receiving any dose of investigational vaccine/placebo.
Criteria for Exclusion:
Any subject who meets any of the following criteria will not qualify for entry into the trial: 
ï‚·Subjects and subjectsâ€™ partners with confirmed ZIKV infection by [CONTACT_6270]-report.
ï‚·Traveling to flavivirus endemic countries or flavivirus endemic regions of the US/US territories*, within 
4 weeks prior to screening or planned travel through toVisit 6 (applicable only to subjects to be enrolled into 
the flavivirus naÃ¯ve cohort).
*CDC website defines the information about the flavivirus endemic countries and US regions and territories 
(see Appendix Dfor the respective website addresses).
ï‚·Known hypersensitivity or allergy to any of the vaccine candidate components (including excipi[INVESTIGATOR_177802]).
ï‚·Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opi[INVESTIGATOR_871], may interfere with the subject's ability to participate in the trial.
ï‚·Individuals with any history of progressive or severe neurologic disorder, seizure disorder or 
neuro -inflammatory disease (eg, Guillain-BarrÃ© syndrome).
ï‚·Individuals with history or any illness that, in the opi[INVESTIGATOR_871], might interfere with the results 
of the trial or pose additional risk to the subjects due to participation in the trial.
ï‚·Known or suspected impairment/alteration of immune function, including:
0021Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflavivirus naÃ¯ve subjects and approximately 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflavivirus naÃ¯ve subjects and approximately 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto the trial as determined by [CONTACT_9870], 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto the trial as determined by [CONTACT_9870], 
physical examination (including vital signs) and eligibility screening tests (hematology, biochemistry and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephysical examination (including vital signs) and eligibility screening tests (hematology, biochemistry and 
Vital signs must be within normal limits (ie, b
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVital signs must be within normal limits (ie, b
Grade 1 as specified in the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers). 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGrade 1 as specified in the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers). 
Screening tests must be within normal limits or not be above Grade 1 as defined in the FDA Toxicity Grading 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening tests must be within normal limits or not be above Grade 1 as defined in the FDA Toxicity Grading 
unteers.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunteers.
The subject signs and dates a written, informed consent form and any required privacy authorization prior to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subject signs and dates a written, informed consent form and any required privacy authorization prior to 
the initiation of any trial procedures, after the nature of the trial has been explained according to local 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe initiation of any trial procedures, after the nature of the trial has been explained according to local 
Individuals who can comply with trial procedures and are available for the duration of follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals who can comply with trial procedures and are available for the duration of follow
female participants of childbearing potential must have a negative serum beta human chorionic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefemale participants of childbearing potential must have a negative serum beta human chorionic 
hCG) pregnancy test at screening and a nega
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsehCG) pregnancy test at screening and a nega
receiving any dose of investigational vaccine/placebo.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceiving any dose of investigational vaccine/placebo.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny subject who meets any of the following criteria will not qualify for entry into the trial: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny subject who meets any of the following criteria will not qualify for entry into the trial: 
Subjects and subjectsâ€™ partners with co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubjects and subjectsâ€™ partners with co
Traveling to flavivirus endemic countries or flavivirus endemic regions of the US/US territories*, within 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTraveling to flavivirus endemic countries or flavivirus endemic regions of the US/US territories*, within 
weeks prior to screening or planned travel through
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks prior to screening or planned travel through
the flavivirus naÃ¯ve cohort).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe flavivirus naÃ¯ve cohort).
*CDC website 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use*CDC website 
(see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(see Appendix
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppendix
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·Known hypersensitivity or allergy to any of the vaccine candidate components (including excipi[INVESTIGATOR_177803]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseKnown hypersensitivity or allergy to any of the vaccine candidate components (including excipi[INVESTIGATOR_177803]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 21of 108
Protocol Amendment 3 Version 7.0 12September 2018
oChronic use of oral steroids (equivalent to 20 mg/day prednisone â‰¥12weeks / â‰¥2mg/kg body 
weight / day prednisone â‰¥2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or 
topi[INVESTIGATOR_177804]).
oReceipt of parenteral steroids (equivalent to 20 mg/day prednisone â‰¥ 12weeks / â‰¥2 mg/kg body 
weight / day prednisone â‰¥2 weeks) within 60 days prior to Day 1.
oReceipt of immunostimulants within 60 days prior to Day 1.
oReceipt of parenteral, epi[INVESTIGATOR_177805]-articular immunoglobulin preparation, blood products, 
and/or plasma derived products within [ADDRESS_208949] be advised not to donate blood during the study period. 
oKnown Human Immunodeficiency Virus (HIV) infection or HIV-related disease.
oGenetic immunodeficiency.
ï‚·Individuals with known current or chronic hepatitis B and/or hepatitis C infections.
ï‚·Abnorma lities of splenic or thymic function.
ï‚·Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
ï‚·Individuals with any serious chronic or progressive disease according to judgment of the investigator (eg, 
neoplasm, insulin-dependent diabetes, cardiac, renal, hepatic or thyroid disease, uncontrolled hypertension, 
uncontrolled asthma).
ï‚·Individuals with body mass index (BMI) greater than or equal to 35 kg/m2 (= weightinkg / [height inmeters 
xheight in meters]).
ï‚·Individuals participating in any clinical trial with another investigational product, including ZIKV vaccine clinical trial within [ADDRESS_208950] of this trial.
ï‚·Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live 
vaccines) prior to Day 1 in this trial or who are planning to receive any vaccine within 28 days of 
investigational vaccine/placebo administration.
ï‚·Individuals involved in the trial conduct or their first degree relatives.
ï‚·Individuals with history of substance or alcohol abuse within the past 2 years.
ï‚·Female subjects who are pregnant or breastfeeding, or are planning to become pregna nt.
ï‚·Any positive or indeterminate pregnancy test.
ï‚·If female subject of childbearing potential, sexually active, and who has not used any of the "acceptable contraceptive methods" for at least 2 months prior to trial entry:
oâ€œOf childbearing potentialâ€ is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years without any other alternative medical cause (as 
confirmed by a healthcare professional), status after bilateral tubal ligation for at least 1 year, status 
after bilateral oophorectomy, or status after hysterectomy.
oAcceptable birth control methods are defined as one or more of the following:
ï‚§Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring).
ï‚§Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse.
ï‚§Intrauterine device.
ï‚§Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to the subjectsâ€™ trial entry.
ï‚·If female subject of childbearing potential and sexually active, refusal to use an "acceptable contraceptive method" from trial entry through [ADDRESS_208951] dose of investigational vaccine/placebo. In addition, 
female subjects of childbe aring potential must be advised not to donate ova during this period.
0022Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemg/kg body 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemg/kg body 
articular immunoglobulin preparation, blood products, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usearticular immunoglobulin preparation, blood products, 
and/or plasma derived products within 3 months prior to Day 1 or planned during the full length of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand/or plasma derived products within [ADDRESS_208952] be advised not to donate blood during the study period. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be advised not to donate blood during the study period. 
related disease.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated disease.
Individuals with known current or chronic hepatitis B and/or hepatitis C infections.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with known current or chronic hepatitis B and/or hepatitis C infections.
Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with a known bleeding diathesis, or any condition that may be associated with a prolonged 
Individuals with any serious chronic or progressive disease according to judgment of the investigator
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with any serious chronic or progressive disease according to judgment of the investigator
dependent diabetes, cardiac, renal, hepatic or thyroid disease, uncontrolled hypertension, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedependent diabetes, cardiac, renal, hepatic or thyroid disease, uncontrolled hypertension, 
Individuals with body mass index (BMI) greater than or equal to 35 kg/m2 (=
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with body mass index (BMI) greater than or equal to 35 kg/m2 (=
Individuals participating in any clinical trial with another investigational product, including ZIKV vaccine 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals participating in any clinical trial with another investigational product, including ZIKV vaccine 
clinical trial within [ADDRESS_208953] trial visit or intent to participate in another clinical trial at any time 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical trial within [ADDRESS_208954] trial visit or intent to participate in another clinical trial at any time 
Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live 
in this trial or who are planning to receive any vaccine within 28 days of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein this trial or who are planning to receive any vaccine within 28 days of 
o administration.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo administration.
Individuals involved in the trial conduct or their first degree relatives.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals involved in the trial conduct or their first degree relatives.
Individuals with history of substance or alcohol abuse within the past 2 years.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with history of substance or alcohol abuse within the past 2 years.
Female subjects who are pregnant or breastfeeding, or are planning to become pregna
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFemale subjects who are pregnant or breastfeeding, or are planning to become pregna
Any positive or indeterminate pregnancy test.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny positive or indeterminate pregnancy test.
If female subject of childbearing potential, sexually active, and who has not used any of the "acceptable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf female subject of childbearing potential, sexually active, and who has not used any of the "acceptable 
contraceptive methods" for at least 2 months prior to trial entry:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontraceptive methods" for at least 2 months prior to trial entry:
â€œOf childbearing potentialâ€ is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€œOf childbearing potentialâ€ is 
following conditions: menopausal for at least 2 years without any other alternative medical cause (as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefollowing conditions: menopausal for at least 2 years without any other alternative medical cause (as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 22of 108
Protocol Amendment 3 Version 7.0 12September 2018
ï‚·To avoid sexual transmission of ZIKV from natural exposure: Refusal to use latex condoms correctly and 
consistently by [CONTACT_177928]. Male subjects must be advised not to donate sperm during this period.
Trial Vaccines:
Investigational Vaccine:
[COMPANY_005]â€™s PI[INVESTIGATOR_177806] -adjuvanted vaccine candidate made from purified formalin-inactivated 
ZIKV. The virus seed was derived from ZIKV strain PRVABC59 propagated through infection of Vero cells (derived 
from the kidney of African green monkey) grown in culture, and further purified prior to inactivation. The inactivated 
purified virus is mixed with aluminum hydroxide to formulate the drug product, PI[INVESTIGATOR_177760], a liquid formulation filled into 
single-use vials and stored at 2-8Â°C. The investigational vaccine is administered IM as a 2- dose regimen of 0.5 mL at 
2, 5, or 10 Âµg antigen pe r dose, 28 days apart. Refer to the IB for more details.
Placebo:
Sodium chloride 0.9% solution is being used as placebo. It is a sterile, clear, colorless liquid solution of sodium 
chloride without preservative designed for parenteral use only. The placebo is presented in single-use vials stored at 2-8Â°C. The placebo is administered IM as a 2-dose regimen of 0.5 mL per dose, 28 days apart.
Duration of the Trial:
Approxim ately 7 or 25 months, following a screening periodPeriod of Evaluation:
7or 25 months
Main Criteria for Evaluation and Analyses:
The primary endpoints for this trial are 
Safety and tolerability of PI[INVESTIGATOR_177760], as determined by:
ï‚·Percentage of subjects with solicited local reactions (injection site: pain, erythema, swelling, and induration), 
in each severity category, during the 7-day period after administration of each dose of PI[INVESTIGATOR_177807].
ï‚·Percentage of subjects experiencing solicited systemic adverse events (AEs) (fever, headache, fatigue, malaise, arthralgia, and myalgia), in each severity category, during the 7-day period after administration of 
each dose of PI[INVESTIGATOR_177807].
ï‚·Percentage of subjects experiencing non-serious unsolicited AEs during the 28-day period after 
administration of each dose of PI[INVESTIGATOR_177807].
ï‚·Percentage of subjects experiencing SAEs during the 28-day period after administration of each dose of 
PI[INVESTIGATOR_177807].
Immunogenicity of PI[INVESTIGATOR_177760], as determined by:
ï‚·Geometric mean titers (GMT) of neutralizing anti-ZIKV antibody levels at [ADDRESS_208955] dose 2.
The secondary endpoints for this trial are 
Safety of PI[INVESTIGATOR_177760], as determined by:
ï‚·Percentage of subjects experiencing SAEs throughout the trial.
Immunogenicity of PI[INVESTIGATOR_177760], as determined by:
ï‚·GMT of neutralizing anti-ZIKV antibody levels at [ADDRESS_208956] dose 2 
in applicable groups.
ï‚·Seropositivity rates (SPR) at each immunogenicity time point ([ADDRESS_208957] dose 2) in applicable groups .
ï‚·Seroconversion rates (SCR) at [ADDRESS_208958] dose 2.
0023Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinactivated 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinactivated 
ZIKV. The virus seed was derived from ZIKV strain PRVABC59 propagated through infection of Vero cells (derived 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV. The virus seed was derived from ZIKV strain PRVABC59 propagated through infection of Vero cells (derived 
from the kidney of African green monkey) grown in culture, and further purified prior to inactivation. The inactivated 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefrom the kidney of African green monkey) grown in culture, and further purified prior to inactivation. The inactivated 
ied virus is mixed with aluminum hydroxide to formulate the drug product, PI[INVESTIGATOR_177760], a liquid formulation filled into 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useied virus is mixed with aluminum hydroxide to formulate the drug product, PI[INVESTIGATOR_177760], a liquid formulation filled into 
dose regimen of 0.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose regimen of 0.5
Sodium chloride 0.9% solution is being used as placebo. It is a sterile, clear, colorless liquid solution of sodium 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSodium chloride 0.9% solution is being used as placebo. It is a sterile, clear, colorless liquid solution of sodium 
o is presented in single
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo is presented in single
mL per dose, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL per dose, 28 days apart.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use28 days apart.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePeriod of Evaluation:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePeriod of Evaluation:
or 25
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor 25 months
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects with solicited local reactions (injection site: pain, erythema, swelling, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects with solicited local reactions (injection site: pain, erythema, swelling, and 
day period after administration of each dose of PI[INVESTIGATOR_177808]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useday period after administration of each dose of PI[INVESTIGATOR_177809] (AEs) (fever, headache, fatigue, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects experiencing solicited systemic adverse events (AEs) (fever, headache, fatigue, 
in each severity category, during the 7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein each severity category, during the 7
Percentage of subjects experiencing non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects experiencing non
administration of each dose of PI[INVESTIGATOR_177808]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministration of each dose of PI[INVESTIGATOR_177810] 28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usege of subjects experiencing SAEs during the 28
Immunogenicity of PI[INVESTIGATOR_177760], as determined by:
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseImmunogenicity of PI[INVESTIGATOR_177760], as determined by:
[CONTACT_177929] (GMT) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGeometric mean titers (GMT) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe secondary endpoints for this trial are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe secondary endpoints for this trial are 
Safety of PI[INVESTIGATOR_177760], as determined by:
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety of PI[INVESTIGATOR_177760], as determined by:
[CONTACT_177930]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects experie
Immunogenicity of PI[INVESTIGATOR_177760], as determined by:
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseImmunogenicity of PI[INVESTIGATOR_177760], as determined by:
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·GMT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGMT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 23of 108
Protocol Amendment 3 Version 7.0 12September 2018
Statistical Considerations:
Analysis sets :
ï‚·Safety Set : The Safety Set will consist of all randomized subjects who received at least one dose of the 
inves tigational vaccine/placebo. 
ï‚·Full Analysis Set (FAS): The FAS will include all randomized subjects who have received at least one dose of 
the investigational vaccine/placebo and provided valid baseline and at least one post-vaccination serology 
result. Subjects will be included in the FAS analysis as randomized.
ï‚·Perâ€“Protocol Set (PPS): The PPS will include all subjects in the FAS who have no major protocol violations. 
The major protocol violation criteria will be defined as part of the blinded data review prior to the unblinding 
of subjectâ€™s investigational vaccine/placebo assignment. The categories of major protocol violations include: 
1 not meeting selected entry criteria, 
2 receiving a wrong investigational vaccine/placebo, 3 receiving prohibited therapi[INVESTIGATOR_014], and 4 other major protocol violations that may be identified during blinded data reviews.
All summaries and analyses of safety data will be based on subjects in the Safety Set. 
The primary immunogenicity analyses will be based on the PPS, and additional immunogenicity analyses will be 
based on the FAS.
Analysis of demographics and other baseline characteristics: Summaries of age, gender, race, and other baseline 
characteristics will be presented by [CONTACT_177931].
Immunogenicity analysis : Descriptive statistics for the primary and secondary immunogenicity endpoints, including 
estimates and 95% confidence intervals (95% CI) for GMT, SPR and SCR, will be provided by [CONTACT_7206] ( 28days 
post dose 1, 28days post dose 2, and 6, 12, and [ADDRESS_208959] dose 2 in applicable groups) and by [CONTACT_177931]. 
Point estimates and 95% CI for ratios in GMT and differences in SPR and SCR will be provided for each pair of active 
study arms to aid a single vaccine dose level selection. Immunogenicity summaries and analyses will be provided by 
[CONTACT_177932] , as well as by [CONTACT_177933]. 
ï‚·Seropositive subjects : Subjects with detectable serum antibodies (tested positive at or above limit of 
detection, LOD) as measured by [CONTACT_177934].
ï‚·Seronegative subjects: Subjects with no detectable serum antibodies (test results are below LOD) as 
measured by [CONTACT_177934] . 
ï‚·Seroconverted subjects : Seronegative subjects at baseline with detectable post-vaccination serum antibodies
(test results are at or above LOD) and seropositive subjects at baseline with different fold increases in post-vaccination antibodies from baseline, as measured by [CONTACT_177934].
Safety Analysis: Reactogenicity will be assessed for 7 days following each dose (including day of vaccine/placebo 
administration) via daily collection of solicited AEs, including local reactions (injection site: pain, erythema, swelling, and induration) and systemic AEs of headache, fatigue, malaise, arthralgia and myalgia. In addition, body temperature 
(preferably measured as oral temperature) as indicator of reactogenicity will be collected (with fever defined as body 
temperature â‰¥ 38.0Â°C/100.4Â°F).
For each solicited AE, including fever, the percentage of subjects will be summarized by [CONTACT_177935] 7 days afte r each vaccine/placebo administration and overall. For subjects with more than 1 epi[INVESTIGATOR_177811], the maximum severity will be used for tabulations.
Unsolicited AEs and SAEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
summarized by [CONTACT_9313] (SOC) and preferred term (PT) for each formulation arm including neurological and neuroinflammatory disorders and new medical conditions with onset after the first vaccination.
Safety summaries will be provided by [CONTACT_177932] , as well as by [CONTACT_177933].
0024Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects who have received at least one dose of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects who have received at least one dose of 
serology 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useserology 
(PPS): The PPS will include all subjects in the FAS who have no major protocol violations. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(PPS): The PPS will include all subjects in the FAS who have no major protocol violations. 
The major protocol violation criteria will be defined as part of the blinded data review prior to the unblinding 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe major protocol violation criteria will be defined as part of the blinded data review prior to the unblinding 
ccine/placebo assignment. The categories of major protocol violations include: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useccine/placebo assignment. The categories of major protocol violations include: 
ified during blinded data reviews.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useified during blinded data reviews.
All summaries and analyses of safety data will be based on subjects in the Safety Set. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll summaries and analyses of safety data will be based on subjects in the Safety Set. 
The primary immunogenicity analyses will be based on the PPS, and additional immunogenicity analyses will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe primary immunogenicity analyses will be based on the PPS, and additional immunogenicity analyses will be 
: Summaries of age, gender, race, and other baseline 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use: Summaries of age, gender, race, and other baseline 
: Descriptive statistics for the primary and secondary immunogenici
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use: Descriptive statistics for the primary and secondary immunogenici
CI) for GMT, SPR and SCR, will be provided by [CONTACT_7206] (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCI) for GMT, SPR and SCR, will be provided by [CONTACT_7206] (
months post dose 2 in applicable groups) and by [CONTACT_177931]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post dose 2 in applicable groups) and by [CONTACT_177931]. 
estimates and 95% CI for ratios in GMT and differences in SPR and SCR will be provided for each pair of active 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useestimates and 95% CI for ratios in GMT and differences in SPR and SCR will be provided for each pair of active 
study arms to aid a single vaccine dose level selection. Immunogenicity summaries and analyses will be provided by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy arms to aid a single vaccine dose level selection. Immunogenicity summaries and analyses will be provided by 
s by [CONTACT_177933]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses by [CONTACT_177933]. 
: Subjects with detectable serum antibodies (tested positive at or above limit of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use: Subjects with detectable serum antibodies (tested positive at or above limit of 
detection, LOD) as measured by [CONTACT_177936]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedetection, LOD) as measured by [CONTACT_177937]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubjects with no detectable serum 
measured by [CONTACT_177936]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemeasured by [CONTACT_177938]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects : Seronegative subjects at baseline with detectable post
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use: Seronegative subjects at baseline with detectable post
(test results are at or above LOD) and seropositive subjects at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(test results are at or above LOD) and seropositive subjects at 
vaccination antibodies from baseline, as measured by [CONTACT_177934].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccination antibodies from baseline, as measured by [CONTACT_177934].
: Reactogenicity will be assessed for 7 days following each dose (including day of vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use: Reactogenicity will be assessed for 7 days following each dose (including day of vaccine/placebo 
administration)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministration) via daily collection of solicited AEs, including local reactions (injection site: pain, erythema, swelling, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevia daily collection of solicited AEs, including local reactions (injection site: pain, erythema, swelling, 
and induration) and systemic AEs of headache, fatigue, malaise, arthralgia and myalgia. In addition, body temperature 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand induration) and systemic AEs of headache, fatigue, malaise, arthralgia and myalgia. In addition, body temperature 
(preferably measured as oral 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(preferably measured as oral 
temperature 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetemperature â‰¥
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ‰¥
For each solicited AE, including fever, the percentage of subjects will be summarized by [CONTACT_177939]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor each solicited AE, including fever, the percentage of subjects will be summarized by [CONTACT_177940] 7 days afte
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor the 7 days afte
event, the maximum severity will be used for tabulations.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevent, the maximum severity will be used for tabulations.
Unsolicited AEs and SAEs will be coded using the Medical Dictionary for Regulatory Activities (Me
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnsolicited AEs and SAEs will be coded using the Medical Dictionary for Regulatory Activities (Me
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 24of 108
Protocol Amendment 3 Version 7.0 12September 2018
Sample Size Justification:
The sample size was not determined based on formal statistical power calculations.
Interim Analyse s:
A first interim analysis will be performed to include immunogenicity and safety data from all flavivirus naÃ¯ve subjects 
up to Visit 6 ( on Day 57, [ADDRESS_208960] dose 2); a second interim analysis will be performed for dose selection,
including safety data from all flavivirus primed subjects up to Visit 4 (on Da y29, [ADDRESS_208961] dose 1). 
Final Analysis:
The final safety and immunogenicity analysis will be performed when all (flavivirus naÃ¯ve and primed) subjects have 
completed Visit 6 (Day 57) to provide data to support the planning and execution of other trials in the development 
plan of PI[INVESTIGATOR_177760]. The subseq uent analyses will include (1) the data up to Visit 9 ([ADDRESS_208962] dose 2) and (2) the data 
up to Visit 11 ([ADDRESS_208963] dose 2). The analyses will be performed by a separate set of unblinded statisticians and 
programmers at a Clinical Research Organization (CRO), who will have access to individual treatment assignments 
and will not be involved in subsequent trial conduct. The study team at [COMPANY_005] will have access to the group level 
unblinded results and will remain blinded to the individual treatment assignment. The re maining personnel (not 
mentioned before) involved in the conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will remain blinded to the individual subject treatment assignment until unblinding after trial completion (database lock for data through Visit 11). More details regarding the analyses will be provided in the Statistical Analysis Plan (SAP).
The final study report will be written for the data up to Visit 6 (Day 57), and two additional addenda will be written: 
one to report the data from Visit 6 (Day 57) to Visit 9 (Day 393, 12months post dose 2), and one to report the data 
from Visit 9 (Day 393) until the end of the study, ie, Visit 11(Day 757, [ADDRESS_208964] dose 2). 
External Data Monitoring Committe e:
An external DMC will have oversight of this trial. The external DMC functions at a program level.
The external DMC will consist of [ADDRESS_208965] 
completed Visit 4 ([ADDRESS_208966] dose 1) for the purpose of recommendation to start vaccinating flavivirus primed 
subjects. The external DMC will review safety data on an ongoing basis and when the following set of AEs are 
reported, the external DMC will review all relevant safety data within 48 hours and consider a possible pause of the 
study, if it deems necessary:
ï‚·Two or more subjects develop the same grade 3 solicited AE starting within 7 days of vaccination
ï‚·Two or more subjects develop the same grade 3 unsolicited AE within 28 days of vaccination
ï‚·Any SAE 
ï‚·Any unexpected, serious, or unanticipated risk to the subjects enrolled.
Further information is available in the external DMC charter.
ZIK-101 Version 7.0(12September 2018 )
0025Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmunogenicity and safety data from all flavivirus naÃ¯ve subjects 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmunogenicity and safety data from all flavivirus naÃ¯ve subjects 
2); a second interim analysis will be performed for dose selection
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2); a second interim analysis will be performed for dose selection ,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use,
The final safety and immunogenicity analysis will be performed when all (flavivirus naÃ¯ve and primed) subjects have 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final safety and immunogenicity analysis will be performed when all (flavivirus naÃ¯ve and primed) subjects have 
completed Visit 6 (Day 57) to provide data to support the planning and execution of other trials in the development 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecompleted Visit 6 (Day 57) to provide data to support the planning and execution of other trials in the development 
uent analyses will include (1) the data up to Visit 9 ([ADDRESS_208967] dose 2) and (2) the data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuent analyses will include (1) the data up to Visit 9 ([ADDRESS_208968] dose 2) and (2) the data 
The analyses will be performed by a separate set of unblinded statisticians and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe analyses will be performed by a separate set of unblinded statisticians and 
zation (CRO), who will have access to individual treatment assignments 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usezation (CRO), who will have access to individual treatment assignments 
will not be involved in subsequent trial conduct. The study team at [COMPANY_005] will have access to the group level 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill not be involved in subsequent trial conduct. The study team at [COMPANY_005] will have access to the group level 
assignment. The re
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassignment. The re maining 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemaining 
involved in the conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvolved in the conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will 
remain blinded to the individual subject treatment assignment until unblinding after trial comple
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useremain blinded to the individual subject treatment assignment until unblinding after trial comple
). More details regarding the analyses will be provided in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use). More details regarding the analyses will be provided in the 
study report will be written for the data up to Visit 6 (Day 57), and two 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy report will be written for the data up to Visit 6 (Day 57), and two 
12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12months post dose 2), and one to report 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post dose 2), and one to report 
(Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Day 757, 24
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use757, 24
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexternal
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexternal
DMC will consist of 5 independent members and an independent non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will consist of 5 independent members and an independent non
face meetings or teleconference calls. The type and frequency of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useface meetings or teleconference calls. The type and frequency of 
scheduled meetings will depend on the subject enrollment and safety event rates. Unscheduled ad hoc meetings will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescheduled meetings will depend on the subject enrollment and safety event rates. Unscheduled ad hoc meetings will 
e occurs, or at any time consultation is requested by [CONTACT_177941]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee occurs, or at any time consultation is requested by [CONTACT_177941]. 
DMC will review the safety and tolerability data of all subjects in the flavivirus naÃ¯ve cohort who have 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will review the safety and tolerability data of all subjects in the flavivirus naÃ¯ve cohort who have 
days post dose 1) for the p
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose 1) for the p
DMC will review 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will review safety data on an ongoing basis and when the following set of AEs are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesafety data on an ongoing basis and when the following set of AEs are 
DMC will review all relevant safety data within 48 hours and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will review all relevant safety data within 48 hours and
Two or more subjects develop the same grade 3 solicited AE starting within 7 days of vaccination
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTwo or more subjects develop the same grade 3 solicited AE starting within 7 days of vaccination
Two or more subjects develop the same grade 3 unsolicited AE within 28 days of vaccination
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTwo or more subjects develop the same grade 3 unsolicited AE within 28 days of vaccination
SAE 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAE 
Any unexpected, serious, or unanticipated risk to the subjects enrolled.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny unexpected, serious, or unanticipated risk to the subjects enrolled.
Further information is available in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFurther information is available in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 25of 108
Protocol Amendment 3 Version 7.0 12September 2018
CONFIDENTIAL2.1 Schedule of Trial Procedures
Visit Number 1A 1B(a)2 3 4 5 6 7 8 9(u)10(u)11(u)In case of 
early 
termination
Visit DayDay -[ADDRESS_208969] and 
second phase 
of the study (b)Flavivirus naÃ¯ve(1)X X X X X X X X X X X X
Flavivirus primed(2)X X X X X X X X X X X X X
Second phase 
of the study (b)Flavivirus primed(3)X X X X X X X X X X X X
Anchored to visit day NADay 1
+
7daysDay 1
+
28daysDay 29
+
7daysDay 29
+
28daysDay 29
+
3Â½moDay 29
+
6moDay 29
+
12moDay 29
+
18moDay 29
+
24mo
Acceptable visit window (days before/ 
days after)(c) NA NA 0/+7 -1/+7 -4/+7 -1/+7 -4/+7 -7/+14 -7/+14 -7/+ 97 -7/+14 -14/+14
Signed informed consent X X(t)
Remind study procedure to flavivirus 
primed subjects identified at Visit 1A(2) X
Assessment of eligibility criteria (d)X X X
Demographics (e)X X(t)
Medical history(f)X X X
Travel history X X X X X X X X X X X X
Concomitant medications/vaccinations(g)X X X X X X X X X X
Physical exam 
(h)Complete X X
Symptom directed (X) (X) (X) (X) (X) (X) (X) (X)
Vital signs (i)X X X X X X X X X X
0026Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use133
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use133 Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDay
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use28days
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsedaysDay
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDay 29
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use29
+
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use+
7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1/+7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1/+7 -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-4/+7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4/+7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(t)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 26of 108
Protocol Amendment 3 Version 7.0 12September 2018
CONFIDENTIALVisit Number 1A 1B(a)2 3 4 5 6 7 8 9(u)10(u)11(u)In case of 
early 
termination
Visit DayDay -15 
to Day 1Day -15 
to Day 1Day 1Day 8Day 29Day 36Day 57Day 133 Day 211 Day 393 Day 575 Day 757
Blood 
collection (j)Flavivirus serostatus X X(t)
Eligibility screening and 
safety laboratory testingX X X X
Serum pregnancy testing
(l) X X
Immun ogenicity and 
assay developmentX X X X X X
Urine collection 
(k)Eligibility screening and 
safety laboratory testing (urinalysis)X X X X
Urine p regnancy test ing
(l) X X
Randomization (m)X
Check contraindications to vaccination 
and criteria for delay of vaccinationX X
Investigational vaccine or placebo 
administration(n) X X
Post-vaccination and injection site 
evaluation (o) X X
Diary card (p)DistributionDays
1-7Days
8-28Days
29-35Days
36-56
Review/collectionDays
1-7Days
8-28Days
29-35Days
36-56X(q)
Solicited AEs (r)X X
Unsolicited AEs (r)X X X X X
SAEs and AEs leading to withdrawal or 
discontinuation (s) X X X X X X X X X X X
(X) indicates procedures that are not mandatory but may be performed if deemed necessary; NA: Not applicable.
(a) Applicable only for flavivirus primed subjects
0027Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9(u
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(u)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDay
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDay 211
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use211
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseX
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAEs and AEs leading to withdrawal or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAEs and AEs leading to withdrawal or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(X) indicates procedures that are not mandatory but may be performed
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(X) indicates procedures that are not mandatory but may be performed
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseApplicable only for flavivirus primed subjects
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseApplicable only for flavivirus primed subjects
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 27of 108
Protocol Amendment 3 Version 7.0 12September 2018
CONFIDENTIAL(b)Staggered enrollment: There will be two study phases
ï‚·The first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only (1).
All subjects who sign the ICF and have confirmed eligibility at Screening Visit 1A will be tested for flavivirus serostatus.
Eligible flavivirus naÃ¯ve subjects enrolled at Screening Visit 1A(1)will be randomized at Visit 2, within two weeks after Screening Visit 1A.
Flavivirus primed subjects will not be enrolled during the first phase of the study (ie, when identified at Screening Visit 1A(2)) and will be invited to come 
back for the second phase of the study. They will be contact[CONTACT_177942]Ã¯ve subjects, when the last flavivirus naÃ¯ve subject has completed study Visit 4 ([ADDRESS_208970] dose 1). These 
flavivirus primed subjects will consequently undergo 2 screening visits: Visit 1A during the first phase of the study, and Visit 1B at the outset of the second 
phase of the study. Flavivirus primed subjects identified at Screening Visit 1A who do not participate in the second phase of the study will be declared screened failure.Enrollment will be put on hold after all naÃ¯ve subjects
(1)have been enrolled and will resume when positive recommendations from the external DMC are 
issued, as described above.
ï‚·The second phase of the study will be aimed at enrolling flavivirus primed subjects only(2 and 3).
Newly identified eligible flavivirus primed subjects at Screening Visit 1B(3)will be enrolled (randomized) at (second phase) Visit 2, within two weeks after 
Screening Visit 1B.
Previously identified flavivirus primed subjects(2)(who were tested at Screening Visit 1A during the first phase and accepted to enter the second phase of the 
study) will retain their initial subject identification (ID) number and undergo an additional screening visit (Visit 1B) to be tested for eligibility criteria again 
(except for the determination of flavivirus serostatus). Flavivirus naÃ¯ve subjects identified at Screening Visit 1B (during the second phase of the study) will be declared screened failure.
(c) If the subject has a temporary clinically significant active infection (as assessed by [CONTACT_093]) or temperature â‰¥38.0Â°C/100.4Â°F, within 3 days of intended 
investigational vaccine/placebo administration, the investigational vaccine/placebo administration may be delayed as per the assessment of the investigator within t he allowed visit window. The visit windows of Visit [ADDRESS_208971] vaccination. Following the same rule, 
the visit windows of Visit 5 and Visit 6 should be calculated from the day of the second vaccination.
(d)One single subject identification (ID) number will be assigned to each subject at Screening Visit (1A or 1B). Eligibility by [CONTACT_177943]/exclusion criteria will be documented before enrollment.
(e) Demographic information, to be obtained at Screening Visit (1A or 1B), will include age (date of birth), sex, race, and ethnicity as provided by [CONTACT_423].(f)Medical history will be collected at Screening Visit(s) (Visit 1A and/or Visit 1B) and at Visit 2 (Day 1) and will include any medical history that may be relevant to subject eligibility for trial participation such as prior vaccinations, concomitant medications, and previous and ongoing illnesses or injuries. 
Relevant medical history can also include any medical history that contributes to the understanding of an AE that occurs during trial participation, if it 
represents an exacerbation of an underlying disease/preexisting problem. Adverse occurrences before administration of the first dose of investigational 
vaccine/placebo are considered medical history.
(g)All medications, vaccines and blood products taken or received by [CONTACT_177944] 3 months prior to the start of the trial are to be recorded on the source 
document (patient record) and entered on the Prior and Concomitant Medications eCRF. The use of antipyretics and/or analgesic medications within [ADDRESS_208972] be identified and the reason for their use (prophylaxis versus treatment) must be described in the source documents and the eCRF. Refer to Section 9.1.2 .
0028Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening Visit 1A will be tested for flavivirus serostatus.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening Visit 1A will be tested for flavivirus serostatus.
will be randomized at Visit 2, within two
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be randomized at Visit 2, within two weeks after Screening Visit 1A.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks after Screening Visit 1A.
ing the first phase of the study (ie, when identified at Screening Visit 1A
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing the first phase of the study (ie, when identified at Screening Visit 1A
back for the second phase of the study. They will be contact[CONTACT_177921]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useback for the second phase of the study. They will be contact[CONTACT_177945]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexternal
safety and tolerability data in flavivirus naÃ¯ve subjects, when the last flavivirus naÃ¯ve subject has completed study Visit 4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesafety and tolerability data in flavivirus naÃ¯ve subjects, when the last flavivirus naÃ¯ve subject has completed study Visit 4
flavivirus primed subjects will consequently undergo 2 screening visits: Visit 1A during the firs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflavivirus primed subjects will consequently undergo 2 screening visits: Visit 1A during the firs t phase of the study, and Visit 1B at the outset of the second 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset phase of the study, and Visit 1B at the outset of the second 
phase of the study. Flavivirus primed subjects identified at Screening Visit 1A who do not participate in the second phase of
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephase of the study. Flavivirus primed subjects identified at Screening Visit 1A who do not participate in the second phase of
have been enrolled and will resume when positive recommendations from the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehave been enrolled and will resume when positive recommendations from the 
The second phase of the study will be aimed at enrolling flavivirus primed subjects only
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe second phase of the study will be aimed at enrolling flavivirus primed subjects only(2 and 3)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(2 and 3)
will be enrolled (randomized) at (second phase) Visit 2, within two
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be enrolled (randomized) at (second phase) Visit 2, within two
(who were tested at Scr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(who were tested at Scr eening Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeening Visit
undergo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useundergo an additional
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usean additional
1B (during the second phase of the study) will be declared screened failure.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1B (during the second phase of the study) will be declared screened failure.
If the subject has a temporary clinically significant active infection 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the subject has a temporary clinically significant active infection (as assessed by [CONTACT_093]) or temperature â‰¥38.0Â°C/100.4Â°F, within 3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(as assessed by [CONTACT_093]) or temperature â‰¥38.0Â°C/100.4Â°F, within 3
investigational vaccine/placebo administration, the investigational vaccine/placebo administration may be delayed as per the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine/placebo administration, the investigational vaccine/placebo administration may be delayed as per the 
he allowed visit window. The visit windows of Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe allowed visit window. The visit windows of Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3 and Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3 and Visit
be calculated from the day of the second vaccination.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe calculated from the day of the second vaccination.
single subject identification (ID) number will be assigned to each subject at Screening Visit (1A or 1B). Eligibility by [CONTACT_177946]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesingle subject identification (ID) number will be assigned to each subject at Screening Visit (1A or 1B). Eligibility by [CONTACT_177947]/exclusion criteria will be documented before enrollment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinclusion/exclusion criteria will be documented before enrollment.
Demographic information, to be obtained at Scree
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDemographic information, to be obtained at Scree ning Visit (1A or 1B), will include age (date of birth), sex, race, and ethnicity as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usening Visit (1A or 1B), will include age (date of birth), sex, race, and ethnicity as 
Medical history will be collected at Screening Visit(s) (Visit 1A and/or Visit 1B) and at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical history will be collected at Screening Visit(s) (Visit 1A and/or Visit 1B) and at Visit
relevant to subject eligibility for trial participation such as prior vaccinations, concomitant medications, and previous and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelevant to subject eligibility for trial participation such as prior vaccinations, concomitant medications, and previous and
Relevant medical history can also include any medical history that contributes to the unde
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelevant medical history can also include any medical history that contributes to the unde
represents an exacerbation of an underlying disease/preexisting problem. Adverse occurrences before administration of the fir
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userepresents an exacerbation of an underlying disease/preexisting problem. Adverse occurrences before administration of the fir
vaccine/placebo are considered medical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo are considered medical 
All medications, vaccines and blood products taken or received by [CONTACT_177944] 3 months prior to the start of the tria
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll medications, vaccines and blood products taken or received by [CONTACT_177944] 3 months prior to the start of the tria
document (patient record) and entered on the Prior and Concomitant Medications eCRF. Th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocument (patient record) and entered on the Prior and Concomitant Medications eCRF. Th
prior to vaccination must be identified and the reason for their use (prophylaxis versus treatment) must be described in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprior to vaccination must be identified and the reason for their use (prophylaxis versus treatment) must be described in the 
9.1.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.2 .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
Purified Inactivated Zika Virus Vaccine (PI[INVESTIGATOR_177760])
Trial No. ZIK -101 Page 28of 108
Protocol Amendment 3 Version 7.0 12September 2018
CONFIDENTIAL(h)Complete physical examination will be performed at Screening Visit(s) (Visit 1A and/or Visit 1B). All subsequent symptom-directed physical examinations, 
performed if deemed necessary or indicated by [CONTACT_98272]â€™s medical history, should assess clinically significant changes from the baseline 
examination. The findings should be documented in the subjectâ€™s source document; findings consistent with the definition of AEs or SAEs (see Section 10.0) 
must be transcribed into the electronic Case Report Form (eCRF). For any procedures at the site, the investigator shall follow his/her standard practice. Refer to 
Section 9.1.4 .
(i) Vital signs include (however, not limited to) systolic/diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature, and should be documented in the 
subjectâ€™s source document and transcribed into the eCRF. Follow standard of care for trial population and operational feasibility. Refer to Section 9.1.5 .
(j)Blood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 1B) for flavivirus serostatus determination (approximately 10mL of blood) and eligibility screening tests (including pregnancy testing) (approximately 10 mL of blo od), at Visits 3 and 5 for routine safety laboratory 
testing (approximately 10 mL of blood) , and at Visits 2, 4, 6, 8, and ( for subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177812] ) 9 and 11 for immunogenicity, as well as for further development and characterization of assays (approximately 60 mL 
of blood) . Should a blood sampling be performed during a vaccination visit, this sampling must occur before the administration of the investigational vaccine or 
placebo. The maximum volume of blood taken at any single visit will be between approximately [ADDRESS_208973]â€™s flavivirus serostatus at screening and the vaccine dose level the 
subject received. All samples will be collected in accordance with acceptable laboratory procedures. Blood samples will be processed and stored at the trial site as described in the provided Laboratory Manual. Refer to Section 9.1.6 .
(k)Urine samples will be collected for all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) and at Visits 3 and 5; and for women of childbearing potential 
at Visits 2 and 4 before each investigational vaccine/placebo administration for pregnancy testing. Urine samples for eligibility screening and routine safety 
laboratory testing will be sent to the central laboratory. Urine pregnancy tests will be performed at the study site using kits provided by [CONTACT_456].
(l) Serum pregnancy tests will be conducted in the central laboratory and urine pregnancy tests will be done at the study site using kits provided by [CONTACT_456] .
Subjects must have a negative urine ï¢-hCG pregnancy test prior to receiving any dose of investigational vaccine/placebo. Refer to Section 9.1.9 .
(m)If eligible, the subject will be randomized at Visit 2. Refer to Sections 9.1.3 and 9.1.10 .
(n)The investigational vaccine/placebo will be administered in the deltoid muscle of the non-dominant arm (approximately at the top middle third).
(o) After vaccine/placebo administration at Visit 2 (on Day 1) and at Visit 4 (Day 29), the subject will be observed for at least 30 minutes for observation of 
solicited AEs, unsolicited AEs, and measurement of body temperature.
(p)Diary cards will be handed out to the subjects at Visits 2, 3, [ADDRESS_208974] and collected at the following visit. Refer to Section 9.3.4 .
(q)In case of early termination during the vaccination period only.
(r)After each dose, solicited AEs (for 7 days including the day of vaccine/placebo administration) and unsolicited AEs (for 28 days including the day of 
vaccine/placebo administration) will be collected on diary cards by [CONTACT_6992]. The investigator will transcribe these data into eCRF. Refer to Section 9.1.7 . 
(s)SAEs and AEs leading to withdrawal from the trial or discontinuation of vaccine/placebo administration will be collected for the duration of the entire trial. 
SAEs will be reported to the sponsor within 24 hours of the investigator becoming aware of the event. AEs leading to early termination will be recorded by [CONTACT_1275].
(t) Only for newly screened subjects at Screening Visit 1B (ie, not for flavivirus primed subjects who were tested at Screening Visit 1A and accepted to enter the 
second phase of the study).
(u)All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177788] 9 at Day 393 
(12months post dose 2) and Visit 11 at Day 757 ([ADDRESS_208975] dose 2), and will also be contact[CONTACT_177923] 575 (Visit 10) for safety follow- up.
0029Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseComplete physical examination will be performed at Screening Visit(s) (Visit 1A and/or Visit 1B). All subsequent symptom
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseComplete physical examination will be performed at Screening Visit(s) (Visit 1A and/or Visit 1B). All subsequent symptom -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-directed physical examinations, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedirected physical examinations, 
formed if deemed necessary or indicated by [CONTACT_98272]â€™s medical history, should assess clinically significant chan
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useformed if deemed necessary or indicated by [CONTACT_98272]â€™s medical history, should assess clinically significant chan
definition of AEs or SAEs (see Section 10.0) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedefinition of AEs or SAEs (see Section 10.0) 
transcribed into the electronic Case Report Form (eCRF). For any procedures at the site, the investigator shall follow his/he
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetranscribed into the electronic Case Report Form (eCRF). For any procedures at the site, the investigator shall follow his/he
systolic/diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature, and should be documented in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesystolic/diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature, and should be documented in the 
document and transcribed into the eCRF. Follow standard of care for trial population and operationa
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocument and transcribed into the eCRF. Follow standard of care for trial population and operationa
ples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 1B) for flavivirus serostatus det
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 1B) for flavivirus serostatus det
mL of blo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL of blo
for subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177795]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177813] 11 for immunogenicity, as well as for further development and characterization of assays
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usend [ADDRESS_208976] occur before the administration of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Should a blood sampling be performed during a vaccination visit, this sampling must occur before the administration of the 
placebo. The maximum volume of blood taken at any single visit will be between approximately 1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplacebo. The maximum volume of blood taken at any single visit will be between approximately [ADDRESS_208977]â€™s flaviv
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL depending on the subjectâ€™s flaviv
subject received. All samples will be collected in accordance with acceptable laboratory procedures. Blood samples will be pr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject received. All samples will be collected in accordance with acceptable laboratory procedures. Blood samples will be pr
Urine samples will be collected for all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) and at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUrine samples will be collected for all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) and at Visit
vaccine/placebo administration for pregnancy testing. Urine samples for eligibility screening and routine safety 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo administration for pregnancy testing. Urine samples for eligibility screening and routine safety 
laboratory. Urine pregnancy tests will be performed at the study site using kits provided by [CONTACT_456].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory. Urine pregnancy tests will be performed at the study site using kits provided by [CONTACT_456].
Serum pregnancy tests will be conducted in the central laboratory and u
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSerum pregnancy tests will be conducted in the central laboratory and u
hCG pregnancy test prior to receiving any dose of investigational vaccine/placebo. Refer to Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsehCG pregnancy test prior to receiving any dose of investigational vaccine/placebo. Refer to Section 
If eligible, the subject will be randomized at Visit 2. Refer to Sections 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf eligible, the subject will be randomized at Visit 2. Refer to Sections 
The investigational vaccine/placebo will be administered in the deltoid muscle of the non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigational vaccine/placebo will be administered in the deltoid muscle of the non
2 (on Day 1) and at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 (on Day 1) and at Visit
solicited AEs, unsolicited AEs, and measurement of body temperature.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesolicited AEs, unsolicited AEs, and measurement of body temperature.
Diary cards will be handed out to the subjects at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDiary cards will be handed out to the subjects at Visits 2, 3, [ADDRESS_208978] and collected at the fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVisits 2, 3, [ADDRESS_208979] and collected at the fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring the vaccination period
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring the vaccination period
After each dose, solicited AEs (for 7 days including the day of vaccine/placebo administration) and unsolicited AEs (for 28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAfter each dose, solicited AEs (for 7 days including the day of vaccine/placebo administration) and unsolicited AEs (for 28
vaccine/placebo administration) will be collected on diary cards by [CONTACT_177948]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo administration) will be collected on diary cards by [CONTACT_177949]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAEs and AEs leading to withdrawal from the trial or di
SAEs will be reported to the sponsor within 24 hours of the investigator becoming aware of the event. AEs leading to early te
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAEs will be reported to the sponsor within 24 hours of the investigator becoming aware of the event. AEs leading to early te
Only for newly screened subjects at Screening Visit 1B (ie, not for flavivirus primed subjects who were tested at Screening V
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOnly for newly screened subjects at Screening Visit 1B (ie, not for flavivirus primed subjects who were tested at Screening V
second phase of the study).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesecond phase of the study).
All subjects who were randomized to the placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll subjects who were randomized to the placebo 
months post dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post dose 2) and Visit 11 at Day 757 ([ADDRESS_208980] dose 2), and will also be contact[CONTACT_177950]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2) and Visit 11 at Day 757 ([ADDRESS_208981] dose 2), and will also be contact[CONTACT_177951] (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 29of 108
Protocol Amendment 3 Version 7.0 12September 2018
3.0 TRIAL REFERENCE INFORMATION
3.1 Trial -Related Responsibilities
The sponsor will perform all trial -related activities with the exception of those identified in the 
Trial -Related Responsibilities template. The identified vendors in the template for specific 
trial-related activities will perform these activities in full or in partnership with the sponsor.
3.2 Principal Investigator/Coordinating Investigator
[INVESTIGATOR_177814] a Signatory Principal Investigator / Coordinating Investigator [INVESTIGATOR_177815]. Selection criteria for this investigator will include 
significant knowledge of the trial protocol, the investigational vaccine, their expertise in the 
therapeutic area and the conduct of clinical research ,as well as trial participation. The Signatory 
Principal Inv estigator / Coordinating Investigator [INVESTIGATOR_177816].
0030Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated activities with the exception of those identified in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated activities with the exception of those identified in the 
Related Responsibilities template. The identified vendors in the template for specific 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelated Responsibilities template. The identified vendors in the template for specific 
with the sponsor.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith the sponsor.
The sponsor will select a Signatory Principal Investigator / Coordinating Investigator [INVESTIGATOR_177817]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsor will select a Signatory Principal Investigator / Coordinating Investigator [INVESTIGATOR_177818]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecriteria for this investigator will include 
significant knowledge of the trial protocol, the investigational vaccine, their expertise in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesignificant knowledge of the trial protocol, the investigational vaccine, their expertise in the 
as well as trial participation. The Signatory 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas well as trial participation. The Signatory 
estigator / Coordinating Investigator [INVESTIGATOR_177819]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useestigator / Coordinating Investigator [INVESTIGATOR_177816].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy report and by [CONTACT_177952].
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208982]
GBS Guillain -BarrÃ© syndrome
GCP Good Clinical Practice
GMT Geometric Mean Titer
ï¢-hCG beta human Chorionic Gonadotropin
HIV Human Immunodeficiency Virus
IB Investigatorâ€™s Brochure
ICF Informed Consent Form 
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
ID Identification
IEC Independent Ethics Committee
Ig Immunoglobulin
IM Intramuscular
IRB Institutional Review Board
IRT Interactive Response Technology
JE Japanese Encephalitis
LOD Limit of Detection
MAC -ELISA IgM-Antibody Capture Enzyme -Linked Immunosorbent assay
0031Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselinked Immunosorbent Assay
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselinked Immunosorbent Assay
Food and Drug Administration
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFood and Drug Administration
Focus Reduction Neutralizing Test
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFocus Reduction Neutralizing Test
BarrÃ© syndrome
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBarrÃ© syndrome
Practice
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePractice
Geometric Mean Titer
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGeometric Mean Titer
beta human Chorionic Gonadotropin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebeta human Chorionic Gonadotropin
Human Immunodeficiency Virus
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHuman Immunodeficiency Virus
Investigatorâ€™s Brochure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigatorâ€™s Brochure
Informed Consent Form 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInformed Consent Form 
International Council for Harmonisation of Technical Requirements for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational Council for Harmonisation of Technical Requirements for 
Pharmaceuticals
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePharmaceuticals
IM
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIM
IRB
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRB
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 31of 108
Protocol Amendment 3 Version 7.0 12September 2018
MedDRA Medical Dictionary for Regulatory Activities
MN Micro -neutralization
NHP Non-Human Primate
PBS Phosphate Buffered Saline solution, ie, water -based salt solution containing 
potassium dihydrogen phosphate (KH 2PO 4), sodium hydrogen phosphate 
(Na 2HPO 4), and sodium chloride
PHEIC Public Health Emergency of International Concern
PI[INVESTIGATOR_177820]-Protocol Analysis Set
PRNT Plaque Reduction Neutralization Test
PT Preferred Term
RT-PCR Reverse Transcription -Polymerase Chain Reaction
RVP Reporter Virus Particle
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SCR Seroconversion Rate
SOC System Organ Class
SPR Seropositivity Rate
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
WHO World Health Organization
WNV West Nile Virus
WRAIR Walter Reed Army Institute of Research
YF Yellow Fever 
ZIKV Zika Virus
0032Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased salt solution containing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased salt solution containing 
), sodium hydrogen phosphate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use), sodium hydrogen phosphate 
Polymerase Chain Reaction
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePolymerase Chain Reaction
Unexpected Serious Adverse Reaction
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnexpected Serious Adverse Reaction
World Health Organization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWorld Health Organization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWest Nile Virus
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWest Nile Virus
Walter Reed Army Institute of Research
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWalter Reed Army Institute of Research
Yellow Fever 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseYellow Fever 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika Virus
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika Virus
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 32of 108
Protocol Amendment 3 Version 7.0 12September 2018
3.4 Corporate Identification
Not applicable.
0033Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 33of 108
Protocol Amendment 3 Version 7.0 12September 2018
4.0 INTRODUCTION
4.1 Background
4.1.1 Zika Virus
Zika virus (ZIKV) is a mosquito -borne single -stranded positive -sense ribonucleic acid (RNA) 
virus (11 kb in size) (26)which belongs to the Flaviviridae family, genus Flavivirus , that often 
causes no or only mild symptoms, including a rash and a febrile flu -like illness in the majority of 
symptomatic individuals. The ZIKV virion shows icosahedral symmetry of its nucleocapsid (27)
and presents structural similarities with other members of the Flaviviridae , including Spondweni 
virus, Yellow Fever (YF) virus, Dengue virus (DENV), West Nile virus (WNV), Japanese 
Encep halitis (JE) virus, and Tick -borne Encephalitis virus. The genome is translated into a single 
polyprotein subsequently cleaved by [CONTACT_177953] (capsid, 
pre-membrane/membrane and envelope) proteins that form the vir ion and seven non -structural 
proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5) (28).
ZIKV was discovered in [ADDRESS_208983] human disease cases were reported in 1952 in Uganda (29)and Tanzania (30). For as long as 
55years, the virus circulated in areas of Africa, Southeast Asia, and the Pacific Islands, and was 
considered a rare disease with mild symptoms (31); only 14 human cases were reported and no 
outbreaks were detected during that period (32).
4.1.[ADDRESS_208984] large outbreak of ZIKV disease was reported in Yap Island (Federal state of Micronesia) 
in 2007 (33), and was followed by [CONTACT_177912] 2013 -2014 (34). The first 
cases of ZIKV disease in South America were reported in Easter Island in 2014 (35), and the first 
reports of locally transmitted infection (ie, by [CONTACT_930]) came from Brazil in May 2015 (36), 
which triggered the third outbreak in2015 -2016. Since then, ZIKV disease has continued 
spreading through the South American continent and to other regions. In the current outbreak that 
started in 2015, there have been estimates of more than 750,000 ZIKV -suspected cases reported 
from more than 60 countries/territories; most of these cases are from the South America continent 
(37, 38).
4.1.[ADDRESS_208985] spread globally (39). Other potential vectors 
for ZIKV include other Aedes species (including Ae.furcifer ,Ae.vittatus ,Ae.dalzieli ,
Ae.metallicus ,Ae.hirsutus ,Ae.unilinaetus ,Ae.africanus ,Ae.taylori ,Ae.hensilli , and 
Ae.luteocephalus ) along with mosquitoes from other genera (such as Anopheles , Mansonia , and 
Culex ) (40), the true extent of the vectors being still unknown. Nonhuman and human primates are 
likely the main reservoirs of the ZIKV as for most arthropod -borne viruses (arboviruses) (41), and 
0034Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesense ribonucleic acid (RNA) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesense ribonucleic acid (RNA) 
Flavivirus
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus , that often 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, that often 
like illness in the majority of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselike illness in the majority of 
The ZIKV virion shows icosahedral symmetry of its nucleocapsid 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe ZIKV virion shows icosahedral symmetry of its nucleocapsid 
, including Spondweni 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, including Spondweni 
virus, Yellow Fever (YF) virus, Dengue virus (DENV), West Nile virus (WNV), Japanese 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevirus, Yellow Fever (YF) virus, Dengue virus (DENV), West Nile virus (WNV), Japanese 
borne Encephalitis virus. The genome is translated into a single 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useborne Encephalitis virus. The genome is translated into a single 
polyprotein subsequently cleaved by [CONTACT_177953] (capsid, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepolyprotein subsequently cleaved by [CONTACT_177953] (capsid, 
membrane/membrane and envelope) proteins that form the vir
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemembrane/membrane and envelope) proteins that form the vir ion and seven non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion and seven non
)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
while testing samples taken from sentinel rhesus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhile testing samples taken from sentinel rhesus 
as bait during a surveillance of YF in the Zika Forest near Entebbe in Uganda. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas bait during a surveillance of YF in the Zika Forest near Entebbe in Uganda. The 
first human disease cases were reported in 1952 in Uganda 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefirst human disease cases were reported in [ADDRESS_208986] Asia, and the Pacific Islands, and was 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears, the virus circulated in areas of Africa, Southeast Asia, and the Pacific Islands, and was 
considered a rare disease with mild symptoms 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsidered a rare disease with mild symptoms (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use31
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use31)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use); only 14 human
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use; only 14 human
outbreaks were detected during that period 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoutbreaks were detected during that period (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(32
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use32)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
The first large outbreak of ZIKV disease was reported in Yap Island (Federal state of Micronesia) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe first large outbreak of ZIKV disease was reported in Yap Island (Federal state of Micronesia) 
, and was followed by [CONTACT_177912] 2013
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and was followed by [CONTACT_177912] 2013
ses of ZIKV disease in South America were reported in Easter Island in 2014 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useses of ZIKV disease in South America were reported in Easter Island in 2014 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereports of locally transmitted infection (ie, by [CONTACT_930]) came from Brazil in May
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereports of locally transmitted infection (ie, by [CONTACT_930]) came from Brazil in May
which triggered the third outbreak 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhich triggered the third outbreak 
spreading through the South American continent and to other regions. In the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespreading through the South American continent and to other regions. In the
started in 2015, there have been estimates of more than 750,000
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestarted in 2015, there have been estimates of more than 750,000
from more than 60
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefrom more than 60 countries/territories; most of these cases are from the South America continent 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecountries/territories; most of these cases are from the South America continent 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.1.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.1.3 Transmission
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTransmission
The primary mode of transmission of ZIKV is through the bite of female mosquitoes, prominently 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe primary mode of transmission of ZIKV is through the bite of female mosquitoes, prominently 
Aedes
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAedes
for ZIKV include other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor ZIKV include other 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 34of 108
Protocol Amendment 3 Version 7.0 12September 2018
anthroponotic (human -to-vector -to-human) transmission is most likely responsible for the rapid 
spreading of the virus during outbreaks.
Vertical transmission from mother to fetus during pregnancy (6, 42-44)and the perinatal period 
(45, 46), sexual contact (47-49), and blood transfusion (50, 51)are also confirmed modes of 
transmission of the disease. Potentially, the virus could be transmitted through laboratory exposure 
and by [CONTACT_177913] (52, 53),eg, tears, urine (54-56), breast milk ,or through solid organ 
transplants (57, 58), but there is limited evidence to support this (59-61).
4.1.4 ZIKV Infection: Detection, Disease, Complications and Treatment
Detection
Testing for ZIKV infection is complicated by [CONTACT_177954] a definitive laboratory diagnosis of ZIKV infection. Viral RNA is the first analyte that 
can be de tected in an infected person in multiple specimen types. In blood, as the immune response 
develops (immunoglobulin M [IgM] titers rise), levels of viral RNA decline. However, viral RNA 
may be detectable in some infected persons for longer periods in certai n specimen types (62, 63).
Whole blood, serum and urine are the primary diagnostic specimens for ZIKV infection. Other 
specimen types such as plasma, cerebrospi[INVESTIGATOR_872], and amniotic fluid are authorized for use with 
some tests that have received a Food and Drug Administration (FDA ) Emergency Use 
Authorization (64). Other specimens that still need validation but might be appropriate for 
evaluating ZIKV disease include saliva (65, 66), semen, peripheral blood mononuclear cells, 
amniotic fluid (43), and t issue samples of, for instance , fetal brain and placenta biopsies (6, 42, 
67).
Testing methods used for ZIKV infection include molecular and serologic testing: reverse 
transcript ion-polymerase chain reaction (RT -PCR) for viral nucleic acid, and IgM -antibody 
capture enzyme -linked immunosorbent assay (MAC -ELISA), as well as focus reduction 
neutralizing test (FRNT), plaque reduction neutralization test (PRNT), micro -neutralization (M N) 
assay, and reporter virus particle (RVP) assay for anti -ZIKV antibodies. Although PRNT typi[INVESTIGATOR_177821], serological assays are subject to cross -reactivity, especially in subjects 
with prior flavivirus infection or immunization histor y. In contrast, diagnosis by [CONTACT_937] -PCR has been 
most successful within 1 week after the onset of clinical illness, though viremia is generally low 
level, which makes viral isolation from clinical samples difficult (68). Data from studies in 
non-human primates (NHP) evaluated for neutralizing antibodies by [CONTACT_177955], MN 
assay and RVP assay suggest that although both FRNT and MN assay strongly correlated with 
EC 50RVP values, RVP assay was more sensitive (69).
Disease
More than 80% of ZIKV infections remain asymptomatic (33), and for the symptomatic cases, the 
disease is in general mild and of short duratio n. Some clinical manifestations include, but are not 
limited to, mild fever, maculopapular rash, conjunctivitis and arthralgia (70).
0035Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand the perinatal period 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand the perinatal period 
are also confirmed modes of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useare also confirmed modes of 
transmission of the disease. Potentially, the virus could be transmitted through laboratory exposure 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmission of the disease. Potentially, the virus could be transmitted through laboratory exposure 
or through solid organ 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor through solid organ 
ZIKV Infection: Detection, Disease, Complications and Treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV Infection: Detection, Disease, Complications and Treatment
the temporal appearance and disappearance of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe temporal appearance and disappearance of 
biologic analytes in the infected person and thus multiple tests and sample types are often needed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebiologic analytes in the infected person and thus multiple tests and sample types are often needed 
to establish a definitive laboratory diagnosis of ZIKV infection. Viral RNA is the first analyte that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto establish a definitive laboratory diagnosis of ZIKV infection. Viral RNA is the first analyte that 
tected in an infected person in multiple specimen types. In blood, as the immune response 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetected in an infected person in multiple specimen types. In blood, as the immune response 
develops (immunoglobulin M [IgM] titers rise), levels of viral RNA decline. However, viral RNA 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelops (immunoglobulin M [IgM] titers rise), levels of viral RNA decline. However, viral RNA 
may be detectable in some infected persons for longer periods in certai
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemay be detectable in some infected persons for longer periods in certai
Whole blood, serum and urine are the primary diagnostic specimens for ZIKV infection. Other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWhole blood, serum and urine are the primary diagnostic specimens for ZIKV infection. Other 
specimen types such as plasma, cerebrospi[INVESTIGATOR_872], and amniotic fluid are authorized for use with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespecimen types such as plasma, cerebrospi[INVESTIGATOR_872], and amniotic fluid are authorized for use with 
some tests that have received a Food and Drug Administration (FDA
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesome tests that have received a Food and Drug Administration (FDA
. Other specimens that still need validation but might be appropriate for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Other specimens that still need validation but might be appropriate for 
(
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(65
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use65, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, 66
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use66
issue samples of, for instance
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useissue samples of, for instance
Testing methods used for ZIKV infection include molecular and serologic testing: reverse 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTesting methods used for ZIKV infection include molecular and serologic testing: reverse 
polymerase chain reaction (RT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepolymerase chain reaction (RT
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselinked immunosorbent assay (MAC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselinked immunosorbent assay (MAC
neutralizing test (FRNT), plaque reduction neutralization test (PRNT), micro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useneutralizing test (FRNT), plaque reduction neutralization test (PRNT), micro
assay, and reporter virus particle (RVP) assay for anti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassay, and reporter virus particle (RVP) assay for anti
provides good specificity, serological assays are subject to cross
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprovides good specificity, serological assays are subject to cross
with prior flavivirus infection or immunization histor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith prior flavivirus infection or immunization histor
most successful within 1 week after the onset of clinical illness, though viremia is generally low 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemost successful within 1 week after the onset of clinical illness, though viremia is generally low 
level, which makes viral isolation from clinical samples difficult 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselevel, which makes viral isolation from clinical samples difficult 
human primates (NHP) evaluated for neutralizing antibodies by [CONTACT_177955], MN 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehuman primates (NHP) evaluated for neutralizing antibodies by [CONTACT_177955], MN 
assay and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassay and 
EC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEC 50
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use50
Disease
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDisease
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 35of 108
Protocol Amendment 3 Version 7.0 12September 2018
The incubation period between infecti on andsymptoms appears to be of 3 to 11 days (3, 4), which 
is similar to that of other mosquito -borne flaviviru s diseases. The course of infection is mostly 
self-limiting. However, pre -existing cross -reactive antibodies directed against other ï¬‚aviviruses 
may exacerbate secondary ZIKV infection through antibody -dependent enhancement (ADE). A 
recent publication has d emonstrated that human dengue virus antibodies enhance in vitro infection 
with ZIKV, suggesting that ADE is not merely a theoretical concern (71). 
Congenital Zika Syndrome
Despi[INVESTIGATOR_177762], ZIKV infection during pregnancy has 
been associated with serious outcomes for the fetus and newborn. The severity of the disease is 
related to the consequences in the fetus and newborn child from women with ZIKV infection 
during pregnancy (42, 72). The spectrum of congenital anomalies associated with ZIKV infection, 
known as Congenital Zika Syndrome (CZS) , consists of severe microcephaly (5-8)with partially 
collapsed skull, cerebral cortices with subcortical calcifications, macular scarring and focal 
pi[INVESTIGATOR_177763], congenital contractures, and marked early hypertonia with symptoms 
of extrapyramidal involvement (9).
The exposure to ZIKV at any moment during pregnancy is a risk for fetal or postnatal 
developmental complications , primarily affecting brain developme nt. Recent analysis of the U.S. 
Zika Pregnancy Registry (USZPR) showed that the prevalence of newborn swith congenital 
defects from pregnancies with laboratory -confirmed ZIKV infection is 10% (95% CI: 7% -14%). 
This is 30 times higher than baseline prevalen ce before more recent Zika outbreaks (10).
Since the beginning of these outbreaks and up to end of September 2017, there have been 
3689confirmed C ZSmalformations potentially associated with ZIKV infection in 27 countries 
and territories of Latin America and the Caribbean .
Guillain -BarrÃ© Syndrome
ZIKV is a neurotropic flavivirus that can potentially cause disease within the central nervous 
system. Worldwide concern over ZIKV causing Guillain -BarrÃ© Syndrome ( GBS )emerged when 
an increased number of GBS cases was temporally associated with the [ADDRESS_208987] ZIKV, compared to 56% in the control group (p<0.0001 )(11-13). Other 
neurological complications, such as encephalitis, meningoencephalitis (14), paresthesia, facial 
paralysis and myelitis (15, 16),have also been associated with ZIKV infection. Based on th ese 
findings, the countries affected by [CONTACT_177916] [ADDRESS_208988] increased 2 to 9.8 times co mpared to baseline before the epi[INVESTIGATOR_177822] (19),and up to 20 times in French Polynesia (12). The association of GBS was only 
reported when the circulating strain was of Asian lineage (21). As of 01 February 2017, ZIKV of 
the Asian lineage was circulating in more than 80% of affected countries, including 48 countries in 
0036Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedependent enhancement (ADE). A 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedependent enhancement (ADE). A 
emonstrated that human dengue virus antibodies enhance in vitro infection 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useemonstrated that human dengue virus antibodies enhance in vitro infection 
Despi[INVESTIGATOR_177762], ZIKV infection during pregnancy has 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDespi[INVESTIGATOR_177762], ZIKV infection during pregnancy has 
for the fetus and newborn. The severity of the disease is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor the fetus and newborn. The severity of the disease is 
related to the consequences in the fetus and newborn child from women with ZIKV infection 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated to the consequences in the fetus and newborn child from women with ZIKV infection 
. The spectrum of congenital anomalies associated with ZIKV infection, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The spectrum of congenital anomalies associated with ZIKV infection, 
, consists of severe microcephaly 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, consists of severe microcephaly 
collapsed skull, cerebral cortices with subcortical calcifications, macular scarring and focal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecollapsed skull, cerebral cortices with subcortical calcifications, macular scarring and focal 
pi[INVESTIGATOR_177763], congenital contractures, and marked early hypertonia with symptoms 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepi[INVESTIGATOR_177763], congenital contractures, and marked early hypertonia with symptoms 
The exposure to ZIKV at any moment during pregnancy is a risk for fetal or postnatal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe exposure to ZIKV at any moment during pregnancy is a risk for fetal or postnatal 
, primarily affecting brain developme
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, primarily affecting brain developme
Zika Pregnancy Registry (USZPR) showed that the prevalence of newborn
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika Pregnancy Registry (USZPR) showed that the prevalence of newborn
confirmed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconfirmed ZIKV infection is
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV infection is
baseline prevalen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebaseline prevalen ce 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usece before more recent Zika outbreaks
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebefore more recent Zika outbreaks
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand up to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand up to 
malformations potentially associated with ZIKV infection
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemalformations potentially associated with ZIKV infection
Latin America and the Caribbean
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLatin America and the Caribbean
ZIKV is a neurotropic flavivirus that can potentially cause disease within the central nervous 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV is a neurotropic flavivirus that can potentially cause disease within the central nervous 
system. Worldwide concern over ZIKV causing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesystem. Worldwide concern over ZIKV causing 
an increased number of GBS cases was temporally associated with the 2013
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usean increased number of GBS cases was temporally associated with the 2013
in French Polynesia, during which 42 GBS cases were reported, all of the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein French Polynesia, during which [ADDRESS_208989] ZIKV, compared to 56% in the control group
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useantibodies against ZIKV, compared to 56% in the control group
neurological complications, such as encephalitis, meningoencephalitis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useneurological complications, such as encephalitis, meningoencephalitis 
paralysis and myelitis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparalysis and myelitis 
findings, the countries affected by [CONTACT_177916] 2015
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefindings, the countries affected by [CONTACT_177916] 2015
extended the surveillance of neurological syndromes. In 2017, after the spre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useextended the surveillance of neurological syndromes. In 2017, after the spre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethroughout the Pacific Islands, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethroughout the Pacific Islands, 
related to ZIKV infection 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated to ZIKV infection 
incidences reported have increased 2 to 9.8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincidences reported have increased 2 to 9.8
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 36of 108
Protocol Amendment 3 Version 7.0 12September 2018
Latin America (22). The overall incidence of ZIKV -associated GBS is estimated to be 24 per 
100,000 cases of ZIKV infec tion (23).
Treatment
No specific antiviral treatment is available for ZIKV infections and no vaccine against ZIKV is 
currently available (73). As the disease is self -limiting, treatment for uncomplicated ZIKV 
infection is supportive and focuses on symptoms. Treatment for more severe forms of ZIKV 
infection should address specific medical issues, and in the case of congenital ZIKV infection, 
neurodevelopmental issues for the infantâ€™s particular needs (74).
Patient care includes proper hydration, monitoring for possible coagulopathy and multiple organ 
failure. Intensive care is recommended for the patients depi[INVESTIGATOR_177823], such as 
showing signs of coagulopathy, tachycardia, hypotension and renal dysfunction. Patients with 
neurological complications such as GBS require hospi[INVESTIGATOR_059] (75). Non -steroidal 
anti-inï¬‚ammatory drugs and aspi[INVESTIGATOR_177824]. Such medications 
should be avoided i n case of concomitant infection with dengue fever virus. In case of suspected 
ZIKV infection in pregnant women, sonography is recommended to monitor the proper fetal 
growth and potential complications of infant microcephaly (76).
The main recommendations to address outbreaks are through prevention (avoiding mosq uito bites, 
reducing sexual transmission, improving the procedures for safe blood transfusion), and vector 
control measures (77, 78). 
4.2 Rational e for the Proposed Trial 
4.2.1 Medical Need
ZIKV has posed a challenging situation for health, public and economic sectors of affected 
countries. The increase in microcephaly cases and other neurological disorders reported in Brazil 
following a similar cluster in the French Polynesia in 2014 (24), prompted the World Health 
Organization (WHO) to declare Zika a Public Health Emergency of International Concern 
(PHEIC) on 01 February 2016 (25)and recommended to focus research on the causal association 
of ZIKV infection during pregnancy and microcephaly and other neurol ogical abnormalities in 
newborns. WHO recommended to standardize and enhance the surveillance for microcephaly and 
GBS particularly in areas of known or high risk of ZIKV transmission and to intensify the research 
into the etiology of new clusters of micro cephaly and other neurological disorders to determine 
whether there is a causative link to ZIKV and/or other factors or co -factors.
Considering the rapid spread of ZIKV and the significant threat to public health especially to 
pregnant women and their chil drenâ€™s health, the U.S. Department of Health and Human Services 
declared Zika a public health emergency in Puerto Rico in August 2016 (79).In November 2016, 
after evaluating the evidence about the causal association of ZIKV infection during pregnancy and
microcephaly and other neurological abnormalities in newborns, WHO announced that Zika no 
longer represents a PHEIC (80)but stressed the need to escalate the disease to a sustained work 
program with dedicated resources to address its long -term nature and its associated consequences.
0037Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNo specific antiviral treatment is available for ZIKV infections and no vaccine against ZIKV is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNo specific antiviral treatment is available for ZIKV infections and no vaccine against ZIKV is 
limiting, treatment for uncomplicated ZIKV 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselimiting, treatment for uncomplicated ZIKV 
infection is supportive and focuses on symptoms. Treatment for more severe forms of ZIKV 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinfection is supportive and focuses on symptoms. Treatment for more severe forms of ZIKV 
should address specific medical issues, and in the case of congenital ZIKV infection, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useshould address specific medical issues, and in the case of congenital ZIKV infection, 
Patient care includes proper hydration, monitoring for possible coagulopathy and multiple organ 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePatient care includes proper hydration, monitoring for possible coagulopathy and multiple organ 
failure. Intensive care is recommended for the patients depi[INVESTIGATOR_177823], such as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefailure. Intensive care is recommended for the patients depi[INVESTIGATOR_177823], such as 
dysfunction. Patients with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedysfunction. Patients with 
75
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use75)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use). Non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Non
inï¬‚ammatory drugs and aspi[INVESTIGATOR_177824]. Such medications 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinï¬‚ammatory drugs and aspi[INVESTIGATOR_177824]. Such medications 
n case of concomitant infection with dengue fever virus. In case of suspected 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen case of concomitant infection with dengue fever virus. In case of suspected 
ZIKV infection in pregnant women, sonography is recommended to monitor the proper fetal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV infection in pregnant women, sonography is recommended to monitor the proper fetal 
growth and potential complications of infant microcephaly 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegrowth and potential complications of infant microcephaly (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(76
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use76
The main recommendations to address outbreaks are through prevention (avoiding mosq
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe main recommendations to address outbreaks are through prevention (avoiding mosq
reducing sexual transmission, improving the procedures for safe blood transfusion), and vector 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereducing sexual transmission, improving the procedures for safe blood transfusion), and vector 
e for the Proposed Trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee for the Proposed Trial 
ZIKV has posed a challenging situation for health, public and economic sectors of affected 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV has posed a challenging situation for health, public and economic sectors of affected 
countries. The increase in microcephaly cases and other neurological disorders reported in Brazil 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecountries. The increase in microcephaly cases and other neurological disorders reported in Brazil 
following a similar cluster 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefollowing a similar cluster in the French Polynesia in 2014 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein the French Polynesia in 2014 
Organization (WHO) to declare Zika a Public Health Emergency of International Concern 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOrganization (WHO) to declare Zika a Public Health Emergency of International Concern 
February
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFebruary 2016 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2016 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof ZIKV infection during pregnancy and microcephaly and other neurol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof ZIKV infection during pregnancy and microcephaly and other neurol
newborns. WHO recommended to standardize and enhance the surveillance for microcephaly and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenewborns. WHO recommended to standardize and enhance the surveillance for microcephaly and 
GBS particularly in areas of known or high risk of ZIKV transmission and to intensify the research 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGBS particularly in areas of known or high risk of ZIKV transmission and to intensify the research 
into the etiology of new clusters of micro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinto the etiology of new clusters of micro
whether there is a causative link to ZIKV and/or other factors or co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhether there is a causative link to ZIKV and/or other factors or co
Considering the rapid spread of ZIKV and the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConsidering the rapid spread of ZIKV and the 
pregnant women and their chil
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepregnant women and their chil
declared Zika a public health emergency in Puerto Rico in August 2016
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedeclared Zika a public health emergency in Puerto Rico in August 2016
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 37of 108
Protocol Amendment 3 Version 7.0 12September 2018
The risk of infection with ZIKV is increasing given that the spread of ZIKV is rapid and intense in 
tropi[INVESTIGATOR_177825]. Vector control is difficult to establish and maintain, and new 
areas continue to be colonized by [CONTACT_177917]. Clim ate changes may also create favorable 
environments to maintain the vector (81). There is an increased urban population and mobility, and 
the role of sex ual transmission may be an important mechanism to spread rapi[INVESTIGATOR_177826], even in regions where the vector is uncommon.
Considering the conclusive associations between ZIKV infections and fetal and postnatal 
abnormalities, as well as strong associations with other medically important complications such as 
GBS, the development of a vaccine that can provide protection is crucial for countries where the 
epi[INVESTIGATOR_177768]/or persist, as well as in countries in whi ch the virus has not yet 
been introduced. In order to address the urgent medical need and in anticipation of possible 
additional outbreaks with rapid onsets, [COMPANY_005] has initiated the development of a purified 
inactivated ZIKV vaccine candidate, PI[INVESTIGATOR_177760], for u se in endemic areas and non -endemic areas for 
prevention of ZIKV associated illness of any severity and/or infection.
4.2.[ADDRESS_208990]
The Biomedical Advanced Research and Development Authority (BARDA) from the U.S. 
Department of Health and Human Servic esâ€™ Office of the Assistant Secretary for Preparedness and 
Response is providing funding to [COMPANY_005] for the US -based PI[INVESTIGATOR_177769] (82).
4.2.[ADDRESS_208991] of these are in preclinical development and many are expected to 
enter Phase I clinical studies in 2017.
4.2.4 Summary of Available Non-clinical Data
There are no non -clinical data currently available for PI[INVESTIGATOR_177760]. 
PI[INVESTIGATOR_177771] a 3 -dose Good Laboratory Practice -compliant, 
repeat -dose toxicity and local tolerance study in New Zealand White Rabbits. Toxicol ogy data will 
be available prior to study start and provided in the Investigatorâ€™s Brochure (IB).
4.2.5 Summary of Available Clinical Data
There are no clinical data currently available for PI[INVESTIGATOR_177760]. 
4.2.6 [COMPANY_005] Vaccine Candidate
[COMPANY_005]â€™s PI[INVESTIGATOR_177806] (alum) -adjuvanted vaccine candidate made from 
purified formalin -inactivated ZIKV. The virus seed was derived from ZIKV strain PRVABC59 
propagated through infection of Vero cells (derived from the kidney of African gre en monkey) 
grown in culture, and further purified prior to inactivation. The choice of ZIKV strain may not be a 
0038Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. There is an increased urban population and mobility, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. There is an increased urban population and mobility, and 
ual transmission may be an important mechanism to spread rapi[INVESTIGATOR_177827]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useual transmission may be an important mechanism to spread rapi[INVESTIGATOR_177828]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConsidering the conclusive associations between ZIKV infections and fetal and postnatal 
well as strong associations with other medically important complications such as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewell as strong associations with other medically important complications such as 
GBS, the development of a vaccine that can provide protection is crucial for countries where the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGBS, the development of a vaccine that can provide protection is crucial for countries where the 
ch the virus has not yet 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usech the virus has not yet 
been introduced. In order to address the urgent medical need and in anticipation of possible 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebeen introduced. In order to address the urgent medical need and in anticipation of possible 
additional outbreaks with rapid onsets, [COMPANY_005] has initiated the development of a purified 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadditional outbreaks with rapid onsets, [COMPANY_005] has initiated the development of a purified 
se in endemic areas and non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usese in endemic areas and non
prevention of ZIKV associated illness of any severity and/or infection.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprevention of ZIKV associated illness of any severity and/or infection.
The Biomedical Advanced Research and Development Authority (BARDA) from the U.S. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Biomedical Advanced Research and Development Authority (BARDA) from the U.S. 
esâ€™ Office of the Assistant Secretary for Preparedness and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useesâ€™ Office of the Assistant Secretary for Preparedness and 
Response is providing funding to [COMPANY_005] for the US
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseResponse is providing funding to [COMPANY_005] for the US -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-based PI[INVESTIGATOR_177829]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased PI[INVESTIGATOR_177830], there is no approved vaccine against ZIKV. Various companies and academic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCurrently, there is no approved vaccine against ZIKV. Various companies and academic 
organizations are using a variety of vaccine approaches, including inactivated virus, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useorganizations are using a variety of vaccine approaches, including inactivated virus, 
based vaccines, live vectored vaccines, subunit vaccines, and live 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased vaccines, live vectored vaccines, subunit vaccines, and live 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecombinant approaches. Most of these are in preclinical development and many are expected to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecombinant approaches. Most of these are in preclinical development and many are expected to 
enter Phase I clinical studies in 2017.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useenter Phase I clinical studies in 2017.
Summary of Available
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSummary of Available
clinical data currently available for PI[INVESTIGATOR_177760]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical data currently available for PI[INVESTIGATOR_177760]. 
PI[INVESTIGATOR_177771] a 3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePI[INVESTIGATOR_177771] a 3
dose toxicity and local tolerance study in New Zealand White Rabbits. Toxicol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose toxicity and local tolerance study in New Zealand White Rabbits. Toxicol
be available prior to study start and provided in the Investigatorâ€™s Brochure (IB).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe available prior to study start and provided in the Investigatorâ€™s Brochure (IB).
4.2.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.2.5 Summary of Available Clinical Data
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSummary of Available Clinical Data
There are no clinical data currently available for PI[INVESTIGATOR_177760]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThere are no clinical data currently available for PI[INVESTIGATOR_177760]. 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 38of 108
Protocol Amendment 3 Version 7.0 12September 2018
critical parameter as evidence suggests that infection with a single ZIKV strain can elicit broadly 
neutralizing antibodies across different str ains (83).
Refer to Section 8.1for additional details.
4.2.[ADDRESS_208992] -in-human study. 
The rationale for the observer -blind app roach is based on the different physical appearance of the 
investigational vaccine compared to the saline solution placebo that was selected and preferred to 
alum -containing placebo to avoid side effects associated with alum. The rationale for the use of 
placebo in this trial is based on the absence of effective treatment or prevention for ZIKV disease.
Due to the need to vaccinate women and men of reproductive age, the primary target population of 
PI[INVESTIGATOR_177770] 9 years of age and older. In this phase 1 stud y, study population is limited to â‰¥18 to 
â‰¤49years, and age expansion will be included in the next phase of development.
To ensure the enrollment of healthy adults, screening tests (hematology, biochemistry and 
urinalysis) will be performed prior to vaccin e administration.
Flavivirus primed adults are included in this study to assess if there is any impact from pre -existing 
flavivirus antibodies. The testing of flaviviral serological status will be performed prior to 
randomization and will enable stratifica tion of randomization.
Due to the ongoing threat of ZIKV disease and the urgent need of a vaccine, ZIK -101 will be 
accelerated to assess dose finding for PI[INVESTIGATOR_177760], in addition to evaluation of safety and 
immunogenicity of the vaccine candidate (PI[INVESTIGATOR_177760]) in both f lavivirus seronegative (naÃ¯ve) and 
seropositive (primed) subjects. 
The reactogenicity/safety of PI[INVESTIGATOR_177831]. Flavivirus naÃ¯ve subjects will be enrolled during 
the first phase of the study. In the absence of clinical data on ZIKV vaccine, it is propose d to 
recruit flavivirus primed subjects in a second stage. If positive recommendations from an external
Data Monitoring Committee (DMC) are issued following the review of safety and tolerability data 
in the flavivirus naÃ¯ve population, when the last flaviv irus naÃ¯ve subject has completed study 
Visit 4 ([ADDRESS_208993] dose 1), vaccination of flavivirus primed subjects will start.
The primary rationale for selection of the three vaccine dose levels can be summarized as follows: 
ï‚·the low -dose level (2 Âµg) was selected for purposes of potentially identify an immunological 
threshold, and based on the limit of the analytical methods for the drug product available at the 
time;
ï‚·the mid -dose level (5 Âµg) was selected to provide a mid -point on the dose response curve. In 
addition, this dose level is based on the Walter Reed Army Institute of Research (WRAIR) 
vaccine currently tested in Phase 1 (84), which was originally based on initial studies in NHPs 
(85); and
ï‚·the high -dose level (10 Âµg) was selected to follow a n approximate 2 -fold range and to further 
define the potential dose -response curve in both naÃ¯ve and primed subjects.
0039Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehuman study. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehuman study. 
roach is based on the different physical appearance of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useroach is based on the different physical appearance of the 
investigational vaccine compared to the saline solution placebo that was selected and preferred to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine compared to the saline solution placebo that was selected and preferred to 
containing placebo to avoid side effects associated with alum. The rationale for the use of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontaining placebo to avoid side effects associated with alum. The rationale for the use of 
lacebo in this trial is based on the absence of effective treatment or prevention for ZIKV disease.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselacebo in this trial is based on the absence of effective treatment or prevention for ZIKV disease.
Due to the need to vaccinate women and men of reproductive age, the primary target population of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDue to the need to vaccinate women and men of reproductive age, the primary target population of 
y, study population is limited to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey, study population is limited to 
years, and age expansion will be included in the next phase of development.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears, and age expansion will be included in the next phase of development.
To ensure the enrollment of healthy adults, screening tests (hematology, biochemistry and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo ensure the enrollment of healthy adults, screening tests (hematology, biochemistry and 
e administration.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee administration.
Flavivirus primed adults are included in this study to assess if there is any impact from pre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed adults are included in this study to assess if there is any impact from pre
flavivirus antibodies. The testing of flaviviral serological status will be performed prior to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflavivirus antibodies. The testing of flaviviral serological status will be performed prior to 
tion of randomization.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetion of randomization.
Due to the ongoing threat of ZIKV disease and the urgent need of a vaccine, ZIK
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDue to the ongoing threat of ZIKV disease and the urgent need of a vaccine, ZIK
accelerated to assess dose finding for PI[INVESTIGATOR_177760], in addition to evaluation of safety and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccelerated to assess dose finding for PI[INVESTIGATOR_177760], in addition to evaluation of safety and 
immunogenicity of the vaccine candidate (PI[INVESTIGATOR_177760]) in both f
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmunogenicity of the vaccine candidate (PI[INVESTIGATOR_177760]) in both f
The reactogenicity/safety of PI[INVESTIGATOR_177831]. Flavivirus naÃ¯ve subjects will be enrolled during 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe reactogenicity/safety of PI[INVESTIGATOR_177831]. Flavivirus naÃ¯ve subjects will be enrolled during 
the first phase of the study. In the absence of clinical data on ZIKV vaccine, it is propose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe first phase of the study. In the absence of clinical data on ZIKV vaccine, it is propose
recruit flavivirus primed subjects in a second stage. If positive recommendations from an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecruit flavivirus primed subjects in a second stage. If positive recommendations from an 
Data Monitoring Committee (DMC) are issued following the review of safety and tolerability data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseData Monitoring Committee (DMC) are issued following the review of safety and tolerability data 
in the flavivirus naÃ¯ve population, when the last flaviv
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein the flavivirus naÃ¯ve population, when the last flaviv
days post dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose
The primary rationale for selection of the three 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe primary rationale for selection of the three 
the low
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe low -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose level (2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose level ([ADDRESS_208994] available at the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethreshold, and based on the limit of the analytical methods for the drug product available at the 
time;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime;
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_208995] immune response and survival 
following wild -type challenge.
PI[INVESTIGATOR_177832] (GMT) of 
neutralizing anti -ZIKV antibody levels at [ADDRESS_208996] dose 2 in both flaviv irus naÃ¯ve and primed 
subjects. 
The trial will be conducted in accordance with the protocol, the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) GCP 
Guidelines and applicable regulatory requirement s.
0040Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePI[INVESTIGATOR_177832] (GMT) of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePI[INVESTIGATOR_177832] (GMT) of 
irus naÃ¯ve and primed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useirus naÃ¯ve and primed 
International Council for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInternational Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHarmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) GCP 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(ICH) GCP 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 40of 108
Protocol Amendment 3 Version 7.0 12September 2018
5.0 TRIAL OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objectives
ï‚·To describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart from three different antigen 
concentrations (2, 5 or 10 Âµg) in flavivirus naÃ¯ve and p rimed healthy adults through [ADDRESS_208997] d ose 2
ï‚·To select a single vaccine dose level of PI[INVESTIGATOR_177833]
5.1.2 Secondary Objectives
ï‚·To describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart in flavivirus naÃ¯ve and primed 
healthy adults through the end of the study
ï‚·To describe the immune response to PI[INVESTIGATOR_177792]Ã¯ve and primed healthy adults at the 
following immunogenicity time points [ADDRESS_208998] dose 2
ï‚·To describe the persistence of immunity to PI[INVESTIGATOR_177793] [ADDRESS_208999] dose 2 in flavivirus 
naÃ¯ve and primed healthy adults from the placebo group and the PI[INVESTIGATOR_177834]
5.2 Endpoints
5.2.1 Primary Endpoints
Safety and Tolerability of PI[INVESTIGATOR_177760], as determined by:
ï‚·Percentage of subjects wit h solicited local reactions (injection site: pain, erythema, swelling, 
and induration), in each severity category, during the 7 -day period after administration of each 
dose of PI[INVESTIGATOR_177807] .
ï‚·Percentage of subjects experiencing solicited systemic adverse events (AEs) (fever, headache, 
fatigue, malaise, arthralgia, and myalgia), in each severity category, during the 7 -day period 
after administration of each dose of PI[INVESTIGATOR_177807] .
ï‚·Percentage of subjects experiencing non -serious unsolicited AEs during the 2 8-day period 
after administration of each dose of PI[INVESTIGATOR_177807] .
ï‚·Percentage of subjects experiencing serious AEs (SAEs) during the 28 -day period after 
administration of each dose of PI[INVESTIGATOR_177807] .
Immunogenicity of PI[INVESTIGATOR_177760], as determined by:
ï‚·Geometric mean titers (GMT) of neutralizing anti -ZIKV antibody levels at [ADDRESS_209000] 
dose 2.
0041Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart from three different antigen 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo describe the safety of two doses of PI[INVESTIGATOR_177790] 28 days apart from three different antigen 
rimed healthy adults through 28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userimed healthy adults through [ADDRESS_209001] a single vaccine dose level of PI[INVESTIGATOR_177800]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo select a single vaccine dose level of PI[INVESTIGATOR_177835]Ã¯ve and primed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays apart in flavivirus naÃ¯ve and primed 
the immune response to PI[INVESTIGATOR_177792]Ã¯ve and primed healthy adults at the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe immune response to PI[INVESTIGATOR_177792]Ã¯ve and primed healthy adults at the 
days post d
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post d ose 1, [ADDRESS_209002] dose 2, and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useose 1, [ADDRESS_209003] dose 2, and
To describe the persistence of immunity to PI[INVESTIGATOR_177793] 12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo describe the persistence of immunity to PI[INVESTIGATOR_177793] 12
naÃ¯ve and primed healthy adults from the placebo group and the PI[INVESTIGATOR_177836]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsenaÃ¯ve and primed healthy adults from the placebo group and the PI[INVESTIGATOR_177837], as determined by:
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety and Tolerability of PI[INVESTIGATOR_177760], as determined by:
[CONTACT_177956]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects wit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh solicited local reactions (injection site: pain, erythema, swelling, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useh solicited local reactions (injection site: pain, erythema, swelling, 
and induration), in each severity category, during the 7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand induration), in each severity category, during the 7
dose of PI[INVESTIGATOR_177808]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose of PI[INVESTIGATOR_177838]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects experiencing solicited systemic adverse 
fatigue, malaise, arthralgia, and myalgia), in each severity category, during the 7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefatigue, malaise, arthralgia, and myalgia), in each severity category, during the 7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useafter administration of each dose of PI[INVESTIGATOR_177808]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useafter administration of each dose of PI[INVESTIGATOR_177839]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects experiencing non
after administration of each dose of PI[INVESTIGATOR_177808]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useafter administration of each dose of PI[INVESTIGATOR_177807]
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·Percentage of subjects experiencing serious AEs (SAEs) during the 28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePercentage of subjects experiencing serious AEs (SAEs) during the 28
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 41of 108
Protocol Amendment 3 Version 7.0 12September 2018
5.2.2 Secondary Endpoints
Safety of PI[INVESTIGATOR_177760], as determined by:
ï‚·Percentage of subjects experiencing SAEs throughout the trial .
Immunogenicity of PI[INVESTIGATOR_177760], as determined by:
ï‚·GMT of neutralizing anti -ZIKV antibody levels at [ADDRESS_209004] dose 2 in applicable groups .
ï‚·Seropositivity rates (SPR) at each immunogenicity time point ([ADDRESS_209005] dose 2 )in applicable groups .
ï‚·Seroconversion rates (SCR) at [ADDRESS_209006] dose 2.
0042Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV antibody levels at [ADDRESS_209007] dose 1, and 6, 12, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV antibody levels at [ADDRESS_209008] dose 1, and 6, 12, and 
eropositivity rates (SPR) at each immunogenicity time point ([ADDRESS_209009] dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeropositivity rates (SPR) at each immunogenicity time point ([ADDRESS_209010] dose
in applicable groups
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein applicable groups .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
days post dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 42of 108
Protocol Amendment 3 Version 7.0 12September 2018
6.0 TRIAL DESIGN AND DESCRIPTION
6.1 Trial Design
This is a phase 1, randomized, observer -blind, placebo -controlled, safety, immunogenicity, and 
dose ranging study of PI[INVESTIGATOR_177780]Ã¯ve and primed healthy adults aged â‰¥18 to 
â‰¤49years , in ZIKV endemic and non -endemic regions.
The trial willlast approximately [ADDRESS_209011] for up to 2 weeks (14 days) prior to randomization, 
with the possibility that some subjects (Flavivirus primed subjects only) will need to repeat some 
screening procedures if they were not randomized right after the screening period (further 
clarification is provided in the schedule of trial procedures).
ï‚·Flavivirus naÃ¯ve subjects: subjects without detectable serum antibodies aga inst a panel of 
flaviviruses as measured by a reactive antibody -based assay (Luminex) (refer to the Serology 
Plan, available on file).
ï‚·Flavivirus primed subjects: subjects with serum antibodies against a panel of flaviviruses as 
measured by a reactive antibody -based assay (Luminex) (refer to the Serology Plan, available 
on file). 
Approximately 240 subjects aged â‰¥18 to â‰¤49 years will be enrolled and equally randomized into 
four groups (arms) (1:1:1:1) of approximately 60 subjects, each comprised of appr oximately 
30flavivirus naÃ¯ve subjects and approximately 30 flavivirus primed subjects. Randomization 
within each cohort (flavivirus naÃ¯ve versus flavivirus primed subjects) will be stratified by 
[CONTACT_177919]: â‰¥18 to â‰¤29 years versus â‰¥30 to â‰¤49 years .
A schematic representation of the trial design is included as Figure 6.a. A schedule of trial 
procedures is provided in Section 2.1.
0043Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontrolled, safety, immunogenicity, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontrolled, safety, immunogenicity, and 
â‰¥18 to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ‰¥[ADDRESS_209012], following a screening period 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths for each subject, following a screening period 
prior to Visit 2. The screening period will last for up to 2 weeks (14 days) prior to randomization, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprior to Visit 2. The screening period will last for up to 2 weeks (14 days) prior to randomization, 
will need to repeat some 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill need to repeat some 
screening procedures if they were not randomized right after the screening period (further 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreening procedures if they were not randomized right after the screening period (further 
Flavivirus naÃ¯ve subjects: subjects without detectable serum antibodies aga
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus naÃ¯ve subjects: subjects without detectable serum antibodies aga
based assay (Luminex) (refer to the Serology 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased assay (Luminex) (refer to the Serology 
Flavivirus primed subjects: subjects with serum antibodies against 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed subjects: subjects with serum antibodies against 
based assay (Luminex) (refer to the Serology Plan, available 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebased assay (Luminex) (refer to the Serology Plan, available 
years
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears will be enrolled and equally randomized into 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be enrolled and equally randomized into 
four groups (arms) (1:1:1:1) of approximately 60
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefour groups (arms) (1:1:1:1) of approximately 60 subjects, each comprised of appr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects, each comprised of appr
flavivirus naÃ¯ve subjects and approximately 30
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflavivirus naÃ¯ve subjects and approximately 30
within each cohort (flavivirus naÃ¯ve versus flavivirus primed subjects) will be stratified by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewithin each cohort (flavivirus naÃ¯ve versus flavivirus primed subjects) will be stratified by 
[CONTACT_177919]: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflavivirus serostatus and age group: â‰¥18 to â‰¤29
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ‰¥18 to â‰¤29
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA schematic representation of the trial design is included as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA schematic representation of the trial design is included as 
procedures is provided in Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedures is provided in Section 2.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2.1
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 43of 108
Protocol Amendment 3 Version 7.0 12September 2018
Figure 6.a Schematic Representation of Trial Design
Staggered enrollment ( Figure 6.b): There will be two study phases. 
ï‚·The first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only. All 
subjects who sign the informed consent form (ICF) and have confirmed eligibility at Screening 
Visit 1A will be tested for flavivirus serostatus.
Eligible flavivirus naÃ¯ve subjects enrolled at Screening Visit 1A will be randomized at Visit 2, 
within two weeks after Scr eening Visit 1A.
Flavivirus primed subjects will not be enrolled during the first phase of the study (ie, when 
identified at Screening Visit 1A) and will be invited to come back for the second phase of the 
study. They will be contact[CONTACT_177957]Ã¯ve subjects, when the 
last flavivirus naÃ¯ve subject has completed study Visit 4 ([ADDRESS_209013] dose 1). These flavivirus 
primed subjects will c onsequently undergo 2 screening visits: Visit 1A during the first phase of 
the study, and Visit 1B at the outset of the second phase of the study. Therefore, it is 
recommended that the key aspects of the ICF already si gned during the Screening Visit 1A are
reinforced with the subject. Flavivirus primed subjects identified at Screening Visit 1A who do 
not participate in the second phase of the study will be declared screened failure (see 
Figure 6.bÂ§).
Enrollment will be put on hold after all naÃ¯ve subjects have been enrolled and will resume 
when positive recommendations from the external DMC are issued, as described above.
0044Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use): There will be two study phases. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use): There will be two study phases. 
The first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only. All 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only. All 
sign the informed consent form (ICF) and have confirmed eligibility at Screening 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesign the informed consent form (ICF) and have confirmed eligibility at Screening 
1A will be tested for flavivirus serostatus.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A will be tested for flavivirus serostatus.
Eligible flavivirus naÃ¯ve subjects enrolled at Screening Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEligible flavivirus naÃ¯ve subjects enrolled at Screening Visit
weeks after Scr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks after Scr
Flavivirus primed subjects will not be enrolled during the first phase of the study (ie, when 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed subjects will not be enrolled during the first phase of the study (ie, when 
identified at Screening Visit 1A) and will be invited to come back for the second phase of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useidentified at Screening Visit 1A) and will be invited to come back for the second phase of the 
study. They will be contact[CONTACT_177958]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy. They will be contact[CONTACT_177959]Ã¯ve subjects, when the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useissued following the review of safety and tolerability data in flavivirus naÃ¯ve subjects, when the 
last flavivirus naÃ¯ve subject has completed study Visit 4 ([ADDRESS_209014] dose 1). These flavivirus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselast flavivirus naÃ¯ve subject has completed study Visit 4 ([ADDRESS_209015] dose 1). These flavivirus 
primed subjects will c
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprimed subjects will c
the study, and Visit 1B at the outset of the second phase of the study.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe study, and Visit 1B at the outset of the second phase of the study.
recommended that the key aspects of the ICF already si
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecommended that the key aspects of the ICF already si
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 44of 108
Protocol Amendment 3 Version 7.0 12September 2018
ï‚·The second phase of the study wi ll be aimed at enrolling flavivirus primed subjects only.
Newly identified eligible flavivirus primed subjects at Screening Visit 1B will be enrolled 
(randomized) at (second phase) Visit 2, within two weeks after Screening Visit 1B.
Previously identified f lavivirus primed subjects (see Figure 6.bÂ§Â§)(who were tested at 
Visit 1A during the first phase and accepted to enter the second phase of the study) will retain 
their initial subject identification (ID) number and undergo an additi onal screening visit 
(Visit 1B) to be tested for eligibility criteria again, (except for the determination of flavivirus 
serostatus). 
Flavivirus naÃ¯ve subjects identified at Screening Visit 1B (during the second phase of the 
study) will be declared screened failure (see Figure 6.bÂ§Â§Â§).
0045Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A during the first phase and accepted to enter the second phase of the study) will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A during the first phase and accepted to enter the second phase of the study) will retain 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useretain 
screening visit 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreening visit 
1B) to be tested for eligibility criteria again, (except for the determination of flavivirus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1B) to be tested for eligibility criteria again, (except for the determination of flavivirus 
1B (during the second phase of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1B (during the second phase of the 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 45of 108
Protocol Amendment 3 Version 7.0 12September 2018
Figure 6.b Staggered Enrollment
* All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177784] 9 at Day 393 ([ADDRESS_209016] dose 2) and Visit 11 at Day 757 ([ADDRESS_209017] dose 2), 
and will also be contact[CONTACT_177923] 575 (Visit 10) for safety follow -up.
Each subject will receive two 0.5 mL doses of either PI[INVESTIGATOR_177760] (2, 5 or 10 Âµg) or placebo 
intramuscu larly (IM) â€“one dose at Visit 2 (on Day 1) and one dose at Visit 4 (on Day 29) IM into 
the middle third of the deltoid muscle, preferably in the non -dominant arm.
0046Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use* All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177785]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use* All subjects who were randomized to the placebo group or the PI[INVESTIGATOR_177784] 9 at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopment will attend Visit 9 at 
and will also be contact[CONTACT_177923] 575 (Visit 10) for safety follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand will also be contact[CONTACT_177923] 575 (Visit 10) for safety follow
Each subject will receive two 0.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach subject will receive two 0.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209018] will be required to attend 7, 8, 9 or 10 clinical visits and will receive 1 or 2phone 
calls depending on their flavivirus serostatus at screening and the vaccine dose level they received:
ï‚·Flavivirus naÃ¯ve subjects identified during the Screening Visit 1A and flavivirus primed 
subjects identified during the Screening Visit 1B will at tend 7 visits and will receive 1 phone 
call, and possibly 2 additional visits and 1 phone call (thus a maximum of 9 visits and 2 phone 
calls) if they were randomized to the placebo group or the PI[INVESTIGATOR_177840]
ï‚·Flavivirus primed subjects identified during the S creening Visit 1A will attend 8 visits 
(including Visit 1A and Visit 1B) and will receive 1 phone call, and possibly 2 additional visits 
and 1 phone call (thus a maximum of 10 visits and 2 phone calls) if the y were randomized to 
the placebo group or the PI[INVESTIGATOR_177841](s) (Visit 1A and/or Visit 1B), Visit 2 at 
Day 1, Visit 3 at Day 8 (7days post dose 1), Visit 4 at Day 29 ([ADDRESS_209019] dose 1), Visit 5 at 
Day 36 ([ADDRESS_209020] dose 2), Visit 6 at Day 57 ([ADDRESS_209021] dose 2), and Visit 8 at Day 211 
(6months post dose 2). All randomized subjects will also be contact[CONTACT_177923] 133 
(Visit 7) for safety foll ow-up. In addition, all subjects who were randomized to the placebo group 
or the PI[INVESTIGATOR_177788] 9 at Day 393 
(12months post dose 2)and Visit 11 at Day 757 ([ADDRESS_209022] dose 2), and will al so be 
contact[CONTACT_177923] 575 (Visit 10) for safety follow -up.
Blood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or 
Visit 1B) for flavivirus serostatus determination and eligibility screening tests (including
pregnancy testing) ; at Visits 3 and 5 for routine safety laboratory testing; and at Visits 2, 4, 6, 8, 
and ( for subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177842] ) 9 and 11 for immun ogenicity ,as well as for further 
development and characterization of assays. Refer to Section 9.1.6 andthe Serology Plan
(available on file ). 
Urine samples will be collected for all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) for 
eligibility screening , and at Visits 3 and 5 for routine safety laboratory testing; and for women of 
childbearing potential at Visits 2 and 4 before each investigational vaccine/placebo administration 
for pregnancy test ing.Refer to Section 9.1.[ADDRESS_209023] solic ited AEs for 7 days after each dose (including 
the days of vaccine/placebo administration), and unsolicited AEs for 28 days after each dose 
(including the days of vaccine/placebo administration). Additional safety assessments will include 
new medical condi tions (neurological and neuroinflammatory disorders) with onset after the first 
vaccination, and SAEs collection for the duration of the entire trial. Immunogenicity will be 
assessed for all subjects 28 days after each vaccine/placebo administration and [ADDRESS_209024] dose 2.
Refer to Section 13.2 for details about sequence of analyses.
0047Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephone 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephone 
visits and 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevisits and 2 phone 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephone 
calls) if they were randomized to the placebo group or the PI[INVESTIGATOR_177843]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecalls) if they were randomized to the placebo group or the PI[INVESTIGATOR_177844] 
1A will attend 8
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A will attend 8 visits 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevisits 
1B) and will receive 1 phone call, and possibly 2 additional visits 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1B) and will receive 1 phone call, and possibly 2 additional visits 
phone calls) if the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephone calls) if the y were randomized to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey were randomized to 
the placebo group or the PI[INVESTIGATOR_177845]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe placebo group or the PI[INVESTIGATOR_177786]
1A and/or Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1A and/or Visit
29 (28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use29 ([ADDRESS_209025] dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose
days post dose
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays post dose 2), and Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2), and Visit
2). All randomized subjects will also be contact[CONTACT_177950]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2). All randomized subjects will also be contact[CONTACT_177960]. In addition, all subjects who were randomized to the placebo group 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup. In addition, all subjects who were randomized to the placebo group 
or the PI[INVESTIGATOR_177846]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor the PI[INVESTIGATOR_177847] 11 at Day 757 ([ADDRESS_209026] dose 2), and will al
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand Visit 11 at Day 757 ([ADDRESS_209027] dose 2), and will al
contact[CONTACT_177923] 575 (Visit 10) for safety follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontact[CONTACT_177923] 575 (Visit 10) for safety follow
Blood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit
1B) for flavivirus serostatus determination and eligibility screening tests
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1B) for flavivirus serostatus determination and eligibility screening tests
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use; at Visits 3 and 5 for routine safety laboratory testing; and at Visits 2, 4, 6, 8, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use; at Visits 3 and 5 for routine safety laboratory testing; and at Visits 2, 4, 6, 8, 
for subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177848]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor subjects who will be randomized to the placebo group or the PI[INVESTIGATOR_177849]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe selected for further development ) 9 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) 9 
development and characterization of assays. Refer to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopment and characterization of assays. Refer to 
ne samples will be collected 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usene samples will be collected 
eligibility screening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeligibility screening , and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and 
childbearing potential 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechildbearing potential 
for pregnancy test
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor pregnancy test ing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach subject will receive diary cards to collect solic
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach subject will receive diary cards to collect solic
the days of vaccine/placebo administration), and unsolicited AEs for 28 days after each dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe days of vaccine/placebo administration), and unsolicited AEs for 28 days after each dose 
(including the days of vaccine/placebo administration). 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(including the days of vaccine/placebo administration). 
new medical condi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenew medical condi
vaccination, and SAEs collection for the duration of the entire trial. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccination, and SAEs collection for the duration of the entire trial. 
assessed for all subjects 28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassessed for all subjects 28
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 47of 108
Protocol Amendment 3 Version 7.0 12September 2018
6.2 Justification for Trial Design, Dose, and Endpoints
The trial design and the collection of solicited and unsolicited AEs following vaccination are 
consiste nt with guidelines on vaccine evaluation trials, including dose -finding studies.
The design of the study answers to the principles outlined in the ICH Considerations on Clinical 
Trials E8 (86)and the WHO Guidelines for Evaluation of Vaccines (87), and more specifically for 
phase 1 trials. As such, the study design, objectives and endpoints were defined so as to assess the 
initial safety and reactogenicity of the vaccine candidate, obtain preliminary information on its 
immunogenicity, and provide data useful for the design of further clinical studies. The 
dose-ranging design adopted is in line with the ICH and FDA guidance (88, 89).The use of 
placebo as control for the investigational vaccine is justified in the absence of a proven 
intervention (90), ie, as no prophylactic vaccine agai nst ZIKV infection is available to date. 
As this is a first in human trial, a relatively high serum volume (60 mL) will be needed for assay 
development and other pre -clinical studies to support possible alternative license pathways which 
may include bridging animal data to human data.
The rationale for the proposed trial is given in Section 4.2.[ADDRESS_209028] â€™s Expected Participation in the Entire Trial
Each enrolled subjectâ€™s participation in the trial will last approximately 7 or 25months, following 
a screening period prior to Visit 2 of two -weeks for flavivirus naÃ¯ve subjects and of more than two 
weeks for flavivirus primed subjects.
6.4 Premature Termination or Suspension of Trial or Investigational Site
6.4.1 Criteria for Premature Termination or Suspension of the Trial
The trial will be completed as planned unless one or more of the following criteria are satisfied that 
require temporary suspension or early termination of the trial.
ï‚·New information or other evaluation regarding the safety or efficacy of the investigational 
vaccine that indicates a change in the known risk/benefit profile, such that the risk /benefit is no 
longer acceptable for subjects participating in the trial.
ï‚·The external DMC recommends that the trial should be suspended or terminated.
ï‚·Significant deviation from Good Clinical Practice (GCP) that compromises the ability to 
achieve the prim ary trial objectives or compromises subject safety.
6.4.2 Criteria for Premature Termination or Suspension of Investigational Sites
A trial site may be terminated prematurely or suspended if the site (including the investigator) is 
found in significant deviation from GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the trial, or as otherwise permitted by [CONTACT_82280].
0048Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConsiderations on Clinical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConsiderations on Clinical 
, and more specifically for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and more specifically for 
phase 1 trials. As such, the study design, objectives and endpoints were defined so as to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephase 1 trials. As such, the study design, objectives and endpoints were defined so as to assess the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useassess the 
initial safety and reactogenicity of the vaccine candidate, obtain preliminary information on its 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinitial safety and reactogenicity of the vaccine candidate, obtain preliminary information on its 
immunogenicity, and provide data useful for the design of further clinical studies. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmunogenicity, and provide data useful for the design of further clinical studies. The 
89
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use89)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.The use of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe use of 
placebo as control for the investigational vaccine is justified in the absence of a proven 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplacebo as control for the investigational vaccine is justified in the absence of a proven 
nst ZIKV infection is available to date. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenst ZIKV infection is available to date. 
As this is a first in human trial, a relatively high serum volume (60
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAs this is a first in human trial, a relatively high serum volume (60 mL) will be needed for assay 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL) will be needed for assay 
clinical studies to support possible alternative license pathways which 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical studies to support possible alternative license pathways which 
4.2.7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.2.7 .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.
â€™s Expected Participation in the Entire Trial
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€™s Expected Participation in the Entire Trial
Each enrolled subjectâ€™s participation in the trial will last approximately 7 or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach enrolled subjectâ€™s participation in the trial will last approximately 7 or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea screening period prior to Visit 2 of two
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea screening period prior to Visit 2 of two
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-weeks for flavivirus naÃ¯ve subjects and of more than two 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks for flavivirus naÃ¯ve subjects and of more than two 
Premature Termination or Suspension of Trial or Investigational Site
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePremature Termination or Suspension of Trial or Investigational Site
Criteria for Premature Termination or Suspension of the Trial
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCriteria for Premature Termination or Suspension of the Trial
The trial will be completed as planned unless one or more of the following criteria are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe trial will be completed as planned unless one or more of the following criteria are 
require temporary suspension or early termination of the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userequire temporary suspension or early termination of the trial.
New information or other evaluation regarding the safety or efficacy of the investigational 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNew information or other evaluation regarding the safety or efficacy of the investigational 
vaccine that indicates a change in the known risk/benefit profile, such that the risk
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine that indicates a change in the known risk/benefit profile, such that the risk
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselonger acceptable for subjects participating in the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselonger acceptable for subjects participating in the trial.
The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe external
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexternal
Significant deviation from Good Clinical Practice (GCP) that compromises the ability to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSignificant deviation from Good Clinical Practice (GCP) that compromises the ability to 
achieve the prim
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useachieve the prim
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 48of 108
Protocol Amendment 3 Version 7.0 12September 2018
6.4.3 Procedures for Premature Termination or Suspension of the Trial or the 
Participation of Investigat ional Site(s)
In the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
(IEC) or regulatory authority elects to terminate or suspend the trial or the participation of an 
investigational site, a trial -specific procedure for early termination or suspension will be provided 
by [CONTACT_456]; the procedure will be followed by [CONTACT_177961].
0049Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
(IEC) or regulatory authority elects to terminate or suspend the trial or the participation of an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(IEC) or regulatory authority elects to terminate or suspend the trial or the participation of an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor early termination or suspension will be provided 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor early termination or suspension will be provided 
by [CONTACT_456]; the procedure will be followed by [CONTACT_177962]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useby [CONTACT_456]; the procedure will be followed by [CONTACT_177963] (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 49of 108
Protocol Amendment 3 Version 7.0 12September 2018
7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL OF SUBJECTS
All entry cr iteria, including test results, need to be confirmed prior to randomization.
7.[ADDRESS_209029] eligibility is determined according to the following criteria:
1.The subject is aged â‰¥18 to â‰¤49 years .
2.Individuals who are in good health at the time of entry into the trial as determined by [CONTACT_177964], physical examination (including vital signs) and eligibility screening tests 
(hematology, biochemistry and urinalysis) and clinical judgment of the inv estigator. Vital 
signs must be within normal limits (ie, below Grade 1 as specified in the FDA Toxicity 
Grad ingScale for Healthy Adult and Adolescent Volunteers , see Appendix E). Screening tests 
must be within normal limits or not be above Grade 1 as defined in the FDA Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers (see Appendix E).
3.The subject signs and dates a written, informed consent form and any required privacy 
authorization prior to the initiation of any trial procedures, after the nature of the trial has been 
explained according to local regulatory requirem ents(Appendix B).
4.Individuals who can comply with trial procedures and are available for the duration of 
follow -up.
5.All female participants of childbearing potential must have a negative serum beta human 
chorionic gonadotropin ( ï¢-hCG) pregnancy test at screening and a negative urine ï¢-hCG 
pregnancy test prior to receiving any dose of investigational vaccine/placebo.
7.[ADDRESS_209030] who meets any of the following criteria will not qualify for entry into the trial:
1.Subjects and subjectsâ€™ partners with confirmed ZIKV infection by [CONTACT_6270] -report.
2.Traveling to flavivirus endemic countries or flavivirus endemic regions of the US/US 
territories*, within 4weeks prior to screening or planned travel through to Visit 6 (applicable 
only to subjects to be enrolled into the flavivirus naÃ¯ve cohort).
*CDC we bsite defines the information about the flavivirus endemic countries and US regions 
and territories (see Appendix Dfor the respective website addresse s).
3.Known hypersensitivity or allergy to any of the vaccine candidate components (including 
excipi[INVESTIGATOR_177850], control or placebo as summarized in Section 8.1).
4.Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opi[INVESTIGATOR_8574], may interfere with the subject's ability to participate in the trial.
5.Individuals with any history o f progressive or severe neurologic disorder, seizure disorder or 
neuro -inflammatory disease (eg, Guillain -BarrÃ© syndrome).
0050Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals who are in good health at the time of entry into the trial as determined by [CONTACT_177965]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals who are in good health at the time of entry into the trial as determined by [CONTACT_177964], physical examination (including vital signs) and eligibility screening tests 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehistory, physical examination (including vital signs) and eligibility screening tests 
(hematology, biochemistry and urinalysis) and clinical judgment of the inv
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(hematology, biochemistry and urinalysis) and clinical judgment of the inv estigator. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useestigator. 
below Grade 1 as specified in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebelow Grade 1 as specified in the FDA Toxicity 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe FDA Toxicity 
Appendix
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppendix
Grade 1 as defined in the FDA Toxicity Grading 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGrade 1 as defined in the FDA Toxicity Grading 
Appendix
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppendix
The subject signs and dates a written, informed consent form and any required privacy 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subject signs and dates a written, informed consent form and any required privacy 
authorization prior to the initiation of any trial procedures, after the nature of the trial has been 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauthorization prior to the initiation of any trial procedures, after the nature of the trial has been 
local regulatory requirem
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselocal regulatory requirem ents
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useents(
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppendix
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAppendix
Individuals who can comply with trial procedures and are available for the duration of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals who can comply with trial procedures and are available for the duration of 
childbearing potential must have a negative serum beta human 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechildbearing potential must have a negative serum beta human 
hCG) pregnancy test at screening and a negative urine 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsehCG) pregnancy test at screening and a negative urine 
pregnancy test prior to receiving any dose of investigational vaccine/placebo.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepregnancy test prior to receiving any dose of investigational vaccine/placebo.
who meets any of the following criteria will not qualify for entry into the trial:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewho meets any of the following criteria will not qualify for entry into the trial:
Subjects and subjectsâ€™ partners with confirmed ZIKV infection by [CONTACT_177966]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubjects and subjectsâ€™ partners with confirmed ZIKV infection by [CONTACT_177967]/US 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTraveling to flavivirus endemic countries or flavivirus endemic regions of the US/US 
territories*, within 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useterritories*, within 
only to subjects to be enrolled into the flavivirus naÃ¯ve cohort).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonly to subjects to be enrolled into the flavivirus naÃ¯ve cohort).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use*CDC we
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use*CDC we bsite 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebsite 
and territories (see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand territories (see 
3.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.Known hypersensitivity or allergy to any of the vaccine 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseKnown hypersensitivity or allergy to any of the vaccine 
excipi[INVESTIGATOR_177850], control or placebo as summarized in Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexcipi[INVESTIGATOR_177850], control or placebo as summarized in Section 
4.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use4.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 50of 108
Protocol Amendment 3 Version 7.0 12September 2018
6.Individuals with history or any illness that, in the opi[INVESTIGATOR_871], might interfere 
with the results of the trial or po se additional risk to the subjects due to participation in the trial.
7.Known or suspected impairment/alteration of immune function, including:
oChronic use of oral steroids (equivalent to 20 mg/day prednisone â‰¥12weeks / 
â‰¥2mg/kg body weight / day prednisone â‰¥2weeks) within 60 days prior to Day 1 (use 
of inhaled, intranasal, or topi[INVESTIGATOR_177804]).
oReceipt of parenteral steroids (equivalent to 20 mg/day prednisone â‰¥12weeks / 
â‰¥2mg/kg body weight / day pred nisone â‰¥2weeks) within 60 days prior to Day 1.
oReceipt of immunostimulants within 60 days prior to Day 1.
oReceipt of parenteral, epi[INVESTIGATOR_177805] -articular immunoglobulin preparation, blood 
products, and/or plasma derived products within [ADDRESS_209031] be advised not to donate 
blood during the study period.
oKnown Human I mmunodeficiency Virus (HIV) infection or HIV -related disease.
oGenetic immunodeficiency.
8.Individuals with known current or chronic hepatitis B and/or hepatitis C infections.
9.Abnormalities of splenic or thymic function.
10.Individuals with a known bleeding diathesis, or any condition that may be associated with a 
prolonged bleeding time.
11.Individuals with any seri ous chronic or progressive disease according to judgment of the 
investigator (eg, neoplasm, insulin -dependent diabetes, cardiac, renal, hepatic or thyroid 
disease, uncontrolled hypertension, uncontrolled asthma).
12.Individuals with body mass index (BMI) grea ter than or equal to 35 kg/m2 (= weight inkg / 
[height inmeters xheight inmeters]) .
13.Individuals participating in any clinical trial with another investigational product, including 
ZIKV vaccine trial, within [ADDRESS_209032] of this trial.
14.Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 
28days (for live vaccines) prior to Day 1in this trial or who are planning to receive any 
vaccine within 28 days of investigational vaccine/placebo administration.
15.Individuals involved in the trial conduct or their first degree relatives.
16.Individuals with history of substance or alcohol abuse within the past [ADDRESS_209033].
0051Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks) within 60 days prior to Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks) within 60 days prior to Day 1 (use 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1 (use 
12
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12weeks / 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweeks / 
days prior to Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays prior to Day
articular immunoglobulin preparation, blood 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usearticular immunoglobulin preparation, blood 
products, and/or plasma derived products within 3 months prior t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useproducts, and/or plasma derived products within [ADDRESS_209034]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject s
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesmust be advised not to donate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be advised not to donate 
mmunodeficiency Virus (HIV) infection or HIV
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemmunodeficiency Virus (HIV) infection or HIV
known current or chronic hepatitis B and/or hepatitis C infections.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useknown current or chronic hepatitis B and/or hepatitis C infections.
Abnormalities of splenic or thymic function.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAbnormalities of splenic or thymic function.
Individuals with a known bleeding diathesis, or any condition that may be associated with a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with a known bleeding diathesis, or any condition that may be associated with a 
ous chronic or progressive disease according to judgment of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useous chronic or progressive disease according to judgment of the 
investigator (eg, neoplasm, insulin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigator (eg, neoplasm, insulin
disease, uncontrolled hypertension, uncontrolled asthma).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedisease, uncontrolled hypertension, uncontrolled asthma).
Individuals with body mass index (BMI) grea
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with body mass index (BMI) grea
x
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usexheight
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useheight
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals participating in any clinical trial with another investigational product, including 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals participating in any clinical trial with another investigational product, including 
ZIKV vaccine trial, within [ADDRESS_209035] trial visit or intent 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZIKV vaccine trial, within [ADDRESS_209036] of this trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical trial at any time during the conduct of this trial.
Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals who received any other vaccines within 14 days (for inactivated vaccines) or 
28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use28days (for live vaccines) prior to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays (for live vaccines) prior to 
vaccine within 28 days of investigational vaccine/placebo administration.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine within 28 days of investigational vaccine/placebo administration.
15.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use15.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209037] of childbearing potential, sexually active, and who has not used any of the 
"acceptable contraceptive methods" for at least 2 months prior to trial entry:
oâ€œOf childbearing potential â€is defined as status post onset of menarche and not meeting 
any of the following conditions: menopausal for at least 2 years without any other 
alternative medical cause (as confirmed by a healthcare professional), status after 
bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status 
after hysterectomy.
oAcceptable birth control methods are defined as one or more of the following:
â€“Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical 
ring).
â€“Barrier (condom with spermicide or diaphragm with spermicide) each and every time 
during intercourse.
â€“Intrauterine device.
â€“Monogamous relationship (only have one sexual partner) with vasectomized partner. 
Partner must have been vasectomized for at least si x months prior to the subjects' trial 
entry.
20.If female subject of childbearing potential and sexually active, refusal to use an "acceptable 
contraceptive method" from trial entry through [ADDRESS_209038] dose of investigational 
vaccine/placebo. In a ddition, female subjects of childbearing potential must be advised not to 
donate ova during this period.
21.To avoid sexual transmission of ZIKV from natural exposure: Refusal to use latex condoms 
correctly and consistently by [CONTACT_177968]. Male subjects must be advised not to 
donate sperm during this period. 
Temporary screening failure
A subject may be a temporary screen failure under the following cir cumstances: due to temporary 
conditions such as receipt of immunosuppressive or immunomodulatory therapi[INVESTIGATOR_014], blood products, 
immunoglobulins, or vaccines, in the respective prohibited periods (see exclusion criteria 7, 13 or 
14), or in the event that a subj ect has an indeterminate pregnancy test result or has not used 
acceptable contraceptive methods in the period defined in the protocol, prior to the start of the 
study (exclusion criteria 19). Subjects screen failed for the above -mentioned reasons may be 
rescreened once they cease to meet the respective exclusion criteria. Should the respective 
repeated test results be available within the initial screening period, no new subject ID numbers 
will be required; the repeated screening will be recorded in the app ropriate CRF (unscheduled lab 
form). Should the respective repeated test results not be available within the initial screening 
period, the subject would need to be screen failed and all screening procedures and tests would 
need to be repeated with a new su bject ID number.
0052Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis defined as status post onset of menarche and not meeting 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useis defined as status post onset of menarche and not meeting 
any of the following conditions: menopausal for at least 2 years without any other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useany of the following conditions: menopausal for at least 2 years without any other 
alternative medical cause (as confirmed by a healthcare professional), status after 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usealternative medical cause (as confirmed by a healthcare professional), status after 
at least 1 year, status after bilateral oophorectomy, or status 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat least 1 year, status after bilateral oophorectomy, or status 
Acceptable birth control methods are defined as one or more of the following:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAcceptable birth control methods are defined as one or more of the following:
Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical 
Barrier (condom with spermicide or diaphragm with spermicide) each and every time 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBarrier (condom with spermicide or diaphragm with spermicide) each and every time 
Monogamous relationship (only have one sexual partner) with vasectomized partner. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMonogamous relationship (only have one sexual partner) with vasectomized partner. 
Partner must have been vasectomized for at least si
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePartner must have been vasectomized for at least si
If female subject of childbearing potential and sexually active, refusal to use an "acceptable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf female subject of childbearing potential and sexually active, refusal to use an "acceptable 
contraceptive method" from trial entry through [ADDRESS_209039] dose of investigational 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontraceptive method" from trial entry through [ADDRESS_209040] dose of investigational 
female subjects of childbearing potential 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefemale subjects of childbearing potential 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo avoid sexual transmission of ZIKV from natural exposure: Refusal to use latex condoms 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo avoid sexual transmission of ZIKV from natural exposure: Refusal to use latex condoms 
correctly and consistently by [CONTACT_177969]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecorrectly and consistently by [CONTACT_177970].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useused from signing the ICF through the end of the trial.
donate sperm during this period. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedonate sperm during this period. 
Temporary screening failure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTemporary screening failure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA subject may be a temporary screen failure under the following cir
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA subject may be a temporary screen failure under the following cir
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconditions such as receipt of immunosuppressive or immunomodulatory therapi[INVESTIGATOR_014], blood products, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconditions such as receipt of immunosuppressive or immunomodulatory therapi[INVESTIGATOR_014], blood products, 
immunoglobulins, or vaccines, in the respective prohibited periods (see exclusion criteria 7, 13 or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmunoglobulins, or vaccines, in the respective prohibited periods (see exclusion criteria 7, 13 or 
14), or in the event that a subj
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use14), or in the event that a subj
acceptable contraceptive methods in the period defined in the protocol, prior to the start of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useacceptable contraceptive methods in the period defined in the protocol, prior to the start of the 
study (exclusion criteria 19). Subjects screen failed for the above
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy (exclusion criteria 19). Subjects screen failed for the above
re
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userescreened once they cease to meet the respective exclusion criteria. Should the respective 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreened once they cease to meet the respective exclusion criteria. Should the respective 
repeated test results be available within the initial screening period, no new subject ID numbers 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userepeated test results be available within the initial screening period, no new subject ID numbers 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 52of 108
Protocol Amendment 3 Version 7.0 12September 2018
7.3 Criteria for Delay of Vaccination and/or Blood Sampling
After enrollment , subjects may encounter clinical circumstances that warrant a delay in the 
administration of the subsequent dose of investigational vaccine/placebo. These situations are 
listed below:
ï‚·Individuals with a clinically significant active infection (as assessed by [CONTACT_093]) or 
temperature â‰¥38.0Â°C /100.4Â°F ,within 3 days of intended investigational vaccine/placebo 
administration.
ï‚·Individuals who received any other vacc ines within [ADDRESS_209041] is otherwise eligible for 
trial partic ipation. The decision to vaccinate in those situations will be taken by [CONTACT_093] .
There are also circumstances under which receipt of further vaccines is a contraindication in this 
trial. These circumstances include anaphylaxis or severe hypersensi tivity reactions following the 
initial vaccine/placebo administration. If these reactions occur, the subject must not receive 
additional vaccinations; however, the subject is encouraged to continue in trial participation for 
safety reasons.
7.[ADDRESS_209042]â€™s trial participation may be terminated early. This means that 
no further trial procedures (including data collection) will be performed on that subject beyond the 
specific date of earl y termination. The primary reason for early termination of the subject from the 
trial should be recorded in the electronic Case Report Form (eCRF â€œend of study visitâ€ page) using 
the following categories. For screen failure subjects, refer to Section 9.1.10 .
1.Adverse Event: The subject has experienced an AE (irrespective of being related / unrelated to 
the Trial Vaccine or trial -related procedures ) that requires early termination because continued 
participation imposes an unacceptable risk to the subjectâ€™s health and / or the subject is 
unwilling to continue participation because of the AE. If the subject is unwilling to continue 
because of the AE the primary reason for early termination in this case will be â€˜withdrawal due 
to AEâ€™ and not â€˜withdrawal of consentâ€™, see below. Any ongoing AEs leading to early 
termination will be followed by [CONTACT_177971].
2.Lost to follow -up: The subject did not return to the clinic and at least three attempts to contact 
[CONTACT_57509]. Attempts to contact [CONTACT_45316].
3.Withdrawal of consent: The subject wishes to withdraw from the trial. The primary reason for 
early termination will be â€˜withdrawal of consentâ€ if the subject withdraws from participation 
due to a non -medical reason (ie, reason other than AE). The reason for withdrawal, if provided, 
should be recorded in the eCRF.
Note: All attempts shou ld be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded. 
0053Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with a clinically significant active infection (as assessed by [CONTACT_093]) or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIndividuals with a clinically significant active infection (as assessed by [CONTACT_093]) or 
within 3 days of intended investigational vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewithin 3 days of intended investigational vaccine/placebo 
planned vaccination.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplanned vaccination.
In the event that a subject meets a criterion for delay of vaccination, the subject may receive trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn the event that a subject meets a criterion for delay of vaccination, the subject may receive trial 
vaccination once the window for delay has passed as long as the subject is otherwise eligible for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccination once the window for delay has passed as long as the subject is otherwise eligible for 
ipation. The decision to vaccinate in those situations will be taken by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useipation. The decision to vaccinate in those situations will be taken by [CONTACT_177973] a contraindication in this 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThere are also circumstances under which receipt of further vaccines is a contraindication in this 
trial. These circumstances include anaphylaxis or severe hypersensi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial. These circumstances include anaphylaxis or severe hypersensi tivity reactions following the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetivity reactions following the 
initial vaccine/placebo administration. If these reactions occur, the subject must not receive 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinitial vaccine/placebo administration. If these reactions occur, the subject must not receive 
additional vaccinations; however, the subject is encouraged to continue in trial participation for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadditional vaccinations; however, the subject is encouraged to continue in trial participation for 
rly Study Termination of a Subject
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userly Study Termination of a Subject
Under some circumstances, a subjectâ€™s trial participation may be terminated early. This means that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnder some circumstances, a subjectâ€™s trial participation may be terminated early. This means that 
no further trial procedures (including data collection) will be performed on that subject beyond the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useno further trial procedures (including data collection) will be performed on that subject beyond the 
y termination. The primary reason for early termination of the subject from the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey termination. The primary reason for early termination of the subject from the 
trial should be recorded in the electronic Case Report Form (eCRF â€œend of study visitâ€ page) using 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial should be recorded in the electronic Case Report Form (eCRF â€œend of study visitâ€ page) using 
the following categories. For screen failure subjects, refer to Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe following categories. For screen failure subjects, refer to Section
Adverse Event: The subject has experienced an AE (irrespective of being related / unrelated to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdverse Event: The subject has experienced an AE (irrespective of being related / unrelated to 
the Trial Vaccine or trial
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe Trial Vaccine or trial -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated procedures
participation imposes an unacceptable risk to the subjectâ€™s health and / or the subject is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticipation imposes an unacceptable risk to the subjectâ€™s health and / or the subject is 
unwilling to continue participation because of the AE. If the subject is unwilling to continue 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunwilling to continue participation because of the AE. If the subject is unwilling to continue 
because of the AE 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebecause of the AE the primary reason for early termination in this case will be â€˜withdrawal due 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe primary reason for early termination in this case will be â€˜withdrawal due 
to AEâ€™ and not â€˜withdrawal of consentâ€™, see below. Any ongoing AEs leading to early 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto AEâ€™ and not â€˜withdrawal of consentâ€™, see below. Any ongoing AEs leading to early 
termination will be followed by [CONTACT_177971].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetermination will be followed by [CONTACT_177971].
Lost to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLost to follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefollow
the subject were unsuccessful. Attempts to contact [CONTACT_45316].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe subject were unsuccessful. Attempts to contact [CONTACT_45316].
3.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.Withdrawal of consent: The subject wishes to withdraw from the trial. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWithdrawal of consent: The subject wishes to withdraw from the trial. The 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 53of 108
Protocol Amendment 3 Version 7.0 12September 2018
4.Premature study termination by [CONTACT_3211], a regulatory agency, the IEC/IRB, or any other 
authority.
If the clinical study is prematurely terminated by [CONTACT_456], the investigator is to promptly 
inform the study subjects and local EC/IRB and should assure appropriate follow up for the 
subjects. The primary reason for early termination in this case will be â€˜trial termination â€.
5.Subjectâ€™s death during trial participation.
6.Other.
Note: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.
7.5 Criteria for Premature Discontinuation of Trial Vaccine Application 
Early (premature) study termination of a subject wi ll by [CONTACT_177974], as the subject will no longer be participating in the study.
In addition to early termination (see Section 7.4) criteria, other situations may apply in which 
subjects may continue participating in the trial (eg, contributing safety data according to protocol) 
but Trial Vaccine application is discontinued selectively. Regar dless of the reasons for 
discontinuation of Trial Vaccine application, this must be documented as protocol deviation. Even 
if the subject is deemed ineligible to continue to receive Trial Vaccine, all efforts should be made 
to continue the collection of sa fety data according to protocol. In addition, the one primary reason 
for premature discontinuation of Trial Vaccine application should be recorded in the eCRF, â€œend 
of Trial Vaccine applicationâ€ page using the following categories.
1.Adverse Event: The subje ct has experienced an AE (irrespective of being related / unrelated to 
the Trial Vaccine or trial -related procedures) for which subsequent Trial Vaccine applications 
impose an unacceptable risk to the subjectâ€™s health, but the subject will continue trial 
participation for safety, or a subset of other study procedures. 
2.Lost to follow -up: The subject did not return to the clinic and at least three attempts to contact 
[CONTACT_57509]. Attempts to contact [CONTACT_45316]
3.Withdrawal of consent: The subject wishes to withdraw from the trial. The primary reason for 
early termination will be â€˜withdrawal of consentâ€ if the subject withdraws from participation 
due to a non -medical reason (ie, reason other than AE). The reason for withdraw al, if provided, 
should be recorded in the eCRF.
4.Premature study termination by [CONTACT_3211], a regulatory agency, the IEC/IRB, or any other 
authority.
If the clinical study is prematurely terminated by [CONTACT_456], the investigator is to promptly 
inform the st udy subjects and local EC/IRB and should assure appropriate follow up for the 
subjects. The primary reason for early termination in this case will be â€˜trial terminationâ€.
5.SubjectÂ´s death during trial participation.
0054Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNote: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNote: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.
Criteria for Premature Discontinuation of Trial Vaccine Application 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCriteria for Premature Discontinuation of Trial Vaccine Application 
ll by [CONTACT_177975]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usell by [CONTACT_177974], as the subject will no longer be participating in the study.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial Vaccine administration, as the subject will no longer be participating in the study.
) criteria, other situations may apply in which 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) criteria, other situations may apply in which 
subjects may continue participating in the trial (eg, contributing safety data according to protocol) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects may continue participating in the trial (eg, contributing safety data according to protocol) 
but Trial Vaccine application is discontinued selectively. Regar
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebut Trial Vaccine application is discontinued selectively. Regar
discontinuation of Trial Vaccine application, this must be documented as protocol deviation. Even 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usediscontinuation of Trial Vaccine application, this must be documented as protocol deviation. Even 
if the subject is deemed ineligible to continue to receive Trial Vaccine, all efforts should be made 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useif the subject is deemed ineligible to continue to receive Trial Vaccine, all efforts should be made 
fety data according to protocol. In addition, the one 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefety data according to protocol. In addition, the one 
for premature discontinuation of Trial Vaccine application should be recorded in the eCRF, â€œend 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor premature discontinuation of Trial Vaccine application should be recorded in the eCRF, â€œend 
of Trial Vaccine applicationâ€ page using the following categories.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof Trial Vaccine applicationâ€ page using the following categories.
ct has experienced an AE (irrespective of being related / unrelated to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usect has experienced an AE (irrespective of being related / unrelated to 
related procedures) for which subsequent Trial Vaccine applications 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userelated procedures) for which subsequent Trial Vaccine applications 
impose an unacceptable risk to the subjectâ€™s health, but 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimpose an unacceptable risk to the subjectâ€™s health, but 
articipation for safety, or a subset of other study procedures. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usearticipation for safety, or a subset of other study procedures. 
up: The subject did not return to the clinic and at least three attempts to contact 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup: The subject did not return to the clinic and at least three attempts to contact 
[CONTACT_57509]. Attempts to contact [CONTACT_177976]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe subject were unsuccessful. Attempts to contact [CONTACT_177977]: The subject wishes to withdraw from the trial. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof consent: The subject wishes to withdraw from the trial. The 
early termination will be â€˜withdrawal of consentâ€ if the subject withdraws from participation 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useearly termination will be â€˜withdrawal of consentâ€ if the subject withdraws from participation 
due to a non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedue to a non -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical reason (ie, reason other than AE). The reason for withdraw
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical reason (ie, reason other than AE). The reason for withdraw
should be recorded in the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useshould be recorded in the eCRF.
Premature study termination by [CONTACT_3211], a regulatory agency, the IEC/IRB, or any other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePremature study termination by [CONTACT_3211], a regulatory agency, the IEC/IRB, or any other 
authority.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauthority.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 54of 108
Protocol Amendment 3 Version 7.0 12September 2018
6.Protocol deviation: A protocol deviation is any change, divergence, or departure from the 
study design or procedures of a study protocol. The subject may remain in the trial unless 
continuation in the trial jeopardizes the subjectâ€™s health, safety or rights (see Section 7.4).
7.Pregnancy: Any subject who, despi[INVESTIGATOR_177851], becomes 
pregnant during the trial will not receive further Trial Vaccine applications. Pregnant subjects 
should, however, be asked to continue participating in the trial contributing data to the safety 
follow -up according to protocol. In addition, the site should maintain contact [CONTACT_177978] a â€œClinical Trial Pregn ancy Formâ€ as soon as possible. The subject 
should be followed -up until the birth of the child, or spontaneous or voluntary termination; 
when pregnancy outcome information becomes available, the information should be captured 
using the same form. Data obta ined from the â€œClinical Trial Pregnancy Formâ€ will be captured 
in the safety database.
8.Other .
Note: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.
0055Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePregnancy: Any subject who, despi[INVESTIGATOR_177851], becomes 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePregnancy: Any subject who, despi[INVESTIGATOR_177851], becomes 
Pregnant subjects 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePregnant subjects 
should, however, be asked to continue participating in the trial contributing data to the safety 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useshould, however, be asked to continue participating in the trial contributing data to the safety 
up according to protocol. In addition, the site should maintain contact [CONTACT_177979]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup according to protocol. In addition, the site should maintain contact [CONTACT_177980]â€ as soon as possible. The subject 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useancy Formâ€ as soon as possible. The subject 
up until the birth of the child, or spontaneous or voluntary termination; 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup until the birth of the child, or spontaneous or voluntary termination; 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhen pregnancy outcome information becomes available, the information should be captured 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhen pregnancy outcome information becomes available, the information should be captured 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useined from the â€œClinical Trial Pregnancy Formâ€ will be captured 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useined from the â€œClinical Trial Pregnancy Formâ€ will be captured 
Note: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNote: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 55of 108
Protocol Amendment 3 Version 7.0 12September 2018
8.0 CLINICAL TRIAL MATERIAL MANAGEMENT
This section contains information regarding all vaccines and materials provided directly by [CONTACT_103], and/or sourced by [CONTACT_11174], that are required by [CONTACT_47519], including important 
sections describing the management of clinical trial material.
8.1 Trial Vaccines and Materials
8.1.1 Dosage Form , Manufacturing, Packaging, and Labeling
In this protocol, the investigational vaccine (PI[INVESTIGATOR_177760]) refers to Zika purified formalin -inactivated 
virus formulated with 200 Âµg aluminum hydroxide, Al(OH) 3, as adjuvant, in phosphate buffered 
saline solution (PBS). T he final liquid formulated product is filled into single -use vials and sealed 
with tamper -evident seals at [COMPANY_005]â€™s manufacturing plant in Hikari, Japan. The vaccine is 
packaged, labeled, and shipped to unblinded study site pharmacist/designee. The investi gational 
vaccine is administered IM as a 2 -dose regimen of 0.5 mL at 2, 5, or 10 Âµg antigen per dose, 
28days apart. Refer to the IB and the Pharmacy Manual for more details.
Sodium chloride (NaCl) 0.9% solution for injection is being used as placebo. It i s supplied in 
single -use vials. It is a sterile, clear, colorless liquid solution of sodium chloride without 
preservative designed for parenteral use only. The placebo is packaged, labelled and shipped to 
unblinded study site pharmacist/designee. The place bo is administered IM as a 2 -dose regimen of 
0.5mL per dose, 28 days apart. Refer to the Pharmacy Manual for more details.
8.1.2 Storage
PI[INVESTIGATOR_177760]/placebo will be shipped in refrigerated and temperature -monitored containers. From receipt 
and prior to use, the invest igational vaccine and the placebo must be protected from light and 
stored at 2Â°C to 8Â°C in a temperature monitored refrigerator with controlled access available only 
to authorized trial personnel. The investigational vaccine/placebo must not be frozen. In case of 
accidental freezing, frozen investigational vaccine/placebo should never been administered to 
subjects. The investigational vaccine/placebo is single use only.
All clinical trial material must be kept in an appropriate, limited -access, secure place until it is used 
or returned to the sponsor or designee for destruction. All sponsor -supplied vaccines/placebos 
must be stored under the conditions specified on the label, and remain in the original container 
until dispensed. A daily temperature log of th e vaccine/placebo storage area must be maintained 
every working day. Temperature excursions must be reported to the sponsor as soon as possible 
and use of these vaccines/placebos requires sponsor approval. Refer to the Pharmacy Manual.
8.1.3 Dose and Regimen
Three formulations of the vaccine containing different antigen concentrations will be used, where 
low dose contains 2 Âµg, medium dose contains 5 Âµg, and high dose contains 10 Âµg of the vaccine. 
Each dose will be packaged and appropriately labeled in complianc e with regional regulatory 
requirements.
0056Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesponsor, and/or sourced by [CONTACT_11174], that are required by [CONTACT_47519], including important 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesponsor, and/or sourced by [CONTACT_11174], that are required by [CONTACT_47519], including important 
In this protocol, the investigational vaccine (PI[INVESTIGATOR_177760]) refers to Zika purified formalin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn this protocol, the investigational vaccine (PI[INVESTIGATOR_177760]) refers to Zika purified formalin inactivated 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinactivated 
, as adjuvant, in phosphate buffered 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, as adjuvant, in phosphate buffered 
he final liquid formulated product is filled into single
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe final liquid formulated product is filled into single -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-use vials and sealed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuse vials and sealed 
evident seals at [COMPANY_005]â€™s manufacturing plant in Hikari, Japan. The vaccine is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevident seals at [COMPANY_005]â€™s manufacturing plant in Hikari, Japan. The vaccine is 
packaged, labeled, and shipped to unblinded study site pharmacist/designee. The investi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepackaged, labeled, and shipped to unblinded study site pharmacist/designee. The investi
mL at 2, 5, or 10 Âµg antigen per dose, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL at 2, 5, or 10 Âµg antigen per dose, 
days apart. Refer to the IB and the Pharmacy Manual for more details.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays apart. Refer to the IB and the Pharmacy Manual for more details.
Sodium chloride (NaCl) 0.9% solution for injection is being used as placebo. It i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSodium chloride (NaCl) 0.9% solution for injection is being used as placebo. It i
use vials. It is a sterile, clear, colorless liquid solution of sodium chloride without 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuse vials. It is a sterile, clear, colorless liquid solution of sodium chloride without 
preservative designed for parenteral use only. The placebo is packaged, labelled and shipped to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepreservative designed for parenteral use only. The placebo is packaged, labelled and shipped to 
unblinded study site pharmacist/designee. The place
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunblinded study site pharmacist/designee. The place bo is administered IM as a 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebo is administered IM as a 2
mL per dose, 28 days apart. Refer to the Pharmacy Manual for more details.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsemL per dose, 28 days apart. Refer to the Pharmacy Manual for more details.
PI[INVESTIGATOR_177760]/placebo will be shipped in refrigerated and temperature
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePI[INVESTIGATOR_177760]/placebo will be shipped in refrigerated and temperature
igational vaccine and the placebo must be protected from light and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useigational vaccine and the placebo must be protected from light and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestored at 2Â°C to 8Â°C in a temperature monitored refrigerator with controlled access available only 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestored at 2Â°C to 8Â°C in a temperature monitored refrigerator with controlled access available only 
to authorized trial personnel. The investigational vaccine/placebo must not be frozen. In 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto authorized trial personnel. The investigational vaccine/placebo must not be frozen. In 
accidental freezing, frozen investigational vaccine/placebo should never been administered to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccidental freezing, frozen investigational vaccine/placebo should never been administered to 
subjects. The investigational vaccine/placebo is single use only.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects. The investigational vaccine/placebo is single use only.
All clinical trial material must be kept in an appropriate, limited
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll clinical trial material must be kept in an appropriate, limited
or returned to the sponsor or designee for destruction. All sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor returned to the sponsor or designee for destruction. All sponsor
must be stored under the conditions specified on the label, and remain in the original container 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be stored under the conditions specified on the label, and remain in the original container 
until dispensed. A daily temperature log of th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuntil dispensed. A daily temperature log of th
every working day. Temperature excursions must be reported to the sponsor as soon as possible 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevery working day. Temperature excursions must be reported to the sponsor as soon as possible 
and use of these vaccines/placebos requires sponsor approval. Refer to the Pharmacy Manual.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand use of these vaccines/placebos requires sponsor approval. Refer to the Pharmacy Manual.
8.1.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8.1.3
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 56of 108
Protocol Amendment 3 Version 7.0 12September 2018
Table 8.adescribes the doses that will be provided to each group.
Table 8.a Sponsor -Supplied Vaccine and Placebo
Treatment Group Dose Treatment Description Timing (Dose 1/Dose 2)
Arm 1 2 doses Placebo Day 1/Day 29
Arm 2 2 doses PI[INVESTIGATOR_177760] 2 Âµg Day 1/Day 29
Arm 3 2 doses PI[INVESTIGATOR_177760] 5 Âµg Day 1/Day 29
Arm 4 2 doses PI[INVESTIGATOR_177760] 10 Âµg Day 1/Day 29
8.2 Investigational Vaccine/Placebo Assignment and Dispensing Procedures
The investigator or investigatorâ€™s designee will access the Interactive Response Technology (IRT) 
at Screening Visit (1A or 1B) to obtain the subject IDnumber. 
The investigator or investigatorâ€™s designee will utilize the IRT to randomize the subject at Visit 2. 
The investigational vaccine/placebo identification numbers to be administered will be assigned by 
[CONTACT_6606]. Details of randomization and the IRT will be covere d in the IRT User Manual.
The investigational vaccine/placebo will be prepared and administered by [CONTACT_177981], according to the instructions in the Pharmacy Manual. All investigational vaccine/placebo 
preparation will be documented.
All doses of the investigational vaccine/placebo will be administered IM into the middle third of 
the deltoid muscle of the subjectâ€™s arm, preferably the non -domin ant arm.
The investigator or designee will be responsible for overseeing the administration of 
investigational vaccine/placebo to subjects enrolled in the trial according to the procedures 
stipulated in this trial protocol.
If vials containing the investig ational vaccine/placebo are lost or damaged, the site can request a 
replacement from the IRT (refer to the IRT manual supplied separately). Expi[INVESTIGATOR_177852].
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING THE TRIAL VACCINE:
Prior to vaccination, a subject must be determined to be eligible for trial vaccination and it must be 
clinically appropriate in the judgment of the investigator to vaccinate. Eligibility for vaccination 
prior to first trial vaccine administration is determine d by [CONTACT_177982] (Sections 7.1and 7.2).
Eligibility for subsequent trial vaccination is determined by [CONTACT_29274] 7.0.
Trial vaccines should not be administered to individuals with known hypersensitivity to any 
component of the vaccines.
0057Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigational Vaccine/Placebo Assignment and Dispensing Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigational Vaccine/Placebo Assignment and Dispensing Procedures
The investigator or investigatorâ€™s designee will access the Interactive Response Technology (IRT) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator or investigatorâ€™s designee will access the Interactive Response Technology (IRT) 
investigator or investigatorâ€™s designee will utilize the IRT to randomize the subject at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigator or investigatorâ€™s designee will utilize the IRT to randomize the subject at Visit
The investigational vaccine/placebo identification numbers to be administered will be assigned by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigational vaccine/placebo identification numbers to be administered will be assigned by 
[CONTACT_6606]. Details of randomization and the IRT will be covere
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe IRT. Details of randomization and the IRT will be covere d in the IRT User Manual.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used in the IRT User Manual.
The investigational vaccine/placebo will be prepared and administered by [CONTACT_177983]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigational vaccine/placebo will be prepared and administered by [CONTACT_177984]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewho is qualified to perform that function under applicable laws and regulations for that specific 
in the Pharmacy Manual. All investigational vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein the Pharmacy Manual. All investigational vaccine/placebo 
All doses of the investigational vaccine/placebo will be administered IM into the middle third of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll doses of the investigational vaccine/placebo will be administered IM into the middle third of 
the deltoid muscle of the subjectâ€™s arm, preferably the non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe deltoid muscle of the subjectâ€™s arm, preferably the non
The investigator or designee will be responsible for overseeing the administration of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator or designee will be responsible for overseeing the administration of 
investigational vaccine/placebo to subjects enrolled in the trial according to the procedures 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine/placebo to subjects enrolled in the trial according to the procedures 
stipulated in this trial protocol.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestipulated in this trial protocol.
If vials containing the investig
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf vials containing the investig
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereplacement from the IRT (refer to the IRT manual supplied separately). Expi[INVESTIGATOR_177853]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereplacement from the IRT (refer to the IRT manual supplied separately). Expi[INVESTIGATOR_177854].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust not be administered.
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING THE TRIAL VACCINE:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePRECAUTIONS TO BE OBSERVED IN ADMINISTERING THE TRIAL VACCINE:
r to vaccination, a subject must be determined to be eligible for trial vaccination and it must be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User to vaccination, a subject must be determined to be eligible for trial vaccination and it must be 
clinically appropriate in the judgment of the investigator to vaccinate. Eligibility for vaccination 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinically appropriate in the judgment of the investigator to vaccinate. Eligibility for vaccination 
prior to first trial vaccine administration is determine
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprior to first trial vaccine administration is determine
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethis protocol (Sections 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethis protocol (Sections 
Eligibility for subsequent trial vaccination is determined by [CONTACT_177985]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEligibility for subsequent trial vaccination is determined by [CONTACT_177986] (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209043] immunization practices are to be observed and care should be t aken to administer the 
injection intramuscularly. In addition, WHO recommendations to reduce anxiety and pain at the 
time of vaccination should be followed (91). Before administering the vaccine, the vaccination site 
is to be disinfected with a skin disinfectant (eg, 70% alcohol). Allow the skin to dry. DO NOT 
inject intravascularly.
As with all injectable vaccines, trained medical personnel and appropriate medical treatment 
should be readily available in case of anaphylactic reactions fo llowing vaccination. For example, 
epi[INVESTIGATOR_238] 1:1000, diphenhydramine, and/or other medications for treating anaphylaxis should 
be available.
8.3 Randomization Code Creation and Storage
Randomization personnel of the IRT provider or designee will generate the randomization 
schedule(s). Randomization information will be stored in a secured area, accessible only by 
[CONTACT_4144].
8.[ADDRESS_209044] Blind Maintenance
This trial is an observer -blind study. The subjects, data collectors (eg, investigator ), and data 
evaluators (eg, trial statisticians) are blinded to the material administered. The investigational 
product assignment will be maintained by [CONTACT_177987].
All care must be taken to ensure that the unblinded reports and docum ents are shared only with 
unblinded personnel and properly stored in a secured area, accessible only by [CONTACT_85983].
8.5 Unblinding Procedure
The investigational vaccine/placebo blind shall not be broken by [CONTACT_177988]/placebo is necessary for the medical treatment 
of the subject. In the event of a medical emergency, if possible, the medical monitor should be 
contact[CONTACT_177989]/placebo blind is broken to discuss th e need for 
unblinding.
For unblinding a subject, the investigational vaccine/placebo blind can be obtained by [CONTACT_1275], by [CONTACT_177990].
The sponsorâ€™s Pharmacovigilance Department must be notified as soon as possible if the 
investigational vac cine/placebo blind is broken by [CONTACT_093]; and if the unblinding was for 
medical reasons (SAE), the completed SAE form must be sent within 24 hours (ie, the site will 
follow the standard process for reporting of SAEs). The date, time, and reason the blind is broken 
must be recorded in the source document and the same information (except the time) must be 
recorded on the eCRF.
If any subject is unblinded, no further doses of investigational vaccine/placebo are to be 
administered. However, the subject will be followed up for safety and safety data will be collected 
according to protocol. 
0058Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Before administering the vaccine, the vaccination site 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Before administering the vaccine, the vaccination site 
with a skin disinfectant (eg, 70% alcohol). Allow the skin to dry. DO NOT 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith a skin disinfectant (eg, 70% alcohol). Allow the skin to dry. DO NOT 
As with all injectable vaccines, trained medical personnel and appropriate medical treatment 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAs with all injectable vaccines, trained medical personnel and appropriate medical treatment 
llowing vaccination. For example, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usellowing vaccination. For example, 
epi[INVESTIGATOR_238] 1:1000, diphenhydramine, and/or other medications for treating anaphylaxis should 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useepi[INVESTIGATOR_238] 1:1000, diphenhydramine, and/or other medications for treating anaphylaxis should 
Randomization personnel of the IRT provider or designee will generate the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRandomization personnel of the IRT provider or designee will generate the 
schedule(s). Randomization information will be stored in a secured area, accessible only by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useschedule(s). Randomization information will be stored in a secured area, accessible only by 
[CONTACT_177991]. The subjects, data collectors (eg,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useblind study. The subjects, data collectors (eg,
evaluators (eg, trial statisticians) are blinded to the material administered. The investigational 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevaluators (eg, trial statisticians) are blinded to the material administered. The investigational 
product assignment will be maintained by [CONTACT_177987].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useproduct assignment will be maintained by [CONTACT_177987].
All care must be taken to ensure that the unblinded reports and docum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll care must be taken to ensure that the unblinded reports and docum
unblinded personnel and properly stored in a secured area, accessible only by [CONTACT_177992]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunblinded personnel and properly stored in a secured area, accessible only by [CONTACT_177993]/placebo blind shall not be broken by [CONTACT_177994]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigational vaccine/placebo blind shall not be broken by [CONTACT_177995]/placebo is necessary for the medical treatment 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useng the investigational vaccine/placebo is necessary for the medical treatment 
of the subject. In the event of a medical emergency, if possible, the medical monitor should be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof the subject. In the event of a medical emergency, if possible, the medical monitor should be 
contact[CONTACT_177989]/placebo blind is broken to discuss th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontact[CONTACT_177989]/placebo blind is broken to discuss th
For unblinding a subject, the investigational vaccine/placebo blind can be obtained by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor unblinding a subject, the investigational vaccine/placebo blind can be obtained by [CONTACT_1275], by [CONTACT_177990].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigator, by [CONTACT_177990].
The sponsorâ€™s Pharmacovigilance Department must be notified as soon as possible if the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsorâ€™s Pharmacovigilance Department must be notified as soon as possible if the 
investigational vac
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vac
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical reasons (SAE), the completed SAE form must be sent within 24 hours (ie, the site will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical reasons (SAE), the completed SAE form must be sent within 24 hours (ie, the site will 
follow the standard process for reporting of SAEs). The date, time, and reason the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefollow the standard process for reporting of SAEs). The date, time, and reason the
must be recorded in the source document and the same information (except the time) must be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be recorded in the source document and the same information (except the time) must be 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 58of 108
Protocol Amendment 3 Version 7.0 12September 2018
8.6 Accountability and Destruction of Sponsor -Supplied Vaccine/Placebo
Investigational vaccine/placebo supplies will be counted and reconciled at the site before being 
returned to the sponsor or designee as noted below. Sites will maintain source documents in 
addition to entering data in the IRT.
The investigator or designee must ensure that the sponsor -supplied vaccine/placebo is used in 
accordance with the approved protoc ol and is administered only to subjects enrolled in the trial. To 
document appropriate use of sponsor -supplied vaccines/placebos, the investigator must maintain 
records of all sponsor -supplied vaccine/placebo delivery to the site, site inventory, administr ation 
and use by [CONTACT_6992], and return to the sponsor or designee.
Upon receipt of sponsor -supplied vaccines/placebos, the investigator or designee must verify the 
contents of the shipments against the packing list. The verifier should ensure that the q uantity is 
correct, the investigational vaccine/placebo is received within the labeled storage conditions (ie, 
no cold chain break has occurred during transit), and is in good condition. If quantity and 
conditions are acceptable, investigator or designee w ill acknowledge receipt of the shipment by 
[CONTACT_117540].
If there are any discrepancies between the packing list versus the actual product received, the 
sponsor or designee must be contact[CONTACT_45320]. The packing list should be filed in the
investigatorâ€™s essential document file.
The investigator must maintain 100% accountability for all sponsor -supplied vaccines/placebos 
received and administered during his or her entire participation in the trial. Proper vaccine/placebo 
accountability incl udes, but is not limited to:
ï‚·Verifying that actual inventory matches documented inventory;
ï‚·Verifying that the log is completed for the vaccine/placebo used to prepare each dose;
ï‚·Verifying that all containers used are documented accurately on the log;
ï‚·Verif ying that required fields are completed accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The investigator must record the current inventory of all sponsor -supplied vaccines/placebos on a 
sponsor -approved vaccine/placebo accountability log. The following information will be recorded 
at a minimum: protocol number and title, name [CONTACT_4236], site identifier and number, 
description of sponsor -supplied vaccines/placebos, date and amo unt. The log should include all 
required information as a separate entry for each subject to whom sponsor -supplied 
vaccine/placebo is administered.
The investigator will be notified of any expi[INVESTIGATOR_177855]. On expi[INVESTIGATOR_4058], the site must 
complete all instructions outlined in the notification, including segregation of expi[INVESTIGATOR_177856].
0059Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplied vaccine/placebo is used in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplied vaccine/placebo is used in 
ol and is administered only to subjects enrolled in the trial. To 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useol and is administered only to subjects enrolled in the trial. To 
supplied vaccines/placebos, the investigator must maintain 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplied vaccines/placebos, the investigator must maintain 
supplied vaccine/placebo delivery to the site, site inventory, administr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplied vaccine/placebo delivery to the site, site inventory, administr
supplied vaccines/placebos, the investigator or designee must verify the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplied vaccines/placebos, the investigator or designee must verify the 
contents of the shipments against the packing list. The verifier should ensure that the q
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontents of the shipments against the packing list. The verifier should ensure that the q
correct, the investigational vaccine/placebo is received within the labeled storage conditions (ie, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecorrect, the investigational vaccine/placebo is received within the labeled storage conditions (ie, 
no cold chain break has occurred during transit), and is in good condition. If quantity and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useno cold chain break has occurred during transit), and is in good condition. If quantity and 
ill acknowledge receipt of the shipment by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useill acknowledge receipt of the shipment by 
[CONTACT_177996], the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf there are any discrepancies between the packing list versus the actual product received, the 
sponsor or designee must be contact[CONTACT_45320]. The packing list should be filed in the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesponsor or designee must be contact[CONTACT_45320]. The packing list should be filed in the
The investigator must maintain 100% accountability for all sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator must maintain 100% accountability for all sponsor
received and administered during his or her entire participation in the trial. Proper vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceived and administered during his or her entire participation in the trial. Proper vaccine/placebo 
udes, but is not limited to:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useudes, but is not limited to:
Verifying that actual inventory matches documented inventory;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVerifying that actual inventory matches documented inventory;
Verifying that the log is completed for the vaccine/placebo used to prepare each dose;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVerifying that the log is completed for the vaccine/placebo used to prepare each dose;
Verifying that all containers used are documented accurately on the log;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVerifying that all containers used are documented accurately on the log;
ying that required fields are completed accurately and legibly.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useying that required fields are completed accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The investigator must record the current inventory of all sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator must record the current inventory of all sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapproved vaccine/placebo accountability log. The following information will be recorded 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapproved vaccine/placebo accountability log. The following information will be recorded 
at a minimum: protocol number and title, name [CONTACT_4236], site identifier and number, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat a minimum: protocol number and title, name [CONTACT_4236], site identifier and number, 
description of sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedescription of sponsor
required information as a separate entry for each subject to whom sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userequired information as a separate entry for each subject to whom sponsor
vaccine/placebo is administered.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo is administered.
The investigator will be notified of any expi[INVESTIGATOR_177857]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator will be notified of any expi[INVESTIGATOR_177858] (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 59of 108
Protocol Amendment 3 Version 7.0 12September 2018
Prior to site closure or at appropriate intervals throughout the trial, before any clinical trial 
materials are returned to the sponsor or its designee for destruction, a representative from the 
sponsor or its designee will perform clinical t rial material accountability and reconciliation. The 
investigator will retain a copy of the documentation regarding clinical trial material accountability, 
return, and/or destruction, and originals will be sent to the sponsor or designee.
The pharmacist (o r designated individual) at each site will be responsible for vaccine/placebo 
accountability and will document receipt, use, return, or destruction of PI[INVESTIGATOR_177760]. Vaccine/placebo 
accountability documentation will be reviewed by [CONTACT_177997].
0060Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userial material accountability and reconciliation. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userial material accountability and reconciliation. The 
investigator will retain a copy of the documentation regarding clinical trial material accountability, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigator will retain a copy of the documentation regarding clinical trial material accountability, 
r designated individual) at each site will be responsible for vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User designated individual) at each site will be responsible for vaccine/placebo 
accountability and will document receipt, use, return, or destruction of PI[INVESTIGATOR_177760]. Vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccountability and will document receipt, use, return, or destruction of PI[INVESTIGATOR_177760]. Vaccine/placebo 
accountability documentation will be reviewed by [CONTACT_177998]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaccountability documentation will be reviewed by [CONTACT_177997].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usering visits.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209045] be obtained at Screening Visit (1A or 1B), prior to the subject entering into 
the trial and before any protocol -directed procedures are performed.
A unique subject ID number will be assigned at Screening Visit (1A or 1B) to each subject after 
informed consent is obtained from the appropriate coding eg, IRT. If all eligibility criteria are 
fulfilled, this subject ID number will be used throughout the trial. Subject ID numbers assigned to 
subjects who fail screening should not be reused (Section 9.1.10 ).
Flavivirus primed subjects who were tested at Screening Visit 1A and accepted to enter th e second 
phase of the study (at Screening Visit 1B) do not need to sign the ICF again. Refer to Section 6.1
for more details about the staggered en rollment.
9.1.2 Demographics, Medical History, Travel History , Prior/Concomitant 
Medications/Vaccinations , and Blood Donation
Demographic information, to be obtained at Screening Visit (1A or 1B), will include age (date of 
birth), sex, race, and ethnicity as provided by [CONTACT_423]. Refer to Section 6.1for more details 
about the staggered enrollment.
Medical history will also be collected at Screening Visit(s) (Visit 1A and/or Visit 1B) and at 
Visit 2 (Day 1) and will include any medical history that may be relevant to subject eligibility for 
trial participation such as prior vaccinations, concomitant medications, and previous and ongoing 
illnesses or i njuries. Relevant medical history can also include any medical history that contributes 
to the understanding of an AE that occurs during trial participation, if it represents an exacerbation 
of an underlying disease/preexisting problem.
Medical occurrences before administration of the first dose of investigational vaccine/placebo are 
considered medical history.
Travel history to flavivirus endemic countries and flavivirus endemic regions of the US/US 
territories within 4weeks prior to screening will be col lected at Screening Visit 1A. Travel history 
to flavivirus endemic countries and flavivirus endemic regions of the US/US territories will be 
collected at each visit.
All medications, vaccines and blood products taken or re ceived by [CONTACT_177944] 3 months 
prior to the start of the trial are to be recorded on the source document (patient record) and entered 
on the Prior and Concomitant Medications eCRF. The use of antipyretics and/or analgesic 
0061Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe following sections describe the trial procedures and data to be collected. For each procedure, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe following sections describe the trial procedures and data to be collected. For each procedure, 
subjects are to be assessed by [CONTACT_177999]. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects are to be assessed by [CONTACT_177999]. The 
Informed consent must be obtained at Screening Visit (1A or 1B), prior to the subject entering into 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInformed consent must be obtained at Screening Visit (1A or 1B), prior to the subject entering into 
Screening Visit (1A or 1B) to each subject after 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening Visit (1A or 1B) to each subject after 
informed consent is obtained from the appropriate coding eg, IRT. If all eligibility criteria are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinformed consent is obtained from the appropriate coding eg, IRT. If all eligibility criteria are 
fulfilled, this subject ID number will be used throughout the trial. Subject ID numbers assigned to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefulfilled, this subject ID number will be used throughout the trial. Subject ID numbers assigned to 
who fail screening should not be reused (Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewho fail screening should not be reused (Section 9.1.10
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.10
Flavivirus primed subjects who were tested at Screening Visit 1A and accepted to enter th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFlavivirus primed subjects who were tested at Screening Visit 1A and accepted to enter th
phase of the study (at Screening Visit 1B) do not need to sign 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usephase of the study (at Screening Visit 1B) do not need to sign 
rollment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userollment.
Demographics, Medical History, Travel History
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDemographics, Medical History, Travel History
, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and Blood Donation
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood Donation
Demographic information, to be obtained at Screening Visit (1A or 1B), will include age (date of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDemographic information, to be obtained at Screening Visit (1A or 1B), will include age (date of 
birth), sex, race, and ethnicity as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebirth), sex, race, and ethnicity as provided
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprovided
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useabout the staggered enrollment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useabout the staggered enrollment.
Medical history will also be collected at Screening 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical history will also be collected at Screening 
1) and will include any medical history that may be relevant to subject eligibility for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1) and will include any medical history that may be relevant to subject eligibility for 
trial participation such as prior vaccinations, concomitant medications, and previous and ongoing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial participation such as prior vaccinations, concomitant medications, and previous and ongoing 
njuries. Relevant medical history can also include any medical history that contributes 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenjuries. Relevant medical history can also include any medical history that contributes 
to the understanding of an AE that occurs during trial participation, if it represents an exacerbation 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto the understanding of an AE that occurs during trial participation, if it represents an exacerbation 
of an underlying disease/preexisting problem.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof an underlying disease/preexisting problem.
Medical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical occurrences
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoccurrences
considered medical history.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsidered medical history.
Travel history to flavivirus endemic countries and flavivirus endemic regions of the US/US 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTravel history to flavivirus endemic countries and flavivirus endemic regions of the US/US 
territories within 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useterritories within 
to flavivirus endemic countries and flavivirus endemic regions of the US/US territories will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto flavivirus endemic countries and flavivirus endemic regions of the US/US territories will be 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209046] be ide ntified and the reason for their use 
(prophylaxis versus treatment) must be described in the source documents and the eCRF.
Medications taken for prophylaxis are those intended to prevent the onset of AEs following 
vaccination. Medications taken for treatm ent are intended to reduce or eliminate the presence of 
symptoms that are present. These data must be recorded in the source documents.
Prohibited Therapi[INVESTIGATOR_014] (See Section 7.2)
ï‚·Parenteral, epi[INVESTIGATOR_177805] -articular immunoglobulin preparation, blood products, and/or 
plasma derivatives within 3 months of trial vaccination. 
ï‚·Immunosuppressive therapy within 3 months or systemic (eg, oral or parenteral) corticosteroid 
treatment within 60 days prior to trial vaccine administration.
ï‚·Other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to 
Day 1in this trial. Any planned vaccinations during the trial should be discuss ed with the 
investigator and if given recorded on the trial eCRFs.
ï‚·Immunostimulants within 60 days prior to trial vaccine administration.
Subjects should not donate blood during the study period . 
Medical history (including corresponding medication) to be obtained will include any significant 
conditions or diseases that have disappeared or resolved at or prior to signing of informed consent.
All subjects will be tested for flaviviral serological status at Screening Visit (1A or 1B) .
9.1.3 Documentation of Trial E ntrance/Randomization
Only subjects who have signed an ICF at Screening Visit (1A or 1B), meet all of the inclusion 
criteria and none of the exclusion criteria, are eligible for entrance/randomization into the 
vaccination phase.
One single subject ID numbe r will be assigned to each subject at Screening Visit (1A or 1B). 
Eligible subjects will be assigned randomly to one of the four study arms in a (1:1:1:1) ratio by a 
computer.
The randomization schedule will be created and controlled by [CONTACT_178000]. T he 
randomization specification will be approved by [CONTACT_456]â€™s trial statistician or designee. 
If the subject is found to be ineligible for randomization/trial phase, the investigator should record 
the primary reason for failure on the subject enrollmen t screening log.
9.1.[ADDRESS_209047] be performed by a qualified health professional in accordance with 
local regulations and licensing requirements designated within the Site Responsibility Delegation 
Log. Complete physical exa mination, including height and weight, will be performed at Screening 
Visit(s) (Visit 1A and/or Visit 1B) according to the investigatorâ€™s standard practice. Measurement 
0062Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent are intended to reduce or eliminate the presence of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent are intended to reduce or eliminate the presence of 
articular immunoglobulin preparation, blood products, and/or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usearticular immunoglobulin preparation, blood products, and/or 
Immunosuppressive therapy within 3 months or systemic (eg, oral or parenteral) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseImmunosuppressive therapy within 3 months or systemic (eg, oral or parenteral) 
Other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOther vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to 
in this trial. Any planned vaccinations during the trial should be discuss
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein this trial. Any planned vaccinations during the trial should be discuss
Immunostimulants within 60 days prior to trial vaccine administration.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseImmunostimulants within 60 days prior to trial vaccine administration.
period
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useperiod . 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. 
Medical history (including corresponding medication) to be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical history (including corresponding medication) to be 
conditions or diseases that have disappeared or resolved at or prior to signing of informed consent.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconditions or diseases that have disappeared or resolved at or prior to signing of informed consent.
flaviviral serological status 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useflaviviral serological status 
ntrance/Randomization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usentrance/Randomization
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOnly subjects who have signed an ICF at Screening Visit (1A or 1B), meet all of the inclusion 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOnly subjects who have signed an ICF at Screening Visit (1A or 1B), meet all of the inclusion 
criteria and none of the exclusion criteria, are eligible for entrance/randomization into the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecriteria and none of the exclusion criteria, are eligible for entrance/randomization into the 
One single subject ID numbe
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOne single subject ID numbe
Eligible subjects will be assigned randomly to one of the four study arms in a (1:1:1:1) ratio by a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEligible subjects will be assigned randomly to one of the four study arms in a (1:1:1:1) ratio by a 
The randomization schedule will be created and controlled by [CONTACT_178000]. T
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe randomization schedule will be created and controlled by [CONTACT_178000]. T
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userandomization specification will be approved by [CONTACT_456]â€™s trial statistician or designee. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userandomization specification will be approved by [CONTACT_456]â€™s trial statistician or designee. 
If the subject is found to be ineligible for randomization/trial phase, the investigator should record 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the subject is found to be ineligible for randomization/trial phase, the investigator should record 
the primary reason for failure on the subject enrollmen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe primary reason for failure on the subject enrollmen
9.1.4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.4
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 62of 108
Protocol Amendment 3 Version 7.0 12September 2018
of height and weight is only required at Screening Visit(s) (Visit 1A and/or Visit 1B). BMI will be 
calculated using standard BMI calculator.
Additional symptom -directed physical examinations may be performed at following visits if 
deemed necessary or indicated by [CONTACT_98272]â€™s medical history, and should assess 
clinically significant changes from the baseline examination.
The following should be documented in the subjectâ€™s source document :
ï‚·The findings of complete physical examinations,
ï‚·the findings of symptom -directed physical examinations,
ï‚·if symptom -directed physical exa minations were not required .
Findings consistent with the definition of AEs or SAEs (see Section 10.0) must be transcribed into 
the eCRF.
9.1.5 Vital Sig ns
Vital signs include (however, not limited to) systolic/diastolic blood pressure, pulse rate, 
respi[INVESTIGATOR_697], and temperature. Follow standard of care for trial population and operational 
feasibility.
Vital signs must be within normal limits (ie, below Grade 1 as specified in the FDA Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers , see Appendix E). 
In the event of abnormal heart rate or blood pressure due to physiological variation or activity, the 
subject may rest for 10 minutes in a quiet room, and then blood pressure and/or heart rate may be 
re-measured. Repeated vital signs may be used to determine eligibility. 
9.1.6 Blood Sample and Urine Sample Collection
Blood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 
1B) for flavivirus serostatus determin ation (see Section [IP_ADDRESS] ) and eligibility screening tests 
(including pregnancy testing) (see Section [IP_ADDRESS] ), at Visits 3 and 5 for routine safety laboratory 
testing (see Section [IP_ADDRESS] ), and at Visits 2, 4, 6, 8, and ( for subjects who will be randomized to 
the placebo group or the PI[INVESTIGATOR_177789] ) 9 and 
11for immunogenicity ,as well as for further development and characterization of ass ays (see 
Section [IP_ADDRESS] ). Should a blood sampling be performed during a vaccination visit, this sampling 
must occur before the administration of the investigational vaccine or placebo. The maximum 
volume of blood taken at any single visit will be between approximately [ADDRESS_209048]â€™s flavivirus serostatus at screening and the vaccine dose level the subject 
received. Blood should be taken from the subject using an aseptic venipuncture technique. Blood 
samples will be sent to the central laboratory.
Urine samples will be collected for all subjects at Screening Visit(s) (Visit 1A and/or Visit 1B) for 
eligibility screening (see Section [IP_ADDRESS] ),and at Visits 3 and 5 for routi ne safety laboratory testing 
0063Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedeemed necessary or indicated by [CONTACT_98272]â€™s medical history, and should assess 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedeemed necessary or indicated by [CONTACT_98272]â€™s medical history, and should assess 
10.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10.0) must be transcribed into 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) must be transcribed into 
systolic/diastolic blood pressure, pulse rate, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesystolic/diastolic blood pressure, pulse rate, 
respi[INVESTIGATOR_697], and temperature. Follow standard of care for trial population and operational 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userespi[INVESTIGATOR_697], and temperature. Follow standard of care for trial population and operational 
belo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebelow Grade 1 as specified in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usew Grade 1 as specified in 
for Healthy Adult and Adolescent Volunteers
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor Healthy Adult and Adolescent Volunteers
In the event of abnormal heart rate or blood pressure due to physiological variation or activity, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn the event of abnormal heart rate or blood pressure due to physiological variation or activity, the 
subject may rest for 10 minutes in a quiet room, and then blood pressure and/or heart rate may 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject may rest for 10 minutes in a quiet room, and then blood pressure and/or heart rate may 
measured. Repeated vital signs may be used to determine eligibility. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemeasured. Repeated vital signs may be used to determine eligibility. 
Blood Sample and Urine Sample Collection
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood Sample and Urine Sample Collection
Blood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood samples will be collected at each site visit: ie, at Screening Visit(s) (Visit 1A and/or Visit 
1B) for flavivirus serostatus determin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1B) for flavivirus serostatus determin
(including pregnancy testing) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(including pregnancy testing) 
testing (see Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetesting (see Section [IP_ADDRESS]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.6.3
the placebo group or the PI[INVESTIGATOR_177797]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe placebo group or the PI[INVESTIGATOR_177859]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor immunogenicity
Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSection [IP_ADDRESS]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.6.[ADDRESS_209049] occur before the administration of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust occur before the administration of 
volume of blood taken at any single visit will be between approximately 1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevolume of blood taken at any single visit will be between approximately 1
the approximate maximum total volume of blood for the whole trial will be 28
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe approximate maximum total volume of blood for the whole trial will be 28
depending on the sub
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedepending on the sub
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 63of 108
Protocol Amendment 3 Version 7.0 12September 2018
(see Section [IP_ADDRESS] ); and for women of childbearing potential at Visit 2 and 4 before each 
investigational vaccine/pl acebo administration for pregnancy test ing(see Section 9.1.9 ). Urine 
samples for eligibility screening and routine safety laboratory testing will be sent to the central 
laboratory. Urine pregnancy tests will be performed at the study site using kits provided by [CONTACT_103].
All samples will be collected in accordance with acceptable laboratory procedures. All samples 
will be processed and stored at the trial site as described in the provided Laboratory Manual.
[IP_ADDRESS] Flavivirus Serostatus Determination
All subjects who sign the ICF will be tested for flavivirus serostatus determination at Screening 
Visit (1A or 1B). For Screening , the subject â€™sserostatus r elevant to major flavivirus(es) will be 
evaluated (including but not limited to Dengue, ZIKA, West Nile, Japanese Encephalitis) .
Blood samples for flavivirus serostatus determination will be approximately [ADDRESS_209050] phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only, while the 
second phase of the study will be aimed at enrolling flavivirus primed subj ects only. Flavivirus 
primed subjects will not be enrolled (randomized) during the first phase of the study (ie, when 
identified at Screening Visit 1A) and will be invited to come back for the second phase of the 
study. Refer to Section 6.1for more details about the staggered enrollment.
[IP_ADDRESS] Eligibility Screening Tests
Screening laboratory tests that will be performed on blood and urine samples at Screen ing Visit(s) 
(Visit 1A and/or Visit 1B) are outlined in Table 9.a. 
In order for the subjects to be enrolled, they must have laboratory values within n ormal limits or 
not be above Grade 1 as defined in the FDA Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers (see Appendix E)within [ADDRESS_209051] ID numbers will be required; the repeated screening tests will be recorded in the 
appropriate CRF (unscheduled lab form). Should the respective rep eated test results not be 
available within the initial screening period, the subject would need to be screen failed and all 
screening procedures and tests would need to be repeated with a new subject ID number.
Blood samples for screening laboratory testin g will be approximately 1 0mL. 
Subjects who are tested flavivirus primed at Screening Visit 1A (during the first phase of the 
study) and accept to enter the second phase of the study will undergo an additional Screening Visit 
(Visit 1B) during which scree ning laboratory testing will be tested again. Refer to Section 6.1for 
more details about the staggered enrollment.
0064Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userine pregnancy tests will be performed at the study site using kits provided by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userine pregnancy tests will be performed at the study site using kits provided by [CONTACT_178001]. All samples 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll samples will be collected in accordance with acceptable laboratory procedures. All samples 
the trial site as described in the provided Laboratory Manual.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe trial site as described in the provided Laboratory Manual.
All subjects who sign the ICF will be tested for flavivirus serostatus determination at Screening 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll subjects who sign the ICF will be tested for flavivirus serostatus determination at Screening 
elevant to major flavivirus(es) will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useelevant to major flavivirus(es) will be 
(including but not limited to Dengue, ZIKA, West Nile, Japanese Encephalitis)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(including but not limited to Dengue, ZIKA, West Nile, Japanese Encephalitis)
Blood samples for flavivirus serostatus determination will be approximately 10
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood samples for flavivirus serostatus determination will be approximately [ADDRESS_209052] will be tested only once for flavivirus serostatus determination.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach subject will be tested only once for flavivirus serostatus determination.
The first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only, while the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe first phase of the study will be aimed at enrolling flavivirus naÃ¯ve subjects only, while the 
second phase of the study will be aimed at enrolling flavivirus primed subj
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesecond phase of the study will be aimed at enrolling flavivirus primed subj
primed subjects will not be enrolled (randomized) during the first phase of the study (ie, when 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprimed subjects will not be enrolled (randomized) during the first phase of the study (ie, when 
identified at Screening Visit 1A) and will be invited to come back for the second phase of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useidentified at Screening Visit 1A) and will be invited to come back for the second phase of the 
for more details about the staggered enrollment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor more details about the staggered enrollment.
Screening laboratory tests that will be performed on blood and urine samples at Screen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseScreening laboratory tests that will be performed on blood and urine samples at Screen
(Visit 1A and/or Visit 1B) are outlined in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Visit 1A and/or Visit 1B) are outlined in 
In order for the subjects to be enrolled, they must have laboratory values 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn order for the subjects to be enrolled, they must have laboratory values 
Grade 1 as defined in the FDA Toxicity Grading Scale 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGrade 1 as defined in the FDA Toxicity Grading Scale 
Adolescent Volunteers 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdolescent Volunteers (see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(see 
tests are out of acceptable range, repeat of screening tests is permitted once, provided there is an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetests are out of acceptable range, repeat of screening tests is permitted once, provided there is an 
alternative explanation for the out of r
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usealternative explanation for the out of r
Should the respective repeated test results be available within the initial screening period, no new 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseShould the respective repeated test results be available within the initial screening period, no new 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject ID numbers will be required; the repeated screening tests will be recorded in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject ID numbers will be required; the repeated screening tests will be recorded in the 
appropriate CRF (unscheduled lab form). Should the respective rep
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useappropriate CRF (unscheduled lab form). Should the respective rep
available within the initial screening period, the subject would need to be screen failed and all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useavailable within the initial screening period, the subject would need to be screen failed and all 
screening procedures 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreening procedures 
Blood samples for screening laboratory testin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBlood samples for screening laboratory testin
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209053]
Blood Hematology Hemoglobin
Platelet count
White blood cell countTotal neutrophilsEosinophilsLymphocytes
PT (prothrombin time)
APTT (activated partial thromboplastin time)
Fibrinogen
Biochemistry Blood urea nitrogen
Creatinine
AST (aspartate transaminase)ALT (alanine transaminase)Alkaline phosphatase
Sodium 
PotassiumChlorideBicarbonate
Pregnancy test ï¢-hCG blood test (only at Screening Visit(s) 
Visit 1A and/or Visit 1 B)
Urine Urinalysis Protein
GlucoseBlood (microscopic)Red blood cells per high power field
[IP_ADDRESS] Safety Laboratory Testing 
Routine safety laboratory parameters that will be performed on blood and urine samples at Visit 3 
(Day 8) and Visit 5 (Day 36) are outlined in Table 9.a.
Each blood sample will be approximately 1 0mL.
[IP_ADDRESS] Immunogenicity Assessments
Subjects in all study arms will undergo blood sampling for serological immunogenicity testing at 
Visit 2 (Day 1), Visit 4 (Day 29), Visit 6 (Day 57), Visit 8 (Day 211), and ( for subjects who will 
be randomized to the placebo group or the PI[INVESTIGATOR_177794] ) Visit 9 (Day 393) and Visit 11 (Day 757) . Should a blood sampling be performed 
during a vaccination visit, this sampling must occur before the administration of the 
investigational vaccine or placebo. Refer to the Serology Plan, available on file.
Each blood sample for immunogenicity assessments will be approximately 60 mL. Some of it will 
be used for further development and character ization of assays if subjects agree and sign the ICF.
0065Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAPTT (activated partial thromboplastin time)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAPTT (activated partial thromboplastin time)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAST (aspartate transaminase)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAST (aspartate transaminase)
ALT (alanine transaminase)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseALT (alanine transaminase)
Alkaline phosphatase
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAlkaline phosphatase
Sodium 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSodium 
Potassium
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotassium
Chloride
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseChloride
Bicarbonate
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBicarbonate
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï¢
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï¢-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-hCG blood test
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsehCG blood test
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety Laboratory Testing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety Laboratory Testing 
Routine safety laboratory parameters that will be performed on blood and urine samples at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRoutine safety laboratory parameters that will be performed on blood and urine samples at Visit
5 (Day 36) are outlined in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5 (Day 36) are outlined in 
Each blood sample will be approximately 1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach blood sample will be approximately 1
Immunogenicity Assessments
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseImmunogenicity Assessments
Subjects in all study arms will undergo blood sampling for serological immunogenicity testing at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubjects in all study arms will undergo blood sampling for serological immunogenicity testing at 
2 (Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 (Day 1), Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1), Visit
be randomized to the placebo group or the PI[INVESTIGATOR_177860]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe randomized to the placebo group or the PI[INVESTIGATOR_177860]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedevelopment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring a vaccination visit, this sampling must occur
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring a vaccination visit, this sampling must occur
investigational vaccine or placebo. Refer to the Serology Plan, available on file.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine or placebo. Refer to the Serology Plan, available on file.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 65of 108
Protocol Amendment 3 Version 7.0 12September 2018
9.1.7 Safety Assessments
During the trial, s afety assessments will include collection and recording of solicited local 
(injection site) and systemic AEs (including fever), unsolicited AEs (serious and non -serious) , and 
new medical conditions (neurological and neuroinflammatory disorders) with onset after the first 
vaccination . Refer to Section 10.[ADDRESS_209054] to use an "acceptable 
contraceptive method" from trial entry through [ADDRESS_209055] dose of trial vaccine, and 
will be advised not to donate ova during this period.
Furthermore, to avoid sexual transmission of ZIKV from natural exposure, all enrolled sexually 
active subjects (both male and female) will have to use latex condoms co rrectly and consistently 
even if other contraceptive measures are used from signing the ICF through the end of the trial.
Male subjects must be advised not to donate sperm during this period.
Refer to Section 7.2for more details.
9.1.9 Pregnancy
In women of childbearing potential, a serum pregnancy testing will be performed at Screening 
Visit(s) (Visit 1A and/or Visit 1B) , and a urine pregnancy testing will be performed at Vi sit2 
(Day 1) before randomization (and thereby [CONTACT_178002]/placebo dose 1 
administration) for confirmation of eligibility, as well as at Visit 4 (Day 29) before investigational 
vaccine/placebo dose 2 administration. 
Serum pregnancy tests will be conducted in the central laboratory (and will be part of the eligibility 
screening tests) and u rine pregnancy tests will be performed at the study site using kits provided by 
[CONTACT_456] . 
Subjects must have a negative serumï¢-hCG pregnancy test at screening and a negative urine 
ï¢-hCG pregnancy test prior to receiving any dose of investigational vaccine/placebo.
To ensure subject safety and the safety of the unborn child, each pregnancy in a subject having 
received a ninvestigational vaccine/placebo must be reported to the sponsor within [ADDRESS_209056] becomes pregnant during the trial, she will not receive 
any further doses of any sponsor -supplied investigational vaccin e/placebo. The pregnancy must be 
followed to determine outcome, including spontaneous or voluntary termination, details of birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. This fol low-up should occur even if the intended duration of safety 
follow -up for the trial has ended.
0066Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and 
new medical conditions (neurological and neuroinflammatory disorders) with onset after the first 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenew medical conditions (neurological and neuroinflammatory disorders) with onset after the first 
afety definitions. Details on collection and reporting of AEs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useafety definitions. Details on collection and reporting of AEs 
for details about the diary cards distribution, review and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor details about the diary cards distribution, review and 
Contraception and Avoidance of Sexually Transmitted Disease Guidance
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseContraception and Avoidance of Sexually Transmitted Disease Guidance
ion on acceptable methods of contraception and of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion on acceptable methods of contraception and of 
Female subject of childbearing potential and sexually active will have to use an "acceptable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFemale subject of childbearing potential and sexually active will have to use an "acceptable 
he last dose of trial vaccine, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe last dose of trial vaccine, and 
Furthermore, to avoid sexual transmission of ZIKV from natural exposure, all enrolled sexually 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFurthermore, to avoid sexual transmission of ZIKV from natural exposure, all enrolled sexually 
active subjects (both male and female) will have to use latex condoms co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useactive subjects (both male and female) will have to use latex condoms co
even if other contraceptive measures are used from signing the ICF through the end of the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeven if other contraceptive measures are used from signing the ICF through the end of the trial.
Male subjects must be advised not to donate sperm during this period.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMale subjects must be advised not to donate sperm during this period.
In women of childbearing potential, a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn women of childbearing potential, a serum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useserum
Visit(s) (Visit 1A and/or Visit 1B)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVisit(s) (Visit 1A and/or Visit 1B) , and a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, and a
1) before randomization (and thereby [CONTACT_178003]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1) before randomization (and thereby [CONTACT_178004]) for confirmation of eligibility, as well as at Visit 4 (Day 29) before 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministration) for confirmation of eligibility, as well as at Visit 4 (Day 29) before 
vaccine/placebo dose 2 administration. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine/placebo dose 2 administration. 
Serum pregnancy tests will be conducted in the central laboratory 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSerum pregnancy tests will be conducted in the central laboratory 
and u
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand u rine pregnancy tests will be performed at the study site
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userine pregnancy tests will be performed at the study site
Subjects must have a negative 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubjects must have a negative 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsehCG pregnancy test prior to receiving any dose of investigational vaccine/placebo.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsehCG pregnancy test prior to receiving any dose of investigational vaccine/placebo.
To ensure subject safety and the safety of the unborn child, each pregnancy in a subject having 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTo ensure subject safety and the safety of the unborn child, each pregnancy in a subject having 
received a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceived a
site learning of its occurrence. If the subject becomes pregnant during the trial, she will not receive 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesite learning of its occurrence. If the subject becomes pregnant during the trial, she will not receive 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 66of 108
Protocol Amendment 3 Version 7.0 12September 2018
Any pregnancy occurring following investigational vaccine/placebo administration should be 
reported immediately, using a pregnancy notification form, to the cont act listed in the Investigator 
Site File.
Should the pregnancy occur after administration of a blinded investigational vaccine/placebo, the 
investigator must inform the subject of their right to receive information on the study 
vaccine/placebo administered . If the subject chooses to receive unblinded information, the 
individual blind should be broken by [CONTACT_178005], as 
described in Section 8.5.
9.1.[ADDRESS_209057] ier should be 
contact[CONTACT_39804] a notification of non -randomization.
The primary reason for non -randomization is recorded in the eCRF using the following categories:
ï‚·Screen failure
odid not meet one or more inclusion criteria
odid meet one or more exclusion crite ria
otested flavivirus naÃ¯ve at Screening Visit 1B (during the second phase of the study)
otested flavivirus primed at Screening Visit 1A (during the first phase of the study) and 
did not come back for the second phase of the study
owith a n on-determinant scr eening test result
ï‚·Withdrawal by [CONTACT_1130],
ï‚·Trial terminated by [CONTACT_3211].
A subject may be a temporary screen failure under the following circumstances: due to temporary 
conditions such as receipt of immunosuppressive or immunomodulatory therapi[INVESTIGATOR_014], blood prod ucts, 
immunoglobulins, or vaccines, in the respective prohibited periods (see exclusion criteria 7, 13 or 
14), or in the event that a subject has an indeterminate pregnancy test result or has not used 
acceptable contraceptive methods in the period defined in the protocol, prior to the start of the 
study (exclusion criteria 19). Subjects screen failed for the above -mentioned reasons may be 
rescreened once they cease to meet the respective exclusion criteria. Should the respective 
repeated test results be ava ilable within the initial screening period, no new subject ID numbers 
will be required; the repeated screening tests will be recorded in the appropriate CRF (unscheduled 
lab form). Should the respective repeated test results not be available within the ini tial screening 
period, the subject would need to be screen failed and all screening procedures and tests would 
need to be repeated with a new subject ID number.
Subject ID numbers assigned to subjects who fail screening should not be reused.
0067Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseShould the pregnancy occur after administration of a blinded investigational vaccine/placebo, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseShould the pregnancy occur after administration of a blinded investigational vaccine/placebo, the 
. If the subject chooses to receive unblinded information, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. If the subject chooses to receive unblinded information, the 
individual blind should be broken by [CONTACT_178005], as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useindividual blind should be broken by [CONTACT_178005], as 
Investigators must account for all subjects who sign an ICF. If the subject is found to be not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigators must account for all subjects who sign an ICF. If the subject is found to be not 
eligible at this visit, the investigator should complete the eCRF. The IRT suppl
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeligible at this visit, the investigator should complete the eCRF. The IRT suppl
randomization is recorded in the eCRF using the following categories:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userandomization is recorded in the eCRF using the following categories:
did not meet one or more inclusion criteria
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedid not meet one or more inclusion criteria
ria
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useria
tested flavivirus naÃ¯ve at Screening Visit 1B (during the second phase of the study)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetested flavivirus naÃ¯ve at Screening Visit 1B (during the second phase of the study)
tested flavivirus primed at Screening Visit 1A (during the first phase of the study) and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetested flavivirus primed at Screening Visit 1A (during the first phase of the study) and 
did not come back for the second phase of the study
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedid not come back for the second phase of the study
determinant scr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedeterminant scr eening test result
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeening test result
Trial terminated by [CONTACT_3211].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial terminated by [CONTACT_3211].
A subject may be a temporary screen failure under the following circumstances: due to temporary 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA subject may be a temporary screen failure under the following circumstances: due to temporary 
conditions such as receipt of immunosuppressive or immunomodulatory therapi[INVESTIGATOR_014], blood prod
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconditions such as receipt of immunosuppressive or immunomodulatory therapi[INVESTIGATOR_014], blood prod
immunoglobulins, or vaccines, in the respective prohibited periods (see exclusion criteria 7, 13 or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmunoglobulins, or vaccines, in the respective prohibited periods (see exclusion criteria 7, 13 or 
14), or in the event that a subject has an indeterminate pregnancy test result or has not used 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use14), or in the event that a subject has an indeterminate pregnancy test result or has not used 
acceptable contraceptive methods in the period defined 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useacceptable contraceptive methods in the period defined 
study (exclusion criteria 19). Subjects screen failed for the above
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy (exclusion criteria 19). Subjects screen failed for the above
rescreened once they cease to meet the respective exclusion criteria. Should the respective 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userescreened once they cease to meet the respective exclusion criteria. Should the respective 
repeated test results be ava
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userepeated test results be ava
will be required; the repeated screening tests will be recorded in the appropriate CRF (unscheduled 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be required; the repeated screening tests will be recorded in the appropriate CRF (unscheduled 
lab form). Should the respective repeated test results not be available within the ini
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselab form). Should the respective repeated test results not be available within the ini
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209058] Treatment Compliance
The investigator records all injections of investigational vaccine/placebo given to the subject in the 
eCRF.
9.3 Schedule of Observations and Procedures
The schedule for all trial -related procedures for all evaluations is shown in Sec tion 2.1. 
Assessments should be completed at the designated visit(s)/time point(s).
9.3.1 Screening Procedures (Screening Visit 1A/ Screening Visit 1B)
Refer to Section 6.1for more details about the staggered enrollment.
The following screening procedures will be performed at Screening Visit(s) (Visit 1A and/or Visit 
1B):
1.Confirm informed consent, and complete and collect ICF (see Section 9.1.1 ). Before 
performing any other trial procedure, the signed ICF needs to be obtained. Only applicable for 
newly screened subjects.
2.Assign subject ID number (see Section 6.1for more details about the staggered enrollment).
3.Assess eligibility criteria (see Sections 7.1and 7.2).
4.Collect demographics (see Section 9.1.2 ). Only applicable for newly screened subjects.
5.Collect medical history, travel history (t o flavivirus endemic countries and flavivirus endemic 
regions of the US/US territories), and prior/concomitant medications/vaccinations (see 
Section 9.1.2 ).
6.Perform â€œcompleteâ€ physical examination (see Section 9.1.4 ).
7.Check vital signs (see Section 9.1.5 ).
8.Collect blood sample for flavivirus seros tatus (only applicable for newly screened subjects, see 
Section [IP_ADDRESS] ) and eligibility screening tests (hematology ,biochemistry and pr egnancy 
testing , see Section [IP_ADDRESS] ). 
9.Collect urine sample for eligibility screening urinalysis (for all subjects, see Section [IP_ADDRESS] ).
10.Provide c ontraception and avoidance of sexually transmitted disease guidance (see 
Section 9.1.8 ).
9.3.2 Pre-Vaccination Procedures (Day 1 and Day 29)
The following procedures will be performed at Visit 2 (Day 1) and Visit 4 (Day 29):
1.Collect medical history, travel history (to flavivirus ende mic countries and flavivirus endemic 
regions of the US/US territories), and concomitant medications/vaccinations (see 
Section 9.1.2 ).
2.Perform sympt om-directed physical examination (if deemed necessary, see Section 9.1.4 ).
0068Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator records all injections of investigational vaccine/placebo given to the subject in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator records all injections of investigational vaccine/placebo given to the subject in the 
2.1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2.1. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. 
The following screening procedures will be performed at Screening Visit(s) (Visit 1A and/or Visit 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe following screening procedures will be performed at Screening Visit(s) (Visit 1A and/or Visit 
Confirm informed consent, and complete and collect ICF (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseConfirm informed consent, and complete and collect ICF (see Section 
performing any other trial procedure, the signed ICF needs to be
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useperforming any other trial procedure, the signed ICF needs to be
for more details about the staggered enrollment).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor more details about the staggered enrollment).
and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand 7.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7.2).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use).
9.1.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.2 ). Only applicable for newly screened subjects.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use). Only applicable for newly screened subjects.
Collect medical history, travel history (t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect medical history, travel history (t o flavivirus endemic countries and flavivirus endemic 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo flavivirus endemic countries and flavivirus endemic 
regions of the US/US territories), and prior/concomitant medications/vaccinations (see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useregions of the US/US territories), and prior/concomitant medications/vaccinations (see 
Perform â€œcompleteâ€ physical examination (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePerform â€œcompleteâ€ physical examination (see Section 
Check vital signs (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCheck vital signs (see Section 
Collect blood sample for flavivirus seros
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect blood sample for flavivirus seros
) and eligibility screening tests (hematology
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use) and eligibility screening tests (hematology
, see Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, see Section
Collect urine sample for eligibility screening urinalysis (for all subjects, see Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect urine sample for eligibility screening urinalysis (for all subjects, see Section
Provide c
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProvide c ontraception and avoidance of sexually transmitted disease 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useontraception and avoidance of sexually transmitted disease 
Section
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSection
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.3.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.3.2
The following procedures will be performed at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe following procedures will be performed at Visit
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 68of 108
Protocol Amendment 3 Version 7.0 12September 2018
3.Assess eligibility criteria (see Sections 7.1and 7.2) at Visit 2 (Day 1).
4.Check vital signs (see Section 9.1.5 ).
5.Perform a urine pregnancy test (if the subject is a woman of childbearing potential, see 
Section 9.1.9 ).
6.Randomize subject (only at Visit 2 on Day 1) (see Section 9.1.3 ).
7.Collect blood s ample for immunogenicity assessment and assay development (see 
Section [IP_ADDRESS] ).
9.3.3 Vaccination Procedures (Day 1 and Day 29)
The following procedures will be performed at Visit 2 (Day 1) and Visit 4 (Day 29):
1.Check contraindications to vaccination and criteria for del ay of vaccination (see Sections 7.2
and7.3).
2.Prepare the investigational vaccine/placebo according to the Pharmacy Man ual (see 
Section 8.2).
3.Administer the investigational vaccine or placebo (see Section 8.2). 
9.3.[ADDRESS_209059] Vaccination Procedures (Day 1 and Day 29)
The following post -vaccination procedures will be performed at Visit 2 (Day 1) and Visit 4 
(Day 29):
1.After vaccination, the subject will be o bserved for at least [ADDRESS_209060]â€™s source documents.
2.Provide the subject with a diary card, and train the subject on how to use it.
Careful training of th e subject on how to record concomitant medications, how to measure 
solicited AEs and body temperature, how to complete the diary card and how often to complete 
the diary card. Training should be directed at the individual(s) who will perform the 
measuremen ts of solicited AEs and those who will enter the information into the diary card. 
This individual may or may not be the subject, but if a person other than the subject enters 
information into the diary card, this personâ€™s identity must be documented in the trial file and 
this person must receive training on the diary card. Training of the subject on how to measure 
an injection site AE should be performed while the subject is under observation after 
vaccination.
Diary card instructions must include the follo wing: The subject must understand that timely 
completion of the diary card on a daily basis is a critical component of trial participation. The 
subject should also be instructed to write clearly and to complete the diary card in pen. Any 
corrections to the diary card that are performed by [CONTACT_178006] 
0069Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useample for immunogenicity assessment and assay development (see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useample for immunogenicity assessment and assay development (see 
will be performed at Visit 2 (Day 1) and Visit 4 (Day 29):
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be performed at Visit 2 (Day 1) and Visit 4 (Day 29):
ay of vaccination (see Sections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useay of vaccination (see Sections
Prepare the investigational vaccine/placebo according to the Pharmacy Man
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrepare the investigational vaccine/placebo according to the Pharmacy Man
Administer the investigational vaccine or placebo (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAdminister the investigational vaccine or placebo (see Section 
Post Vaccination Procedures (Day 1 and Day 29)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePost Vaccination Procedures (Day 1 and Day 29)
vaccination procedures will be performed at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccination procedures will be performed at Visit
After vaccination, the subject will be o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAfter vaccination, the subject will be o bserved for at least 30 minutes including observation for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebserved for at least 30 minutes including observation for 
immediate reactions and body temperature measurement. Information should be recorded in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmediate reactions and body temperature measurement. Information should be recorded in 
the eCRF as immediate reactions. The investigator or delegate will take the opportunity to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe eCRF as immediate reactions. The investigator or delegate will take the opportunity to 
how to measure solicited AEs and body temperature as part of this 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehow to measure solicited AEs and body temperature as part of this 
observation period. All safety data will be collected in the subjectâ€™s source documents.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useobservation period. All safety data will be collected in the subjectâ€™s source documents.
Provide the subject with a diary card, and train the subject on how to use it.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProvide the subject with a diary card, and train the subject on how to use it.
Careful training of th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCareful training of th
solicited AEs and body temperature, how to complete the diary card and how often to complete 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesolicited AEs and body temperature, how to complete the diary card and how often to complete 
the diary card. Training should be directed at the individual(s) who will perform the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe diary card. Training should be directed at the individual(s) who will perform the 
measuremen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemeasuremen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis individual may or may not be the subject, but if a person other than the subject enters 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis individual may or may not be the subject, but if a person other than the subject enters 
information into the diary card, this personâ€™s identity must be documented in the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinformation into the diary card, this personâ€™s identity must be documented in the
this person must receive training on the diary card. Training of the subject on how to measure 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethis person must receive training on the diary card. Training of the subject on how to measure 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 69of 108
Protocol Amendment 3 Version 7.0 12September 2018
include a single strikethrough line with a brief explanation for any change and be initialed and 
dated.
Please note:
Diary cards will be the only source document allowed for remo te collection of solicited local 
and systemic AEs (including body temperature measurements). The following additional rules 
apply to the documentation of safety information collected by [CONTACT_178007]:
oDiary cards should be reviewed with the subject.
oNo correc tions or additions to the diary card will be allowed after it is reviewed with 
the investigator/designee.
oAny data that areidentified as implausible or incorrect, and confirmed by [CONTACT_178008] a transcription error should be corrected by [CONTACT_178009] (the 
correction should include a single strikethrough line and should be initialed and dated 
by [CONTACT_423]).
oAny blank or illegible fields on the diary card not otherwise corrected as above will be 
missing in the eCRF.
oThe site must ente r all readable entries on the diary card into the eCRF.
oAny newly described solicited safety information should be added to the diary card by 
[CONTACT_178010]. Any new unsolicited safety information would be 
recorded in the subject sourc e document as a verbally reported event and therefore 
captured as an AE and recorded in the AE eCRF.
oStarting on the day of vaccine/placebo administration, the subject will check for 
specific types of events at the injection site (solicited local AEs), any specific 
generalized symptoms (solicited systemic AEs), body temperature (preferably oral), 
any other symptoms or change in the subjectâ€™s health status, and any medications taken 
(excluding vitamins and minerals). These solicited AEs and body temperature will be 
recorded in the diary. Assessments should preferably take place in the evening at dayâ€™s 
end using the same route of measurement every day.
oTemperature measurement is to be performed using the thermometer provided by [CONTACT_39722]. If the subject feels u nusually hot or cold during the day, the subject should check 
his/her temperature. The highest body temperature observed that day should be 
recorded on the diary card.
oThe measurement of solicited local AEs (erythema, swelling, and induration) is to be 
performed using the ruler provided by [CONTACT_779]. If multiple measurements are taken 
during the day, the highest measured value should be recorded on the diary card.
oThe collection on the diary card of body temperature, solicited local AEs, and solicited 
system ic AEs will continue for a total of 7 days following each vaccine/placebo 
administration. The collection on the diary card of unsolicited AEs and medications 
will continue for 28 days following each vaccine/placebo administration.
0070Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete collection of solicited local 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usete collection of solicited local 
and systemic AEs (including body temperature measurements). The following additional rules 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand systemic AEs (including body temperature measurements). The following additional rules 
tions or additions to the diary card will be allowed after it is reviewed with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetions or additions to the diary card will be allowed after it is reviewed with 
identified as implausible or incorrect, and confirmed by [CONTACT_178011]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useidentified as implausible or incorrect, and confirmed by [CONTACT_178008] a transcription error should be corrected by [CONTACT_178012]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe a transcription error should be corrected by [CONTACT_178009] (the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon the diary card (the 
correction should include a single strikethrough line and should be initialed and dated 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecorrection should include a single strikethrough line and should be initialed and dated 
Any blank or illegible fields on the diary card not otherwise corrected as above will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny blank or illegible fields on the diary card not otherwise corrected as above will be 
r all readable entries on the diary card into the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User all readable entries on the diary card into the eCRF.
Any newly described solicited safety information should be added to the diary card by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny newly described solicited safety information should be added to the diary card by 
[CONTACT_178010]. Any new unsolicited safety information would be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe subject and initialed and dated. Any new unsolicited safety information would be 
recorded in the subject sourc
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecorded in the subject sourc e document as a verbally reported event and therefore 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee document as a verbally reported event and therefore 
captured as an AE and recorded in the AE eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecaptured as an AE and recorded in the AE eCRF.
Starting on the day of vaccine/placebo administration, the subject will check for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseStarting on the day of vaccine/placebo administration, the subject will check for 
specific types of events at the injection site (solicited local AEs), any
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespecific types of events at the injection site (solicited local AEs), any
generalized symptoms (solicited systemic AEs), body temperature (preferably oral), 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegeneralized symptoms (solicited systemic AEs), body temperature (preferably oral), 
any other symptoms or change in the subjectâ€™s health status, and any medications taken 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useany other symptoms or change in the subjectâ€™s health status, and any medications taken 
(excluding vitamins and minerals). These solicited AEs and body temperature 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(excluding vitamins and minerals). These solicited AEs and body temperature 
recorded in the diary. Assessments should preferably take place in the evening at dayâ€™s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecorded in the diary. Assessments should preferably take place in the evening at dayâ€™s 
end using the same route of measurement every day.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useend using the same route of measurement every day.
Temperature measurement is to be performed using the thermometer provided by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTemperature measurement is to be performed using the thermometer provided by [CONTACT_39722]. If the subject feels u
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesite. If the subject feels u
his/her temperature. The highest body temperature observed that day should be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehis/her temperature. The highest body temperature observed that day should be 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 70of 108
Protocol Amendment 3 Version 7.0 12September 2018
oThe healthcare profession al reviewing the data on the diary cards will discuss the AEs 
(if any) reported by [CONTACT_178013]/or 
AEs are present and/or concomitant medications have been used.
3.At Visit 4 (Day 29), review the previous dia ry card with the subject and collect it (see 
Section 9.3.4 ).
4.Provide contraception and avoidance of sexually transmitted disease guidance (see 
Section 9.1.8 ).
5.Provide the subject with a written reminder of the next planned trial activity. The subject will 
be reminded to complete the diary card daily and to contact [CONTACT_178014] (or as soon as the subject is medically stable) if the subject 
has a medical condition that leads to a hospi[INVESTIGATOR_177861]. All contact [CONTACT_178015]. 
6.Schedule the next trial clinic visit with the subject.
9.3.5 Clinic Visits after Vaccination (Day 8, Day 36, Day 57, Day 211, and Day 393)
The following procedures will be performed at Visit 3 (Day 8), Visit 5 (Day 36), Visit 6 (Day 57), 
andfor subjects randomized to the placebo group or the PI[INVESTIGATOR_177862], Visit 8 (Day 211) and Visit 9 (Day 393) :
1.Collect travel history (to flavivirus ende mic countries and flavivirus endemic regions of the 
US/US territories) and concomitant medications/vaccinations (see Section 9.1.2 ).
2.Perform symptom -directed physical examination (i f deemed necessary, see Section 9.1.4 ).
3.Check vital signs (see Section 9.1.5 ).
4.Collect blood sample for routine safety laboratory testing (only at Visit 3 on Day 8 and Visit 5 
on Day 36, see Section 9.1.6 .3) and immunogenicity assessment and assay development (only 
at Visit 6 on Day 57, Visit 8 (Day 211), and Visit 9(Day 393); see Section [IP_ADDRESS] ).
5.Collect urine sample for routine safety laboratory testing (urinalysis; only at Visit 3 on Day 8 
and Visit 5 on Day 36; see Section [IP_ADDRESS] ).
6.Review the previous diary card with the subject and collect it (see Section 9.3.4 ).
7.At Visi t 3 (Day 8) and Visit 5 (Day 36), provide the subject with a new diary card, and remind 
the subject on how to use it (see Section 9.3.4 ).
8.Provide c ontraception and avoidance of sexually transmitted disease guidance (see 
Section 9.1.8 ).
9.Provide the subject with a written reminder of the next pla nned trial activity. The subject will 
be reminded (only at Visit 3 on Day 8 and Visit 5 on Day 36) to complete the diary card daily. 
The subject will be reminded to contact [CONTACT_178016] (or as soon as the subject is medically stable) if the subject has a medical 
0071Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProvide contraception and avoidance of sexually transmitted disease guidance (see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProvide contraception and avoidance of sexually transmitted disease guidance (see 
Provide the subject with a written reminder of the next planned trial activity. The subject will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProvide the subject with a written reminder of the next planned trial activity. The subject will 
card daily and to contact [CONTACT_178017]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecard daily and to contact [CONTACT_178014] (or as soon as the subject is medically stable) if the subject 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand to contact [CONTACT_29261] (or as soon as the subject is medically stable) if the subject 
has a medical condition that leads to a hospi[INVESTIGATOR_177863]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehas a medical condition that leads to a hospi[INVESTIGATOR_177864]. All contact [CONTACT_178015]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useise perceived as serious. All contact [CONTACT_178015]. 
Clinic Visits after Vaccination (Day 8, Day 36, Day 57, Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinic Visits after Vaccination (Day 8, Day 36, Day 57, Day
at Visit 3 (Day 8), Visit 5 (Day 36), Visit 6 (Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useat Visit 3 (Day 8), Visit 5 (Day 36), Visit 6 (Day
for subjects randomized to the placebo group or the PI[INVESTIGATOR_177865]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor subjects randomized to the placebo group or the PI[INVESTIGATOR_177866] 9 (Day 393)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand Visit 9 (Day 393)
Collect travel history (to flavivirus ende
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect travel history (to flavivirus ende mic countries and flavivirus endemic regions of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemic countries and flavivirus endemic regions of the 
US/US territories) and concomitant medications/vaccinations (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUS/US territories) and concomitant medications/vaccinations (see Section 
directed physical examination (i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedirected physical examination (i
Check vital signs (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCheck vital signs (see Section 9.1.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.[ADDRESS_209061] blood sample for routine safety laboratory testing (only at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect blood sample for routine safety laboratory testing (only at Visit
36, see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use36, see Section 9.1.6
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use9.1.6
57, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use57, Visit 8 (Day 211), 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVisit 8 (Day 211), 
Collect urine sample for routine safety laboratory testing (urinalysis; only at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect urine sample for routine safety laboratory testing (urinalysis; only at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5 on Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5 on Day
Review the previous diary card with the subject and collect it (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseReview the previous diary card with the subject and collect it (see Section 
At Visi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAt Visi t 3 (Day 8) and Visit 5 (Day 36), provide the subject with a new diary card, and remind 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset 3 (Day 8) and Visit 5 (Day 36), provide the subject with a new diary card, and remind 
the subject on how to use it (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe subject on how to use it (see Section 
8.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8.Provide c
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProvide c
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209062] s(Day 133 and Day 575)
A phone contact [CONTACT_178018] 133 (Visit 7) and Day 575 (Visit 10) with each subject to 
collect SAEs that may have occurred since Visit 6 (Day 57) and Visit 9 (Day 393), respectively, 
and to remind the subject of the next planned (end of) trial activity. The subject will also be 
reminded to contact [CONTACT_178019], and to contact [CONTACT_29261] (or as 
soon as the subject is medically stable) if the subject has a me dical condition that leads to a 
hospi[INVESTIGATOR_177867]. All contact [CONTACT_178020]. The subject should be reminded to contact [CONTACT_178021] e ICF to discuss medical questions. 
Travel history (to flavivirus endemic countries and flavivirus endemic regions of the US/US 
territories) will be collected.
If the subject wishes to describe safety information, this information should only be collected by a 
trained healthcare professional at the site, and the safety data described must be written down in 
source documents.
The subject will be interviewed according to a script, and information relating to SAEs and/or AEs 
leading to trial or vaccine withdr awal and concomitant medications or vaccinations associated 
with those events will be collected. All safety information described by [CONTACT_178022] a designated location within the source documents and not written on the script used fo r 
the telephone call.
The site should schedule the next clinic visit with the subject, as appropriate. 
9.3.7 Final Visit (Day 211 or Day 757)
The Final Visit will be performed at Visit 8 (Day 211) or, for subjects randomized to the placebo 
group or the PI[INVESTIGATOR_177868], Visit 11 at Day 757 
(24months post dose 2 ). If a subject terminates earlier, Final Visit procedures should be 
performed, if possible.
The following procedures will be performed at Visit 8 (Day 211) or Visit 11(Day 757):
1.Collect travel history (to flavivirus endemic countries and flavivirus endemic regions of the 
US/US territories) and concomitant medications/vaccinations (see Section 9.1.2 ).
2.Perform symptom -directed physical examination (i f deemed necessary, see Section 9.1.4 ).
3.Check vital s igns (see Section 9.1.5 ).
4.Collect blood sample for immunogenicity assessment and assay development (see 
Section [IP_ADDRESS] ).
0072Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeach subject to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeach subject to 
Visit 9 (Day 393), respectively, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVisit 9 (Day 393), respectively, 
to remind the subject of the next planned (end of) trial activity. The subject will also be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto remind the subject of the next planned (end of) trial activity. The subject will also be 
reminded to contact [CONTACT_178019], and to contact [CONTACT_29261] (or as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereminded to contact [CONTACT_178019], and to contact [CONTACT_29261] (or as 
dical condition that leads to a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedical condition that leads to a 
hospi[INVESTIGATOR_177867]. All contact [CONTACT_178023]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehospi[INVESTIGATOR_177867]. All contact [CONTACT_178020]. The subject should be reminded to contact [CONTACT_178024]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be provided to the subject. The subject should be reminded to contact [CONTACT_178025] (to flavivirus endemic countries and flavivirus endemic regions of the US/US 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTravel history (to flavivirus endemic countries and flavivirus endemic regions of the US/US 
If the subject wishes to describe safety information, this information should only be collected
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the subject wishes to describe safety information, this information should only be collected
trained healthcare professional at the site, and the safety data described must be written down in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrained healthcare professional at the site, and the safety data described must be written down in 
The subject will be interviewed according to a script, and information relating to SAEs and/or AEs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subject will be interviewed according to a script, and information relating to SAEs and/or AEs 
awal and concomitant medications or vaccinations associated 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useawal and concomitant medications or vaccinations associated 
with those events will be collected. All safety information described by [CONTACT_178026]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith those events will be collected. All safety information described by [CONTACT_178022] a designated location within the source documents and not written on the script used fo
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedown in a designated location within the source documents and not written on the script used fo
The site should schedule the next clinic visit with the subject, as appropriate. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe site should schedule the next clinic visit with the subject, as appropriate. 
Final Visit (Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFinal Visit (Day 211 or Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use211 or Day
The Final Visit will be performed at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe Final Visit will be performed at Visit
group or the PI[INVESTIGATOR_177869]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegroup or the PI[INVESTIGATOR_177870]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useing group that was selected 
months post dose 2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post dose 2
performed, if possible.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useperformed, if possible.
The following procedures will be performed at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe following procedures will be performed at Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect travel history (to flavivirus endemic countries and flavivirus endemic regions of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollect travel history (to flavivirus endemic countries and flavivirus endemic regions of the 
US/US territories) and concomitant medications/vaccinations (see Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUS/US territories) and concomitant medications/vaccinations (see Section 
2.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209063] -trial care will be provided.
9.4 Biological Sample Retention and Destruction
In this trial, specimens for immune response testing will be collected as described in 
Section [IP_ADDRESS] . After blood draw and serum processing, the serum samples will be preserved and 
retained at a central storage location that was contracted by [CONTACT_178027] [ADDRESS_209064] the subjectsâ€™ personal information to ensure optimal confidentiality and defined 
standard processes for sample and data collection, storage, analysis, and destruction.
Serum samples will be used for the analyses define d in this protocol, but can also, with permission 
from the subject, be used to assess, improve or develop tests related to the disease(s) or the vaccine 
under trial that will allow more reliable measurement of the response to the vaccine.
0073Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn this trial, specimens for immune response testing will be collected as described in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn this trial, specimens for immune response testing will be collected as described in 
After blood draw and serum processing, the serum samples will be preserved and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAfter blood draw and serum processing, the serum samples will be preserved and 
retained at a central storage location that was contracted by [CONTACT_178028]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useretained at a central storage location that was contracted by [CONTACT_178027] 20 years or as required by [CONTACT_1289]. The sponsor h
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebut not longer than [ADDRESS_209065] a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas put into place a 
system to protect the subjectsâ€™ personal information to ensure optimal confidentiality and defined 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesystem to protect the subjectsâ€™ personal information to ensure optimal confidentiality and defined 
standard processes for sample and data collection, storage, analysis, and destruction.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestandard processes for sample and data collection, storage, analysis, and destruction.
d in this protocol, but can also, with permission 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Used in this protocol, but can also, with permission 
from the subject, be used to assess, improve or develop tests related to the disease(s) or the vaccine 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefrom the subject, be used to assess, improve or develop tests related to the disease(s) or the vaccine 
under trial that will allow more reliable measurement of the response to the vaccine.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useunder trial that will allow more reliable measurement of the response to the vaccine.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 73of 108
Protocol Amendment 3 Version 7.0 12September 2018
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a trial vaccine; it does not necessarily have to have a causal relationship with trial 
vaccine administration.
An AE can the refore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory finding), symptom, or disease temporally associated with the administration of a trial 
vaccine whether or not it is considered related to the trial vaccine.
AEs will be graded by [CONTACT_178029]:
Mild Grade 1ï‚·Awareness of symptoms that are easily tolerated, causing minimal 
discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment.
Moderate Grade 2ï‚·Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment.
Severe Grade 3ï‚·Extreme distress, causing significant impairment of functioning or 
incapacitation. Prevents normal everyday activities. Not relieved with 
symptomatic treatment
10.1.2 Solicited Adverse Events
The occurrence of selected indicators of safety ( Table 10.a) will be measured/collected for 7 days 
after each dose (including the days of vaccine administration) and will be recorded on the â€œLocal 
and Systemic AEsâ€ eCRF as applicable. These will be su mmarized in the final report under the 
category â€œsolicited adverse eventsâ€ to differentiate them from other AEs which were not solicited. 
Any solicited local or systemic AE observed as continuing beyond 7 days after vaccination will be 
recorded as an unsol icited AE on the Adverse Event eCRF. Any solicited local (injection site) or 
systemic AE observed as continuing beyond 7 days following each trial vaccination will be 
additionally recorded on the Adverse Event eCRF for follow -up. For these persistent/prolo nged 
solicited AEs, the end date will be captured on the Adverse Event eCRF to permit a separate 
analysis from the unsolicited AEs.
0074Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn AE is defined as any untoward medical occurrence in a clinical investigation subject 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAn AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a trial vaccine; it does not necessarily have to have a causal relationship with trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministered a trial vaccine; it does not necessarily have to have a causal relationship with trial 
refore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory finding), symptom, or disease temporally associated with the administration of a trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory finding), symptom, or disease temporally associated with the administration of a trial 
Awareness of symptoms that are easily tolerated, causing minimal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAwareness of symptoms that are easily tolerated, causing minimal 
discomfort and not interfering with everyday activities. Relieved with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usediscomfort and not interfering with everyday activities. Relieved with 
or without symptomatic treatment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor without symptomatic treatment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSufficient discomfort is present to cause interference with normal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSufficient discomfort is present to cause interference with normal 
activity. Only partially relieved with symptomatic treatment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useactivity. Only partially relieved with symptomatic treatment.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseExtreme distress, causing significant impairment of functioning or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseExtreme distress, causing significant impairment of functioning or 
incapacitation. Prevents normal ever
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincapacitation. Prevents normal ever
symptomatic treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesymptomatic treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSolicited Adverse Events
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSolicited Adverse Events
The occurrence of selected indicators of safety (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe occurrence of selected indicators of safety (
after each dose (including the days of vaccine administration) and will be recorded on the â€œLocal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useafter each dose (including the days of vaccine administration) and will be recorded on the â€œLocal 
and Systemic AEsâ€ eCRF as applicable. These will be su
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand Systemic AEsâ€ eCRF as applicable. These will be su
category â€œsolicited adverse eventsâ€ to differentiate them from other AEs which were not solicited. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecategory â€œsolicited adverse eventsâ€ to differentiate them from other AEs which were not solicited. 
Any solicited local or systemic AE observed as continuing beyond 7 days after vaccination will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAny solicited local or systemic AE observed as continuing beyond 7 days after vaccination will be 
recorded as an unsol
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userecorded as an unsol icited AE on the Adverse Event eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicited AE on the Adverse Event eCRF.
systemic AE observed as continuing beyond 7
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesystemic AE observed as continuing beyond 7
additionally recorded on the Adverse Event eCRF for follow
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadditionally recorded on the Adverse Event eCRF for follow
solicited AEs, the end date will be captured on the Adverse Event eCRF to permit a separate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesolicited AEs, the end date will be captured on the Adverse Event eCRF to permit a separate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanalysis from the unsolicited AEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanalysis from the unsolicited AEs.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 74of 108
Protocol Amendment 3 Version 7.0 12September 2018
Table 10.a Local and Systemic AEs
Local AEs (injection site): Pain
Erythema
Swelling
Induration
Systemic AEs: Fever(a)
Headache
Fatigue
Malaise
Arthralgia
Myalgia
(a) Based on recorded body temperature, fever is defined as body temperature â‰¥38.0Â°C/100.4Â°F regardless of method 
taken (Brighton Case Definition (92)).
The intensity of solicited safety parameters will be assessed as described in Table 10.b.
0075Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ‰¥
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ‰¥38.0Â°C/100.4Â°F regardless of method 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use38.0Â°C/100.4Â°F regardless of method 
The intensity of solicited safety parameters will be assessed as described in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe intensity of solicited safety parameters will be assessed as described in 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 75of 108
Protocol Amendment 3 Version 7.0 12September 2018
Table 10.b Solicited Safety Parameters
Adverse Event Intensity grade Severity/Intensity
Pain at injection site 0 None
1 Mild: No interference with daily activity
2 Moderate: Interference with daily activity with or without treatment
3 Severe: Prevents daily activity with or without treatment
Erythema at injection 
site(a)0 <25mm
1 Mild: >25 â€“â‰¤50mm
2 Moderate: >50 â€“â‰¤100mm
3 Severe: >100mm
Induration at injection 
site(a)0 <25mm
1 Mild: >25 â€“â‰¤50mm
2 Moderate: >50 â€“â‰¤100mm
3 Severe: >100mm
Swelling at injection 
site(a)0 <25mm
1 Mild: >25 â€“â‰¤50mm 
2 Moderate: >50 â€“â‰¤100mm
3 Severe: >100mm
Fever(b)Record body temperature in Â°C/Â°F
Headache 0 None
1 Mild: No interference with daily activity
2 Moderate: Interference with daily activity with or without treatment
3 Severe: Prevents normal activity with or without treatment
Fatigue 0 None
1 Mild: No interference with daily activity
2 Moderate: Interference with daily activity
3 Severe: Prevents daily activity
Malaise 0 None
1 Mild: No interference with daily activity
2 Moderate: Interference with daily activity
3 Severe: Prevents daily activity
Arthralgia 0 None
1 Mild: No interference with daily activity
2 Moderate: Interference with daily activity
3 Severe: Prevents daily activity
Myalgia 0 None
1 Mild: No interference with daily activity
2 Moderate: Interference with daily activity
3 Severe: Prevents daily activity
(a) Subjects are to record greatest surface diameter in mm in the Diary.
(b) Based on recorded body temperature, fever is defined as body temperature â‰¥38.0Â°C/100.4Â°F regardless of method taken 
(Brighton Case Definition (92)).
0076Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInterference with daily activity with or without treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInterference with daily activity with or without treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use100
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use100mm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemm
mm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemm
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMild: No interference with daily activity
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMild: No interference with daily activity
Moderate: Interference with daily activity with or without treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseModerate: Interference with daily activity with or without treatment
Severe: Prevents normal activity with or without treatment
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSevere: Prevents normal activity with or without treatment
None
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNone
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1
2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMyalgia
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMyalgia
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 76of 108
Protocol Amendment 3 Version 7.0 12September 2018
10.1.3 Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that:
1.Results in DEATH.
2.Is LIFE THREATENING.
ï‚·The term â€œlife threateningâ€ refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3.Requires inpatient HOSPI[INVESTIGATOR_177871].
4.Results in persistent or significant DISABILITY/INCAPACITY.
5.Leads to a CONGENITAL ANOMALY/BIRTH DEFECT in the offspring of a subject.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:
ï‚·May require intervention to prevent items 1 through 5 above.
ï‚·May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
10.2 Causality of AEs
Relatedness (causality) to vaccine will also be as sessed by [CONTACT_093]. The relationship of 
each AE, including solicited systemic AEs (solicited local AEs are considered as related) to trial 
vaccine(s) will be assessed using the following categories:
Related: There is suspi[INVESTIGATOR_177872] a relat ionship between the trial vaccine and the 
AE (without determining the extent of probability); there is a reasonable 
possibility that the trial vaccine contributed to the AE.
Not Related: There is no suspi[INVESTIGATOR_177872] a relationship between the trial vaccine and the 
AE; there are other more likely causes and administration of the trial vaccine is not suspected to have contributed to the AE.
10.2.1 Relationship to Trial Procedures
Relationship (causality) to trial procedures should be determined for all AEs.
The relationship should be assessed as â€œYesâ€ if the investigator considers that there is reasonable 
possibility that an event is due to a trial procedure. Otherwise, the relationship should be assessed 
as â€œNoâ€.
0077Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useterm â€œlife threateningâ€ refers to an event in which the subject was at risk of death at the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useterm â€œlife threateningâ€ refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime of the event; it does not refer to an event that hypothetically might have caused death 
ion of existing hospi[INVESTIGATOR_059].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useion of existing hospi[INVESTIGATOR_059].
Leads to a CONGENITAL ANOMALY/BIRTH DEFECT in the offspring of a subject.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLeads to a CONGENITAL ANOMALY/BIRTH DEFECT in the offspring of a subject.
Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIs an IMPORTANT MEDICAL EVENT that satisfies any of the following:
intervention to prevent items 1 through 5 above.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useintervention to prevent items [ADDRESS_209066] to danger, even though the event is not immediately life 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMay expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethreatening or fatal or does not result in hospi[INVESTIGATOR_059].
Relatedness (causality) to vaccine will also be as
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelatedness (causality) to vaccine will also be as
each AE, including solicited systemic AEs (solicited local AEs are considered as related) to trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeach AE, including solicited systemic AEs (solicited local AEs are considered as related) to trial 
vaccine(s) will be assessed using the following categories:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevaccine(s) will be assessed using the following categories:
There is suspi[INVESTIGATOR_177872] a relat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThere is suspi[INVESTIGATOR_177872] a relat
AE (without determining the extent of probability); there is a reasonable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAE (without determining the extent of probability); there is a reasonable 
possibility that the trial vaccine contributed to the AE.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepossibility that the trial vaccine contributed to the AE.
There is no suspi[INVESTIGATOR_177872] a relationship between the trial
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThere is no suspi[INVESTIGATOR_177872] a relationship between the trial
AE; there are other more likely causes and administration of the trial vaccine is 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAE; there are other more likely causes and administration of the trial vaccine is 
not suspected to have contributed to the AE.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenot suspected to have contributed to the AE.
Relationship to Trial Procedures
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelationship to Trial Procedures
Relationship (causality) to trial procedures should be determined for all AEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRelationship (causality) to trial procedures should be determined for all AEs.
The relationship should be assessed as â€œYesâ€ if the investigator considers that there is reasonable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe relationship should be assessed as â€œYesâ€ if the investigator considers that there is reasonable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepossibility that an event is due to a trial procedure. Otherwise, the relationship should be assessed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepossibility that an event is due to a trial procedure. Otherwise, the relationship should be assessed 
as â€œNoâ€.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useas â€œNoâ€.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 77of 108
Protocol Amendment 3 Version 7.0 12September 2018
10.2.2 Outcome of AEs
Resolved: The subject has fully recovered from the event or the condition has 
returned to the level observed at baseline
Resolving: The event is improving but the subject is still not fully recovered
Not resolved: The event is ongoing at the time of reporting and the subject has still not 
recovered
Resolved with 
sequelae :As a result of the AE, the subject suffered persistent and significant 
disability/incapacity (eg, became blind, deaf or paralyzed)
Fatal: The subject died due to the event. If the subject died due to other 
circumstances than the event, the outcome of the event per se should be 
stated otherwise (eg, Not Resolved or Resolving)
Unknown: If outcome is not known or not reported.
10.[ADDRESS_209067] occurrence generally may:
ï‚·Indicate a new diagnosis or unexpected worsening of a pre -existing condition. Intermittent 
events for pre -existing conditions or underlying disease should not be considered as AEs.
ï‚·Necessitate therapeutic intervention.
ï‚·Require an invasive diagnostic procedure.
ï‚·Requir e vaccine discontinuation or a change in concomitant medication.
ï‚·Be considered unfavorable by [CONTACT_109307].
Diagnoses vssigns and symptoms:
ï‚·Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values) or symptoms should NOT be recorded as additional AEs. If a 
diagnosis is unknown, signs or symptoms should be recorded appropriately as AEs.
Worsening of AEs:
ï‚·If the subject experiences a worsening or complication of an AE after sta rting administration of 
the trial vaccine, the worsening or complication should be recorded as a new AE. Investigators 
should ensure that the AE term recorded captures the change in the condition (eg, â€œworsening 
ofâ€¦â€).
ï‚·If the subject experiences a worsenin g or complication of an AE after any change in trial 
vaccine, the worsening or complication should be recorded as a new AE. Investigators should 
ensure that the AE term recorded captures the change in the condition (eg, â€œworsening ofâ€¦â€).
0078Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe event is improving but the subject is still not fully recovered
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe event is improving but the subject is still not fully recovered
The event is ongoing at the time of reporting and the subject has 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe event is ongoing at the time of reporting and the subject has still not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestill not 
As a result of the AE, the subject suffered persistent and significant 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAs a result of the AE, the subject suffered persistent and significant 
disability/incapacity (eg, became blind, deaf or paralyzed)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedisability/incapacity (eg, became blind, deaf or paralyzed)
The subject died due to the event. If the subject died due to other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subject died due to the event. If the subject died due to other 
umstances than the event, the outcome of the event per se should be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useumstances than the event, the outcome of the event per se should be 
stated otherwise (eg, Not Resolved or Resolving)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestated otherwise (eg, Not Resolved or Resolving)
If outcome is not known or not reported.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf outcome is not known or not reported.
new diagnosis or unexpected worsening of a pre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenew diagnosis or unexpected worsening of a pre
existing conditions or underlying disease should not be considered as AEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexisting conditions or underlying disease should not be considered as AEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNecessitate therapeutic intervention.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNecessitate therapeutic intervention.
Require an invasive diagnostic procedure.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRequire an invasive diagnostic procedure.
e vaccine discontinuation or a change in concomitant medication.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee vaccine discontinuation or a change in concomitant medication.
Be considered unfavorable by [CONTACT_109307].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBe considered unfavorable by [CONTACT_109307].
signs and symptoms:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesigns and symptoms:
Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEach event should be recorded to represent a single diagnosis. Accompanying signs (including 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useormal laboratory values) or symptoms should NOT be recorded as additional AEs. If a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useormal laboratory values) or symptoms should NOT be recorded as additional AEs. If a 
diagnosis is unknown, signs or symptoms should be recorded appropriately as AEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usediagnosis is unknown, signs or symptoms should be recorded appropriately as AEs.
Worsening of AEs:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWorsening of AEs:
If the subject experiences a worsening or complication of an AE after sta
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the subject experiences a worsening or complication of an AE after sta
the trial vaccine, the worsening or complication should be recorded as a new AE. Investigators 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe trial vaccine, the worsening or complication should be recorded as a new AE. Investigators 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 78of 108
Protocol Amendment 3 Version 7.0 12September 2018
Changes in severit y of AEs:
ï‚·If the subject experiences changes in severity of an AE, the event should be captured once with 
the maximum severity recorded.
Preplanned surgeries or procedures:
ï‚·Preplanned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
informed consent are not considered AEs. Complications resulting from any planned surgery 
should be reported as AEs.
Elective surgeries or procedures:
ï‚·Elective procedures performed where there is no change in the subjectâ€™s medical condition 
should not be recorded as AEs; however, these procedures should be documented in the 
subjectâ€™s source documents. Complications resulting from an elective surgery should be 
reported as AEs.
Medical occurrences emerging during the time between signing of informed conse nt and the first 
administration of investigational vaccine /placebo will be recorded onthe medical history eCRF 
page. However ,if such medical occurrence is assessed as â€™related to a study procedure â€™this should 
be re ported as an AEâ€˜related to study procedure â€™in the eCRF.
10.4 Procedures
10.4.1 Collection and Reporting of AEs
All AEs, whether considered related with the use of the investigational vaccine/placebo or not, 
must be monitored until symptoms subside and any abnormal laboratory values have returned to 
baseline, or until there is a satisfactory explanation for the changes observed, or until death, in 
which case a full pathologistâ€™s report should be supplied, if possible. All findings must be reported 
on an AE eCRF and on the SAE form, if necessary (see S ection 10.4.2 ). All findings in subjects 
experiencing AEs must also be reported in the subjectâ€™s source documents. Any unsolicited AEs 
will be coll ected for 28 days after each vaccine/placebo administration (ie, through trial Day 28 
and trial Day 56) via diary cards. AEs leading to withdrawal or discontinuation will be collected 
throughout the trial.
The following information will be documented for e ach event:
ï‚·Reported term for the Adverse Event,
ï‚·Start and end date,
ï‚·Serious (Y/N),
ï‚·Severity,
ï‚·Investigatorâ€™s opi[INVESTIGATOR_177873] (relationship) between the event and administration of 
trial vaccine(s) (â€œrelatedâ€ or â€œnot relatedâ€),
0079Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the subject experiences changes in severity of an AE, the event should be captured once with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf the subject experiences changes in severity of an AE, the event should be captured once with 
Preplanned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePreplanned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof 
informed consent are not considered AEs. Complications resulting from any planned surgery 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinformed consent are not considered AEs. Complications resulting from any planned surgery 
Elective procedures performed where there is no change in the subjectâ€™s medical condition 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseElective procedures performed where there is no change in the subjectâ€™s medical condition 
be recorded as AEs; however, these procedures should be documented in the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe recorded as AEs; however, these procedures should be documented in the 
subjectâ€™s source documents. Complications resulting from an elective surgery should be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjectâ€™s source documents. Complications resulting from an elective surgery should be 
edical occurrences emerging during the time between
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useedical occurrences emerging during the time between signing of informed conse
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesigning of informed conse
will be recorded 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be recorded 
if such medical occurrence is assessed as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useif such medical occurrence is assessed as 
procedure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocedure â€™
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€™in the eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein the eCRF.
Collection and Reporting of AEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection and Reporting of AEs
All AEs, whether considered related with the use of the investigational vaccine/placebo or not, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll AEs, whether considered related with the use of the investigational vaccine/placebo or not, 
must be monitored until symptoms subside and any abnormal laboratory values have returned to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be monitored until symptoms subside and any abnormal laboratory values have returned to 
baseline, or until there is a satisfactory explanation for the changes observed, or until death, in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebaseline, or until there is a satisfactory explanation for the changes observed, or until death, in 
which case a full pathologistâ€™s report should be supplied, if possible. All findings must be reported 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhich case a full pathologistâ€™s report should be supplied, if possible. All findings must be reported 
on an AE eCRF and on the SAE form, if necessary (see S
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon an AE eCRF and on the SAE form, if necessary (see S
experiencing AEs must also be reported in the subjectâ€™s source documents. Any unsolicited AEs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexperiencing AEs must also be reported in the subjectâ€™s source documents. Any unsolicited AEs 
ected for 28 days after each vaccine/placebo administration (ie, through trial Day 28 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useected for 28 days after each vaccine/placebo administration (ie, through trial Day 28 
and trial Day 56) via diary cards. AEs leading to withdrawal or discontinuation will be collected 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand trial Day 56) via diary cards. AEs leading to withdrawal or discontinuation will be collected 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethroughout the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethroughout the trial.
The following information will be documented for e
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe following information will be documented for e
Reported term for the Adverse Event,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseReported term for the Adverse Event,
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 79of 108
Protocol Amendment 3 Version 7.0 12September 2018
ï‚·Investigatorâ€™s opi[INVESTIGATOR_177873] (relationship) to trial procedure(s), including the details 
of the suspected procedure,
ï‚·Action taken with the trial treatment (trial vaccine),
ï‚·Outcome of event.
10.4.2 Collection and Reporting of Solicited AEs
The occurrence of selected i ndicators of safety will be collected on diary cards by [CONTACT_178030] 
7days following each investigational vaccine/placebo administration (ie, the day of vaccination 
+6subsequent days) and will be recorded on the â€œLocal and Systemic AEâ€ eCRF, as appli cable. 
These will be summarized in the final report under the category â€œsolicited adverse eventsâ€ to 
differentiate them from unsolicited AEs. Any solicited local (injection site) or systemic AE 
observed as continuing beyond 7 days following each trial vacc ination will be additionally 
recorded on the Adverse Event eCRF for follow -up. For these persistent/prolonged solicited AEs, 
the end date will be captured on the Adverse Event eCRF to permit a separate analysis from the 
unsolicited AEs. 
Any solicited AE t hat meets any of the following criteria must be entered as an AE on the Adverse 
Event eCRF.
ï‚·Solicited local or systemic AEs that lead the subject to withdraw from the trial.
ï‚·Solicited local or systemic AEs that lead to the subject being withdrawn from the trial or to 
discontinuation of vaccination by [CONTACT_093].
ï‚·Solicited local and systemic AEs that otherwise meet the definition of an SAE (see 
Section 10.1.2 ).
10.4.[ADDRESS_209068] administered the 
investigational vaccine/placebo (Day 1). Routine collection of SAEs will continue up to the end of 
the trial at Visit 8 (Day 211) or Visit 11 (Day 757) for subjects who were randomized to the 
placebo group or the PI[INVESTIGATOR_177786] .
SAEs should be reported according to the following procedure:
A sponsor SAE form must be compl eted, in English, and signed by [CONTACT_57801] [ADDRESS_209069] onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum:
ï‚·A short description of the event and the reason why the event is categorized as serious.
ï‚·Subject identification number.
ï‚·Investigatorâ€™s name.
ï‚·Name [CONTACT_178090](s) â€“in a blinded way at all times, unless there is a valid reason to 
unblind.
0080Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usendicators of safety will be collected on diary cards by [CONTACT_178031]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usendicators of safety will be collected on diary cards by [CONTACT_178032]/placebo administration (ie, the day of vaccination 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays following each investigational vaccine/placebo administration (ie, the day of vaccination 
subsequent days) and will be recorded on the â€œLocal and Systemic AEâ€ eCRF, as appli
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubsequent days) and will be recorded on the â€œLocal and Systemic AEâ€ eCRF, as appli
These will be summarized in the final report under the category â€œsolicited adverse eventsâ€ to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThese will be summarized in the final report under the category â€œsolicited adverse eventsâ€ to 
differentiate them from unsolicited AEs. Any solicited local (injection site) or systemic AE 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedifferentiate them from unsolicited AEs. Any solicited local (injection site) or systemic AE 
ination will be additionally 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useination will be additionally 
up. For these persistent/prolonged solicited AEs, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup. For these persistent/prolonged solicited AEs, 
the end date will be captured on the Adverse Event eCRF to permit a separate analysis from the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe end date will be captured on the Adverse Event eCRF to permit a separate analysis from the 
hat meets any of the following criteria must be entered as an AE on the Adverse 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehat meets any of the following criteria must be entered as an AE on the Adverse 
Solicited local or systemic AEs that lead the subject to withdraw from the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSolicited local or systemic AEs that lead the subject to withdraw from the trial.
Solicited local or systemic AEs that lead to the subject being withdrawn from the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSolicited local or systemic AEs that lead to the subject being withdrawn from the 
discontinuation of vaccination by [CONTACT_093].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usediscontinuation of vaccination by [CONTACT_093].
Solicited local and systemic AEs that otherwise meet the definition of an SAE (see 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSolicited local and systemic AEs that otherwise meet the definition of an SAE (see 
Collection and Reporting of SAEs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection and Reporting of SAEs
Collection of SAEs will commence from the time that the subject is first administered the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection of SAEs will commence from the time that the subject is first administered the 
investigational vaccine/placebo (Day 1). Routine collection of SAEs will continue up to the end of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine/placebo (Day 1). Routine collection of SAEs will continue up to the end of 
8 (Day
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8 (Day
placebo group or the PI[INVESTIGATOR_177845]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useplacebo group or the PI[INVESTIGATOR_177874]:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSAEs should be reported according to the following procedure:
A sponsor SAE form must be compl
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA sponsor SAE form must be compl
within [ADDRESS_209070] onset or notification of the event. The information should be completed as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewithin [ADDRESS_209071] onset or notification of the event. The information should be completed as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefully as possible but contain, at a minimum:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefully as possible but contain, at a minimum:
ï‚·
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useï‚·
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 80of 108
Protocol Amendment 3 Version 7.0 12September 2018
ï‚·Causality assessment.
The SAE form should be transmitted within [ADDRESS_209072](s) in the list 
provided to each site. 
Note: For this study, SAE reporting will be performed via eCRF. Only if the Electronic Data 
Capture system (EDC) is unavailable, a paper sponsor SAE form should be compl eted, signed by 
[CONTACT_178033] [ADDRESS_209073] report becomes available at a later date, the 
investigator should complete a follow -up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copi[INVESTIGATOR_1672] 
(eg, laboratory tests, discharge summary, post mortem results) should be sent to the sponsor.
All SAEs should be followed up until resolution or permanent outcome of the event(s) or until they 
are otherwise explained (outside of the trial, after Visit 11 at Day 757, whichever applicable). The 
timelines and procedure for follow -up reports are the same as those for the initial report.
10.5.3 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor or designee will be responsible for the reporting of all suspected unexpected serious
adverse reactions (S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities, investigators 
and IRBs or IECs, as applicable, in accordance with national regulations in the countries where the 
trial is conducted. Relative to the first awareness of th e event by/or further provision to the sponsor 
or sponsorâ€™s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_209074]-Trial Events
Any SAE that occurs outside of the protocol -specified observation period or a fter the end of the 
trial but considered to be caused by [CONTACT_178034](s) must be reported to the sponsor. These 
SAEs will be processed by [CONTACT_456]â€™s Pharmacovigilance Department. Instructions for how to 
submit these SAEs will be provided in a hando ut in the Investigator Site File.
0081Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNote: For this study, SAE reporting will be performed via eCRF. Only if the Electronic Data 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNote: For this study, SAE reporting will be performed via eCRF. Only if the Electronic Data 
eted, signed by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeted, signed by 
[CONTACT_178033] [ADDRESS_209075] be entered into the eCRF once 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe investigator and transmitted within [ADDRESS_209076] be entered into the eCRF once 
All AEs will be monitored until resolution or a stable status is reached or until a formal diagnosis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll AEs will be monitored until resolution or a stable status is reached or until a formal diagnosis 
If information not available at the time of the first report becomes available at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIf information not available at the time of the first report becomes available at 
up SAE form or provide other written documentation and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copi[INVESTIGATOR_113902]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefax it immediately within 24 hours of receipt. Copi[INVESTIGATOR_1672] 
(eg, laboratory tests, discharge summary, post
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(eg, laboratory tests, discharge summary, post mortem results) should be sent to the sponsor.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemortem results) should be sent to the sponsor.
All SAEs should be followed up until resolution or permanent outcome of the event(s) or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll SAEs should be followed up until resolution or permanent outcome of the event(s) or 
are otherwise explained (outside of the trial, after Visit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useare otherwise explained (outside of the trial, after Visit
up reports are the same as those for the initial report.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup reports are the same as those for the initial report.
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsor or designee will be responsible for the reporting of all suspected unexpected serious
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsor or designee will be responsible for the reporting of all suspected unexpected serious
adverse reactions (S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities, investigators 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadverse reactions (S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities, investigators 
and IRBs or IECs, as applicable, in accordance with national regulations in the countries where the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand IRBs or IECs, as applicable, in accordance with national regulations in the countries where the 
trial is conducted. Relative to the first awareness of th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial is conducted. Relative to the first awareness of th
or sponsorâ€™s designee, S[LOCATION_003]Rs will be submitted within 7 days for fatal and life
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor sponsorâ€™s designee, S[LOCATION_003]Rs will be submitted within 7 days for fatal and life
events and 15 days for other S[LOCATION_003]Rs, unless otherwise required by [CONTACT_2091]. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useevents and 15 days for other S[LOCATION_003]Rs, unless otherwise required by [CONTACT_2091]. The 
sponsor will also prepar
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesponsor will also prepar
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usealter the current benefit
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usealter the current benefit
sufficient to consider changes in the trial vaccine administration or in the overa
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesufficient to consider changes in the trial vaccine administration or in the overa
trial. The investigational site also will forward a copy of all expedited reports to their IRB or IEC 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial. The investigational site also will forward a copy of all expedited reports to their IRB or IEC 
in accordance with national regulations.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein accordance with national regulations.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 81of 108
Protocol Amendment 3 Version 7.0 12September 2018
11.0 TRIAL -SPECIFIC REQUI REMENTS
11.1 Data Monitoring Committee Guidelines for Possible Study Pause
The external DMC will review safety data on an ongoing basis (refer to Section 11.2.1 ). More 
specifically, when the following set of AEs are reported, the external DMC will review all relevant 
safety data within 48 hours and consider a possible pause of the study, if itdeem snecessary:
ï‚·Two or more subjects develop the same grade 3 solicited AE starting within 7 days of 
vaccination
ï‚·Two or more subjects develop the same grade 3 unsolicited AE within 28 days of vaccination
ï‚·Any SAE 
ï‚·Any unexpected, serious, or unanticipated risk t o the subjects enrolled.
11.[ADDRESS_209077] oversight of this trial. The external DMC functions at a program level 
and further information is available in the external DMC Charter. The external DMC may review 
the data in an unblinded manner; however, the study team will remain blinded. The external DMC 
will receive predefined standard tables and listings of exposure and demographic data, solicited 
and unsolicited AEs, SAEs, new medical cond itions (neurological and neuroinflammatory 
disorders) with onset after the first vaccination, and laboratory data obtained at specific data lock 
points for review. Any additional data requested by [CONTACT_178035]. 
The externalDMC will consist of [ADDRESS_209078] 
enrollment and safety event rates. Unscheduled ad hoc meetings will occur at any time 
consultation is requested by [CONTACT_177941]. The recommendations will be 
communicated by [CONTACT_178036] a timely 
manner. [COMPANY_005] Vaccines will notify investigators and the appropriate regulatory authorities if the 
study is modified, placed on hold, completed, or closed.
0082Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use). More 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use). More 
DMC will review all relevant 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will review all relevant 
necessary:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenecessary:
days of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedays of 
Two or more subjects develop the same grade 3 unsolicited AE within 28 days of vaccination
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTwo or more subjects develop the same grade 3 unsolicited AE within 28 days of vaccination
o the subjects enrolled.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo the subjects enrolled.
DMC will have oversight of this trial. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will have oversight of this trial. The external
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexternal
external
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexternal DMC Charter. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC Charter. The 
the data in an unblinded manner; however, the study team will remain blinded. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe data in an unblinded manner; however, the study team will remain blinded. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill receive predefined standard tables and listings of exposure and demographic data, solicited 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill receive predefined standard tables and listings of exposure and demographic data, solicited 
new medical cond
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenew medical cond itions (neurological and neuroinflammatory 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useitions (neurological and neuroinflammatory 
disorders) with onset after the first vaccination, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedisorders) with onset after the first vaccination, 
points for review. Any additional data requested by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepoints for review. Any additional data requested by [CONTACT_178037] 5 independent members and an independent non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC will consist of [ADDRESS_209079] of open and closed face
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDMC meetings will consist of open and closed face
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useteleconference calls. The type and frequency of scheduled meetings will depend on the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useteleconference calls. The type and frequency of scheduled meetings will depend on the 
enrollment and safety event rates. Unscheduled ad hoc meetings will occur at any time 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useenrollment and safety event rates. Unscheduled ad hoc meetings will occur at any time 
consultation is requested by [CONTACT_177941]. The recommendations will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconsultation is requested by [CONTACT_177941]. The recommendations will be 
communicated by [CONTACT_178038]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecommunicated by [CONTACT_178038]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemanner. [COMPANY_005] Vaccines will notify investigators and the appropriate regulatory authorities if the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemanner. [COMPANY_005] Vaccines will notify investigators and the appropriate regulatory authorities if the 
study is modified, placed on hold, completed, or closed.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestudy is modified, placed on hold, completed, or closed.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 82of 108
Protocol Amendment 3 Version 7.0 12September 2018
12.0 DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_177875] g will be documented in the Data Management Plan. 
AEs, medical history, and concurrent conditions will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA â€“System Organ Class [SOC], High Level Group Term [HLGT], 
High Level Term [HLT], Lowest Level Term [LLT], Preferred Term [PT], and their 
corresponding descriptive terms). Drugs will be coded using the WHO Drug Dictionary.
12.1 Electronic CRFs (eCRF)
Completed eCRFs are required for each subject who provides a signed ICF.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF .These forms are used to 
transmit the information collected in the performance of this trial to the sponsor and regulatory 
authorities. eCRFs must be completed in English.
After completion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_174376] (or designees) and will be answered by [CONTACT_779].
Corrections to eCRFs are recorded in an audit trail that captures the old information, th e new 
information, identification of the person making the correction, the date the correction was made, 
and the reason for change.
The principal investigator [INVESTIGATOR_177876]. Furthermore, the investigator must retain 
full responsibility for the accuracy and authenticity of all data entered on the eCRFs .
eCRFs will be reviewed for completeness and acceptability at the trial site during periodic vi sits by 
[CONTACT_55752]. The sponsor or its designee will be permitted to review the subjectâ€™s medical and 
hospi[INVESTIGATOR_177877]. The completed eCRFs are 
the sole property of the sponsor and should not be ma de available in any form to third parties, 
except for authorized representatives of appropriate governmental health or regulatory authorities, 
without written permission of the sponsor.
12.[ADDRESS_209080] Retention
The investigator agrees to keep the records of the eC RF and those documents that include (but are 
not limited to) the trial -specific documents, the identification log of all participating subjects, 
source documents. Temporary media such as thermal sensitive paper should be copi[INVESTIGATOR_177878], source worksh eets, all original signed and dated ICFs, subject authorization forms 
regarding the use of personal health information (if separate from the ICFs), electronic copy of 
eCRFs, including the audit trail, and detailed records of vaccine disposition to enable e valuations 
or audits from regulatory authorities, the sponsor or its designees. Furthermore, ICH E6 (2)
Section 4.9.5 requires the investigator to retain essential documents specified in ICH E6 (2)
Section [ADDRESS_209081] 2 years 
0083Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useg will be documented in the Data Management Plan. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useg will be documented in the Data Management Plan. 
AEs, medical history, and concurrent conditions will be coded using the Medical Dictionary for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAEs, medical history, and concurrent conditions will be coded using the Medical Dictionary for 
System Organ Class [SOC], High Level Group Term [HLGT], 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSystem Organ Class [SOC], High Level Group Term [HLGT], 
corresponding descriptive terms). Drugs will be coded using the WHO Drug Dictionary.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecorresponding descriptive terms). Drugs will be coded using the WHO Drug Dictionary.
designee will supply investigative sites with access to eCRFs. The sponsor will 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedesignee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemake arrangements to train appropriate site staff in the use of the eCRF .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.These forms are used to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThese forms are used to 
transmit the information collected in the performance of this trial to the sponsor and regulatory 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmit the information collected in the performance of this trial to the sponsor and regulatory 
After completion of the entry process, computer logic checks will be run to identify
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAfter completion of the entry process, computer logic checks will be run to identify
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_178039]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_174376] (or designees) and will be answered by [CONTACT_779].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepersonnel (or designees) and will be answered by [CONTACT_779].
Corrections to eCRFs are recorded in an audit trail that captures the old information, th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCorrections to eCRFs are recorded in an audit trail that captures the old information, th
information, identification of the person making the correction, the date the correction was made, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinformation, identification of the person making the correction, the date the correction was made, 
The principal investigator [INVESTIGATOR_177879]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe principal investigator [INVESTIGATOR_177880]. Furthermore, the investigator must retain 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useappropriate eCRFs as indicated. Furthermore, the investigator must retain 
full responsibility for the accuracy and authenticity of all data entered on the eCRFs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefull responsibility for the accuracy and authenticity of all data entered on the eCRFs
eCRFs will be reviewed for completeness and acceptability at the trial site during periodic vi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeCRFs will be reviewed for completeness and acceptability at the trial site during periodic vi
trial monitors. The sponsor or its designee will be permitted to review the subjectâ€™s medical and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial monitors. The sponsor or its designee will be permitted to review the subjectâ€™s medical and 
hospi[INVESTIGATOR_177877]. The completed eCRFs are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehospi[INVESTIGATOR_177877]. The completed eCRFs are 
the sole property of the sponsor and should not be ma
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe sole property of the sponsor and should not be ma
except for authorized representatives of appropriate governmental health or regulatory authorities, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useexcept for authorized representatives of appropriate governmental health or regulatory authorities, 
without written permission of the sponsor.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewithout written permission of the sponsor.
Record Retention
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRecord Retention
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator agrees to keep the records of the eC
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator agrees to keep the records of the eC
not limited to) the trial
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenot limited to) the trial
source documents. Temporary media such as thermal sensitive paper should be copi[INVESTIGATOR_177881]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesource documents. Temporary media such as thermal sensitive paper should be copi[INVESTIGATOR_177878], source worksh
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecertified, source worksh
regarding the use of personal health information (if separate from the ICFs), electronic copy of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useregarding the use of personal health information (if separate from the ICFs), electronic copy of 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 83of 108
Protocol Amendment 3 Version 7.0 12September 2018
after the investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 
(2)Section 4.9.5 states that the trial records should be retained until an amount of time specified by 
[CONTACT_63227] a time specified in the Clinical Study Site Agreement 
between the investigator and sponsor.
Refer to the Cli nical Study Site Agreement for the sponsorâ€™s requirements on record retention. The 
investigator should contact [CONTACT_39811].
0084Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenical Study Site Agreement for the sponsorâ€™s requirements on record retention. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenical Study Site Agreement for the sponsorâ€™s requirements on record retention. The 
investigator should contact [CONTACT_178040]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigator should contact [CONTACT_178041] (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 84of 108
Protocol Amendment 3 Version 7.0 12September 2018
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stat istical analysis plan (SAP) will be prepared and finalized prior to unblinding of subjectâ€™s 
treatment assignment. This document will provide further details regarding the definition of 
analysis variables and analysis methodology to address all trial object ives.
A blinded data review will be conducted prior to unblinding of subjectâ€™s vaccination assignment. 
This review will assess the accuracy and completeness of the trial database, subject evaluability, 
and appropriateness of the planned statistical methods .
13.1.1 Analysis Sets
ï‚·Safety Set : The Safety Set will consist of all randomized subjects who received at least one 
dose of the investigational vaccine/placebo .
ï‚·Full Analysis Set (FAS): The FAS will include all randomized subjects who have received at 
least one dose of the investigational vaccine/placebo and provided valid baseline and at least 
one post -vaccination serology result . Subjects will be included in the FAS analysis â€˜as 
randomized â€™.
ï‚·Perâ€“Protocol Set (PPS): The PPS will include all subjects in the FAS who have no major 
protocol violations. The major protocol violation criteria will be defined as part of the blinded 
data review prior to the unblinding of subjectâ€™s investigational vaccine/placebo assignment. 
The categories of major protocol violations inc lude: 
a)not meeting selected entry criteria, 
b)receiving a wrong investigational vaccine/placebo, 
c)receiving prohibited therapi[INVESTIGATOR_014], and 
d)other major protocol violations that may be identified during blinded data reviews.
All summaries and analyses of safety d ata will be based on subjects in the Safety Set. 
The primary immunogenicity analyses will be based on the PPS, and additional immunogenicity 
analyses will be based on the FAS.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Summaries of age, g ender, race, and other baseline characteristics will be presented by 
[CONTACT_177931].
13.1.3 Immunogenicity Analysis
ï‚·Seropositive subjects : Subjects with detectable serum antibodies (tested positive at or above 
limit of detection, LOD) as measured by [CONTACT_178042].
0085Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useistical analysis plan (SAP) will be prepared and finalized prior to unblinding of subjectâ€™s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useistical analysis plan (SAP) will be prepared and finalized prior to unblinding of subjectâ€™s 
treatment assignment. This document will provide further details regarding the definition of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetreatment assignment. This document will provide further details regarding the definition of 
A blinded data review will be conducted prior to unblinding of subjectâ€™s vaccination assignment. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA blinded data review will be conducted prior to unblinding of subjectâ€™s vaccination assignment. 
This review will assess the accuracy and completeness of the trial database, subject evaluability, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThis review will assess the accuracy and completeness of the trial database, subject evaluability, 
subjects who received at least one 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects who received at least one 
randomized 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userandomized 
dose of the investigational vaccine/placebo and provided valid baseline and at least 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedose of the investigational vaccine/placebo and provided valid baseline and at least 
. Subjects will be included in the FAS analysis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. Subjects will be included in the FAS analysis 
(PPS): The PPS will include all subjects in the FAS 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(PPS): The PPS will include all subjects in the FAS 
protocol violations. The major protocol violation criteria will be defined as part of the blinded 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprotocol violations. The major protocol violation criteria will be defined as part of the blinded 
data review prior to the unblinding of subjectâ€™s investigational vaccine/placebo assignment. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedata review prior to the unblinding of subjectâ€™s investigational vaccine/placebo assignment. 
The categories of major protocol violations inc
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe categories of major protocol violations inc
not meeting selected entry criteria, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenot meeting selected entry criteria, 
receiving a wrong investigational vaccine/placebo, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceiving a wrong investigational vaccine/placebo, 
receiving prohibited therapi[INVESTIGATOR_014], and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereceiving prohibited therapi[INVESTIGATOR_014], and 
other major protocol violations that may be identified during blinded data reviews.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useother major protocol violations that may be identified during blinded data reviews.
All summaries and analyses of safety d
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll summaries and analyses of safety d
The primary immunogenicity analyses will be based on the PPS, and additional immunogenicity 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe primary immunogenicity analyses will be based on the PPS, and additional immunogenicity 
analyses will be based on the FAS.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useanalyses will be based on the FAS.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use13.1.2
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use13.1.2 Analysis of Demographics and Other Baseline Characteristics
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAnalysis of Demographics and Other Baseline Characteristics
Summaries of age, g
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSummaries of age, g
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useformulation arm.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useformulation arm.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 85of 108
Protocol Amendment 3 Version 7.0 12September 2018
ï‚·Seronegative subjects : Subjects with no detectable serum antibodies (test results are below 
LOD) as measured by [CONTACT_177934].
ï‚·Seroconverted subjects : Seronegative subjects at baseline with detectable post -vaccination 
serum antibodies (test results are at or above LOD) and seropositive subjects at baseline with 
different fold increases in post -vaccination antibodies from baseline, as measu red by [CONTACT_178043].
Descriptive statistics for the primary and secondary im munogenicity endpoints, including 
estimates and 95% confidence intervals (95% CI) for GMT, SPR and SCR, will be provided by 
[CONTACT_7206] ([ADDRESS_209082] dose 2 in 
applicable groups) and by [CONTACT_177931].
Point estimates and 95% CI for ratios in GMT and differences in SPR and SCR will be provided 
for each pair of active study arms (ie, low, medium and high doses) to aid a single vaccine dose 
level selection.
Immunogenicity summaries and analyses will b e provided by [CONTACT_177932] ,as well as by 
[CONTACT_177933].
13.1.4 Safety Analysis
Reactogenicity will be assessed for 7 days following each dose (including day of vaccine/placebo 
administration) via daily collection of solicited AEs, includin g local reactions (injection site: pain, 
erythema, swelling, and induration) and systemic AEs of headache, fatigue, malaise, arthralgia and 
myalgia. In addition, body temperature (preferably measured as oral temperature) as indicator of 
reactogenicity will be collected (with fever defined as body temperature â‰¥38.0Â°C/100.4Â°F).
For each solicited AE and fever, the percentage of subjects will be summarized by [CONTACT_178044] 7 days after each vaccine/placebo administration and overall. For subjects with 
more than 1 epi[INVESTIGATOR_177882], the maximum severity will be used for tabulations.
Unsolicited AEs and SAEs will be coded using MedDRA and summarized by [CONTACT_178045] (neurological and neuroinflammatory 
disorders) with onset after the first vaccination.
In general, unsolicited AEs will be tabulated at each of the following levels: overall summary 
(subject with at least 1 AE), and by [CONTACT_3592]. Unsolicited AEs will be summarized as follows: 
by [CONTACT_6214]; by [CONTACT_3592]; by [CONTACT_2946], PT, and severity; by [CONTACT_2946], PT, and relationship (causality) to the 
investigational vaccine/placebo; and by [CONTACT_3592], including events with frequency greater than 
a pre -defined frequency. 
Safety summaries will be pro vided by [CONTACT_177932] ,as well as by [CONTACT_178046].
0086Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(test results are at or above LOD) and seropositive subjects at baseline with 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(test results are at or above LOD) and seropositive subjects at baseline with 
red by [CONTACT_177972]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usered by [CONTACT_178047], including 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemunogenicity endpoints, including 
estimates and 95% confidence intervals (95% CI) for GMT, SPR and SCR, will be provided by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useestimates and 95% confidence intervals (95% CI) for GMT, SPR and SCR, will be provided by 
[CONTACT_178048]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post dose
Point estimates and 95% CI for ratios in GMT and differences in SPR and SCR will be provided 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePoint estimates and 95% CI for ratios in GMT and differences in SPR and SCR will be provided 
for each pair of active study arms (ie, low, medium and high doses) to aid a single vaccine dose 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor each pair of active study arms (ie, low, medium and high doses) to aid a single vaccine dose 
e provided by [CONTACT_178049]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee provided by [CONTACT_178050] 7 days following each dose (including day of vaccine/placebo 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseReactogenicity will be assessed for 7 days following each dose (including day of vaccine/placebo 
administration) via daily collection of solicited AEs, includin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadministration) via daily collection of solicited AEs, includin
erythema, swelling, and induration) and systemic AEs of headache, fatigue, malaise, arthralgia and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useerythema, swelling, and induration) and systemic AEs of headache, fatigue, malaise, arthralgia and 
myalgia. In addition, body temperature (preferably measured as oral temperature) as indicator of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemyalgia. In addition, body temperature (preferably measured as oral temperature) as indicator of 
be collected (with fever defined as body temperature 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe collected (with fever defined as body temperature 
For each solicited AE and fever, the percentage of subjects will be summarized by [CONTACT_178051]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor each solicited AE and fever, the percentage of subjects will be summarized by [CONTACT_178044] 7 days after each vaccine/placebo administration and overall. For 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor each day for the 7 days after each vaccine/placebo administration and overall. For 
more than 1 epi[INVESTIGATOR_177882], the maximum severity will be used for tabulations.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemore than 1 epi[INVESTIGATOR_177882], the maximum severity will be used for tabulations.
Unsolicited AEs and SAEs will be coded using MedDRA and summarized by [CONTACT_178052]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUnsolicited AEs and SAEs will be coded using MedDRA and summarized by [CONTACT_178053]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeach formulation arm including
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincluding
disorders) with onset after the first vaccination.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedisorders) with onset after the first vaccination.
In general, unsolicited AEs will be tabulated at each of the following levels: overall summary 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn general, unsolicited AEs will be tabulated at each of the following levels: overall summary 
(subject with at least 1 AE), and by [CONTACT_3592]. Unsolicited AEs will be summarized as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(subject with at least 1 AE), and by [CONTACT_3592]. Unsolicited AEs will be summarized as 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useby [CONTACT_6214]; by [CONTACT_3592]; by [CONTACT_2946], PT, and severity; by [CONTACT_2946], PT, and relationship (causality) to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useby [CONTACT_6214]; by [CONTACT_3592]; by [CONTACT_2946], PT, and severity; by [CONTACT_2946], PT, and relationship (causality) to the 
investigational vaccine/placebo; and by [CONTACT_3592], including events with frequency greater than 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine/placebo; and by [CONTACT_3592], including events with frequency greater than 
a pre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usea pre -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-defined frequency. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedefined frequency. 
Safety summaries will be pro
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety summaries will be pro
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209083] interim analysis will be performed to include immunogenicity and safety data from all 
flavivirus naÃ¯ve subjects up to Visit 6 (on Day 57, [ADDRESS_209084] dose 2); a second interim analysis 
will be performed for dose selection ,including safety data from all flavivirus primed subjects up to 
Visit 4 (on Day 29, [ADDRESS_209085] dose 1).
The final safety and immunogenicity analysis will be per formed when all (flavivirus naÃ¯ve and 
primed) subjects have completed Visit 6 (Day 57) to provide data to support the planning and 
execution of other trials in the development plan of PI[INVESTIGATOR_177760]. The subsequent analyses will include 
(1) the data up to Visit 9 ([ADDRESS_209086] dose 2) and (2) the data up to Visit 11 ([ADDRESS_209087] 
dose 2). The analyses will be performed by a separate set of unblinded statisticians and 
programmers at a Clinical Research Organization (CRO), who will have access to individual 
treatme nt assignments and will not be involved in subsequent trial conduct. The study team at 
[COMPANY_005] will have access to the group level unblinded results and will remain blinded to the 
individual treatment assignment. The remaining personnel (not mentioned befor e) involved in the 
conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will remain blinded to 
the individual subject treatment assignment until unblinding after trial completion (database lock 
for data through Visit 11).
More det ails regarding the analyses will be provided in the SAP.
The final study report will be written for the data up to Visit 6 (Day 57), and two additional 
addenda will be written: one to report the data from Visit 6 (Day 57) to Visit 9 (Day 393, 12 
months pos t dose 2), and one to report the data from Visit 9 (Day 393) until the end of the study, ie, 
Visit 11 (Day 757, [ADDRESS_209088] dose 2).
13.[ADDRESS_209089] that the proposed sample size is deemed adequate under a variety of 
decision -making scenarios.
0087Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2); a second interim analysis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2); a second interim analysis 
including safety data from all flavivirus primed subjects up to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincluding safety data from all flavivirus primed subjects up to 
formed when all (flavivirus naÃ¯ve and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useformed when all (flavivirus naÃ¯ve and 
57) to provide data to support the planning and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use57) to provide data to support the planning and 
The subsequent analyses will include 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subsequent analyses will include 
[ADDRESS_209090] dose 2) and (2) the data up to Visit 11 ([ADDRESS_209091] 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2 months post dose 2) and (2) the data up to Visit 11 ([ADDRESS_209092] 
The analyses will be performed by a separate set of unblinded statisticians and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe analyses will be performed by a separate set of unblinded statisticians and 
programmers at a Clinical Research Organization (CRO), who will have access to individual 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprogrammers at a Clinical Research Organization (CRO), who will have access to individual 
will not be involved in subsequent trial conduct. The study team at 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill not be involved in subsequent trial conduct. The study team at 
will remain blinded to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill remain blinded to the 
individual treatment assignment. The remaining personnel (not mentioned befor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useindividual treatment assignment. The remaining personnel (not mentioned befor
conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will remain blinded to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useconduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will remain blinded to 
the individual subject treatment assignment until unblinding after trial completion (database lock 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe individual subject treatment assignment until unblinding after trial completion (database lock 
ails regarding the analyses will be provided in the SAP.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useails regarding the analyses will be provided in the SAP.
The final study report will be written for the data up to Visit 6 (Day 57), and two additional 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe final study report will be written for the data up to Visit 6 (Day 57), and two additional 
addenda will be written: one to report the data from Visit 6 (Day 57) to Visit 9 (Day 393, 12 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaddenda will be written: one to report the data from Visit 6 (Day 57) to Visit 9 (Day 393, 12 
t dose 2), and one to report the data from Visit 9 (Day 393) until the end of the study, ie, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset dose 2), and one to report the data from Visit 9 (Day 393) until the end of the study, ie, 
months post dose 2).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemonths post dose 2).
Determination of Sample Size
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDetermination of Sample Size
The sample size was not determined based on formal statistical power calculations. Stochast
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sample size was not determined based on formal statistical power calculations. Stochast
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesimulations suggest that the proposed sample size is deemed adequate under a variety of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesimulations suggest that the proposed sample size is deemed adequate under a variety of 
making scenarios.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemaking scenarios.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 87of 108
Protocol Amendment 3 Version 7.0 12September 2018
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Trial -Site Monitoring Visits
Monitoring visits to the trial site will be made periodically during the trial to ensure that all aspects 
of the protocol are followed. Source documents will be reviewed for verification of data recorded 
on the eCRFs. Source documents are defined as original documents, data, and records. The 
investigator and institution gua rantee access to source documents by [CONTACT_3552] 
(CRO) and by [CONTACT_4186].
All aspects of the trial and its documentation will be subject to review by [CONTACT_36613] 
(as long as blinding is not jeopardized), including but not li mited to the Investigatorâ€™s Binder, 
investigational vaccine/placebo, subject medical records, ICF documentation, documentation of 
subject authorization to use personal health information (if separate from the ICF), and review of 
eCRFs and associated source documents. It is important that the investigator and other trial 
personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
14.[ADDRESS_209093] to trial subjects. Should other unexpected circumstances arise that will require 
deviation from protocol -specified procedures, the investigator should consult with the medical 
monitor (and IRB or IEC, as requir ed) to determine the appropriate course of action. There will be 
no exemptions (a prospective approved deviation) from the inclusion or exclusion criteria.
14.[ADDRESS_209094] the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities wher e laboratory samples are collected, 
where the vaccine/placebo is stored and prepared, and any other facility used during the trial. In 
addition, there is the possibility that this trial may be inspected by [CONTACT_17513], including 
those of foreign go vernments (eg, the FDA, the [LOCATION_008] Medicines and Healthcare 
products Regulatory Agency, the Pharmaceuticals and Medical Devices Agency of Japan). If the 
trial site is contact[CONTACT_63224] a regulatory body, the sponsor should be notified 
immediately. The investigator and institution guarantee access for quality assurance auditors to all 
trial documents as described in Section 14.1.
0088Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe trial to ensure that all aspects 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe trial to ensure that all aspects 
of the protocol are followed. Source documents will be reviewed for verification of data recorded 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof the protocol are followed. Source documents will be reviewed for verification of data recorded 
on the eCRFs. Source documents are defined as original documents, data, and records. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useon the eCRFs. Source documents are defined as original documents, data, and records. The 
rantee access to source documents by [CONTACT_178054]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userantee access to source documents by [CONTACT_178055]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll aspects of the trial and its documentation will be subject to review by [CONTACT_178056]â€™s Binder, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemited to the Investigatorâ€™s Binder, 
investigational vaccine/placebo, subject medical records, ICF documentation, documentation of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigational vaccine/placebo, subject medical records, ICF documentation, documentation of 
subject authorization to use personal health information (if separate from the ICF), and review of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject authorization to use personal health information (if separate from the ICF), and review of 
documents. It is important that the investigator and other trial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocuments. It is important that the investigator and other trial 
personnel are available during the monitoring visits and that sufficient time is devoted to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepersonnel are available during the monitoring visits and that sufficient time is devoted to the 
The investigator should not deviate from the protocol, except whe
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe investigator should not deviate from the protocol, except whe
immediate hazard to trial subjects. Should other unexpected circumstances arise that will require 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmediate hazard to trial subjects. Should other unexpected circumstances arise that will require 
specified procedures, the investigator should consult with the medical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usespecified procedures, the investigator should consult with the medical 
ed) to determine the appropriate course of action. There will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useed) to determine the appropriate course of action. There will be 
no exemptions (a prospective approved deviation) from the inclusion or exclusion criteria.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useno exemptions (a prospective approved deviation) from the inclusion or exclusion criteria.
Quality Assurance Audits and Regulatory Agency Inspections
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseQuality Assurance Audits and Regulatory Agency Inspections
The trial site also may be subject to quality assurance audits by [CONTACT_63222]. In this 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe trial site also may be subject to quality assurance audits by [CONTACT_63222]. In this 
circumstance, the sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecircumstance, the sponsor designated auditor will contact [CONTACT_178057]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedesignated auditor will contact [CONTACT_63223]. The auditor may ask to visit the facilities wher
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauditing visit. The auditor may ask to visit the facilities wher
where the vaccine/placebo is stored and prepared, and any other facility used during the trial. In 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhere the vaccine/placebo is stored and prepared, and any other facility used during the trial. In 
addition, there is the possibility that this trial may be inspected by [CONTACT_17513], including 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaddition, there is the possibility that this trial may be inspected by [CONTACT_17513], including 
those of foreign go
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethose of foreign go
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevernments (eg, the FDA, the [LOCATION_008] Medicines and Healthcare 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevernments (eg, the FDA, the [LOCATION_008] Medicines and Healthcare 
products Regulatory Agency, the Pharmaceuticals and Medical Devices Agency of Japan). If the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useproducts Regulatory Agency, the Pharmaceuticals and Medical Devices Agency of Japan). If the 
trial site is contact[CONTACT_63224] a regulatory body, the sponsor should be notified 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial site is contact[CONTACT_63224] a regulatory body, the sponsor should be notified 
immediately. The investigator and institution guarantee access for quality assurance auditors to all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useimmediately. The investigator and institution guarantee access for quality assurance auditors to all 
trial documents as described in Section 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial documents as described in Section 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209095] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki (1), and ICH E6 (2). Each investigator will conduct the trial according to appl icable local 
or regional regulatory requirements and align his or her conduct in accordance with the 
â€œResponsibilities of the Investigatorâ€ that are listed in Appendix A.
. The principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and investigator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable requirements of each participating 
region. The sponsor or designee will require documentation noting all names and titles of members 
who make up the respective IRB or IEC. If any member of the IRB or IEC has direct participation 
in this t rial, written notification regarding his or her abstinence from voting must also be obtained.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocolâ€™s review and approval. This protocol, the IB, a copy of the ICF, and, if 
applicable, subject recruitment materials and/or advertisements and other documents required by 
[CONTACT_1763], must be submitted to a central or local IRB or IEC for 
approval. The IRBâ€™s or IECâ€™s written appr oval of the protocol and subject ICF must be obtained 
and submitted to the sponsor or designee before commencement of the trial (ie, before shipment of 
the sponsor -supplied Vaccine or trial specific screening activity). The IRB or IEC approval must 
refer t o the trial by [CONTACT_1764], number, and version date; identify versions of other 
documents (eg, ICF) reviewed; and state the approval date. The sponsor will notify the site once 
the sponsor has confirmed the adequacy of site regulatory documentati on and, when applicable, 
the sponsor has received permission from the competent authority to begin the trial. Until the site 
receives notification ,no protocol activities, including screening may occur.
Sites must adhere to all requirements stipulated by t heir respective IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruitment 
materials intended for viewing by [CONTACT_1766], local safety reporting requirements, reports and 
updates regarding the on going review of the trial at intervals specified by [CONTACT_178058], and submission of the investigatorâ€™s final status report to IRB or IEC. All IRB and IEC 
approvals and relevant documentation for these items must be provided to the sponsor or i ts 
designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by [CONTACT_4197].
15.[ADDRESS_209096] Authorization
Written consent documents will embody t he elements of informed consent as described in the 
Declaration of Helsinki (1)and ICH E6 (2)and will be in accordance with all applicable laws and 
regulations. The ICF, subject authorization form (if applicable), and subject information sheet (if 
0089Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicable local 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useicable local 
. The principles of Helsinki are addressed through the protocol and through appendices containing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. The principles of Helsinki are addressed through the protocol and through appendices containing 
to the applicable requirements of each participating 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto the applicable requirements of each participating 
region. The sponsor or designee will require documentation noting all names and titles of members 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useregion. The sponsor or designee will require documentation noting all names and titles of members 
who make up the respective IRB or IEC. If any member of the IRB or IEC has direct participation 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewho make up the respective IRB or IEC. If any member of the IRB or IEC has direct participation 
rial, written notification regarding his or her abstinence from voting must also be obtained.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userial, written notification regarding his or her abstinence from voting must also be obtained.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocolâ€™s review and approval. This protocol, the IB, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIEC for the protocolâ€™s review and approval. This protocol, the IB, 
applicable, subject recruitment materials and/or advertisements and other documents required by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapplicable, subject recruitment materials and/or advertisements and other documents required by 
[CONTACT_1763], must be submitted to a central or local IRB or IEC for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useall applicable laws and regulations, must be submitted to a central or local IRB or IEC for 
oval of the protocol and subject ICF must be obtained 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoval of the protocol and subject ICF must be obtained 
and submitted to the sponsor or designee before commencement of the trial (ie, before shipment of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand submitted to the sponsor or designee before commencement of the trial (ie, before shipment of 
supplied Vaccine or trial specific screening activity). The IRB or IEC approval must 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesupplied Vaccine or trial specific screening activity). The IRB or IEC approval must 
o the trial by [CONTACT_1764], number, and version date; identify versions of other 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo the trial by [CONTACT_1764], number, and version date; identify versions of other 
documents (eg, ICF) reviewed; and state the approval date. The sponsor will notify the site once 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocuments (eg, ICF) reviewed; and state the approval date. The sponsor will notify the site once 
the sponsor has confirmed the adequacy of site regulatory documentati
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe sponsor has confirmed the adequacy of site regulatory documentati
the sponsor has received permission from the competent authority to begin the trial. Until 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe sponsor has received permission from the competent authority to begin the trial. Until 
no protocol activities, including screening may occur.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useno protocol activities, including screening may occur.
Sites must adhere to all requirements stipulated by t
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSites must adhere to all requirements stipulated by t
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruitment 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenotification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruitment 
materials intended for viewing by [CONTACT_1766], local safety reporting requirements, reports and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usematerials intended for viewing by [CONTACT_1766], local safety reporting requirements, reports and 
updates regarding the on
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useupdates regarding the on
IEC, and submission of the investigatorâ€™s final status report to IRB or IEC. All IRB and IEC 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIEC, and submission of the investigatorâ€™s final status report to IRB or IEC. All IRB and IEC 
approvals and relevant documentation for these items must be provided to the sponsor or i
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapprovals and relevant documentation for these items must be provided to the sponsor or i
designee.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedesignee.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject incentives should not exert undue influence for participation. Payments to subjects must 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by [CONTACT_4197].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe approved by [CONTACT_4197].
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 89of 108
Protocol Amendment 3 Version 7.0 12September 2018
applicable) describe the planned and permitted uses, transfers, and disclosures of the subjectâ€™s 
personal and personal health information for purposes of conducting the trial. The ICF and the 
subject information sheet (if applicable) further explain the nature of the trial, its objectives, and 
potential risks and bene fits, as well as the date informed consent / is given. The ICF will detail the 
requirements of the participant and the fact that he or she is free to withdraw at any time without 
giving a reason and without prejudice to his or her further medical care.
Theinvestigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the subject authorization form. The ICF, subject authorization form (if 
applicable), and subject information sheet (if applicable) must be appr oved by [CONTACT_178059].
The ICF, subject authorization form (if applicable), and subject information sheet (if applicable) 
must be written in a language fully comprehensible to the prospective subject. It is the 
responsibi lity of the investigator to explain the detailed elements of the ICF, subject authorization 
form (if applicable), and subject information sheet (if applicable) to the subject. Information 
should be given in both oral and written form whenever possible and in the manner deemed 
appropriate by [CONTACT_4186] .
The subject must be given ample opportunity to: (1) inquire about details of the trial and (2) decide 
whether or not to participate in the trial. If the subject determines he or she will participate in th e 
trial, then the informed consent and subject authorization form (if applicable) must be signed and 
dated by [CONTACT_423], at the time of consent and prior to the subject entering into the trial. The 
subject should be instructed to sign using their legal n ames, not nicknames, using blue or black 
ballpoint ink. The investigator must also sign and date the informed consent and subject 
authorization (if applicable) at the time of consent and prior to subject entering into the trial; 
however, the sponsor may al low a designee of the investigator to sign to the extent permitted by 
[CONTACT_1289].
Once signed, the original ICF, subject authorization form (if applicable), and subject information 
sheet (if applicable) will be stored in the investigatorâ€™s site file. T he investigator must document 
the date the subject signs the ICF in the subjectâ€™s medical record and eCRF. Copi[INVESTIGATOR_4082], the signed subject authorization form (if applicable), and subject information sheet (if 
applicable) shall be given to the subject.
All revised ICFs must be reviewed and signed by [CONTACT_178060]. The date the revised consent was obtained should be recorded in the subjectâ€™s 
medical record and eCRF, and the subject should receive a co py of the revised ICF.
15.[ADDRESS_209097]â€™s right to protection 
against invasion of privacy. Throughout this trial, a subjectâ€™s source data will only be linked to the 
sponsorâ€™s c linical trial database or documentation via a unique identification number. As permitted 
by [CONTACT_1763], limited subject attributes, such as sex, age, or date of birth, 
and subject initials may be used to verify the subject and accu racy of the subjectâ€™s unique 
identification number.
0090Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject information sheet (if applicable) further explain the nature of the trial, its objectives, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject information sheet (if applicable) further explain the nature of the trial, its objectives, and 
fits, as well as the date informed consent / is given. The ICF will detail the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefits, as well as the date informed consent / is given. The ICF will detail the 
requirements of the participant and the fact that he or she is free to withdraw at any time without 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userequirements of the participant and the fact that he or she is free to withdraw at any time without 
investigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the subject authorization form. The ICF, subject authorization form (if 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand if applicable, the subject authorization form. The ICF, subject authorization form (if 
oved by [CONTACT_178061]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoved by [CONTACT_178062], subject authorization form (if applicable), and subject information sheet (if applicable) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe ICF, subject authorization form (if applicable), and subject information sheet (if applicable) 
must be written in a language fully comprehensible to the prospective subject. It is the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemust be written in a language fully comprehensible to the prospective subject. It is the 
lity of the investigator to explain the detailed elements of the ICF, subject authorization 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselity of the investigator to explain the detailed elements of the ICF, subject authorization 
form (if applicable), and subject information sheet (if applicable) to the subject. Information 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useform (if applicable), and subject information sheet (if applicable) to the subject. Information 
should be given in both oral and written form whenever possible and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useshould be given in both oral and written form whenever possible and 
The subject must be given ample opportunity to: (1) inquire about details of the trial and (2) decide 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe subject must be given ample opportunity to: (1) inquire about details of the trial and (2) decide 
whether or not to participate in the trial. If the subject determines he or she will participate in th
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewhether or not to participate in the trial. If the subject determines he or she will participate in th
trial, then the informed consent and subject authorization form (if applicable) must be signed and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetrial, then the informed consent and subject authorization form (if applicable) must be signed and 
dated by [CONTACT_423], at the time of consent and prior to the subject entering into the trial. The 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedated by [CONTACT_423], at the time of consent and prior to the subject entering into the trial. The 
subject should be instructed to sign using their legal n
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubject should be instructed to sign using their legal n
ballpoint ink. The investigator must also sign and date the informed consent and subject 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useballpoint ink. The investigator must also sign and date the informed consent and subject 
authorization (if applicable) at the time of consent and prior to subject entering into the trial; 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauthorization (if applicable) at the time of consent and prior to subject entering into the trial; 
low a designee of the investigator to sign to the extent permitted by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselow a designee of the investigator to sign to the extent permitted by 
[CONTACT_178063], the original ICF, subject authorization form (if applicable), and subject information 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOnce signed, the original ICF, subject authorization form (if applicable), and subject information 
sheet (if applicable) will be stored in the investigatorâ€™s site file. T
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesheet (if applicable) will be stored in the investigatorâ€™s site file. T
the date the subject signs the ICF in the subjectâ€™s medical record and eCRF. Copi[INVESTIGATOR_177883]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe date the subject signs the ICF in the subjectâ€™s medical record and eCRF. Copi[INVESTIGATOR_177883]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseICF, the signed subject authorization form (if applicable), and subject information sheet (if 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseICF, the signed subject authorization form (if applicable), and subject information sheet (if 
applicable) shall be given to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapplicable) shall be given to the 
All revised ICFs must be reviewed and signed by [CONTACT_178064]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAll revised ICFs must be reviewed and signed by [CONTACT_178060]. The date the revised consent was obtained should be recorded in the subjectâ€™s 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useoriginal ICF. The date the revised consent was obtained should be recorded in the subjectâ€™s 
medical record and eCRF, and the subject should receive a co
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemedical record and eCRF, and the subject should receive a co
15.3
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use15.[ADDRESS_209098]â€™s right to protection 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsor and designees affirm and uphold the principle of the subjectâ€™s right to protection 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 90of 108
Protocol Amendment 3 Version 7.0 12September 2018
To comply with ICH E6 (2)and to verify compliance with this protocol, the sponsor requires the 
investigator to permit its monitor or designeeâ€™s monitor, representatives from any regulatory 
authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and 
Medical Devices Agency), the sponsorâ€™s designated auditors, and the appropriate IRBs and IECs 
to review the subjectâ€™s original medical records (source data or documents), i ncluding, but not 
limited to, laboratory test result reports, electrocardiography reports, admission and discharge 
summaries for hospi[INVESTIGATOR_1684] a subjectâ€™s trial participation, and autopsy 
reports. Access to a subjectâ€™s original medic al records requires the specific authorization of the 
subject as part of the ICF process (see Section 15.2).
Copi[INVESTIGATOR_177884] t hat are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subjectâ€™s eCRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The results of this trial are expected to be published in a scientific journal. It is anticipated that 
clinical and laboratory co -investigators will participate in authorship. The order of authorship and 
choice of journal will be proposed by [CONTACT_178065](s), to be eventually 
agreed upon by [CONTACT_15064]. The data analysis center for this trial will provide the analyses needed 
for publication. Information regarding this trial will be posted on ClinicalTri als.gov.
15.4.[ADDRESS_209099] information, along 
with investigatorâ€™s city, country, and recruiting status will be registered a nd available for public 
viewing.
15.4.[ADDRESS_209100] the results of this clinical trial, regardless of outcome, on ClinicalTrials.gov 
or other publicly accessible websites, as required by [CONTACT_178066]/or regulatio ns.
Trial completion corresponds to the date on which the final subject was examined or received an 
intervention for the purposes of final collection of data for the primary outcome, whether the 
clinical trial concluded according to the pre -specified protocol or was terminated.
15.[ADDRESS_209101] is participating. If a local underwriter is required, then the sponsor o r sponsorâ€™s 
designee will obtain clinical trial insurance against the risk of injury to clinical trial subjects. Refer 
0091Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(eg, FDA, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(eg, FDA, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and 
Medical Devices Agency), the sponsorâ€™s designated auditors, and the appropriate IRBs and IECs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMedical Devices Agency), the sponsorâ€™s designated auditors, and the appropriate IRBs and IECs 
ncluding, but not 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usencluding, but not 
limited to, laboratory test result reports, electrocardiography reports, admission and discharge 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselimited to, laboratory test result reports, electrocardiography reports, admission and discharge 
summaries for hospi[INVESTIGATOR_1684] a subjectâ€™s trial participation, and autopsy 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesummaries for hospi[INVESTIGATOR_1684] a subjectâ€™s trial participation, and autopsy 
al records requires the specific authorization of the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useal records requires the specific authorization of the 
hat are provided to the sponsor must have certain 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehat are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepersonally identifiable information removed (ie, subject name, address, and other identifier fields 
Publication, Disclosure, and Clinical Trial Registration Policy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePublication, Disclosure, and Clinical Trial Registration Policy
The results of this trial are expected to be published in a scientific journal. It is anticipated that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe results of this trial are expected to be published in a scientific journal. It is anticipated that 
investigators will participate in authorship. The order of authorship and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinvestigators will participate in authorship. The order of authorship and 
proposed by [CONTACT_178065](s), to be eventually 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useproposed by [CONTACT_178065](s), to be eventually 
agreed upon by [CONTACT_15064]. The data analysis center for this trial will provide the analyses needed 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useagreed upon by [CONTACT_15064]. The data analysis center for this trial will provide the analyses needed 
for publication. Information regarding this trial will be posted on ClinicalTri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefor publication. Information regarding this trial will be posted on ClinicalTri
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable law, regulation and guidance, the sponsor will, at a minimum register all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecomply with applicable law, regulation and guidance, the sponsor will, at a minimum register all 
ted in subjects that it sponsors anywhere in the world on ClinicalTrials.gov or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useted in subjects that it sponsors anywhere in the world on ClinicalTrials.gov or 
other publicly accessible websites before trial initiation. The sponsor contact [CONTACT_3031], along 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useother publicly accessible websites before trial initiation. The sponsor contact [CONTACT_3031], along 
with investigatorâ€™s city, country, and recruiting status will be registered a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith investigatorâ€™s city, country, and recruiting status will be registered a
Clinical Trial Results Disclosure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Trial Results Disclosure
The sponsor will post the results of this clinical trial, regardless of outcome, on ClinicalTrials.gov 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe sponsor will post the results of this clinical trial, regardless of outcome, on ClinicalTrials.gov 
or other publicly accessible websites, as required by [CONTACT_178066]/or regulatio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useor other publicly accessible websites, as required by [CONTACT_178066]/or regulatio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial completion corresponds to the date on which the final subject was examined or received an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTrial completion corresponds to the date on which the final subject was examined or received an 
intervention for the purposes of final collection of data for the primary outcome, whether the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useintervention for the purposes of final collection of data for the primary outcome, whether the 
clinical trial concluded according to the pre
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical trial concluded according to the pre
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 91of 108
Protocol Amendment 3 Version 7.0 12September 2018
to the Clinical Study Site Agreement regarding the sponsorâ€™s policy on subject compensation and 
treatment for injury. If the investigator has questions regarding this policy, he or she should contact 
[CONTACT_4209]â€™s designee.
0092Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 92of 108
Protocol Amendment 3 Version 7.0 12September 2018
16.0 REFERENCES
1.WMA. World Medical Association Declaration of Helsinki: ethical principles for medical 
research involving human subjects. Jama. 2 013;310(20):2191 -4. Epub 2013/10/22.
2.ICH. Harmonised Tripartite Guideline E6(R1) Guideline for Good Clinical Practice. Step 4. 
June 1996. 1996 [27 January 2017]; Available from: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/ E6/E6_R
1_Guideline.pdf .
3.Zanluca C, Dos Santos CN. Zika virus -an overview. Microbes and infection. 
2016;18(5):295 -301. Epub 2016/03/20.
4.Musso D, Gubler DJ. Zika Virus. Clinical microbiology reviews. 2016;29(3):487 -524. Epub 
2016/04/01.
5.Carod -Artal FJ. Epi [INVESTIGATOR_177885]: a 
new emerging neurotropic virus. Revista de neurologia. 2016;62(7):317 -28. Epub 2016/03/19.
6.Mlakar J, Korva M, Tul N, Popovic M, Poljsak -Prijatelj M, Mraz J, et al. Zika Virus 
Associ ated with Microcephaly. The New England journal of medicine. 2016;374(10):951 -8. 
Epub 2016/02/11.
7.Schuler -Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, et al. 
Possible Association Between Zika Virus Infection and Microcephaly -Brazil, 2015. MMWR 
Morbidity and mortality weekly report. 2016;65(3):59 -62. Epub 2016/01/29.
8.van der Linden V, Pessoa A, Doby[INVESTIGATOR_2115] W, Barkovich AJ, Junior HV, Filho EL, et al. Description 
of 13 Infants Born During October 2015 -January 2016 With Congenital Zika Virus Infection 
Without Microcephaly at Birth -Brazil. MMWR Morbidity and mortality weekly report. 
2016;65(47):1343 -8. Epub 2016/12/03.
9.Moore CA, Staples JE, Doby[CONTACT_178067], Pessoa A, Ventura CV, Fonseca EB, et al. Characterizing 
the Pattern of Anomalies in C ongenital Zika Syndrome for Pediatric Clinicians. JAMA 
pediatrics. 2016. Epub 2016/11/05.
10.Reynolds MR, Jones AM, Petersen EE, Lee EH, Rice ME, Bingham A, et al. Vital Signs: 
Update on Zika Virus -Associated Birth Defects and Evaluation of All U.S. Infants w ith 
Congenital Zika Virus Exposure -U.S. Zika Pregnancy Registry, 2016. MMWR Morbidity 
and mortality weekly report. 2017;66(13):366 -73. Epub 2017/04/07.
11.Oehler E, Watrin L, Larre P, Leparc -Goffart I, Lastere S, Valour F, et al. Zika virus infection 
compli cated by [CONTACT_151708] -Barre syndrome --case report, French Polynesia, December 2013. 
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
communicable disease bulletin. 2014;19(9):7 -9. Epub 2014/03/15.
12.Cao-Lormeau VM, Blake A, Mons S , Lastere S, [COMPANY_002] C, Vanhomwegen J, et al. 
Guillain -Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a 
case-control study. Lancet. 2016;387([ZIP_CODE]):1531 -9. Epub 2016/03/08.
13.PAHO. Cumulative Zika suspected and confirmed case s reported by [CONTACT_178068], 2015 -2016. Pan American Health Organization; 2016 [17 November 2016]; 
Available from: Cumulative Zika suspected and confirmed cases reported by [CONTACT_178069], 2015 -2016.
0093Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseICH. Harmonised Tripartite Guideline E6(R1) Guideline for Good Clinical Practice. Step 4. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseICH. Harmonised Tripartite Guideline E6(R1) Guideline for Good Clinical Practice. Step 4. 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/ E6/E6_R
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseE6/E6_R
an overview. Microbes and infection. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usean overview. Microbes and infection. 
Clinical microbiology reviews. 2016;29(3):487
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical microbiology reviews. 2016;29(3):487
demiology and neurological complications of infection by [CONTACT_178070]: a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedemiology and neurological complications of infection by [CONTACT_178070]: a 
new emerging neurotropic virus. Revista de neurologia. 2016;62(7):317
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usenew emerging neurotropic virus. Revista de neurologia. 2016;62(7):317
Prijatelj M, Mraz J, et al. Zika Virus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrijatelj M, Mraz J, et al. Zika Virus 
ated with Microcephaly. The New England journal of medicine. 2016;374(10):951
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useated with Microcephaly. The New England journal of medicine. 2016;374(10):951
Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFaccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, et al. 
Possible Association Between Zika Virus Infection and Microcephaly 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePossible Association Between Zika Virus Infection and Microcephaly 
Morbidity and mortality weekly report. 2016;65(3):59
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMorbidity and mortality weekly report. 2016;65(3):59
van der Linden V, Pessoa A, Doby[INVESTIGATOR_2115] W, Barkovich AJ, Junior HV, Filho EL, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevan der Linden V, Pessoa A, Doby[INVESTIGATOR_2115] W, Barkovich AJ, Junior HV, Filho EL, et al. 
of 13 Infants Born During October 2015
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof 13 Infants Born During October 2015 -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-January 2016 With Congenital Zika
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseJanuary 2016 With Congenital Zika
Brazil. MMWR Morbidity and mortality weekly report. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBrazil. MMWR Morbidity and mortality weekly report. 
8. Epub 2016/12/03.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8. Epub 2016/12/03.
Moore CA, Staples JE, Doby[CONTACT_178067], Pessoa A, Ventura CV, Fonseca EB, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMoore CA, Staples JE, Doby[CONTACT_178067], Pessoa A, Ventura CV, Fonseca EB, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe Pattern of Anomalies in C
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe Pattern of Anomalies in C ongenital Zika Syndrome for Pediatric Clinicians. JAMA 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useongenital Zika Syndrome for Pediatric Clinicians. JAMA 
pediatrics. 2016. Epub 2016/11/05.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepediatrics. 2016. Epub 2016/11/05.
Reynolds MR, Jones AM, Petersen EE, Lee EH, Rice ME, Bingham A, et al. Vital Signs: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseReynolds MR, Jones AM, Petersen EE, Lee EH, Rice ME, Bingham A, et al. Vital Signs: 
Update on Zika Virus
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseUpdate on Zika Virus -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-Associated Birth Defects and Evaluation of All U.S. Infants w
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAssociated Birth Defects and Evaluation of All U.S. Infants w
Congenital Zika Virus Exposure 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCongenital Zika Virus Exposure 
and mortality weekly report. 2017;66(13):366
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand mortality weekly report. 2017;66(13):366
Oehler E, Watrin L, Larre P, Leparc
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOehler E, Watrin L, Larre P, Leparc
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecompli
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecompli cated by [CONTACT_178071]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecated by [CONTACT_178072] : bulletin Europeen sur les maladies transmissibles = European 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuro surveillance : bulletin Europeen sur les maladies transmissibles = European 
communicable disease bulletin. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecommunicable disease bulletin. 
12.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use12.Cao
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCao Lormeau VM, Blake A, Mons S
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLormeau VM, Blake A, Mons S
Guillain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGuillain
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 93of 108
Protocol Amendment 3 Version 7.0 12September 2018
14.Carteaux G, Maquart M, Bedet A, Contou D, Brugieres P, Fourati S, et al. Zika Virus 
Associated with Meningoencephalitis. The New England journal of medicine. 
2016;374(16):1595 -6. Epub 2016/03/10.
15.Araujo LM, Ferreira ML, Nascimento OJ. Guillain -Barre syndrom e associated with the Zika 
virus outbreak in Brazil. Arquivos de neuro -psiquiatria. 2016;74(3):253 -5. Epub 2016/04/07.
16.Mecharles S, Herrmann C, Poullain P, Tran TH, Deschamps N, Mathon G, et al. Acute 
myelitis due to Zika virus infection. Lancet. 2016;387( [ZIP_CODE]):1481. Epub 2016/03/08.
17.WHO. Zika situation report. 8 December 2016. 2016 [14 December 2016]; Available from: 
http://www.who.int/emergencies/zika -virus/situation -report/8 -december -2016/en/ .
18.WHO. Zika -Epi[INVESTIGATOR_177886]. World Health Organization; 2017 [updated 27 April 
201705 May 2017]; Available from: 
http://www2.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gi
d=[ZIP_CODE]&lang=en .
19.Dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, et al. Zika 
Virus and the Guillain -Barre Syndrome -Case Series from Seven Countries. The New England 
journal of medicine. 2016;375(16):1598 -601. Epub 2016/11/01.
20.Dirlikov E, Major CG, Mayshack M, Medina N, Matos D, Ryff KR, et al. Guillain -Barre 
Syndrome During Ongoing Zika Virus Transmission -Puerto Rico, January 1 -July 31, 2016. 
MMWR Morbidity and mortality weekly report. 2016;65(34):910 -4. Epub 2016/09/02.
21.Krauer F, Riesen M, Reveiz L, Oladapo OT, Martinez -Vega R, Porgo TV, et al. Zika Virus 
Infection as a Cause of Congenital Brain Abnormalities and Guillain -Barre Syndrome: 
Systematic Review. PLoS medicine. 2017;14(1):e1002203. Epub 2017/01/04.
22.The L. Another kind of Zika public health emergency. Lancet. 2017;389([ZIP_CODE]):573. Epub 
2017/02/15.
23.Uncini A, Shahrizaila N, Kuwabara S. Zika virus infection and Guillain -Barre syndrome: a 
review focused on clinical and electrophysiological subtypes. Journal of neurology, 
neurosurgery, and psychiatry. 2017;88(3):266 -71. Epub 2016/11/02.
24.Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette -Artur P, Eyrolle -Guignot D, et al. 
Association between Zika virus and microcephaly in French Polynesia, 2013 -15: a 
retrospective study. Lancet. 2016;387([ZIP_CODE]):2125 -32. Epub 2016/03/20.
25.WHO. WHO statement on the first meeting of the Internation al Health Regulations (2005) 
(IHR 2005) Emergency Committee on Zika virus and observed increase in neurological 
disorders and neonatal malformations. 2016 [30 November 2016]; Available from: 
http://www.who.int/mediacentre/news/statements/2016/1st -emergency -committee -zika/en/ .
26.Du Toit A. Zika virus structure, epi[INVESTIGATOR_177887]. Nature Reviews Microbiology. 
2016;14(267).
27.Sirohi D, Chen Z, Sun L, Klose T, Pi[INVESTIGATOR_151616], Rossmann MG, et al. The 3.8 A resolution 
cryo-EM structure of Zika virus. Science. 20 16;352(6284):467 -70. Epub 2016/04/02.
28.Pi[INVESTIGATOR_98803] T, Diamond M. Flaviviruses. In: Knipe DM HP, editor. Fields Virology. 6th ed. 
Philadelphia: Lippi[INVESTIGATOR_4431] & Wilkins; 2013. p. 747e94.
0094Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee associated with the Zika 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee associated with the Zika 
5. Epub 2016/04/07.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5. Epub 2016/04/07.
Mecharles S, Herrmann C, Poullain P, Tran TH, Deschamps N, Mathon G, et al. Acute 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMecharles S, Herrmann C, Poullain P, Tran TH, Deschamps N, Mathon G, et al. Acute 
[ZIP_CODE]):1481. Epub 2016/03/08.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use10026):1481. Epub 2016/03/08.
WHO. Zika situation report. 8 December 2016. 2016 [14 December 2016]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. Zika situation report. 8 December 2016. 2016 [14 December 2016]; Available from: 
2016/en/
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2016/en/
Organization; 2017 [updated 27 April 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOrganization; 2017 [updated 27 April 
http://www2.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gi
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www2.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gi
Dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, et al. 
Case Series from Seven Countries. The New England 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCase Series from Seven Countries. The New England 
601. Epub 2016/11/01.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use601. Epub 2016/11/01.
Dirlikov E, Major CG, Mayshack M, Medina N, Matos D, Ryff KR, et al. Guillain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDirlikov E, Major CG, Mayshack M, Medina N, Matos D, Ryff KR, et al. Guillain
Zika Virus Transmission 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika Virus Transmission 
MMWR Morbidity and mortality weekly report. 2016;65(34):910
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMMWR Morbidity and mortality weekly report. 2016;65(34):910
Krauer F, Riesen M, Reveiz L, Oladapo OT, Martinez
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseKrauer F, Riesen M, Reveiz L, Oladapo OT, Martinez
Congenital Brain Abnormalities and Guillain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCongenital Brain Abnormalities and Guillain
Systematic Review. PLoS medicine. 2017;14(1):e1002203. Epub 2017/01/04.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSystematic Review. PLoS medicine. 2017;14(1):e1002203. Epub 2017/01/04.
The L. Another kind of Zika public health emergency. Lancet. 2017;389([ZIP_CODE]):573. Epub 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe L. Another kind of Zika public health emergency. Lancet. 2017;389([ZIP_CODE]):573. Epub 
Kuwabara S. Zika virus infection and Guillain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseKuwabara S. Zika virus infection and Guillain
review focused on clinical and electrophysiological subtypes. Journal of neurology, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usereview focused on clinical and electrophysiological subtypes. Journal of neurology, 
neurosurgery, and psychiatry. 2017;88(3):266
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useneurosurgery, and psychiatry. 2017;88(3):[ADDRESS_209102] P, Dub T, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCauchemez S, Besnard M, Bompard P, Dub T, 
Association between Zika virus and microcephaly in French Polynesia, 2013
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAssociation between Zika virus and microcephaly in French Polynesia, 2013
retrospective study. Lancet. 2016;387([ZIP_CODE]):2125
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useretrospective study. Lancet. 2016;387([ZIP_CODE]):2125
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. WHO statement on the first meeting of the Internation
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. WHO statement on the first meeting of the Internation
(IHR 2005) Emergency Committee on Zika virus and observed increase in neurological 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(IHR 2005) Emergency Committee on Zika virus and observed increase in neurological 
disorders and neonatal malformations. 2016 [30 November 2016]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedisorders and neonatal malformations. 2016 [30 November 2016]; Available from: 
http://www.who.int/mediacentre/news/statements/2016/1st
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.who.int/mediacentre/news/statements/2016/1st
26.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use26.Du Toit A. Zika virus structure, epi[INVESTIGATOR_177887]. Nature Reviews Microbiology. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDu Toit A. Zika virus structure, epi[INVESTIGATOR_177887]. Nature Reviews Microbiology. 
2016;14(267).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2016;14(267).
27.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use27.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 94of 108
Protocol Amendment 3 Version 7.0 12September 2018
29.Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serologi cal specificity. 
Transactions of the Royal Society of Tropi[INVESTIGATOR_177888]. 1952;46(5):509 -20. 
Epub 1952/09/01.
30.Macnamara FN. Zika virus: a report on three cases of human infection during an epi[INVESTIGATOR_177889]. Transactions of the Roy al Society of Tropi[INVESTIGATOR_177888]. 
1954;48(2):139 -45. Epub 1954/03/01.
31.Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of 
dengue, chikungunya and Zika virus infections -an unprecedented epi[INVESTIGATOR_177890] -borne viruses in the Pacific 2012 -2014. Euro surveillance : bulletin Europeen sur les 
maladies transmissibles = European communicable disease bulletin. 2014;19(41):pii: [ZIP_CODE]. 
Epub 2014/10/28.
32.Smithburn KC. Neutralizing antibodies against certain r ecently isolated viruses in the sera of 
human beings residing in East Africa. J Immunol. 1952;69(2):223 -34. Epub 1952/08/01.
33.Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus 
outbreak on Yap Island, Federated States of Micr onesia. The New England journal of 
medicine. 2009;360(24):2536 -43. Epub 2009/06/12.
34.Cao-Lormeau VM, [COMPANY_002] C, Teissier A, Robin E, Berry AL, Mallet HP, et al. Zika virus, 
French polynesia, South pacific, 2013. Emerging infectious diseases. 2014;20(6):1085 -6. 
Epub 2014/05/27.
35.Tognarelli J, Ulloa S, Villagra E, Lagos J, Aguayo C, Fasce R, et al. A report on the outbreak of 
Zika virus on Easter Island, South Pacific, 2014. Archives of virology. 2016;161(3):665 -8. 
Epub 2015/11/28.
36.Zanluca C, Melo VC, Mosimann AL , Santos GI, Santos CN, Luz K. First report of 
autochthonous transmission of Zika virus in Brazil. Memorias do Instituto Oswaldo Cruz. 
2015;110(4):569 -72. Epub 2015/06/11.
37.WHO. Zika situation report -Zika virus, Microcephaly and Guillain -BarrÃ© syndrome. W orld 
Health Organization; 2017 [updated 10 March 201705 May 2017]; Available from: 
http://www.who.int/emergencies/zika -virus/situation -report/10 -march -2017/en/ .
38.Ikejezie J, Shapi[INVESTIGATOR_177891], Kim J, Chiu M, Almiron M, Ugarte C, et al. Zika Virus Transmission -
Region of the Americas, May 15, 2015 -December 15, 2016. MMWR Morbidity and mortality 
weekly report. 2017;66(12):329 -34. Epub 2017/03/31.
39.Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global 
distribution of the arbovirus vectors A edes aegypti and Ae. albopi[INVESTIGATOR_40643]. eLife. 2015;4:e08347. 
Epub 2015/07/01.
40.Ayres CF. Identification of Zika virus vectors and implications for control. The Lancet 
Infectious diseases. 2016;16(3):278 -9. Epub 2016/02/09.
41.Gubler DJ. The global emergence/resurgen ce of arboviral diseases as public health problems. 
Archives of medical research. 2002;33(4):330 -42. Epub 2002/09/18.
42.Martines RB, Bhatnagar J, Keating MK, Silva -Flannery L, Muehlenbachs A, Gary J, et al. 
Notes from the Field: Evidence of Zika Virus Infect ion in Brain and Placental Tissues from 
Two Congenitally Infected Newborns and Two Fetal Losses --Brazil, 2015. MMWR Morbidity 
and mortality weekly report. 2016;65(6):159 -60. Epub 2016/02/20.
0095Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMacnamara FN. Zika virus: a report on three cases of human infection during an epi[INVESTIGATOR_177892]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMacnamara FN. Zika virus: a report on three cases of human infection during an epi[INVESTIGATOR_177893]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useal Society of Tropi[INVESTIGATOR_177888]. 
Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRoth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of 
an unprecedented epi[INVESTIGATOR_177894]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usean unprecedented epi[INVESTIGATOR_177895] : bulletin Europeen sur les 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuro surveillance : bulletin Europeen sur les 
2014;19(41):pii: [ZIP_CODE]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2014;19(41):pii: [ZIP_CODE]. 
ecently isolated viruses in the sera of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useecently isolated viruses in the sera of 
human beings residing in East Africa. J Immunol. 1952;69(2):223
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehuman beings residing in East Africa. J Immunol. 1952;69(2):223 -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-34. Epub 1952/08/01.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use34. Epub 1952/08/01.
Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDuffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus 
onesia. The New England journal of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonesia. The New England journal of 
Lormeau VM, [COMPANY_002] C, Teissier A, Robin E, Berry AL, Mallet HP, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLormeau VM, [COMPANY_002] C, Teissier A, Robin E, Berry AL, Mallet HP, et al. 
French polynesia, South pacific, 2013. Emerging infectious diseases. 2014;20(6):1085
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFrench polynesia, South pacific, 2013. Emerging infectious diseases. 2014;20(6):1085
Tognarelli J, Ulloa S, Villagra E, Lagos J, Aguayo C, Fasce R, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTognarelli J, Ulloa S, Villagra E, Lagos J, Aguayo C, Fasce R, et al. 
Zika virus on Easter Island, South Pacific, 2014. Archives of virology. 2016;161(3):665
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika virus on Easter Island, South Pacific, 2014. Archives of virology. 2016;161(3):665
Zanluca C, Melo VC, Mosimann AL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZanluca C, Melo VC, Mosimann AL , Santos GI, Santos CN, Luz K. First report of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use, Santos GI, Santos CN, Luz K. First report of 
autochthonous transmission of Zika virus in Brazil. Memorias do Instituto Oswaldo Cruz. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useautochthonous transmission of Zika virus in Brazil. Memorias do Instituto Oswaldo Cruz. 
72. Epub 2015/06/11.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use72. Epub 2015/06/11.
WHO. Zika situation report 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. Zika situation report -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika virus, Microcephaly and Guillain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika virus, Microcephaly and Guillain
Health Organization; 2017 [updated 10 March 201705 May 2017]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHealth Organization; 2017 [updated 10 March 201705 May 2017]; Available from: 
http://www.who.int/emergencies/zika
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.who.int/emergencies/zika
Ikejezie J, Shapi[INVESTIGATOR_177891], Kim J, Chiu M, Almiron M, Ugarte C, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIkejezie J, Shapi[INVESTIGATOR_177891], Kim J, Chiu M, Almiron M, Ugarte C, et al. 
gion of the Americas, May 15, 2015
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usegion of the Americas, May 15, 2015
weekly report. 2017;66(12):329
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useweekly report. 2017;66(12):329
Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseKraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global 
distribution of the arbovirus vectors A
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedistribution of the arbovirus vectors A
Epub 2015/07/01.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEpub 2015/07/01.
Ayres CF. Identification of Zika virus vectors and implications for control. The Lancet 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAyres CF. Identification of Zika virus vectors and implications for control. The Lancet 
Infectious diseases. 2016;16(3):278
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInfectious diseases. 2016;16(3):278
41.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use41.Gubler DJ. The global emergence/resurgen
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGubler DJ. The global emergence/resurgen
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 95of 108
Protocol Amendment 3 Version 7.0 12September 2018
43.Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, et al. Detection and 
sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case 
study. The Lancet Infectious diseases. 2016;16(6):653 -60. Epub 2016/02/22.
44.Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampai o S, Bispo de Filippis 
AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of 
the iceberg? Ultrasound in obstetrics & gynecology : the official journal of the International 
Society of Ultrasound in Obstetrics and Gyne cology. 2016;47(1):6 -7. Epub 2016/01/06.
45.Besnard M, Lastere S, Teissier A, Cao -Lormeau V, Musso D. Evidence of perinatal 
transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro 
surveillance : bulletin Europeen sur les maladies t ransmissibles = European communicable 
disease bulletin. 2014;19(13):[ZIP_CODE]. Epub 2014/04/12.
46.Dupont -Rouzeyrol M, Biron A, O'Connor O, Huguon E, Descloux E. Infectious Zika viral 
particles in breastmilk. Lancet. 2016;387([ZIP_CODE]):1051. Epub 2016/03/06.
47.Foy BD, Koby[CONTACT_1057], Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, et 
al. Probable non -vector -borne transmission of Zika virus, Colorado, [LOCATION_003]. Emerging 
infectious diseases. 2011;17(5):880 -2. Epub 2011/05/03.
48.Musso D, [COMPANY_002] C, Robin E, Nhan T, Teissier A, Cao -Lormeau VM. Potential sexual 
transmission of Zika virus. Emerging infectious diseases. 2015;21(2):359 -61. Epub 
2015/01/28.
49.D'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Pi[INVESTIGATOR_177896] G, et al. 
Evidence of Sexual Transmission of Zika Virus. The New England journal of medicine. 
2016;374(22):2195 -8. Epub 2016/04/14.
50.Musso D, Nhan T, Robin E, [COMPANY_002] C, Bierlaire D, Zisou K, et al. Potential for Zika virus 
transmission through blood transfusio n demonstrated during an outbreak in French Polynesia, 
November 2013 to February 2014. Euro surveillance : bulletin Europeen sur les maladies 
transmissibles = European communicable disease bulletin. 2014;19(14). Epub 2014/04/18.
51.Vasquez AM, Sapi[INVESTIGATOR_177897], Basavaraju SV, Kuehnert MJ, Rivera -Garcia B. Survey of Blood 
Collection Centers and Implementation of Guidance for Prevention of 
Transfusion -Transmitted Zika Virus Infection --Puerto Rico, 2016. MMWR Morbidity and 
mortality weekly report. 2016;65(14):375 -8.Epub 2016/04/15.
52.Chen LH, Wilson ME. Transmission of dengue virus without a mosquito vector: nosocomial 
mucocutaneous transmission and other routes of transmission. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America. 2004;39(6):e56 -60. Epub 
2004/10/09.
53.CDC. Clinical Guidance for Healthcare Providers for Prevention of Sexual Transmission of 
Zika Virus. 2016 [01 December 2016]; Available from: 
http://www.cdc.gov/zika/hc -providers/clinical -guidance/sexualtrans mission.html .
54.Landry ML, St George K. Laboratory Diagnosis of Zika Virus Infection. Archives of 
pathology & laboratory medicine. 2017;141(1):60 -7. Epub 2016/10/21.
55.Parra B, Lizarazo J, Jimenez -Arango JA, Zea -Vera AF, Gonzalez -Manrique G, Vargas J, et al. 
Guillain -Barre Syndrome Associated with Zika Virus Infection in Colombia. The New 
England journal of medicine. 2016;375(16):1513 -23. Epub 2016/11/01.
0096Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo S, Bispo de Filippis 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo S, Bispo de Filippis 
AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of 
the iceberg? Ultrasound in obstetrics & gynecology : the official journal of the International 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe iceberg? Ultrasound in obstetrics & gynecology : the official journal of the International 
7. Epub 2016/01/06.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use7. Epub 2016/01/06.
Lormeau V, Musso D. Evidence of perinatal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLormeau V, Musso D. Evidence of perinatal 
transmission of Zika virus, French Polynesia, December 2013 and February 2014. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmission of Zika virus, French Polynesia, December 2013 and February 2014. 
ransmissibles = European communicable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useransmissibles = European communicable 
Rouzeyrol M, Biron A, O'Connor O, Huguon E, Descloux E. Infectious Zika viral 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRouzeyrol M, Biron A, O'Connor O, Huguon E, Descloux E. Infectious Zika viral 
particles in breastmilk. Lancet. 2016;387([ZIP_CODE]):1051. Epub 2016/03/06.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparticles in breastmilk. Lancet. 2016;387([ZIP_CODE]):1051. Epub 2016/03/06.
Koby[CONTACT_1057], Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, et 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseKoby[CONTACT_1057], Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, et 
borne transmission of Zika virus, Colorado, [LOCATION_003]. Emerging 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useborne transmission of Zika virus, Colorado, [LOCATION_003]. Emerging 
2. Epub 2011/05/03.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2. Epub 2011/05/03.
Musso D, [COMPANY_002] C, Robin E, Nhan T, Teissier A, Cao
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMusso D, [COMPANY_002] C, Robin E, Nhan T, Teissier A, Cao -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-Lormeau VM. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLormeau VM. 
transmission of Zika virus. Emerging infectious diseases. 2015;21(2):359
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmission of Zika virus. Emerging infectious diseases. 2015;21(2):359
D'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Pi[INVESTIGATOR_177896] G,
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseD'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Pi[INVESTIGATOR_177896] G,
Evidence of Sexual Transmission of Zika Virus. The New England journal of medicine. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEvidence of Sexual Transmission of Zika Virus. The New England journal of medicine. 
8. Epub 2016/04/14.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use8. Epub 2016/04/14.
Musso D, Nhan T, Robin E, [COMPANY_002] C, Bierlaire D, Zisou K, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMusso D, Nhan T, Robin E, [COMPANY_002] C, Bierlaire D, Zisou K, et al. 
transmission through blood transfusio
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmission through blood transfusio n demonstrated during an outbreak in French Polynesia, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen demonstrated during an outbreak in French Polynesia, 
November 2013 to February 2014. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNovember 2013 to February 2014. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuro surveillance : bulletin Europeen sur les maladies 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuro surveillance : bulletin Europeen sur les maladies 
transmissibles = European communicable disease bulletin. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransmissibles = European communicable disease bulletin. 
Vasquez AM, Sapi[INVESTIGATOR_177897], 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVasquez AM, Sapi[INVESTIGATOR_177897], Basavaraju SV, Kuehnert MJ, Rivera
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBasavaraju SV, Kuehnert MJ, Rivera
Collection Centers and Implementation of Guidance for Prevention of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCollection Centers and Implementation of Guidance for Prevention of 
Transmitted Zika Virus Infection
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTransmitted Zika Virus Infection
mortality weekly report. 2016;65(14):375
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemortality weekly report. 2016;65(14):375
Chen LH, Wilson ME. Transmission of dengue virus without a mosquito vector: nosocomial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseChen LH, Wilson ME. Transmission of dengue virus without a mosquito vector: nosocomial 
mucocutaneous transmission and other routes of transmission. Clinical infectious diseases : an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemucocutaneous transmission and other routes of transmission. Clinical infectious diseases : an 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useofficial publication of the Infectious Diseases Society 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useofficial publication of the Infectious Diseases Society 
2004/10/09.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2004/10/09.
CDC. Clinical Guidance for Healthcare Providers for Prevention of Sexual Transmission of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC. Clinical Guidance for Healthcare Providers for Prevention of Sexual Transmission of 
Zika Virus. 2016 [01 December 2016]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseZika Virus. 2016 [01 December 2016]; Available from: 
http://www.cdc.gov/zika/hc
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.cdc.gov/zika/hc
54.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use54.
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 96of 108
Protocol Amendment 3 Version 7.0 12September 2018
56.Murray KO, Gorchakov R, Carlson AR, Berry R, Lai L, Natrajan M, et al. Prolonged Detection 
of Zika Virus in Vaginal Secretions and Whole Blood. Emerging infectious diseases. 
2017;23(1):99 -101. Epub 2016/10/18.
57.Miner JJ, Sene A, Richner JM, Smith AM, Santeford A, Ban N, et al. Zika Virus Infection in 
Mice Causes Panuveitis with Shedding of Virus in Tears. Cell r eports. 2016;16(12):3208 -18. 
Epub 2016/09/11.
58.Swaminathan S, Schlaberg R, Lewis J, Hanson KE, Couturier MR. Fatal Zika Virus Infection 
with Secondary Nonsexual Transmission. The New England journal of medicine. 
2016;375(19):1907 -9. Epub 2016/09/30.
59.WHO. Zi ka Virus. Transmission and risks. World Health Organization; 2017 [updated 28 
April 201705 May 2017]; Available from: https://www.cdc.gov/zika/transmission/index.html .
60.WHO. Zika virus. Fact sheet. 2017 [updated September 201605 May 2017]; Available from: 
http://www.who.int/mediacentre/factsheets/zika/en/ .
61.ECDC. Rapid risk assessment: Zika virus disease epi[INVESTIGATOR_901]. Tenth update. Stockholm: 
European Centre for Disease Prevention and Control; 2017 [updated 04 April 201705 May 
2017]; Available from: 
http://ecdc.e uropa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55a
d51-4aed -4d32 -b960 -af70113dbb90&ID=1671#sthash.LjiTcDRg.dpuf .
62.CDC. Guidance for U.S. Laboratories Testing for Zika Virus Infection. November 16, 2016. 
2016 [21 December 2016]; Avai lable from: 
https://www.cdc.gov/zika/laboratories/lab -guidance.html .
63.WHO. Laboratory testing for Zika virus infection. Interim guidance. 
WHO/ZIKV/LAB/1612016.
64.CDC. Guidance for U.S. Laboratory Testing for Zika Virus Infection: Implications for Health 
Care Providers. Announcement November 25, 2016. 2016 [21 December 2016]; Available 
from: https://www.cdc.gov/mmwr/volumes/65/wr/mm6546a7.htm?s_cid=mm6546a7_w .
65.Barzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E, et al. Isolation of 
infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning 
from the Dominican Republic to Italy, January 2016. Euro surveillance : bulletin Europeen sur 
les maladies transmissibles = European communicable disease bulletin. 2016;21(10). Ep ub 
2016/03/19.
66.Musso D, [COMPANY_002] C, Nhan TX, Robin E, Teissier A, Cao -Lormeau VM. Detection of Zika virus 
in saliva. Journal of clinical virology : the official publication of the Pan American Society for 
Clinical Virology. 2015;68:53 -5. Epub 2015/06/14.
67.Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jaaskelainen AJ, Smura T, et al. Zika Virus 
Infection with Prolonged Maternal Viremia and Fetal Brain Abnormalities. The New England 
journal of medicine. 2016;374(22):2142 -51. Epub 2016/03/31.
68.Lanciotti RS, Kosoy OL , Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and 
serologic properties of Zika virus associated with an epi[INVESTIGATOR_901], Yap State, Micronesia, 2007. 
Emerging infectious diseases. 2008;14(8):1232 -9. Epub 2008/08/06.
0097Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMiner JJ, Sene A, Richner JM, Smith AM, Santeford A, Ban N, et al. Zika Virus Infection in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMiner JJ, Sene A, Richner JM, Smith AM, Santeford A, Ban N, et al. Zika Virus Infection in 
eports. 2016;16(12):3208
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useeports. 2016;16(12):3208 -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-18. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use18. 
Swaminathan S, Schlaberg R, Lewis J, Hanson KE, Couturier MR. Fatal Zika Virus Infection 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSwaminathan S, Schlaberg R, Lewis J, Hanson KE, Couturier MR. Fatal Zika Virus Infection 
with Secondary Nonsexual Transmission. The New England journal of medicine. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewith Secondary Nonsexual Transmission. The New England journal of medicine. 
ka Virus. Transmission and risks. World Health Organization; 2017 [updated 28 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useka Virus. Transmission and risks. World Health Organization; 2017 [updated 28 
April 201705 May 2017]; Available from: https://www.cdc.gov/zika/transmission/index.html
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseApril 201705 May 2017]; Available from: https://www.cdc.gov/zika/transmission/index.html
WHO. Zika virus. Fact sheet. 2017 [updated September 201605 May 2017]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. Zika virus. Fact sheet. 2017 [updated September 201605 May 2017]; Available from: 
ECDC. Rapid risk assessment: Zika virus disease epi[INVESTIGATOR_901]. Tenth update. Stockholm: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseECDC. Rapid risk assessment: Zika virus disease epi[INVESTIGATOR_901]. Tenth update. Stockholm: 
European Centre for Disease Prevention and Control; 2017 [updated 04 April 201705 May 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEuropean Centre for Disease Prevention and Control; 2017 [updated 04 April 201705 May 
uropa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55a
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuropa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55a
af70113dbb90&ID=1671#sthash.LjiTcDRg.dpuf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaf70113dbb90&ID=1671#sthash.LjiTcDRg.dpuf
CDC. Guidance for U.S. Laboratories Testing for Zika Virus Infection. November 16, 2016. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC. Guidance for U.S. Laboratories Testing for Zika Virus Infection. November 16, 2016. 
lable from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselable from: 
https://www.cdc.gov/zika/laboratories/lab
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttps://www.cdc.gov/zika/laboratories/lab -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-guidance.html
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useguidance.html
WHO. Laboratory testing for Zika virus infection. Interim guidance. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. Laboratory testing for Zika virus infection. Interim guidance. 
CDC. Guidance for U.S. Laboratory Testing for Zika Virus Infection: Implications for Health 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC. Guidance for U.S. Laboratory Testing for Zika Virus Infection: Implications for Health 
Providers. Announcement November 25, 2016. 2016 [21 December 2016]; Available 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProviders. Announcement November 25, 2016. 2016 [21 December 2016]; Available 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefrom: https://www.cdc.gov/mmwr/volumes/65/wr/mm6546a7.htm?s_cid=mm6546a7_w
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefrom: https://www.cdc.gov/mmwr/volumes/65/wr/mm6546a7.htm?s_cid=mm6546a7_w
Barzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBarzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E, et al. 
virus from saliva and prolonged viral RNA shedding in a traveller returning 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevirus from saliva and prolonged viral RNA shedding in a traveller returning 
from the Dominican Republic to Italy, January 2016. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usefrom the Dominican Republic to Italy, January 2016. 
les maladies transmissibles = European communicable disease bulletin. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useles maladies transmissibles = European communicable disease bulletin. 
2016/03/19.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2016/03/19.
Musso D, [COMPANY_002] C, Nhan TX, Robin E, Teissier A, Cao
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMusso D, [COMPANY_002] C, Nhan TX, Robin E, Teissier A, Cao
in saliva. Journal of clinical virology : the official publication of the Pan American Society for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein saliva. Journal of clinical virology : the official publication of the Pan American Society for 
Clinical Virology. 2015;68:53
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Virology. 2015;68:53
67.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use67.Drig
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDrig
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 97of 108
Protocol Amendment 3 Version 7.0 12September 2018
69.Dowd KA, Ko SY, Morabito KM, Yan g ES, Pelc RS, DeMaso CR, et al. Rapid development 
of a DNA vaccine for Zika virus. Science. 2016;354(6309):237 -40. Epub 2016/10/07.
70.Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Gunther S, et al. Zika virus 
infections imported to Italy: clinic al, immunological and virological findings, and public 
health implications. Journal of clinical virology : the official publication of the Pan American 
Society for Clinical Virology. 2015;63:32 -5. Epub 2015/01/21.
71.Paul LM, Carlin ER, Jenkins MM, Tan AL, Ba rcellona CM, Nicholson CO, et al. Dengue virus 
antibodies enhance Zika virus infection. Clinical & translational immunology. 
2016;5(12):e117. Epub 2017/01/17.
72.Brasil P, Pereira JP, Jr., Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et 
al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. The New England journal of 
medicine. 2016;375(24):2321 -34. Epub 2016/03/05.
73.CDC. Zika Virus Treatment. 2016 [23 December 2016]; Available from: 
https://www.cdc.gov/zika/symptoms/treatment.html .
74.CDC. Developmental disabilities. Atlanta, GA: US Department of Health and Human 
Services2015 [21 December 2016]; Available from: 
http://www.cdc.gov/ncbddd/developmentaldisabilities/index.html .
75.Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain -Barre Syndrome. 
Annals of Indian Academy of Neurology. 2011;14(Suppl 1):S73 -81. Epub 2011/08/19.
76.CDC. CDCâ€™s Response to Zika. Updated Interim Pregnancy Guidance. 2016 [01 February 
2017]; Available from: https://www.cdc.gov/zika/pdfs/testing_algorithm.pdf .
77.Nasci RS, Wirtz RA, Brogdon WG. Protection against mosquitoes, ticks, and other arthropods. 
In: CDC health information for international travel. [LOCATION_001], NY: Oxford University Press; 
2015 [21 December 2016]; Available from: 
http://wwwnc.cdc.gov/travel/ye llowbook/2016/the -pre-travel -consultation/protection -against -
mosquitoes -ticks -other -arthropods .
78.CDC. Travel notices. Atlanta, GA: US Department of Health and Human Services2016 [21 
December 2016]; Available from: http://wwwnc.cdc.gov/travel/notices .
79.HHS. HHS declares a public health emergency in Puerto Rico in response to Zika outbreak. 
U.S. Department of Health & Human Services (HHS) Press Office2016 [30 November 2016]; 
Available from: 
https://www.hhs.gov/about/news/2016/08/12/hhs -declares -public -health -emergency -in-puert
o-rico-in-response -to-zika-outbreak.html .
80.WHO. WHO statement. Fifth meeting of the Emergency Committee under the International 
Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika 
virus. 18 November 2016. 2016 [02 December 2016]; Available from: 
http://www.who.int/mediacentre/news/statements/2016/zika -fifth-ec/en/.
81.Yang YT, Sarfaty M. Zika virus: A call to action for physicians in the era of climate change. 
Preventive medicine reports. 2016;4:444 -6. Epub 2 016/09/13.
82.HHS. HHS awards $ 19.8 million to Japanese company to accelerate development of a Zika 
vaccine. U.S. Department of Health & Human Services (HHS) Press Office2016 [14 
0098Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealth implications. Journal of clinical virology : the official publication of the Pan American 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealth implications. Journal of clinical virology : the official publication of the Pan American 
Dengue virus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDengue virus 
antibodies enhance Zika virus infection. Clinical & translational immunology. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useantibodies enhance Zika virus infection. Clinical & translational immunology. 
Brasil P, Pereira JP, Jr., Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBrasil P, Pereira JP, Jr., Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et 
Virus Infection in Pregnant Women in Rio de Janeiro. The New England journal of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseVirus Infection in Pregnant Women in Rio de Janeiro. The New England journal of 
CDC. Zika Virus Treatment. 2016 [23 December 2016]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC. Zika Virus Treatment. 2016 [23 December 2016]; Available from: 
Developmental disabilities. Atlanta, GA: US Department of Health and Human 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDevelopmental disabilities. Atlanta, GA: US Department of Health and Human 
http://www.cdc.gov/ncbddd/developmentaldisabilities/index.html
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.cdc.gov/ncbddd/developmentaldisabilities/index.html
Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMeena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain
Annals of Indian Academy of Neurology. 2011;14(Suppl 1):S73
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAnnals of Indian Academy of Neurology. 2011;14(Suppl 1):S73
CDC. CDCâ€™s Response to Zika. Updated Interim Pregnancy Guidance. 2016 [01 February 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC. CDCâ€™s Response to Zika. Updated Interim Pregnancy Guidance. 2016 [01 February 
2017]; Available from: https://www.cdc.gov/zika/pdfs/testing_algorithm.pdf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2017]; Available from: https://www.cdc.gov/zika/pdfs/testing_algorithm.pdf
Nasci RS, Wirtz RA, Brogdon WG. Protection against mosquitoes, ticks, and other arthropods. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseNasci RS, Wirtz RA, Brogdon WG. Protection against mosquitoes, ticks, and other arthropods. 
In: CDC health information for international travel. [LOCATION_001], NY: Oxford University Press; 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIn: CDC health information for international travel. [LOCATION_001], NY: Oxford University Press; 
2015 [21 December 2016]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2015 [21 December 2016]; Available from: 
http://wwwnc.cdc.gov/travel/ye
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://wwwnc.cdc.gov/travel/ye llowbook/2016/the
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usellowbook/2016/the
other
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useother -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-arthropods
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usearthropods
CDC. Travel notices. Atlanta, GA: US Department of Health and Human Services2016 [21 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCDC. Travel notices. Atlanta, GA: US Department of Health and Human Services2016 [21 
December 2016]; Available from: http://wwwnc.cdc.gov/travel/notices
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDecember 2016]; Available from: http://wwwnc.cdc.gov/travel/notices
HHS declares a public health emergency in Puerto Rico in response to Zika outbreak. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHHS declares a public health emergency in Puerto Rico in response to Zika outbreak. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseU.S. Department of Health & Human Services (HHS) Press Office2016 [30 November 2016]; 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseU.S. Department of Health & Human Services (HHS) Press Office2016 [30 November 2016]; 
Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAvailable from: 
https://www.hhs.gov/about/news/2016/08/12/hhs
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttps://www.hhs.gov/about/news/2016/08/12/hhs
o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useo-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-rico
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userico-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-in
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usein
80.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use80.WHO. WHO statement. Fifth meeting of the Emergency Committee under the International 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. WHO statement. Fifth meeting of the Emergency Committee under the International 
Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHealth Regulations (2005) regarding microcephaly, other neurological disorders and Zika 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 98of 108
Protocol Amendment 3 Version 7.0 12September 2018
December 2016]; Press release 1 September 2016]. Available from: 
https://www.hh s.gov/about/news/2016/09/01/hhs -awards -19-8-million -japanese -company -ac
celerate -development -zika-vaccine.html .
83.Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith AR, Goo L, et al. Broadly Neutralizing 
Activity of Zika Virus -Immune Sera Identifies a Single Viral Serotype. Cell reports. 
2016;16(6):1485 -91. Epub 2016/08/03.
84.WRAIR, NIAID. A Phase 1, Randomized, Double -Blind Placebo -Controlled Clinical Trial to 
Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika 
Virus Purified Ina ctivated Vaccine Plus Alum Adjuvant in Healthy Adults. ClinicalTrials.gov 
Identifier: [STUDY_ID_REMOVED]; 2016 [16 January 2017]; Available from: 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=zika+wrair&rank=1.
85.Abbink P, Larocca RA, De La Barrera RA, Brica ult CA, Moseley ET, Boyd M, et al. 
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus 
monkeys. Science. 2016;353(6304):1129 -32. Epub 2016/08/06.
86.ICH. Harmonised Tripartite Guideline E8 General Considerations for Clinic al Trials. Step 4. 
July 1997. 1997 [10 January 2017]; Available from: 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/general -consideration
s-for-clinical -trials.html .
87.WHO. Clinical evaluation. Guidelines on clinical evaluation of va ccines: regulatory 
expectations. Fifty -second report, Geneva, ECBS, 2004;TRS 924,Annex 1. 2004 [10 January 
2017]; Available from: 
http://www.who.int/biologicals/publications/trs/areas/vaccines/clinical_evaluation/en/ .
88.ICH. Harmonised Tripartite Guideline E 4 Dose -Response Information to Support Drug 
Registration. Step 4. March 1994. 1994 [10 January 2017]; Available from: 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/dose -response -inform
ation -to-support -drug-registration.html .
89.FDA. Guidance for Industry. Exposure -Response Relationships â€”Study Design, Data 
Analysis, and Regulatory Applications. 2003 [10 January 2017]; Available from: 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u
cm072109.pdf .
90.ICH. Harmonised Tripartite Guideline E10 Choice of Control Group and Related Issues in 
Clinical Trials. Step 4. July 2000. 2000 [10 January 2017]; Available from: 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/choice -of-control -gro
up-and-related -issues -in-clinical -trials.html .
91.WHO. Weekly epi[INVESTIGATOR_177898]. Reducing pain at the time of vaccination: September 
2015. WHO position paper. 2015;90(39):505 -16.
92.Kohl KS, Marcy SM, Blum M, Connell Jones M, Dagan R, Hansen J, et al. Fever after 
immunization: current concepts and improved future scientific understanding. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 
2004;39(3):389 -94. Epub 2004/08/13.
0099Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDowd KA, DeMaso CR, Pelc RS, Speer SD, Smith AR, Goo L, et al. Broadly Neutralizing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDowd KA, DeMaso CR, Pelc RS, Speer SD, Smith AR, Goo L, et al. Broadly Neutralizing 
Controlled Clinical Trial to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseControlled Clinical Trial to 
Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEvaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika 
ctivated Vaccine Plus Alum Adjuvant in Healthy Adults. ClinicalTrials.gov 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usectivated Vaccine Plus Alum Adjuvant in Healthy Adults. ClinicalTrials.gov 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=zika+wrair&rank=1.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttps://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=zika+wrair&rank=1.
ult CA, Moseley ET, Boyd M, et al. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useult CA, Moseley ET, Boyd M, et al. 
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProtective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus 
32. Epub 2016/08/06.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use32. Epub 2016/08/06.
ICH. Harmonised Tripartite Guideline E8 General Considerations for Clinic
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseICH. Harmonised Tripartite Guideline E8 General Considerations for Clinic
http://www.ich.org/products/guidelines/efficacy/efficacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.ich.org/products/guidelines/efficacy/efficacy -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-single/article/general
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesingle/article/general
WHO. Clinical evaluation. Guidelines on clinical evaluation of va
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. Clinical evaluation. Guidelines on clinical evaluation of va
second report, Geneva, ECBS, 2004;TRS 924,Annex 1. 2004 [10 January 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesecond report, Geneva, ECBS, 2004;TRS 924,Annex 1. 2004 [10 January 
http://www.who.int/biologicals/publications/trs/areas/vaccines/clinical_evaluation/en/
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.who.int/biologicals/publications/trs/areas/vaccines/clinical_evaluation/en/
ICH. Harmonised Tripartite Guideline E
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseICH. Harmonised Tripartite Guideline E
Registration. Step 4. March 1994. 1994 [10 January 2017]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRegistration. Step 4. March 1994. 1994 [10 January 2017]; Available from: 
http://www.ich.org/products/guidelines/efficacy/efficacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.ich.org/products/guidelines/efficacy/efficacy
registration.html
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useregistration.html
Guidance for Industry. Exposure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseGuidance for Industry. Exposure
Analysis, and Regulatory Applications. 2003 [10 January 2017]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAnalysis, and Regulatory Applications. 2003 [10 January 2017]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u
cm072109.pdf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecm072109.pdf .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use. cm072109.pdf . cm072109.pdf
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecm072109.pdf . cm072109.pdf
CH. Harmonised Tripartite Guideline E10 Choice of Control Group and Related Issues in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseCH. Harmonised Tripartite Guideline E10 Choice of Control Group and Related Issues in 
Clinical Trials. Step 4. July 2000. 2000 [10 January 2017]; Available from: 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseClinical Trials. Step 4. July 2000. 2000 [10 January 2017]; Available from: 
http://www.ich.org/products/guidelines/efficacy/efficacy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehttp://www.ich.org/products/guidelines/efficacy/efficacy
u
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useup
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepupu
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useupu-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand
91.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use91.WHO. Weekly epi[INVESTIGATOR_177898]. Reducing pain at the time of vaccination: September 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWHO. Weekly epi[INVESTIGATOR_177898]. Reducing pain at the time of vaccination: September 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 99of 108
Protocol Amendment 3 Version 7.0 12September 2018
93.FDA. Guidance for Industry. Toxicit y Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007 [22 December 2016]; 
Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977 .
0100Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209103] to ICH GCP and all the applicable 
local laws and regulations.
The investigator agrees to assume the following responsibilities:
1.Conduct the trial in accordance with the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that trial related procedures, including trial specific (non -routine/non -standard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of written 
approval from relevant governing bodies/authorities.
4.Ensure that all colleagues and employees assisting in the conduct of the trial are informed of 
these obligations.
5.Secure prior approval of the trial and any changes by [CONTACT_4215]/IEC that conform to 
21 CFR Part 56, ICH, and loca l regulatory requirements.
6.Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the trial to the 
IRB/IEC, and issue a final report within [ADDRESS_209104]â€™s medical chart. Valid ICF is the most current version 
approved by [CONTACT_1201]/IEC. Each ICF should contain a subject authorization section that 
descri bes the uses and disclosures of a subjectâ€™s personal information (including personal 
health information) that will take place in connection with the trial. If an ICF does not include 
such a subject authorization, then the investigator must obtain a separat e subject authorization 
form from each subject.
9.Prepare and maintain adequate case histories of all persons entered into the trial, including 
eCRFs, hospi[INVESTIGATOR_1097], laboratory results, etc ., and maintain these data for a minimum of 
2years following noti fication by [CONTACT_178073]. The investigator should 
contact [CONTACT_178074].
10.Allow possible inspection and copying by [CONTACT_174394] -specified essential 
documents.
11.Maintain current records of the receipt, administration, and disposition of sponsor -supplied 
vaccines, and return all unused sponsor -supplied vacc ines to the sponsor.
12.Report AEs to the sponsor promptly. In the event of an SAE, notify the sponsor within 
24hours.
13.Review and provide a signature [CONTACT_178091].
0101Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesponsor are subject to ICH GCP and all the applicable 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesponsor are subject to ICH GCP and all the applicable 
routine/non
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useroutine/non -
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-standard panel) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usestandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of written 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usescreening assessments are NOT performed on potential subjects, prior to the receipt of written 
Ensure that all colleagues and employees assisting in the conduct of the trial are informed of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnsure that all colleagues and employees assisting in the conduct of the trial are informed of 
Secure prior approval of the trial and any changes by [CONTACT_4215]/IEC that conform to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSecure prior approval of the trial and any changes by [CONTACT_4215]/IEC that conform to 
l regulatory requirements.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usel regulatory requirements.
Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnsure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useof the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
yearly reports on the progress of the trial to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyearly reports on the progress of the trial to the 
IRB/IEC, and issue a final report within 3 months of trial completion.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseIRB/IEC, and issue a final report within 3 months of trial completion.
Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH, and local 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseEnsure that requirements for informed consent, as outlined in [ADDRESS_209105] who participates in the trial, and document 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemed consent from each subject who participates in the trial, and document 
the date of consent in the subjectâ€™s medical chart. Valid ICF is the most current version 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe date of consent in the subjectâ€™s medical chart. Valid ICF is the most current version 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapproved by [CONTACT_1201]/IEC. Each ICF should contain a subject authorization section that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapproved by [CONTACT_1201]/IEC. Each ICF should contain a subject authorization section that 
bes the uses and disclosures of a subjectâ€™s personal information (including personal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebes the uses and disclosures of a subjectâ€™s personal information (including personal 
health information) that will take place in connection with the trial. If an ICF does not include 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehealth information) that will take place in connection with the trial. If an ICF does not include 
such a subject authorization, then the investigator must obtain a separat
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesuch a subject authorization, then the investigator must obtain a separat
form from each subject.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useform from each subject.
Prepare and maintain adequate case histories of all persons entered into the trial, including 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePrepare and maintain adequate case histories of all persons entered into the trial, including 
eCRFs, hospi[INVESTIGATOR_1097], laboratory results, etc
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeCRFs, hospi[INVESTIGATOR_1097], laboratory results, etc
years following noti
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyears following noti
that the regulatory authority has approved the marketing application. The investigator should 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethat the regulatory authority has approved the marketing application. The investigator should 
contact [CONTACT_178075]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecontact [CONTACT_178075]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocum
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocum ents.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useents.
Allow possible inspection and copying by [CONTACT_178076]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAllow possible inspection and copying by [CONTACT_178077].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedocuments.
11.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use11.Maintain current records of the receipt, administration, and disposition of sponsor
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMaintain current records of the receipt, administration, and disposition of sponsor
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209106]:
1.A statement that the trial involves research.
2.An explanation of the purposes of the research.
3.The expected duration of the subjec tâ€™s participation.
4.A description of the procedures to be followed, including invasive procedures.
5.The identification of any procedures that are experimental.
6.The estimated number of subjects involved in the trial.
7.A description of the subjectâ€™s responsibil ities.
8.A description of the conduct of the trial.
9.A statement describing the vaccination(s) and the probability for random assignment to each 
treatment.
10.A description of the possible side effects following vaccine administration that the subject may 
receiv e.
11.A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12.A description of any benefits to the subject or to others that reasonably may be expected from 
the research. Wh en there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential ri sks and benefits.
14.A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By [CONTACT_2960] a written informed consent, the subject is 
authorizing such access.
15.For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of or where further information may be obtained.
16.The anticipated prorated payment(s), if any, to the subject for participating in the trial.
17.The anticipated expenses, if any, to the subject for participating in the trial.
18.An e xplanation of whom to contact [CONTACT_39831] 
(investigator), subjectâ€™s rights, and IRB/IEC and whom to contact [CONTACT_44751] a 
research -related injury to the subject.
19.A statement that participation is voluntary, tha t refusal to participate will involve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.
20.The consequences of a subjectâ€™s decision to withdraw from the research and procedures for 
orderly termination of participation by [CONTACT_423].
21.A statement that the subject will be informed in a timely manner if information becomes 
available that may be rel evant to the subjectâ€™s willingness to continue participation in the trial.
0102Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA description of the procedures to be followed, including invasive procedures.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA description of the procedures to be followed, including invasive procedures.
A statement describing the vaccination(s) and the probability for random assignment to each 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA statement describing the vaccination(s) and the probability for random assignment to each 
A description of the possible side effects following vaccine administration that the subject may 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA description of the possible side effects following vaccine administration that the subject may 
A description of any reasonably foreseeable risks or discomforts to the subject and, when 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useapplicable, to an embryo, fetus, or nursing infant.
A description of any benefits to the subject or to others that reasonably may be expected from 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA description of any benefits to the subject or to others that reasonably may be expected from 
en there is no intended clinical benefit to the subject, the subject should be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useen there is no intended clinical benefit to the subject, the subject should be 
Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseDisclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential ri
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useadvantageous to the subject and their important potential ri
A statement describing the extent to which confidentiality of records identifying the subject 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand the monitor may inspect the records. By 
[CONTACT_178078].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useauthorizing such access.
For research involving more than minimal risk, an explanation as to whether any compensation 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFor research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand an explanation as to whether any medical treatments are available if injury occurs 
so, what they consist of or where further information may be obtained.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useso, what they consist of or where further information may be obtained.
The anticipated prorated payment(s), if any, to the subject for participating in the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe anticipated prorated payment(s), if any, to the subject for participating in the trial.
The anticipated expenses, if any, to the subject for participating in the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe anticipated expenses, if any, to the subject for participating in the trial.
xplanation of whom to contact [CONTACT_178079]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usexplanation of whom to contact [CONTACT_39831] 
(investigator), subjectâ€™s rights, and IRB/IEC and whom to contact [CONTACT_44751] a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(investigator), subjectâ€™s rights, and IRB/IEC and whom to contact [CONTACT_44751] a 
research
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useresearch
19.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use19.A statement that participation is voluntary, tha
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA statement that participation is voluntary, tha
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useloss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209107]â€™s participation in the trial 
may be terminated.
24.A written subject authorization (either contained within the informed consent or provided as a 
separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subjectâ€™s personal information (including personal health information) for 
purposes of conducting the trial. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subjectâ€™s personal information:
a)that personal information (including personal health information) may be processed by [CONTACT_87859], including, without limitation, to the following: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b)it is possible that personal information (including pe rsonal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, [COMPANY_005] will make every effort to keep your personal information confidential, 
and your name [CONTACT_87873] [CONTACT_2371];
c)that personal information (including personal health information) may be added to 
[COMPANY_005]â€™s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safety and effectiveness of the investigational vaccine(s), studying other therapi[INVESTIGATOR_82256], developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of 
future clinical studies;
d)that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the trial to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the resea rch; and
e)that the subjectâ€™s identity will remain confidential in the event that trial results are 
published.
25.The vaccination may involve risks to the subject (or to the embryo or fetus, if the subject is or 
may become pregnant) that are currently unforesee able. Female subjects of childbearing 
potential, sexually active, must use "acceptable contraceptive methods" for at least [ADDRESS_209108] dose of investigational vaccine/placebo. 
Regular pregnancy tests wil l be performed throughout the trial for all female subjects of 
childbearing potential. If a subject is found to be pregnant during trial, no further vaccine doses 
will be administered and the investigator will offer the subject the choice to receive unblin ded 
treatment information .In addition, female subject of childbearing potential must be advised 
not to donate ova during the study period.
26.To avoid sexual transmission of ZIKV from natural exposure: Sexually active subjects (both 
male and female) should u se latex condoms correctly and consistently even if other 
contraceptive measures are used from signing the ICF through the end of the trial. Male 
subjects must be advised not to donate sperm during this period.
0103Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA written subject authorization (either contained within the informed consent or provided as a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseA written subject authorization (either contained within the informed consent or provided as a 
separate document) describing to the subject the contemplated and permissible uses 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useseparate document) describing to the subject the contemplated and permissible uses and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand 
disclosures of the subjectâ€™s personal information (including personal health information) for 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedisclosures of the subjectâ€™s personal information (including personal health information) for 
purposes of conducting the trial. The subject authorization must contain the following 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepurposes of conducting the trial. The subject authorization must contain the following 
information:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinformation:
that personal information (including personal health information) may be processed by [CONTACT_178080]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethat personal information (including personal health information) may be processed by [CONTACT_178081]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransferred to other parties in other countries for clinical research and safety reporting 
[COMPANY_005], its affiliates, and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselicensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepartners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
rsonal health information) may be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usersonal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprocessed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesubjects the same level of protection as the data protection laws within this country; 
however, [COMPANY_005] will make every effort to keep 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehowever, [COMPANY_005] will make every effort to keep your personal information confidential, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useyour personal information confidential, 
and your name [CONTACT_87873] [CONTACT_2371];
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand your name [CONTACT_87873] [CONTACT_2371];
that personal information (including personal health information) may be added to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethat personal information (including personal health information) may be added to 
[COMPANY_005]â€™s research databases for purposes of developi[INVESTIGATOR_177899]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[COMPANY_005]â€™s research databases for purposes of developi[INVESTIGATOR_177900](s), studying other therapi[INVESTIGATOR_177901]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesafety and effectiveness of the investigational vaccine(s), studying other therapi[INVESTIGATOR_82256], developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepatients, developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of 
to restrict the use and disclosure of their personal information 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useto restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the trial to the extent that 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(including personal health information) upon withdrawal from the trial to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe restricted use or disclosure of such information may impact the scientific integrity of 
rch; and
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Userch; and
that the subjectâ€™s identity will remain confidential in the event that trial results are 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethat the subjectâ€™s identity will remain confidential in the event that trial results are 
The vaccination may involve risks to the subject (or to the embryo or fetus, if the subject is or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe vaccination may involve risks to the subject (or to the embryo or fetus, if the subject is or 
may become pregnant) 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemay become pregnant) 
potential, sexually active, must use "acceptable contraceptive methods" for at least 2 months 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usepotential, sexually active, must use "acceptable contraceptive methods" for at least 2 months 
prior to trial entry through
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprior to trial entry through
Regular pregnancy tests wil
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseRegular pregnancy tests wil
childbearing potential. If a subject is found to be pregnant during trial, no further vaccine doses 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usechildbearing potential. If a subject is found to be pregnant during trial, no further vaccine doses 
will be administered and the investigator will offer the subject the choice to receive unblin
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill be administered and the investigator will offer the subject the choice to receive unblin
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209109] intending to donate blood/blood product for transfusion might have positive ZIKV 
serological test result due to the participation in this study. Subject will be required to inform 
the health professional about the participation in the ZIKV vaccine study when intending to 
donate blood/blood product.
0104Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject will be required to inform 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject will be required to inform 
the health professional about the participation in the ZIKV vaccine study when intending to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe health professional about the participation in the ZIKV vaccine study when intending to 
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -[ADDRESS_209110] and retain personal information of investigator, including his or her name, 
address, and other personally identifiable information. In addition, investigatorâ€™s personal 
information may be transferred to other parties located in countries thro ughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
ï‚·[COMPANY_005], its affiliates, and licensing partners.
ï‚·Business partners assisting [COMPANY_005], its affiliates, and licensing partners.
ï‚·Regulatory agencies and other health a uthorities.
ï‚·IRBs and IECs.
Investigatorâ€™s personal information may be retained, processed, and transferred by [CONTACT_117578]:
ï‚·Assessment of the suitability of investigator for the trial and/or o ther clinical studies.
ï‚·Management, monitoring, inspection, and audit of the trial.
ï‚·Analysis, review, and verification of the trial results.
ï‚·Safety reporting and pharmacovigilance relating to the trial.
ï‚·Preparation and submission of regulatory filings, corr espondence, and communications to 
regulatory agencies relating to the trial.
ï‚·Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other vaccines used in other clinical studies that may cont ain the 
same chemical compound present in the investigational vaccine.
ï‚·Inspections and investigations by [CONTACT_178082].
ï‚·Self-inspection and internal audit within [COMPANY_005], its affiliates, and licensing partners.
ï‚·Archiving and audit of trial records.
ï‚·Posting investigator site contact [CONTACT_3031], trial details and results on publicly accessible 
clinical trial registries, databases, and websites.
Investigatorâ€™s personal information may be transferred to other countries that do no t have data 
protection laws that offer the same level of protection as data protection laws in investigatorâ€™s own 
country. Investigator acknowledges and consents to the use of his or her personal information by 
[CONTACT_178083].
0105Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill collect and retain personal information of investigator, including his or her name, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usewill collect and retain personal information of investigator, including his or her name, 
ughout the world (eg, the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useughout the world (eg, the 
Investigatorâ€™s personal information may be retained, processed, and transferred by [CONTACT_178084]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigatorâ€™s personal information may be retained, processed, and transferred by [CONTACT_117578]:
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethese other parties for research purposes including the following:
Assessment of the suitability of investigator for the trial and/or o
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAssessment of the suitability of investigator for the trial and/or o
Management, monitoring, inspection, and audit of the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseManagement, monitoring, inspection, and audit of the trial.
Analysis, review, and verification of the trial results.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAnalysis, review, and verification of the trial results.
Safety reporting and pharmacovigilance relating to the trial.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSafety reporting and pharmacovigilance relating to the trial.
Preparation and submission of regulatory filings, corr
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePreparation and submission of regulatory filings, corr
Preparation and submission of regulatory filings, correspondence, and communications to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePreparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other vaccines used in other clinical studies that may cont
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useregulatory agencies relating to other vaccines used in other clinical studies that may cont
same chemical compound present in the investigational vaccine.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesame chemical compound present in the investigational vaccine.
Inspections and investigations by [CONTACT_178082].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInspections and investigations by [CONTACT_178082].
inspection and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useinspection and internal audit within [COMPANY_005], its affiliates, and licensing partners.
audit of trial records.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useaudit of trial records.
Posting investigator site contact [CONTACT_3031], trial details and results on publicly accessible 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePosting investigator site contact [CONTACT_3031], trial details and results on publicly accessible 
clinical trial registries, databases, and websites.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useclinical trial registries, databases, and websites.
Investigatorâ€™s personal information may be transferred to other countries that do no
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseInvestigatorâ€™s personal information may be transferred to other countries that do no
protection laws that offer the same level of protection as data protection laws in investigatorâ€™s own 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useprotection laws that offer the same level of protection as data protection laws in investigatorâ€™s own 
country. Investigator acknowledges and consents to the use of his or her personal information by 
[CONTACT_79060]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecountry. Investigator acknowledges and consents to the use of his or her personal information by 
[CONTACT_178085]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use[COMPANY_005] and other parties for the purposes des
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 105of 108
Protocol Amendment 3 Version 7.0 12September 2018
Appendix DCDC W ebsites
ï‚·World Map of Areas with Risk of Zika: 
https://wwwnc.cdc.gov/travel/page/world -map-areas -with-zika
ï‚·Travel & Dengue Outbreaks: https://www.cdc.gov/dengue/traveloutbreaks/index.html
ï‚·Yellow Fever Maps: https://www.cdc.gov/yellowfever/maps/index.html
ï‚·Geographic Distribution of Japanese Encephalitis Virus: 
https://www.cdc.gov/japaneseencephalitis/maps/index.html
0106Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTravel & Dengue Outbreaks: https://www.cdc.gov/dengue/traveloutbreaks/index.html
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTravel & Dengue Outbreaks: https://www.cdc.gov/dengue/traveloutbreaks/index.html
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 106of 108
Protocol Amendment 3 Version 7.0 12September 2018
Appendix EFDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials 
Toxicity grading scales for laboratory abnormalities should consider the local laboratory reference 
values when the parameter limit values are defined. The characterization of laboratory parameters 
among some populations of healthy adults and adolescents may require the exercise of clinical 
judgment. Source: U.S. Department of Health and Human Services, Food and Drug 
Administration, and Center for Biologics Evaluation and Resear ch, September 2007 (93)
Table 16.a Table for Laboratory Abnormalities (Serum)
Serum(a)Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life 
Threatening
(Grade 4)(b)
Sodium â€“Hyponatremia mEq/L 132 â€“134 130 â€“131 125 â€“129 < 125
Sodium â€“Hypernatremia mEq/L 144 â€“145 146 â€“147 148 â€“150 > 150
Potassium â€“Hyperkalemia mEq/L 5.1 â€“5.2 5.3 â€“5.4 5.5 â€“5.6 > 5.6
Potassium â€“Hypokalemia mEq/L 3.5 â€“3.6 3.3 â€“3.4 3.1 â€“3.2 < 3.1
Glucose â€“Hypoglycemia mg/dL 65 â€“69 55 â€“64 45 â€“54 < 45
Glucose â€“Hyperglycemia
Fasting â€“ mg/dL
Random â€“mg/dL100 â€“110
110 â€“125111 â€“125
126 â€“200>125
>200Insulin requirements or 
hyperosmolar coma
Blood Urea Nitrogen
BUN mg/dL23-26 27 â€“31 > 31 Requires dialysis
Creatinine â€“mg/dL 1.5 â€“1.7 1.8 â€“2.0 2.1 â€“2.5 > 2.5 or requires dialysis
Calcium â€“hypocalcemia mg/dL 8.0 â€“8.4 7.5 â€“7.9 7.0 â€“7.4 < 7.0
Calcium â€“hypercalcemia mg/dL 10.5 â€“11.0 11.1 â€“11.5 11.6 â€“12.0 > 12.0
Magnesium â€“hypomagnesemia mg/dL 1.3 â€“1.5 1.1 â€“1.2 0.9 â€“1.0 < 0.9
Phosphorous â€“hypophosphatemia mg/dL 2.3 â€“2.5 2.0 â€“2.2 1.6 â€“1.9 < 1.6
CPK â€“mg/dL 1.25 â€“1.[ADDRESS_209111](c)1.6 â€“3.0 x 
ULN3.1 â€“[ADDRESS_209112]> [ADDRESS_209113]
Albumin â€“Hypoalbuminemia g/dL 2.8 â€“3.1 2.5 â€“2.7 < 2.5 --
Total Protein â€“Hypoproteinemia g/dL 5.5 â€“6.0 5.0 â€“5.4 < 5.0 --
Alkaline phosphate â€“increase by [CONTACT_12245] 1.1 â€“2.0 x 
ULN2.1 â€“3.0 x 
ULN3.1 â€“[ADDRESS_209114]> [ADDRESS_209115]
Liver Function Tests â€“ALT, AST increase by [CONTACT_12245] 1.1 â€“2.5 x 
ULN2.6 â€“5.0 x 
ULN5.1 â€“[ADDRESS_209116]> [ADDRESS_209117]
Bilirubin â€“when accompanied by [CONTACT_178086]1.1 â€“1.25 x 
ULN1.26 â€“1.5 x 
ULN1.51 â€“1.[ADDRESS_209118]> 1.[ADDRESS_209119]
Bilirubin â€“when Liver Function Test is normal; 
increase by [CONTACT_12245]1.1 â€“1.5 x 
ULN1.6 â€“2.0 x 
ULN2.0 â€“3.[ADDRESS_209120]> 3.[ADDRESS_209121]
Cholesterol 201 â€“210 211 â€“225 > 226 ---
Pancreatic enzymes â€“amylase, lipase 1.1 â€“1.5 x 
ULN1.6 â€“2.0 x 
ULN2.1 â€“5.[ADDRESS_209122]> 5.[ADDRESS_209123]
0107Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseToxicity grading scales for laboratory abnormalities should consider the local laboratory reference 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseToxicity grading scales for laboratory abnormalities should consider the local laboratory reference 
laboratory parameters 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselaboratory parameters 
among some populations of healthy adults and adolescents may require the exercise of clinical 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useamong some populations of healthy adults and adolescents may require the exercise of clinical 
ch, September 2007 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usech, September 2007 (
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(93
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use93)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Grade 3)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Grade 3)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially Life 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially Life 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThreatening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThreatening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Grade 4)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Grade 4)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use125 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use125 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“129
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use129
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use148 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use148 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“150
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use150
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5.5 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use5.5 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use3.4
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use55 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use55 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“64
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use64
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use110
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use110
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“125
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use125
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use111 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use111 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use23
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use23-
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use-26
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use26
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1.5 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1.5 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehypomagnesemia mg/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehypomagnesemia mg/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehypophosphatemia mg/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehypophosphatemia mg/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHypoalbuminemia g/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHypoalbuminemia g/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHypoproteinemia g/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHypoproteinemia g/dL
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAlkaline phosphate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseAlkaline phosphate 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLiver Function Tests 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseLiver Function Tests 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBilirubin 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseBilirubin 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFunction Test increase by [CONTACT_178087]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFunction Test increase by [CONTACT_178087]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 107of 108
Protocol Amendment 3 Version 7.0 12September 2018
(a) The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
(b) The clinical signs or symptoms associated with laboratory abnormalities might result in ch aracterization of the laboratory 
abnormalities as Potentially Life Threatening (Grade 4). For example. a low sodium value that falls within a grade 3 paramete r 
(125-129 mE q/L) should be recorded as a grade [ADDRESS_209124] had a new seiz ure associated with the low 
sodium value.
(c) â€œULNâ€ is the upper limit of the normal range.
Table 16.b Table for Laboratory Abnormalities (Hematology)
Hematology(a)Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life Threatening
(Grade 4)
Hemoglobin (Female) â€“gm/dL 11.0 â€“12.0 9.5 â€“10.9 8.0 â€“9.4 < 8.0
Hemoglobin (Female) change from 
baseline value â€“gm/dLAny 
decrease â€“
1.51.6 â€“2.0 2.1 â€“5.0 > 5.0
Hemoglobin (Male) â€“gm/dL 12.5 â€“13.5 10.5 â€“12.4 8.5 â€“10.4 < 8.5
Hemoglobin (Male) change from 
baseline value â€“gm/dLAny 
decrease â€“
1.51.6 â€“2.0 2.1 â€“5.0 > 5.0
WBC Increase â€“cell/mm310,800 â€“
15,[ZIP_CODE],001 â€“
20,[ZIP_CODE],001 â€“25, 
000> 25,000
WBC Decrease â€“ cell/mm3 2,500 â€“
3,5001,500 â€“2,4991,000 â€“
1,499< 1,000
Lymphocytes Decrease â€“cell/mm3750 â€“1,000 500 â€“749 250 â€“499 < 250
Neutrophils Decrease â€“cell/mm31,500 â€“
2,0001,000 â€“1,499 500 â€“999 < 500
Eosinophils â€“cell/mm3650 â€“1500 1501 -5000 > 5000 Hypereosinophilic
Platelets Decreased â€“cell/mm3125,000 â€“
140,000100,000 â€“
124,[ZIP_CODE],000 â€“
99,000< 25,000
PT â€“increase by [CONTACT_12245] 
(prothrombin time)1.0 â€“1.[ADDRESS_209125](b)Ã¯â‚¬1.11 â€“1.20 x 
ULN1.21 â€“1.[ADDRESS_209126]> 1.[ADDRESS_209127]
PTT â€“increase by [CONTACT_12245] (partial 
thromboplastin time)1.0 â€“1.2 x 
ULN1.21 â€“1.4 x 
ULN1.41 â€“1.[ADDRESS_209128]> 1.[ADDRESS_209129]
Fibrinogen increase â€“mg/dL 400 â€“500 501 â€“600 > 600 --
Fibrinogen decrease â€“mg/dL 150 â€“200 125 â€“149 100 â€“124 < 100 or associated with gross bleeding or 
disseminated intravascular coagulation (DIC)
(a) The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
(b) â€œULNâ€ is the upper limit of the normal range.
0108Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useabnormalities as Potentially Life Threatening (Grade 4). For example. a low sodium value that falls within a grade 3 paramete
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useabnormalities as Potentially Life Threatening (Grade 4). For example. a low sodium value that falls within a grade 3 paramete r 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of User 
ure associated with the low 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useure associated with the low 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially Life Threatening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially Life Threatening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use< 8.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use< 8.5
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 5.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 5.0
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use20,001 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use20,001 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use000
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use000
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“2,499
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use2,499
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1,000 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1,000 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use500 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use500 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“749
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use749
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1,000 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1,000 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use650 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use650 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“1500
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use1500
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use125,000 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use125,000 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use140,000
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use140,000
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincrease by [CONTACT_12245] (partial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useincrease by [CONTACT_12245] (partial 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetime)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFibrinogen increase 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFibrinogen increase 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFibrinogen decrease 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFibrinogen decrease 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(a)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(a) The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
(b)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(b)
Purified Inactivated Zika Virus Vaccine (PI [INVESTIGATOR_177760])
Trial No. ZIK -101 Page 108of 108
Protocol Amendment 3 Version 7.0 12September 2018
Table 16.c Table for Laboratory Abnormalities (Urine)
Urine(a)Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life Threatening
(Grade 4)
Protein Trace 1+ 2+ Hospi[INVESTIGATOR_177902] 1+ 2+ Hospi[INVESTIGATOR_160148] (microscopic) â€“red b lood cells 
per high power field1 -10 11 -50 > 50 and/or 
gross bloodHospi[INVESTIGATOR_177903] (PRBC) transfusion
(a)The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
Table 16.d Table for Clinical Abnormalities (Vital S igns)
Vital Signs(a)Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life Threatening
(Grade 4)
Fever (Â°C)(b)
(Â°F)(b)38.0 â€“38.4
100.4 â€“
101.138.5 â€“38.9
101.2 â€“
102.039.0 â€“40
102.1 â€“
104> 40
> 104
Tachycardia â€“beats per minute 101 â€“115 116 â€“130 > 130 ER visit or hospi[INVESTIGATOR_177904] â€“beats per minute(c)50 â€“54 45 â€“49 < 45 ER visit or hospi[INVESTIGATOR_177905] (systolic) â€“mm 
Hg141 â€“150 151 â€“155 > 155 ER visit or hospi[INVESTIGATOR_177906] (diastolic) â€“mm 
Hg91 â€“95 96 â€“100 > 100 ER visit or hospi[INVESTIGATOR_177907] (systolic) â€“mm Hg 85 â€“89 80 â€“84 < 80 ER visit or hospi[INVESTIGATOR_177908] â€“breaths per 
minute17 â€“20 21 â€“25 > 25 Intubation
(a)Subject should be at rest for all vital sign measurements.
(b)Oral temperature; no recent hot or cold beverages or smoking.
(c)When resting heart rate is between 60 â€“[ADDRESS_209130] populations, for example, conditioned athletes.
0109Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehyperglycemia
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehyperglycemia
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHospi[INVESTIGATOR_177909]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHospi[INVESTIGATOR_177909]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransfusion
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usetransfusion
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseThe laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useparameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially Life Threatening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePotentially Life Threatening
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Grade 4)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(Grade 4)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use40
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use40
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use102.1 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use102.1 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use104
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use104
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 40
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 40
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 104
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 104
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 130
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use> 130
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use49
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use49
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use< 45
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use< 45
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use151 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use151 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“155
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use155
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use96 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use96 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use85 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use85 â€“
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useâ€“89
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use89
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebreaths per 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebreaths per 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use17 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use17 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject should be at rest for all vital sign measurements.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseSubject should be at rest for all vital sign measurements.
Oral temperature; no recent hot or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseOral temperature; no recent hot or 
When resting heart rate is between 60 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseWhen resting heart rate is between [ADDRESS_209131] populations, for example, conditioned athletes.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebradycardia among some healthy subject populations, for example, conditioned athletes.
6LJQDWXUH3DJHIRU=,.3URWRFRO$PHQGPHQW9HUVLRQ6HSWHPEHU
7LWOH$3KDVH5DQGRPL]HG2EVHUYHU%OLQG3ODFHER&RQWUROOHG6DIHW\,PPXQR
'RFXPHQW1XPEHU7$.Y$SSURYDO
$SSURYDO
$SSURYDO
$SSURYDO
0110[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only1XPEHU1XPEOnof Useof
erms of 
nly and Subject to the Applicable Term